[go: up one dir, main page]

WO2025207921A1 - Methods for methylation enrichment using cpg-specific deamination - Google Patents

Methods for methylation enrichment using cpg-specific deamination

Info

Publication number
WO2025207921A1
WO2025207921A1 PCT/US2025/021808 US2025021808W WO2025207921A1 WO 2025207921 A1 WO2025207921 A1 WO 2025207921A1 US 2025021808 W US2025021808 W US 2025021808W WO 2025207921 A1 WO2025207921 A1 WO 2025207921A1
Authority
WO
WIPO (PCT)
Prior art keywords
dna
sample
dntp
deaminase
sequencing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/021808
Other languages
French (fr)
Inventor
Andrew Kennedy
James GHADIALI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guardant Health Inc
Original Assignee
Guardant Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guardant Health Inc filed Critical Guardant Health Inc
Publication of WO2025207921A1 publication Critical patent/WO2025207921A1/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C12Q1/6855—Ligating adaptors

Definitions

  • the disclosure relates to methods for enrichment of methylated DNA using CpG-specific deamination, e g., including differential processing of the uracil product of CpG-specific deamination.
  • Such methods can be useful for accurately detecting the methylation status and variants present in DNA, which, in turn, can be used to infer information about the cells and subject from which the DNA sample is derived.
  • the DNA molecule is from a subject having or suspected of having a disease or disorder, such as cancer.
  • Cancer is responsible for millions of deaths per year worldwide. Early cancer detection may result in improved outcomes because early-stage cancer tends to be more susceptible to treatment.
  • epigenetically modified (e.g., methylated) DNA in certain DNA samples may change upon carcinogenesis.
  • sufficiently sensitive epigenetic (e.g., DNA methylation) profiling can be used to detect aberrant methylation in DNA of a sample.
  • the contribution of DNA from cells in or around a cancer or neoplasm to a sample may be relatively small relative to the contribution from other cells, and the DNA contributed from other cells may be uninformative as to cancer status. Isolating and processing cell-free DNA useful for further analysis in liquid biopsy procedures can be a useful part of these methods.
  • the present disclosure aims to meet the need for improved analysis of methylated DNA, such as in a cfDNA sample, provide other benefits, or at least provide the public with a useful choice.
  • the present disclosure provides methods for enriching methylated DNA in a sample through differential processing of uracil products of CpG-specific deamination.
  • the disclosed methods can improve enrichment and analysis of methylated DNA in a sample by deaminating DNA in the sample with a CpG-specific deaminase and amplifying methylated CpGs or conversion products of methylated CpGs.
  • Embodiment l is a method of enriching methylated DNA in a sample comprising:
  • Embodiment 2 is the method of embodiment 1, wherein selectively amplifying DNA in the converted sample comprises amplifying the DNA using a uracil-intolerant DNA polymerase.
  • Embodiment 3 is the method of embodiment 1, wherein selectively amplifying DNA in the converted sample comprises:
  • Embodiment 5 is the method of the immediately preceding embodiment, wherein the AP lyase is an endonuclease VIII.
  • Embodiment 6 is the method of embodiment 4 or 5, wherein the DNA comprises adapters and amplifying DNA that was not cut by the AP lyase using the DNA polymerase comprises amplification using primers that bind sites in the adapters.
  • Embodiment 8 is the method of the immediately preceding embodiment, wherein the DNA comprises adapters and amplifying DNA that was not cut comprises amplification using primers that bind sites in the adapters.
  • Embodiment 9 is the method of embodiment 4 or 7, wherein the DNA polymerase is an AP site-intolerant DNA polymerase or a uracil-intolerant DNA polymerase.
  • Embodiment 10 is the method of embodiment 1, wherein the deaminase is a dsDNA deaminase, and wherein selectively amplifying DNA in the converted sample comprises:
  • Embodiment 11 is the method of the immediately preceding embodiment, wherein the MME is mismatch endonuclease I.
  • Embodiment 12 is the method of embodiment 10 or 11, wherein the DNA comprises adapters and amplifying DNA that was not cut comprises amplification using primers that bind sites in the adapters.
  • Embodiment 13 is the method of any one of the preceding embodiments, wherein the DNA comprises barcodes.
  • Embodiment 14 is the method of any one of the preceding embodiments, wherein the method comprises ligating adapters comprising barcodes to the DNA.
  • Embodiment 15 is the method of any one of embodiments 1-14, wherein the method comprises ligating adapters comprising barcodes to the DNA prior to the amplifying.
  • Embodiment 16 is the method of any one of embodiments 1-15, wherein the method comprises ligating adapters comprising barcodes to the DNA prior to the contacting the DNA with the deaminase.
  • Embodiment 17 is the method of any one of embodiments 4-12, wherein the method comprises ligating adapters to the DNA after cutting the DNA.
  • Embodiment 18 is the method of any one of embodiments 12 or 14-17, wherein the adapters are Y-shaped adapters.
  • Embodiment 19 is the method of any one of the preceding embodiments, wherein the deaminase is thermally inactivated after step (a).
  • Embodiment 20 is the method of any one of embodiments 4-6, wherein the steps of contacting the DNA with the UDG and cutting DNA comprising the AP sites using the AP lyase are in the same reaction mixture.
  • Embodiment 21 is the method of any one of the preceding embodiments, wherein the deaminase is a dsDNA deaminase.
  • Embodiment 22 is the method of any one of embodiments 1-9, wherein the deaminase is a ssDNA deaminase.
  • Embodiment 23 is the method of any one of embodiments 1-9, wherein the deaminase is a methyl insensitive deaminase.
  • Embodiment 24 is the method of the immediately preceding embodiment, wherein the methyl insensitive deaminase is A3 A.
  • Embodiment 25 is the method of any one of embodiments 1-22, wherein the deaminase is a methyl sensitive deaminase.
  • Embodiment 27 is the method of any one of embodiments 1-26, further comprising, prior to step (a): subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules, wherein the end repair is performed using deoxynucleotide triphosphates (dNTPs), wherein at least one type of dNTP comprises a modified base, and the at least one dNTP comprising a modified base is incorporated into a repaired region of the end-repaired DNA molecules at one or more locations.
  • dNTPs deoxynucleotide triphosphates
  • Embodiment 28 is the method of embodiment 27, wherein the end repair is performed using a DNA polymerase that does not have 5’-3’ exonuclease activity and/or is not a strand displacing DNA polymerase.
  • Embodiment 29 is the method of embodiment 27, wherein the end repair is performed using a DNA polymerase that has 5 ’-3’ exonuclease activity and/or is a strand displacing DNA polymerase.
  • Embodiment 30 is the method of any one of embodiments 27-29, wherein the at least one type of dNTP which comprises a modified base, wherein the modified base includes a dNTP comprising 5-caryboxylcytosine (5-caC), 4-methylcytosine (4mC), a dNTP comprising 5- methylcytosine (5mC), a dNTP comprising 5-hydroxymethyl-cytosine (5hmC), a dNTP comprising N6-methyladenosine (6mA), a dNTP comprising bromodeoxyuridine (BrdU) and/or a dNTP comprising 8-oxoguanine (8oxoG).
  • the modified base includes a dNTP comprising 5-caryboxylcytosine (5-caC), 4-methylcytosine (4mC), a dNTP comprising 5- methylcytosine (5mC), a dNTP comprising 5-hydroxymethyl-cytosine (5hmC), a
  • Embodiment 31 is the method of any one of embodiments 1-30, further comprising performing an A-tailing reaction, optionally after a step of subjecting a DNA sample to end repair.
  • Embodiment 32 is the method of embodiment 31, wherein the end-repair and the A- tailing reaction are performed in the same reaction mixture, optionally wherein the end-repair and the A-tailing reaction are performed a single tube and/or optionally wherein the end-repair and the A-tailing reaction are performed without an intervening clean-up step.
  • Embodiment 33 is the method of embodiment 31 or 32, wherein the A-tailing is performed using a DNA polymerase that does not possess 5’-3’ exonuclease activity and/or is not a strand displacing DNA polymerase, optionally wherein the DNA polymerase is HemoKlen Taq.
  • Embodiment 34 is the method of any one of embodiments 31-33, wherein the A-tailing is performed using a thermostable DNA polymerase.
  • Embodiment 35 is the method of any one of embodiments 1-34, prior to step (a), performing a methylation-preserving amplification of the DNA of the sample.
  • Embodiment 36 is the method of the immediately preceding embodiment, wherein the methylation-preserving amplification is a linear, methylation-preserving amplification.
  • Embodiment 37 is the method of any one of embodiments 35-36, wherein the methylation-preserving amplification comprises contacting the DNA with a methyltransferase.
  • Embodiment 38 is the method of any one of embodiments 35-37, wherein the methylation-preserving amplification comprises one or more of polymerase chain reaction, linear amplification, rolling circle amplification, ligase chain reaction, strand displacement amplification, nucleic acid sequence-based amplification, and self-sustained sequence-based replication.
  • Embodiment 39 is the method of any one of embodiments35-37, wherein the methylation-preserving amplification comprises thermocycled amplification.
  • Embodiment 40 is the method of any one of embodiments 35-37, wherein the methylation-preserving amplification comprises isothermal amplification.
  • Embodiment 41 is the method of any one of embodiments 1-40, wherein the step of contacting the DNA in the sample with a deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs, comprises APOBEC-coupled epigenetic (ACE) conversion, enzymatic methyl-seq (EM-seq) or single-enzyme 5- methylcytosine sequencing (SEM-seq) method.
  • ACE APOBEC-coupled epigenetic
  • EM-seq enzymatic methyl-seq
  • SEM-seq single-enzyme 5- methylcytosine sequencing
  • Embodiment 42 is the method of any one of the preceding embodiments, further comprising sequencing at least a portion of the amplified DNA.
  • Embodiment 46 is the method of the immediately preceding embodiment, wherein the NGS is pyrosequencing, sequencing-by-synthesis, semiconductor sequencing, sequencing-by- ligation, or sequencing-by-hybridization.
  • Embodiment 51 is the method of the immediately preceding embodiment, further comprising analyzing the sequence data to determine a level of measured artifacts in the cfDNA.
  • Embodiment 52 is the method of any one of embodiments 1-51, further comprising subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules, wherein the end repair is performed using at least one type of dNTP which comprises a modified base, wherein the modified base is other than 5mC or 5hmC, and the at least one type of dNTP comprising a modified base is incorporated into a repaired region of the end-repaired DNA molecules at one or more locations.
  • Embodiment 53 is the method of any one of embodiments 1-51, further comprising subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules, wherein the end repair is performed using at least one type of dNTP which comprises a modified base, wherein the modified base is a methylated cytosine, optionally wherein the methylated base is 5mC or 5hmC, and the at least one type of dNTP comprising a modified base is incorporated into a repaired region of the end-repaired DNA molecules at one or more locations.
  • the end repair is performed using at least one type of dNTP which comprises a modified base, wherein the modified base is a methylated cytosine, optionally wherein the methylated base is 5mC or 5hmC, and the at least one type of dNTP comprising a modified base is incorporated into a repaired region of the end-repaired DNA molecules at one or more locations.
  • Embodiment 54 is the method of any one of embodiments 1-51, further comprising subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules, wherein the end repair is performed using at least one type of dNTP which comprises a modified base, wherein the modified base is a methylated cytosine, optionally wherein the methylated base is 5mC or 5hmC, wherein the at least one type of dNTP comprising a modified base is incorporated into a repaired region of the end-repaired DNA molecules at one or more locations, and the repaired region is defined as:
  • Embodiment 55 is the method of any one of embodiments 27-34 or 52-54 , wherein adapters are ligated to the end-repaired DNA molecules or the adapters are ligated to the DNA molecules.
  • Embodiment 58 is the method of embodiment 57, wherein the plurality of target regions comprises epigenetic target regions.
  • Embodiment 59 is the method of embodiment 58, wherein the epigenetic target regions comprise hypermethylation variable target regions.
  • Embodiment 60 is the method of embodiment 58 or 59, wherein the epigenetic target regions comprise hypomethylation variable target regions.
  • Embodiment 64 is the method of any one of the preceding embodiments, wherein the DNA sample is from a subject.
  • Embodiment 65 is the method of any one of the preceding embodiments, wherein the DNA sample is from a subject and the method further comprises determining the presence or absence of cancer in the subject based at least in part on the sequencing data.
  • Embodiment 66 is the method of any one of embodiments 64-65, wherein the subject is an animal.
  • Embodiment 67 is the method of the immediately preceding embodiment, wherein the subject is a human.
  • Embodiment 68 is the method of any one of embodiments 64-67, wherein the subject has or is at risk of having a cancer.
  • Embodiment 69 is the method of any one of embodiments 64-68, further comprising determining the presence or status of a cancer in the subject.
  • the results of the methods disclosed herein are used as an input to generate a report.
  • the report may be in a paper or electronic format.
  • the true methylation status of cytosines or variants, as obtained by the methods disclosed herein, or information derived therefrom, can be displayed directly in such a report.
  • diagnostic information or therapeutic recommendations which are at least in part based on the methods disclosed herein can be included in the report.
  • FIGS. 1A-1D illustrate exemplary workflows according to certain embodiments of the disclosure.
  • FIG. 1A is a schematic which shows a methylation enrichment method using a methyl-insensitive CpG-specific deaminase (labeled as “CpG deaminase”) or a methyl -sensitive CpG deaminase, followed by amplification using a uracil-intolerant DNA polymerase.
  • CpG deaminase methyl-insensitive CpG-specific deaminase
  • a methyl -sensitive CpG deaminase methyl-sensitive CpG deaminase
  • IB is a schematic which shows a methylation enrichment method using a methyl -insensitive CpG-specific deaminase (labeled as “CpG deaminase”) or a methyl -sensitive CpG deaminase, followed by a uracil-DNA glycosylase (UDG), and amplification using an apyrimidinic (AP) site-intolerant DNA polymerase.
  • CpG deaminase methyl -insensitive CpG-specific deaminase
  • UDG uracil-DNA glycosylase
  • AP apyrimidinic
  • FIG. 1C is a schematic which shows a methylation enrichment method using a methyl-insensitive CpG-specific deaminase (labeled as “CpG deaminase”) or a methyl-sensitive CpG deaminase, followed by a UDG, an AP lyase, and amplification using a DNA polymerase.
  • FIG. ID is a schematic which shows a methylation enrichment method using a methyl-sensitive CpG deaminase followed by a mismatch endonuclease and amplification using a DNA polymerase (e.g., a uracil-intolerant DNA polymerase).
  • a DNA polymerase e.g., a uracil-intolerant DNA polymerase
  • FIG. 2 is a schematic which shows an exemplary methylation enrichment method that uses differential processing of the uracil product of CpG-specific deamination for identifying methylated CpG sites and retaining end-repair resynthesized CpGs. End-repair and A-tailing reactions are performed on a DNA sample, followed by ligation of next-generation sequencing (NGS) adapters to the DNA, deamination of the DNA using a methyl -insensitive CpG-specific deaminase, and uracil-intolerant amplification of the DNA.
  • NGS next-generation sequencing
  • FIG. 3 is a schematic diagram of an example of a system suitable for use with some embodiments of the disclosure.
  • a “type of dNTP” refers to a dNTP comprising a specific base, including A, T, G or C. Accordingly, wherein an end repair reaction is performed with dNTPs, wherein at least one type of dNTP comprises a modified base, the end repair reaction may be performed using dCTP comprising 5mC, and dATP, dTTP and dGTP all comprising non-modified bases.
  • “Capable of identifying the base modification in the at least one type of dNTP” refers to the ability of a modification-sensitive sequencing method to detect the presence or absence of the base modification in the at least one type of dNTP comprising a modified base used in the end repair.
  • This detection of the base modification may be direct, such as in nanopore sequencing or single molecule real time sequencing, wherein the sequencing data itself indicates the presence or absence of a base modification.
  • the detection of the base modification may be indirect, for example wherein the method involves a conversion procedure which alters the base pairing specificity dependent on the base modification status. It is these changes in base pairing specificity which can be detected by the sequencing method, e.g. through the comparison of the sequencing data to a reference sequence.
  • Bases of the “same identity” refer to the same base, regardless of modification status of that base.
  • cytosine is considered to be the “same identity” as 5-methylcytosine (5mC) and/or 5-hydroxymethyl-cytosine (5hmC), despite them having different modification statuses.
  • Cell-free DNA include DNA molecules that naturally occur in a subject in extracellular form (e.g., in blood, serum, plasma, or other bodily fluids such as lymph, cerebrospinal fluid, urine, or sputum). While the cfDNA originally existed in a cell or cells in a large complex biological organism, e.g., a mammal, it has undergone release from the cell(s) into a fluid found in the organism, and may be obtained from a sample of the fluid without the need to perform an in vitro cell lysis step.
  • 3C methylation comprises addition of a methyl group to the 3C position of the cytosine to generate 3 -methylcytosine (3mC).
  • Methylation can also occur at non-CpG sites, for example, methylation can occur at a CpA, CpT, or CpC site.
  • DNA methylation can change the activity of methylated DNA region. For example, when DNA in a promoter region is methylated, transcription of the gene may be repressed. DNA methylation is critical for normal development and abnormality in methylation may disrupt epigenetic regulation. The disruption, e.g., repression, in epigenetic regulation may cause diseases, such as cancer. Promoter methylation in DNA may be indicative of cancer.
  • the “modified nucleoside profile of DNA” means the position and identity of the nucleoside and the modification status of the nucleoside, such as methylations, within a DNA sequence.
  • different modification sensitive sequencing methods can be used to detect such modifications. This includes methods which involve conversion followed by sequencing detect one or more different types of modified or unmodified nucleoside.
  • the TAPS method detects, but does not distinguish between, 5-methylcytosine (5mC) and 5-hydroxymethyl-cytosine (5hmC).
  • a method for analyzing the modified nucleoside profile of DNA in a sample typically means identifying particular modifications or groups of modification, such as 5mC and/or 5hmC.
  • Modified nucleosides are identified according to the specific method/conversion procedure being used as described above. This generally involves comparing sequence data obtained from DNA that has been subjected to a conversion procedure to a reference sequence. Typically, the method involves (i) comparing the sequence data with (A) one or more pre-determined reference sequence; or (B) sequence data obtained by sequencing a sub-sample of the DNA that was not subjected to the conversion procedure, for example a subsample that was separated before subjecting a separate subsample to the conversion procedure, for example as described herein; and (ii) identifying point differences between the converted DNA sequences and the reference sequence(s) (A) or non-converted DNA sequences (B) as nucleosides (in the initial sample) having a modification status that permits a change in base pairing specificity on exposure to the conversion procedure.
  • first and second target regions are 50 kb and 500 kb, respectively (giving a normalization factor of 0.1)
  • the DNA corresponding to the first target region set is captured with a higher yield than DNA corresponding to the second target region set when the mass per volume concentration of the captured DNA corresponding to the first target region set is more than 0.1 times the mass per volume concentration of the captured DNA corresponding to the second target region set.
  • Capturing one or more target nucleic acids refers to preferentially isolating or separating the one or more target nucleic acids from non-target nucleic acids.
  • a “captured set” of nucleic acids refers to nucleic acids that have undergone capture.
  • a “target-region set” or “set of target regions” refers to a plurality of genomic loci targeted for capture and/or targeted by a set of probes (e.g., through sequence complementarity).
  • “Corresponding to a target region set” means that a nucleic acid, such as cfDNA, originated from a locus in the target region set or specifically binds one or more probes for the target-region set.
  • a “differentially methylated region” refers to a region of DNA having a detectably different degree of methylation in at least one cell or tissue type relative to the degree of methylation in the same region of DNA from at least one other cell or tissue type; or having a detectably different degree of methylation in at least one cell or tissue type obtained from a subject having a disease or disorder relative to the degree of methylation in the same region of DNA in the same cell or tissue type obtained from a healthy subject.
  • a DMR has a detectably higher degree of methylation (e.g., a hypermethylated region) in at least one cell or tissue type relative to the degree of methylation in the same region of DNA from at least one other cell or tissue type or from the same cell or tissue type from a healthy subject.
  • a DMR has a detectably lower degree of methylation (e.g., a hypomethylated region) in at least one cell or tissue type relative to the degree of methylation in the same region of DNA from at least one other cell or tissue type or from the same cell or tissue type from a healthy subject.
  • binds in the context of a probe or other oligonucleotide and a target sequence means that under appropriate hybridization conditions, the oligonucleotide or probe hybridizes to its target sequence, or replicates thereof, to form a stable probe:target hybrid, while at the same time formation of stable probemon-target hybrids is minimized.
  • a probe hybridizes to a target sequence or replicate thereof to a sufficiently greater extent than to a nontarget sequence, to enable capture or detection of the target sequence.
  • Appropriate hybridization conditions are well-known in the art, may be predicted based on sequence composition, or can be determined by using routine testing methods (see, e.g., Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) at ⁇ 1.90-1.91, 7.37-7.57, 9.47-9.51 and 11.47-11.57, particularly ⁇ 9.50-9.51, 11.12- 11.13, 11.45-11.47 and 11.55-11.57, incorporated by reference herein).
  • Sequence-variable target region set refers to a set of target regions that may exhibit changes in sequence such as nucleotide substitutions (i.e., single nucleotide variations), insertions, deletions, or gene fusions or transpositions in neoplastic cells (e g., tumor cells and cancer cells).
  • Epigenetic target region set refers to a set of target regions that may show sequenceindependent changes in neoplastic cells (e.g., tumor cells and cancer cells) or that may show sequence-independent changes in cfDNA from subjects having cancer relative to cfDNA from healthy subjects.
  • sequence-independent changes include, but not limited to, changes in methylation (increases or decreases), nucleosome distribution, CTCF binding, transcription start sites, and regulatory protein binding regions.
  • loci susceptible to neoplasia-, tumor-, or cancer-associated focal amplifications and/or gene fusions may also be included in an epigenetic target region set because detection of a change in copy number by sequencing or a fused sequence that maps to more than one locus in a reference genome tends to be more similar to detection of exemplary epigenetic changes discussed above than detection of nucleotide substitutions, insertions, or deletions, e.g., in that the focal amplifications and/or gene fusions can be detected at a relatively shallow depth of sequencing because their detection does not depend on the accuracy of base calls at one or a few individual positions.
  • hypermethylation refers to an increased level or degree of methylation of nucleic acid molecule(s) relative to the other nucleic acid molecules within a population (e.g., sample) of nucleic acid molecules.
  • hypermethylated DNA can include DNA molecules comprising at least 1 methylated residue, at least 2 methylated residues, at least 3 methylated residues, at least 5 methylated residues, or at least 10 methylated residues.
  • hypomethylation refers to a decreased level or degree of methylation of nucleic acid molecule(s) relative to the other nucleic acid molecules within a population (e.g., sample) of nucleic acid molecules.
  • hypomethylated DNA includes unmethylated DNA molecules.
  • hypomethylated DNA can include DNA molecules comprising 0 methylated residues, at most 1 methylated residue, at most 2 methylated residues, at most 3 methylated residues, at most 4 methylated residues, or at most 5 methylated residues.
  • methylation status can refer to the presence or absence of methyl group on a DNA base (e.g. cytosine) at a particular genomic position in a nucleic acid molecule. It can also refer to the degree of methylation in a nucleic acid sequence (e.g., highly methylated, low methylated, intermediately methylated or unmethylated nucleic acid molecules). The methylation status can also refer to the number of nucleotides methylated in a particular nucleic acid molecule.
  • mutation refers to a variation from a known reference sequence and includes mutations such as, for example, single nucleotide variants (SNVs), and insertions or deletions (indels).
  • SNVs single nucleotide variants
  • Indels insertions or deletions
  • a mutation can be a germline or somatic mutation.
  • a reference sequence for purposes of comparison is a wildtype genomic sequence of the species of the subject providing a test sample, typically the human genome.
  • the DNA comprises barcodes.
  • the adapters comprise barcodes.
  • the method comprises ligating adapters comprising barcodes to the DNA.
  • the ligation of the adapters comprising barcodes occurs prior to amplifying the DNA (e.g., the selective amplification of the DNA in the converted sample).
  • the ligation of the adapters comprising barcodes occurs prior to contacting the DNA with the deaminase.
  • the method comprises ligating adapters to the DNA after cutting the DNA.
  • the adapters are Y-shaped adapters.
  • the deaminase is a methyl -sensitive deaminase, including e.g., modification-sensitive DNA deaminase A (MsddA) or a modification-sensitive DNA deaminase A (MsddA)-like deaminase.
  • MsddA modification-sensitive DNA deaminase A
  • MsddA modification-sensitive DNA deaminase A
  • the disclosed methods can be combined with analysis of one or more additional biomarkers.
  • the disclosed methods are combined with one or more methods, such as but not limited to, methods for assessing DNA methylation patterns, DNA mutations (such as somatic mutations), nucleic acid fragmentation patterns, non-coding RNA (such as micro RNAs (miRNAs), ribosomal RNAs, transfer RNAs, small nucleolar RNAs (snow RNAs), and/or small nuclear RNAs (snRNAs)) levels, and/or cell type proportions/levels, cellular locations, and/or structural modifications of one or more proteins (such as in a sample from a subject).
  • DNA mutations such as somatic mutations
  • nucleic acid fragmentation patterns such as DNA methylation patterns, DNA mutations (such as somatic mutations), nucleic acid fragmentation patterns, non-coding RNA (such as micro RNAs (miRNAs), ribosomal RNAs, transfer RNAs, small nucleolar RNAs (s
  • the disclosed methods are combined with one or more analyses of genetic variations including mutations, rare mutations, indels, rearrangements, copy number variations, transversions, translocations, recombinations, inversion, deletions, aneuploidy, partial aneuploidy, polyploidy, chromosomal instability, chromosomal structure alterations, gene fusions, chromosome fusions, gene truncations, gene amplification, gene duplications, chromosomal lesions, DNA lesions, abnormal changes in nucleic acid chemical modifications, abnormal changes in epigenetic patterns, and/or abnormal changes in nucleic acid 5-methylcytosine.
  • the subject may be a human, a mammal, an animal, a primate, rodent (including mice and rats), or other common laboratory, domestic, companion, service or agricultural animal, for example a rabbit, dog, cat, horse, cow, sheep, goat or pig.
  • the DNA sample is from a human.
  • the subject may in some cases have or be suspected of having a cancer, tumor, or neoplasm. In other cases, the subject may not have cancer or a detectable cancer symptom.
  • the subject may have been treated with one or more cancer therapy, e g., any one or more of chemotherapies, antibodies, vaccines or biologies.
  • the subject may be in remission, e.g.
  • a population of nucleic acids is obtained from a serum, plasma or blood sample from a subject having or suspected of having neoplasia, a tumor, precancer, or cancer or previously diagnosed with neoplasia, a tumor, precancer, or cancer.
  • the population includes nucleic acids having varying levels of sequence variation and/or epigenetic variation, such as post-translation modifications (PTMs) of chromatin and/or nucleobase modifications, e.g., modifications of cytosine, particularly at the 5-position of the nucleobase, e.g., 5- methylcytosine, 5-hydroxymethylcytosine, 5-formylcytosine and 5-carboxylcytosine.
  • PTMs post-translation modifications
  • modifications of cytosine particularly at the 5-position of the nucleobase, e.g., 5- methylcytosine, 5-hydroxymethylcytosine, 5-formylcytosine and 5-carboxylcytosine.
  • the sample comprises whole blood.
  • Exemplary volumes of sampled whole blood are 0.4-40 mL, 5-20 mL, 10-20 mL, 1-6 mL, 1-3 mL, and 3-5 mL.
  • the volume can be 0.5 mL, 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, 10 mL, 20 mL, 30 mL, or 40 mL.
  • a volume of sampled whole blood may be 5 to 20 mL.
  • the sample volume is 1-5 mL of whole blood, such as 2.5 mL of whole blood.
  • a volume of sampled leukocytes from leukapheresis may be 1 to 10 mL.
  • the sample volume is 0.1-0.6 mL of leukocytes from leukapheresis, such as 0.4 mL of leukocytes, per 10 mL whole blood.
  • the DNA sample may be or comprise cell free nucleic acids or cfDNA.
  • the cfDNA may be obtained from a test subject, for example as described above.
  • the sample for analysis may be plasma or serum containing cell-free nucleic acids.
  • Cell-free DNA “cfDNA molecules,” or “cfDNA”, for example, include DNA molecules that naturally occur in a subject in extracellular form (e.g., in blood, serum, plasma, or other bodily fluids such as lymph, cerebrospinal fluid, urine, or sputum).
  • cell-free nucleic acids or cfDNA are nucleic acids or DNA not contained within or otherwise bound to a cell, or the nucleic acids or DNA remaining in a sample after removing intact cells.
  • Cell-free nucleic acids have an exemplary size distribution of about 100-500 nucleotides, with molecules of 110 to about 230 nucleotides representing about 90% of molecules, with a mode of about 168 nucleotides and a second minor peak in a range between 240 to 440 nucleotides.
  • Cell-free nucleic acids can be isolated from bodily fluids through a fractionation or partitioning step in which cell-free nucleic acids, as found in solution, are separated from intact cells and other non-soluble components of the bodily fluid. Partitioning may include techniques such as centrifugation or filtration. Alternatively, cells in bodily fluids can be lysed and cell-free and cellular nucleic acids processed together. Generally, after addition of buffers and wash steps, nucleic acids can be precipitated with an alcohol. Further clean up steps may be used such as silica-based columns to remove contaminants or salts. Non-specific bulk carrier nucleic acids, DNA or protein for sequencing, hybridization, and/or ligation, may be added throughout the reaction to optimize certain aspects of the procedure such as yield.
  • samples can include various forms of nucleic acid including double stranded DNA, single stranded DNA and single stranded RNA.
  • single stranded DNA and RNA can be converted to double stranded forms so they are included in subsequent processing and analysis steps.
  • the methods disclosed herein are also particularly suited for the analysis of DNA from formalin-fixed paraffin-embedded (FFPE) tissue samples. While the formalin fixation process adequately preserves the ultrastructure of the tissues, it results in various types of damage to the DNA within the tissues, such as nicks in the DNA. As explained elsewhere herein, these nicks can lead to synthesis of regions of the DNA molecule in the end repair process. The methods disclosed herein allow for these regions to be identified and the sequence data to be interpreted accordingly.
  • FFPE formalin-fixed paraffin-embedded
  • the disclosed methods comprise subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules.
  • the end repair is performed before contacting the DNA in the sample with a deaminase.
  • the end repair is performed using deoxynucleotide triphosphates (dNTPs).
  • dNTPs deoxynucleotide triphosphates
  • at least one type of dNTP comprises a modified base, and the at least one dNTP comprising a modified base is incorporated into repaired regions of the end-repaired DNA molecules at one or more locations.
  • a 5 ’overhang refers to the 5’ end of a DNA strand which extends beyond the 3 ’end of the paired strand, resulting in one or more unpaired nucleotides at the 5 ’end of the DNA strand.
  • the process of end repair involves the conversion of double-stranded DNA with 3’overhangs and/or 5’overhangs to double-stranded DNA without overhangs. This can be done using one or more enzymes such as T4 DNA polymerase and/or Klenow fragment.
  • the 3’ to 5’ exonuclease activity of these enzymes removes the 3 ’ends at 3’overhangs and the 5’ to 3’ polymerase activity of these enzymes extends the 3’ ends at 5’ overhangs to remove the 5’ overhang, thereby generating a blunt-ended DNA molecule.
  • end repair is conducted in the presence of dATP, dCTP, dGTP and dTTP.
  • End repair can also include a second step, which involves the addition of a phosphate group to the 5' ends of DNA, by an enzyme such as polynucleotide kinase. This makes the 5’ends of the end-repaired DNA molecules compatible with the subsequent action of DNA polymerases and DNA ligases.
  • a second step which involves the addition of a phosphate group to the 5' ends of DNA, by an enzyme such as polynucleotide kinase.
  • A-tailing refers to the addition of a single deoxyadenosine residue to the end of a blunt-ended double-stranded DNA fragment to form a 3' deoxyadenosine single-base overhang.
  • a tailing reactions are conducted with polymerases which have the ability to add a non-templated A to the 3' end of a blunt, double-stranded DNA molecule.
  • Polymerases capable of A-tailing typically do not possess 3 ’-5’ exonuclease activity.
  • A- tailing is performed as a separate reaction to end repair, it is typically conducted in the presence of dATP, but the absence of dCTP, dTTP and dGTP.
  • A-tailed fragments are not compatible for self-ligation (i.e., self-circularizatian and concantenation of the DNA), but they are compatible with 3' T-overhangs, which can be used on adapters.
  • Methods comprising end repair, A-tailing and ligation to adapters with 3' T-overhangs can result in higher efficiency ligation, compared to blunt ended ligation, as blunt ligation can lead to self-ligation of the adapters and/or DNA molecules.
  • the methods disclosed herein comprise end repair of the DNA molecules followed by blunt end ligation of adapters.
  • the methods disclosed herein comprise end repair of the DNA molecules followed by A-tailing and sticky-end ligation of T-tailed adapters.
  • the methods disclosed herein comprise an A-tailing step, it may be performed separately from the end repair with an intervening reaction clean-up step or it may be performed in the same reaction as the end repair (e.g. using NEBNext® UltraTM II End Repair/dA-Tailing Module (E7546)).
  • the reaction clean-up step removes unincorporated dNTPs.
  • the sticky-end ligation may be performed with a mixture of T-tailed adapters and C-tailed adapters.
  • end repair can lead to 3 ’fill in with unmethylated cytosines, which may not reflect the true methylation status of that position in the DNA molecule prior to the generation of the 5 ’overhang.
  • polymerases which contain 5’ to 3’ exonuclease activity and/or strand displacement activity can lead to the synthesis of internal regions of the DNA molecule through nick translation. If the end repair reaction is conducted with non-methylated deoxy cytidine triphosphate (dCTP), the synthesized regions will incorporate the non-methylated dCTP, potentially at positions which initially comprised methylated cytosines.
  • dCTP non-methylated deoxy cytidine triphosphate
  • the end-repair and the A-tailing reactions are performed in a single tube.
  • the A tailing reaction can be performed at a higher temperature than the end repair.
  • end repair is performed at ambient temperature (e.g. 15-35°C) and A tailing is performed at a temperature over 60°C, including e.g., about 60°C-75°C.
  • the A tailing reaction can be performed using a thermostable polymerase (e g. Taq DNA polymerase, TH DNA polymerase, Bst DNA Polymerase, Large Fragment or Tth DNA polymerase) and the method further comprises increasing temperature of the sample after the end repair to inactivate the polymerase used in end repair (e.g.
  • the A-tailing is performed using a DNA polymerase that: (i) does not possess 5 ’-3’ exonuclease activity; and/or (ii) is not a strand displacing DNA polymerase. These properties reduce the ability of the DNA polymerase to extend from nick. This reduces the level of synthesis which may occur during the end repair and A-tailing reactions thus reducing the proportion of sequencing data that may be fdtered out as potentially containing artifactual data. Accordingly, in some embodiments, the A-tailing is performed using a DNA polymerase that cannot extend from a nick in the DNA such as HemoKlen Taq.
  • the A- tailing is performed using Taq DNA polymerase. In other embodiments, the A-tailing is performed using Tfl polymerase, Bst DNA Polymerase, Large Fragment or Tth polymerase. [0199] .
  • the end repair reaction can be performed using DNA polymerases can be used which lack 5 ’to 3’ exonuclease activity and/or strand displacement activity (e.g. T4 DNA polymerase or Klenow fragment).
  • nick translation is reduced in end repair through the use of polymerases which lack 5’to 3’ exonuclease activity and/or strand displacement activity.
  • the separation of the end repair and A tailing reaction by a reaction clean-up means that only dATP (not dCTP, dTTP or dGTP) is present in the A tailing reaction. This means that efficient nick translation cannot occur in the A tailing reaction because the three of the four nucleotide components are not present in the reaction mixture.
  • the gaps can be filled in with DNA polymerases used in the end repair reaction, regardless of whether they possess 5’ to 3’ exonuclease activity or strand displacement activity.
  • the end-repair is performed with a polymerase which lacks 5’to 3’ exonuclease activity and/or strand displacement activity.
  • the polymerase used in the end repair reaction may be Q5® High-Fidelity DNA Polymerase, Q5U® Hot Start High- Fidelity DNA Polymerase, Phusion® High-Fidelity DNA Polymerase, Hemo Klen aq, phi29 DNA Polymerase, T7 DNA Polymerase, DNA Polymerase I (E. coli), DNA Polymerase I, Large (Klenow) Fragment (“KI enow fragment”) or T4 DNA Polymerase.
  • the polymerase used in the end repair is T4 DNA Polymerase or Klenow fragment.
  • the end repair is performed with a DNA polymerase which has 5 ’-3’ exonuclease activity and/or is a strand displacing DNA polymerase.
  • the methods disclosed herein comprise an A tailing reaction after the end repair and before the ligation reaction, wherein the end repair and A tailing reactions are separated by a reaction cleanup.
  • the A tailing reaction is typically performed in the presence of dATP, but in the absence of dCTP, dTTP and dGTP.
  • the A tailing reaction is performed using Klenow Fragment lacking 3'-5' exonuclease activity.
  • a dNTP that comprises a modified base is used in end repair, which may be any modified base wherein the presence or the absence of the modification can be detected by a type of sequencing.
  • a dNTP comprising a modified base can be used in a combined end repair and A-tailing reaction.
  • the modified base is incorporated in the synthesized regions at both CpG sites and CpH sites (i.e. CpA, CpC and CpT sites). While methylation of cytosines in non-CpG contexts has been described, it is thought to comprise 0.02% of total methyl-cytosine in differentiated somatic cells (Jang et al. Genes (Basel).
  • a dNTP that comprises a modified base may comprise any modified base wherein the presence or the absence of the modification can be detected by a type of sequencing.
  • the modified base may be 5-caryboxylcytosine (5-caC), 4-methylcytosine (4mC), 5-methylcytosine (5mC), 5-hydroxymethyl-cytosine (5hmC), N6-methyladenosine (6mA), bromodeoxyuridine (BrdU), 5-fluorodeoxyuridine (FldU), 5 -iododeoxyuridine (IdU), 5- ethynyldeoxyuridine (EdU) and/or 8-oxoguanine (8oxoG).
  • a dNTP comprising a modified base when used, it may be used in place of the equivalent unmodified base in the end repair reaction. For instance, if a dCTP comprising 5mC is used in the end repair reaction, there may be no dCTP comprising an unmodified cytosine. This would ensure that dCTPs incorporated into the DNA molecule during the end repair reaction contain 5mC.
  • multiple types of dNTP comprising a modified base are used in the end repair. For example, dATP comprising 6mA and dCTP comprising 5mC can be used in the end repair reaction in place of dATP comprising unmodified adenine and dCTP comprising unmodified cytosine.
  • dNTP double-modified DNA
  • end of a synthesized region can be defined as the first unmodified adenine or unmodified cytosine after a stretch of containing 6mAs and/or 5mCs, rather than relying on the detection of solely an unmodified adenine or solely an unmodified cytosine.
  • the sequencing method used will depend on the type of modified base used in the endrepair reaction such that the specific modification can be detected. Exemplary conversion-based methods are described above alongside the base modification which they can detect. Moreover, nanopore-based sequencing can be used to detect 5-caC, 4mC, 5mC, 5hmC, 6mA, BrdU, FldU, IdU, and EdU. and single-molecule real time (SMRT) sequencing from Pacific Biosciences can be used to detect 5-caC, 4mC, 5mC, 5hmC, 6mA, and 8oxoG.
  • SMRT single-molecule real time
  • the disclosed methods use at least one type of dNTP which comprises a modified base (e.g. a methylated deoxy cytidine triphosphate, such as deoxycytidine triphosphate comprising 5- methylcytosine (5mC) and/or 5 -hydroxymethyl -cytosine (5hmC)) in the end repair reaction.
  • a modified base e.g. a methylated deoxy cytidine triphosphate, such as deoxycytidine triphosphate comprising 5- methylcytosine (5mC) and/or 5 -hydroxymethyl -cytosine (5hmC)
  • the dNTP is 5mC.
  • the methylated deoxycytidine triphosphate will be incorporated into the synthesized regions regardless of the sequence context. This will result in methylated cytosines in non-CpG positions (i.e., methylated cytosines in a CpH context), which are very rare in nature.
  • the modified base is a methylated cytosine, such as 5mC or 5hmC.
  • the modified base is other than 5mC or 5hmC.
  • a repaired region is defined as (i) the sequence between two non-modified bases spanning a modified base, wherein the bases are of the same identity to the modified bases present in the at least one type of dNTP; and/or (ii) the sequence between a non-modified base and the end of a sequence read, wherein there is no additional non-modified bases between the non-modified base and the end of the sequence read, where the non-modified bases are the same identity as the modified base present in the at least one type of dNTP.
  • a repaired region is defined as (i) the sequence between two non-methylated cytosines which span one or more methylated CpH cytosines; and/or (ii) the sequence between a methylated CpH cytosine and an end of a sequence read, wherein the methylated CpH cytosine is the CpH cytosine most distant from the end of the sequence read, or a subsequence thereof comprising one or more methylated CpH cytosines.
  • the methods comprise ligating adapters to DNA.
  • DNA molecules can be subjected to blunt-end ligation with blunt-ended adapters.
  • DNA molecules can be subjected to sticky-end ligation with sticky-ended adapters.
  • once the DNA has been end-repaired it can be subjected to blunt-end ligation with blunt-ended adapters, in cases where A-tailing is not performed, or sticky end ligation with T-tailed adapters, when A tailing is performed.
  • DNA molecules can be ligated to adapters at either one end or both ends.
  • DNA molecules can be ligated with at least partially double stranded adapter (e.g., a Y shaped or bell-shaped adapter).
  • the ligation step can take place before or after the conversion step.
  • conversion step or “conversion procedure” refers to any step or procedure that changes the base pairing specificity of one or more nucleotides.
  • the conversion step comprises contacting DNA (e.g., DNA in a sample) with a deaminase.
  • the conversion step of contacting DNA (e.g., DNA in a sample) with a deaminase provides a converted sample in which unmethylated CpGs in the DNA are converted to UpGs.
  • the ligation step is performed after the conversion step. In some embodiments, the ligation step occurs before contacting the DNA with a deaminase. In some embodiments, the ligation step occurs before selectively amplifying the DNA in the converted sample. In some embodiments, the ligation step occurs after contacting the DNA with a deaminase and before selectively amplifying the DNA in the converted sample.
  • adapters are ligated to end-repaired DNA molecules or the adapters are ligated to the DNA molecule or a plurality of DNA molecules. In some such embodiments, the ligation reaction also seals nicks present in the end-repaired DNA.
  • DNA ligase and adapters are added to ligate DNA molecules in the sample with an adapter on one or both ends, i.e. to form adapted DNA.
  • adapter refers to short nucleic acids (e.g., less than about 500, less than about 100 or less than about 50 nucleotides in length, or be 20-30, 20-40, 30-50, 30-60, 40-60, 40-70, 50-60, 50-70, 20-500, or 30-100 bases from end to end) that are typically at least partially double-stranded and can be ligated to the end of a given sample DNA molecule.
  • two adapters can be ligated to a single sample DNA molecule, with one adapter ligated to each end of the sample nucleic acid molecule.
  • the ligase used in ligation reactions can act on both single strand DNA nicks and double stranded DNA ends.
  • the ligase is T4 DNA ligase or T3 DNA ligase.
  • Adapters can include nucleic acid primer binding sites to permit amplification of a sample DNA molecule flanked by adapters at both ends, and/or a sequencing primer binding site, including primer binding sites for sequencing applications, such as various next generation sequencing (NGS) applications.
  • NGS next generation sequencing
  • Adapters can include a sequence for hybridizing to a solid support, e.g., a flow cell sequence. Adapters can also include binding sites for capture probes, such as an oligonucleotide attached to a flow cell support or the like. Adapters can also include sample indexes and/or molecular barcodes. These are typically positioned relative to amplification primer and sequencing primer binding sites, such that the sample index and/or molecular barcode is included in amplicons and sequencing reads of a given DNA molecule.
  • Adapters of the same or different sequence can be linked to the respective ends of a sample DNA molecule.
  • adapters of the same or different sequence are linked to the respective ends of the DNA molecule except that the sample index and/or molecular barcode differs in its sequence.
  • the adapter is a Y-shaped adapter in which one end is blunt ended or tailed as described herein, for joining to a nucleic acid molecule, which is also blunt ended or tailed with one or more complementary nucleotides to those in the tail of the adapter.
  • an adapter is a bell-shaped adapter that includes a blunt or tailed end for joining to a DNA molecule to be analyzed.
  • exemplary adapters include T-tailed, C- tailed or hairpin shaped adapters.
  • a hairpin shaped adaptor can comprise a complementary double stranded portion and a loop portion, where the double stranded portion can be attached (e.g. ligated) to a double-stranded polynucleotide.
  • Hairpin shaped sequencing adaptors can be attached to both ends of a polynucleotide fragment to generate a circular molecule, which can be sequenced multiple times.
  • the adapters used in the methods of the present disclosure comprise one or more known modified nucleosides, such as methylated nucleosides.
  • either or both of the adapters may comprise one or more known modified nucleosides.
  • the primer binding site(s), sequencing primer binding site(s), sample index(es) and/or molecular barcode(s), if present do not comprise the known modified nucleosides that change base pairing specificity as a result of the conversion procedure.
  • adapters may be added to the DNA or a subsample thereof.
  • Adapters can be ligated to DNA at any point in the methods herein.
  • adapters are ligated to the DNA in a sample or DNA in a converted sample prior to amplification.
  • adapters are ligated to the DNA in the sample prior to contacting the DNA with a deaminase.
  • adapters are ligated to the DNA in a sample or DNA in a converted sample prior to cutting DNA (e.g., DNA comprising an AP site) using an AP lyase.
  • adapters are ligated to the DNA of a sample or subsample thereof prior to annealing primers to the DNA for capture probe generation.
  • the adapter-ligated DNA is amplified prior to annealing primers to the DNA for capture probe generation.
  • adapters are ligated to the DNA of a sample or subsample thereof before the DNA is contacted with the capture probes.
  • the DNA to which the adapters are ligated is in the same sample or subsample as the DNA used as a template to generate capture probes.
  • the DNA to which the adapters are ligated is in a different sample or subsample, e.g., a second sample or a second subsample of a first sample, than the DNA used as a template to generate capture probes.
  • the adapters ligated to DNA captured by the capture probes are in a different sample or subsample, e.g., a second sample or a second subsample of a first sample.
  • the primers used to generate capture probes are not complementary to adapters, and the resulting capture probes therefore do not comprise adapters.
  • Adapter-ligated DNA can therefore be selectively amplified in the presence of capture probes that do not comprise adapters.
  • adapter-ligated DNA can be separated from DNA that does not comprise adapters.
  • the disclosed methods comprise analyzing DNA in a sample. In such methods, adapters may be added to the DNA. This may be done concurrently with an amplification procedure, e.g., by providing the adapters in a 5’ portion of a primer (where PCR is used, this can be referred to as library prep-PCR or LP-PCR), before, or after an amplification step.
  • adapters are added by other approaches, such as ligation.
  • first adapters are added to the 3’ ends of the nucleic acids by ligation, which may include ligation to single-stranded DNA.
  • first adapters prior to any partitioning or capturing steps, first adapters are added to the nucleic acids by ligation, which may include ligation to single-stranded DNA (e.g., to the 3’ ends thereof).
  • the capture probes can be isolated after partitioning and ligation.
  • the hypomethylated partition can be ligated with adapters and a portion of the ligated hypomethylated partition can then be used to generate the capture probes for rearrangements.
  • the adapter can be used as a priming site for second-strand synthesis, e.g., using a universal primer and a DNA polymerase.
  • a second adapter can then be ligated to at least the 3’ end of the second strand of the now double-stranded molecule.
  • the first adapter comprises an affinity tag, such as biotin, and nucleic acid ligated to the first adapter is bound to a solid support (e.g., bead), which may comprise a binding partner for the affinity tag such as streptavidin.
  • a solid support e.g., bead
  • nucleic acids are amplified.
  • the single-stranded DNA library preparation is performed in a one-step combined phosphorylation/ligation reaction, e.g., as described in Troll et al., BMC Genomics, 20: 1023 (2019), available at https://doi.org/10.1186/sl2864-019-6355-0.
  • This method called Single Reaction Single- stranded LibrarY (“SRSLY,”) can be performed without end-polishing.
  • SRSLY may be useful for converting short and fragmented DNA molecules, e.g., cfDNA fragments, into sequencing libraries while retaining native lengths and ends.
  • the SRSLY method can create sequencing libraries (e.g., Illumina sequencing libraries) from fragmented or degraded template (input) DNA.
  • template DNA is first heat denatured and then immediately cold shocked to render the template DNA molecules singlestranded.
  • the DNA can be maintained as single-stranded throughout the ligation reaction by the inclusion of a thermostable single-stranded binding protein (SSB).
  • SSB thermostable single-stranded binding protein
  • the template DNA which at this point can be single- stranded and coated with SSB, is placed in a phosphorylation/ligation dual reaction with directional dsDNA NGS adapters that contain singlestranded overhangs.
  • Both the forward and reverse sequencing adapters can share similar structures but differ in which termini is unblocked in order to facilitate proper ligations.
  • Both sequencing adapters can comprise a dsDNA portion and a single-stranded splint overhang of random nucleotides that occurs on the 3 -prime terminus of the bottom strand of the forward adapter and the 5-prime terminus of the bottom strand of the reverse adapter.
  • the forward adapter e.g., (P5) Illumina adapter
  • the reverse adapter e.g., (P7) Illumina adapter
  • the native polarity of input DNA molecules can be retained.
  • T4 Polynucleotide Kinase can be used to prepare template DNA termini for ligation by phosphorylating 5-prime termini and dephosphorylating 3-prime termini.
  • T4 PNK works on both ssDNA and dsDNA molecules and has no activity on the phosphorylation state of proteins.
  • the random nucleotides of the splint adapter can be annealed to the single-stranded template molecule.
  • the library DNA can be, e.g., purified and placed directly into standard NGS indexing PCR, compatible with both traditional single or dual index primers.
  • the adapters include different tags of sufficient numbers that the number of combinations of tags results in a low probability e.g., 95, 99 or 99.9% of two nucleic acids with the same start and stop points receiving the same combination of tags.
  • Adapters, whether bearing the same or different tags, can include the same or different primer binding sites, but preferably adapters include the same primer binding site.
  • the nucleic acids are subject to amplification.
  • the amplification can use, e.g., universal primers that recognize primer binding sites in the adapters.
  • the DNA or a sub sample or portion of the DNA is partitioned, comprising contacting the DNA with an agent that preferentially binds to nucleic acids bearing an epigenetic modification.
  • the nucleic acids are partitioned into at least two partitioned subsamples differing in the extent to which the nucleic acids bear the modification from binding to the agents. For example, if the agent has affinity for nucleic acids bearing the modification, nucleic acids overrepresented in the modification (compared with median representation in the population) preferentially bind to the agent, whereas nucleic acids underrepresented for the modification do not bind or are more easily eluted from the agent.
  • the nucleic acids can then be amplified from primers binding to the primer binding sites within the adapters. Partitioning may be performed instead before adapter attachment, in which case the adapters may comprise differential tags that include a component that identifies which partition a molecule occurred in.
  • the nucleic acids are linked at both ends to Y-shaped adapters including primer binding sites and tags.
  • the molecules are amplified.
  • the DNA molecules of the sample may be tagged with sample indexes and/or molecular barcodes (referred to generally as “tags”).
  • the DNA molecules of the sample comprise barcodes.
  • Tags can be molecules, such as nucleic acids, containing information that indicates a feature of the molecule with which the tag is associated.
  • DNA molecules can bear a sample tag or sample index (which distinguishes molecules in one sample from those in a different sample), a partition tag (which distinguishes molecules in one partition from those in a different partition) and/or a molecular tag/molecular barcode (which distinguishes different molecules from one another (in both unique and non-unique tagging scenarios)).
  • Tagging strategies can be divided into unique tagging and non-unique tagging strategies.
  • unique tagging all or substantially all of the molecules in a sample bear a different tag, so that reads can be assigned to original molecules based on tag information alone.
  • tags used in such methods are sometimes referred to as “unique tags”.
  • non-unique tagging different molecules in the same sample can bear the same tag, so that other information in addition to tag information is used to assign a sequence read to an original molecule.
  • Such information may include start and stop coordinate, coordinate to which the molecule maps, start or stop coordinate alone, etc.
  • Tags used in such methods are sometimes referred to as “non-unique tags”. Accordingly, it is not necessary to uniquely tag every molecule in a sample.
  • a tag can comprise one or a combination of barcodes.
  • barcode refers to a nucleic acid molecule having a particular nucleotide sequence, or to the nucleotide sequence, itself, depending on context.
  • a barcode can have, for example, between 10 and 100 nucleotides.
  • a collection of barcodes can have degenerate sequences or can have sequences having a certain Hamming distance, as desired for the specific purpose.
  • a molecular barcode can be comprised of one barcode or a combination of two barcodes, each attached to different ends of a molecule.
  • different sets of molecular barcodes, molecular tags, or molecular indexes can be used such that the barcodes serve as a molecular tag through their individual sequences and also serve to identify the partition and/or sample to which they correspond based the set of which they are a member.
  • barcodes can be used to allow the origin of the DNA (e.g., the subject, biological sample (e.g., samples collected at various time points), enriched DNA sample (e.g., enriched DNA comprising an epigenetic target region set or enriched DNA comprising a sequence-variable target region set), partition, or similar) to be identified, e.g., following pooling of a plurality of samples for parallel sequencing.
  • Tags comprising barcodes can be incorporated into or otherwise joined to adapters.
  • Tags can be incorporated by ligation, overlap extension PCR among other methods.
  • Tags can be used to label the individual polynucleotide population partitions so as to correlate the tag (or tags) with a specific partition.
  • tags can be used in embodiments of the disclosure that do not employ a partitioning step.
  • a single tag can be used to label a specific partition.
  • multiple different tags can be used to label a specific partition.
  • the set of tags used to label one partition can be readily differentiated for the set of tags used to label other partitions.
  • the tags may have additional functions, for example the tags can be used to index sample sources or used as unique molecular identifiers (which can be used to improve the quality of sequencing data by differentiating sequencing errors from mutations, for example as in Kinde et al., Proc Nat’l Acad Sci USA 108: 9530-9535 (2011), Kou et al., PLoS ONE, 11 : eO 146638 (2016)) or used as non-unique molecule identifiers, for example as described in US Pat. No. 9,598,731.
  • the tags may have additional functions, for example the tags can be used to index sample sources or used as nonunique molecular identifiers (which can be used to improve the quality of sequencing data by differentiating sequencing errors from mutations).
  • Tags may be incorporated into or otherwise joined to adapters by chemical synthesis, ligation (e.g., as described above, e.g. by blunt-end ligation or sticky-end ligation), or overlap extension polymerase chain reaction (PCR), among other methods. Such adapters are ultimately joined to the sample DNA molecule.
  • one or more rounds of amplification cycles may be applied to introduce sample indexes to a nucleic acid molecule using conventional nucleic acid amplification methods.
  • the amplifications may be conducted in one or more reaction mixtures (e.g., a plurality of microwells in an array).
  • Molecular barcodes and/or sample indexes may be introduced simultaneously, or in any sequential order.
  • molecular barcodes and/or sample indexes are introduced prior to and/or after any conversion procedure. In the case of molecular barcodes and/or sample indexes being introduced through amplification processes, the conversion step will occur before the molecular barcodes and/or sample indexes are introduced.
  • molecular barcodes and/or sample indexes are introduced prior to and/or after sequence capturing steps, if present, are performed. In some embodiments, only the molecular barcodes are introduced prior to probe capturing and the sample indexes are introduced after sequence capturing steps are performed. In some embodiments, both the molecular barcodes and the sample indexes are introduced prior to performing probe-based capturing steps, if present. In some embodiments, the sample indexes are introduced after sequence capturing steps are performed, if present. In some embodiments, sample indexes are incorporated through overlap extension polymerase chain reaction (PCR).
  • PCR overlap extension polymerase chain reaction
  • the tags may be located at one end or at both ends of the sample DNA molecule.
  • tags are predetermined or random or semi -random sequence oligonucleotides.
  • the tag(s) may together be less than about 500, 200, 100, 50, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 nucleotides in length.
  • tags are about 5 to 20 or 6 to 15 nucleotides in length.
  • the tags may be linked to sample DNA molecules randomly or non-randomly.
  • each sample or partition (discussed below) is uniquely tagged with a sample index or a combination of sample indexes.
  • each nucleic acid molecule of a sample or sub-sample is uniquely tagged with a molecular barcode or a combination of molecular barcodes.
  • a plurality of molecular barcodes may be used such that molecular barcodes are not necessarily unique to one another in the plurality (e.g., non-unique molecular barcodes).
  • molecular barcodes are generally attached (e.g., by ligation as part of an adapter) to individual molecules such that the combination of the molecular barcode and the sequence it may be attached to creates a unique sequence that may be individually tracked.
  • Detection of non-unique molecular barcodes in combination with endogenous sequence information typically allows for the assignment of a unique identity to a particular molecule.
  • endogenous sequence information e.g., the beginning (start) and/or end (stop) genomic location/position corresponding to the sequence of the original DNA molecule in the sample, start and stop genomic positions corresponding to the sequence of the original DNA molecule in the sample, the beginning (start) and/or end (stop) genomic location/position of the sequence read that is mapped to the reference sequence, start and stop genomic positions of the sequence read that is mapped to the reference sequence, sub-sequences of sequence reads at one or both ends, length of sequence reads, and/or length of the original DNA molecule in the sample) typically allows for the assignment of a unique identity to a particular molecule.
  • beginning region comprises the first 1, first 2, the first 5, the first 10, the first 15, the first 20, the first 25, the first 30 or at least the first 30 base positions at the 5' end of the sequencing read that align to the reference sequence.
  • end region comprises the last 1, last 2, the last 5, the last 10, the last 15, the last 20, the last 25, the last 30 or at least the last 30 base positions at the 3' end of the sequencing read that align to the reference sequence.
  • the length, or number of base pairs, of an individual sequence read are also optionally used to assign a unique identity to a given molecule.
  • fragments from a single strand of nucleic acid having been assigned a unique identity may thereby permit subsequent identification of fragments from the parent strand, and/or a complementary strand.
  • the number of different tags used can be sufficient that there is a very high likelihood (e.g., at least 99%, at least 99.9%, at least 99.99% or at least 99.999% that all DNA molecules of a particular group bear a different tag. It is to be noted that when barcodes are used as tags, and when barcodes are attached, e.g., randomly, to both ends of a molecule, the combination of barcodes, together, can constitute a tag.
  • This number is a function of the number of molecules falling into the calls.
  • the class may be all molecules mapping to the same start-stop position on a reference genome.
  • the class may be all molecules mapping across a particular genetic locus, e.g., a particular base or a particular region (e.g., up to 100 bases or a gene or an exon of a gene).
  • the number of different tags used to uniquely identify a number of molecules, z, in a class can be between any of 2*z, 3*z, 4*z, 5*z, 6*z, 7*z, 8*z, 9*z, 10*z, 11 *z, 12*z, 13*z, 14*z, 15*z, 16*z, 17*z, 18*z, 19*z, 20*z or 100*z (e.g., lower limit) and any of 100,000*z, 10,000*z, 1000*z or 100*z (e.g., upper limit).
  • molecular barcodes are introduced at an expected ratio of a set of identifiers (e.g., a combination of unique or non-unique molecular barcodes) to molecules in a sample.
  • a set of identifiers e.g., a combination of unique or non-unique molecular barcodes
  • One example format uses from about 2 to about 1,000,000 different molecular barcode sequences, or from about 5 to about 150 different molecular barcode sequences, or from about 20 to about 50 different molecular barcode sequences, ligated to both ends of a target molecule. Alternatively, from about 25 to about 1,000,000 different molecular barcode sequences may be used.
  • 20-50 x 20-50 molecular barcode sequences i.e., one of the 20-50 different molecular barcode sequences can be attached to each end of the target molecule
  • Such numbers of identifiers are typically sufficient for different molecules having the same start and stop points to have a high probability (e.g., at least 94%, 99.5%, 99.99%, or 99.999%) of receiving different combinations of identifiers.
  • about 80%, about 90%, about 95%, or about 99% of molecules have the same combinations of molecular barcodes.
  • the assignment of unique or non-unique molecular barcodes in reactions is performed using methods and systems described in, for example, U.S. Patent Application Nos. 20010053519, 20030152490, and 20110160078, and U.S. Patent Nos. 6,582,908, 7,537,898, 9,598,731, and 9,902,992, each of which is hereby incorporated by reference in its entirety.
  • different nucleic acid molecules of a sample may be identified using only endogenous sequence information (e.g., start and/or stop positions, sub-sequences of one or both ends of a sequence, and/or lengths).
  • Tags can be linked to sample nucleic acids randomly or non-randomly.
  • the tagged nucleic acids are sequenced after loading into a microwell plate.
  • the microwell plate can have 96, 384, or 1536 microwells. In some cases, they are introduced at an expected ratio of unique tags to microwells.
  • the unique tags may be loaded so that more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, 50,000, 100,000, 500,000, 1,000,000, 10,000,000, 50,000,000 or 1,000,000,000 unique tags are loaded per genome sample.
  • the unique tags may be loaded so that less than about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, 50,000, 100,000, 500,000, 1,000,000, 10,000,000, 50,000,000 or 1,000,000,000 unique tags are loaded per genome sample.
  • the average number of unique tags loaded per sample genome is less than, or greater than, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, 50,000, 100,000, 500,000, 1,000,000, 10,000,000, 50,000,000 or 1,000,000,000 unique tags per genome sample.
  • a format uses 20-50 different tags (e.g., barcodes) ligated to both ends of target nucleic acids. For example, 35 different tags (e.g., barcodes) ligated to both ends of target molecules creating 35 x 35 permutations, which equals 1225 for 35 tags. Such numbers of tags are sufficient so that different molecules having the same start and stop points have a high probability (e.g., at least 94%, 99.5%, 99.99%, 99.999%) of receiving different combinations of tags.
  • Other barcode combinations include any number between 10 and 500, e.g., about 15x15, about 35x35, about 75x75, about 100x100, about 250x250, about 500x500.
  • unique tags may be predetermined or random or semi-random sequence oligonucleotides.
  • a plurality of barcodes may be used such that barcodes are not necessarily unique to one another in the plurality.
  • barcodes may be ligated to individual molecules such that the combination of the barcode and the sequence it may be ligated to creates a unique sequence that may be individually tracked.
  • detection of non-unique barcodes in combination with sequence data of beginning (start) and end (stop) portions of sequence reads may allow assignment of a unique identity to a particular molecule.
  • the length or number of base pairs, of an individual sequence read may also be used to assign a unique identity to such a molecule.
  • fragments from a single strand of nucleic acid having been assigned a unique identity may thereby permit subsequent identification of fragments from the parent strand.
  • the method includes adding one or more internal control DNAs and forward and reverse primers for amplifying the internal control DNAs.
  • the internal control DNAs may be added before amplification using the primers that anneal upstream and downstream of the rearrangement breakpoints.
  • the forward and reverse primers for amplifying the internal control DNAs may be included with, or added at the same time as, the primers that anneal upstream and downstream of the rearrangement breakpoints.
  • the internal control DNAs may comprise or consist of sequences that do not occur in the genome of the subject, or that do not occur in the genome of the species of which the subject is a member (e.g., the human genome).
  • the predetermined threshold may be established, e.g., based on historical data or by testing the method on samples of DNA from test subjects, such as healthy volunteers. For example, amplification and detection of the one or more internal control DNAs provides confirmation that the amplification process proceeded properly, thus reducing the likelihood of a false negative.
  • the methods disclosed herein can comprise contacting DNA in a sample with a deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs.
  • This step can be referred to as, or be included in, a conversion procedure, such as any of the conversion procedures described elsewhere herein.
  • DNA in the converted sample that comprises methylated CpGs or conversion products of methylated CpGs is then selectively amplified.
  • the selectively amplified DNA is sequenced, and a level of methylation at one or more differentially methylated regions of the DNA is quantified.
  • Such embodiments may also comprise a step of end-repair prior to the sequencing.
  • the deaminase (e.g., the methyl-insensitive deaminase or the methyl-sensitive deaminase) comprises any one or more of the following deaminases or a truncated version thereof, such as any of the truncated versions disclosed in Vaisvila et al. (2023) Discovery of novel DNA cytosine deaminase activities enables a nondestructive single-enzyme methylation sequencing method for base resolution high-coverage methylome mapping of cell- free and ultra-low input DNA. bioRxiv; DOI: 10.1101/2023.06.29.547047, available at https://www.biorxiv.org/content/10. !
  • the deaminase (e.g., the methyl -insensitive deaminase or the methyl -sensitive deaminase) comprises a mutant deaminase or an alternatively truncated deaminase.
  • the mutant deaminase or an alternatively truncated comprises any one or more a mutant StsDaOl comprising the C-terminus of MGYPDa829, in which the mutant StsDaOl comprises the amino acid sequence of
  • MLPCPSELEAGLEKAKNAS SFERPGGMSGHAKLSDGTSHDLS SGGDGRNLRSDWEAPP GTTDENFHHLENQTAALMRQSGSHEAYLYLHKAEGAAYGACKYCVSAMREMLPQGS KLMVIWRNEEGAIRNRVFIGTSNDPKMSSRYKGN (SEQ ID NO: 78); an alternatively truncated MGYPDa829 with 11 amino acids at the C terminus deleted, in which the alternatively truncated MGYPDa829 comprises the amino acid sequence of MNLPEYDGKTTHGVLVLDNGTQVQLVSGNGDPRYTNYRNNGHVEQKAAIYMRENNIS NATVYHNNTNGTCGYCNTMTATFLPEGATLTVVPPKNAVANNSRAIAYVKTYTGTSN (SEQ ID NO: 79); an alternatively truncated HcDaOl with 21 amino acids at the N terminus deleted, in which the alternatively truncated HcDaOl
  • the conversion procedure used in the methods of the disclosure is one that changes the base pairing specificity of an unmodified nucleoside (e.g. cytosine), but does not change the base pairing specificity of the corresponding modified nucleoside (e.g. methylated cytosine, such as 5hmC and/or 5mC) or does not change the base pairing specificity of any modified nucleoside (e.g. modified cytosine, adenosine, guanosine and thymidine (or uracil)).
  • an unmodified nucleoside e.g. cytosine
  • the corresponding modified nucleoside e.g. methylated cytosine, such as 5hmC and/or 5mC
  • any modified nucleoside e.g. modified cytosine, adenosine, guanosine and thymidine (or uracil)
  • Random non-conversion methods can maximally affect a low percent of bases within a region, and thus the specificity of methylation change detection can be maximized (reduce false positives) by placing a threshold on percentage of bases within a region that are methylated/non- methylated. Hence, in some cases, a conversion procedure that does not involve denaturation is preferred.
  • TET2 and T4-[3GT or 5-hydroxymethylcytosine carbamoyltransferase can be used to convert 5mC and 5hmC into substrates that cannot be deaminated by a deaminase (e.g., APOBEC3A), and then a deaminase (e.g., APOBEC3A) can be used to deaminate unmodified cytosines, converting them to uracils.
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 13, which is the amino acid sequence of NsDaOl (Accession: D3A5B8; database: UniProt):
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 14, which is the amino acid sequence of SzDaOl (Accession: G2GKN7; database: UniProt):
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 17, which is the amino acid sequence of MGYPDa23 (Accession:
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 18, which is the amino acid sequence of WWTPDaO7 (Accession: tigOOOOl 818- 10- 11279730_497; database: GeneBank):
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 19, which is the amino acid sequence of PdDaOl (Accession: JH605467.1; database: GeneBank):
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 20, which is the amino acid sequence of MGYPDa25 (Accession:
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 28, which is the amino acid sequence of CsDaOl (Accession: A0A3E1NUV0; database: UniProt):
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 29, which is the amino acid sequence of MGYPDa22 (Accession:
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 31, which is the amino acid sequence of MGYPDa24 (Accession: MGYP000620945751; database: MGnify):
  • the amino acid sequence of the methyl -sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 32, which is the amino acid sequence of AaDaO2 (Accession: A0A2S8AG27; database: UniProt):
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 34, which is the amino acid sequence of PbDaOl (Accession: MCL1918637.1; database: GeneBank):
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 35, which is the amino acid sequence of BcDaO2 (Accession: KVH32961.1; database: GeneBank):
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 36, which is the amino acid sequence of LsfDaOl (Accession: UHQ21442.1; database: GeneBank): MTTAAKHFDPQLGIDIHMYVFPPVPLPVPLPTPHIGIVLDPFDYLPFLGGTVHVNGIKRAT AGTGGLNLHIPMGAYHPAFLPKLPTGPQTDDELFMGSMTVSADGDPFSKLAMPVLDCN VVGMVPPFRLRKPKKPKLSLTLPTAVNLAIPTNVNVGGPPTISLMAMAMKGLFKLLGPV FKRGGKAFKKLRQKVFGNMKPGFLKCKVLRAEPVDIRTGSVSVTHEDFVVPGRLPLAW TREYGSNNDHVGACGYGWETPADIRLELDADGSVLFHSGEGVAV
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 37, which is the amino acid sequence of SmgDaOl (Accession:
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 38, which is the amino acid sequence of DaDaOl (Accession: tr
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 39, which is the amino acid sequence of EcDaOl (Accession: WP_001289064.1; database: GeneBank):
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 40, which is the amino acid sequence of EcDaO2 (Accession: ABG02915.1; database: GeneBank):
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 41, which is the amino acid sequence of NgDaO2 (Accession: WP_003703542.1; database: GeneBank):
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 43, which is the amino acid sequence of AsDaOl (Accession: WP_005802165.1; database: GeneBank):
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 44, which is the amino acid sequence of HgmDaOl (Accession:
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 45, which is the amino acid sequence of MsDaO2 (Accession: tr
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 46, which is the amino acid sequence of XinDaOl (Accession: tr
  • the amino acid sequence of the methyl -sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 51, which is the amino acid sequence of BaDaOl (Accession: tr
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 54, which is the amino acid sequence of CrDaOl (Accession: tr
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 55, which is the amino acid sequence of MGYPDal5 (Accession:
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 56, which is the amino acid sequence of MGYPDal6 (Accession:
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 57, which is the amino acid sequence of MGYPDal7 (Accession:
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 58, which is the amino acid sequence of BaDaO2 (Accession: tr
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 59, which is the amino acid sequence of VsDaOl (Accession: tr
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 60, which is the amino acid sequence of MGYPDal 8 (Accession:
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 61, which is the amino acid sequence of MGYPDal9 (Accession: MGYP000654575191; database: MGnify): GVSIGSNPEGKSKPGITVEGAYSNSETEGVARATIGEGEIIVRDGDGDGIKAADLEAEAD AAEAEGDTARAEALRTEADREAAEDKTTTETQLANINRDPDAVVVVTSRKEEGFELYLS DTSLEKAVEGIEVTGKALGEAFRALGEELAASGALTPSELDTAKTVAKAIDEGDLDLRA LVTCSGRRGFNLWDLVVSSAHAATGCVLFDENGREIAELTPREREACVQMLSRLLEEYA RDYLVGERGDTELPASITKTAETLREMASDEVLVAGAQSLGMSVSLIRDVSMRLALGEE KY
  • PVFGVNSSVLVRDTDKELGRSWADTLGVKYGQGTGQYLTHGEAHSLMRAYEKSRGSM PSTVNMFVDRYSCSFCRDPKALPDLAQRMGIENLNLTFKDGSTAVINSGRFISK (SEQ ID NO: 61).
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 62, which is the amino acid sequence of HmDaO6 (Accession:
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 63, which is the amino acid sequence of MmgDaO2 (Accession:
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 64, which is the amino acid sequence of HgmDaO2 (Accession:
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 65, which is the amino acid sequence of CgmDaOl (Accession:
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 66, which is the amino acid sequence of FbiDaOl (Accession:
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 67, which is the amino acid sequence of PvmDaOl (Accession: WFLX011519007; database: GeneBank):
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 71, which is the amino acid sequence of RaDaOl (Accession: A0A373WC03; database: UniProt):
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 72, which is the amino acid sequence of MGYPDa624 (Accession:
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 73, which is the amino acid sequence of AvDaOl (Accession: tr
  • MAGAISGGLTLASLAVRMVHDLVRDAISDIIGKIASKVTIGVLTAGLAAPWVVQSVISDV ASWVTRLTKEITDVVTSARNLKNLLDKATTLLDDVGEKFAGMAAMALGYGSKNTDNA AKGAKHADDAADAAKGADGAVPPSKGGGDGGGTPPGKGDKDGGGGGDDPAKKSQE AQQRAAEKAKEVNTKKAYKSKTVSSDHVKTLSGWSARRPEGFQDPNIDNVLTKCDEIG HTPEPHDFKDNGVPGQYHASHAEKQLSLTAKEPYIGVSKAMCPDCQGYFSKLAQHEGR DWYVTDPNNSWIFHADGTVTKQ (SEQ ID NO: 73).
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 74, which is the amino acid sequence of CbDaOl (Accession: NLK69555.1; database: GeneBank):
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 75, which is the amino acid sequence of PfDaOl (Accession: tr
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 76, which is the amino acid sequence ofNoDaOl (Accession: WP_223985731.1; database: GeneBank):
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 77, which is the amino acid sequence of SsdA (Accession: WP_046719483.1; database: GeneBank): MSAAARVNDPIEHTGSLTGLLAGLAIGAIGAALVVGTGGLAAVAIVGASAATGAGVGQ LIGSLSCCNHQTGQIVSGSSNVYINGEPAARAHADQAKCDEHSSRPQVIAQGSSNVYING HPAARVGDRTACDAKIVVGSSNVFIGGGTETTDPINPEVPELLERGILLVGLASAFVLASP VIVIAGLVGGIAGGTVGSMGGAQLFGEGTDGQKLMAFGGALLGGGLGAKGGKWFDTR YDIKVQGVGSNLGNLKITPKGAAKVSNIAESEAALGRASQARADLPQSKELKVKTVSSN DKKTL
  • the methyl-sensitive deaminase comprises the APOBEC3A protein containing a substitution mutation at Y130, such as Y130L, Y130W, or Y130H.
  • the methyl-sensitive deaminase comprises the APOBEC3A protein containing a substitution mutation at Y132, such as Y132P or Y132H, e.g., in addition to a substitution at Y130, e.g., Y132H and either Y130V or Y130W.
  • the methyl -sensitive deaminase comprises the APOBEC3A protein containing a substitution mutation at Y130 and Y132.
  • the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 2 and contains the Y130L mutation.
  • the Y130 substitution mutation is Y130W (e.g., SEQ ID NO: 3):
  • the Y132 substitution mutation is Y132P (e.g., SEQ ID NO: 4): MEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQHRGFLHNQ AKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQEN THVRLRIFAARIYDPDPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGCPFQP WDGLDEHSQALSGRLRAILQNQGN.
  • SEQ ID NO: 4 MEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQHRGFLHNQ AKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQEN THVRLRIFAARIYDPDPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGCPFQP WDGLDE
  • the amino acid sequence of the methyl -sensitive deaminase has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 6 and contains the Y130W and Y132H.
  • the deaminase e.g., the methyl-insensitive deaminase or the methyl-sensitive deaminase
  • the conversion procedure further includes enzymatic protection of 5hmCs, such as by glucosylation of the 5hmCs (e.g., using GT) or by carbamoylation of the 5hmCs (e.g., using 5-hydroxymethylcytosine carbamoyltransferase), in the DNA prior to the deamination of unprotected modified cytosines.
  • enzymatic protection of 5hmCs such as by glucosylation of the 5hmCs (e.g., using GT) or by carbamoylation of the 5hmCs (e.g., using 5-hydroxymethylcytosine carbamoyltransferase), in the DNA prior to the deamination of unprotected modified cytosines.
  • a TET protein can be used to convert 5mC and optionally 5hmC (but not unmodified C) into substrates (e.g., 5caC) that cannot be deaminated by a deaminase, and then a deaminase (e.g., APOBEC3A) can be used to deaminate unmodified cytosines, converting them to uracils.
  • a deaminase e.g., APOBEC3A
  • Various TET enzymes may be used in the disclosed methods as appropriate.
  • the DNA is not contacted with a glucosyltransferase (such as PGT), e.g., to protect 5hmC from conversion.
  • the one or more TET enzymes comprise TETv.
  • TETv is described in US Patent 10,260,088 and its sequence is SEQ ID NO: 1 therein.
  • the one or more TET enzymes comprise TETcd.
  • TETcd is described in US Patent 10,260,088 and its sequence is SEQ ID NO: 3 therein.
  • the one or more TET enzymes comprise TET1.
  • the one or more TET enzymes comprise TET2.
  • TET2 may be expressed and used as a fragment comprising TET2 residues 1129-1480 joined to TET2 residues 1844-1936 by a linker as described, e.g., in US Patent 10,961,525.
  • the one or more TET enzymes comprise TET1 and TET2. In some embodiments, the one or more TET enzymes comprise a T1372 TET mutant, such as T1372S. In some embodiments, the one or more TET enzymes comprise a VI 900 TET mutant, such as a V1900A, V1900C, V1900G, VI 9001, or V1900P TET mutant. In some embodiments, the one or more TET enzymes comprise a VI 900 TET2 mutant, such as a V1900A, V1900C, V1900G, VI 9001, or V1900P TET2 mutant.
  • the TET enzyme comprises a mutation that increases formation of 5-caC. Exemplary mutations are set forth above.
  • a mutation that increases formation of 5-caC means that the TET enzyme having the mutation produces more 5-caC than a TET enzyme that lacks the mutation but is otherwise identical.
  • 5-caC production can be measured as described, e.g., in Liu et al., Nat Chem Biol 13: 181-187 (2017) (see Online Methods section, TET reactions in vitro subsection, “driving” conditions). Any variants and/or mutants described in Liu et al. (2017) can be used in the disclosed methods as appropriate.
  • the one or more TET enzymes comprise a TET2 enzyme comprising a T1372S mutation, such as TET2-CS-T1372S and TET2-CD-T1372S.
  • TET2 comprising a T1372S mutation is described in US Patent 10,961,525 and may be expressed and used as a fragment comprising TET2 residues 1129-1480 joined to TET2 residues 1844-1936 by a linker.
  • Position 1372 of TET2 corresponds to position 258 of SEQ ID NO: 21 (wild type TET2 catalytic domain) of US Patent 10,961,525.
  • a heterogeneous nucleic acid sample is partitioned into two or more partitions (sub-samples).
  • each partition is differentially tagged.
  • Tagged partitions can then be pooled together for collective sample prep and/or sequencing.
  • the partitioning-tagging-pooling steps can occur more than once, with each round of partitioning occurring based on a different characteristics, and tagged using differential tags that are distinguished from other partitions and partitioning means.
  • the partitioning step can occur before or after contacting the DNA (e.g., DNA in a sample) with a deaminase. In some embodiments, the partitioning step occurs before contacting the DNA with a deaminase.
  • the partitioning step occurs after contacting the DNA with a deaminase In some embodiments, the partitioning step occurs before selectively amplifying the DNA in the converted sample. In some embodiments, the partitioning step occurs after contacting the DNA with a deaminase and before selectively amplifying the DNA in the converted sample. In some embodiments, the partitioning step occurs before or after a conversion step. In some embodiments, the conversion step comprises contacting DNA (e.g., DNA in a sample) with a deaminase.
  • the conversion step of contacting DNA e.g., DNA in a sample
  • a deaminase provides a converted sample in which unmethylated CpGs in the DNA are converted to UpGs.
  • the partitioning step occurs before a conversion step. In some embodiments, the partitioning step occurs after a conversion step.
  • partitioning examples include sequence length, methylation level, nucleosome binding, sequence mismatch, immunoprecipitation, and/or proteins that bind to DNA.
  • Resulting partitions can include one or more of the following nucleic acid forms: single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), shorter DNA fragments and longer DNA fragments.
  • partitioning based on a cytosine modification (e.g., cytosine methylation) or methylation generally is performed and is optionally combined with at least one additional partitioning step, which may be based on any of the foregoing characteristics or forms of DNA.
  • a heterogeneous population of nucleic acids is partitioned into nucleic acids with one or more base modifications and without the one or more base modifications. Examples of base modifications are described elsewhere herein.
  • a heterogeneous population of nucleic acids can be partitioned into nucleic acid molecules associated with nucleosomes and nucleic acid molecules devoid of nucleosomes.
  • a heterogeneous population of nucleic acids may be partitioned into single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA).
  • ssDNA single-stranded DNA
  • dsDNA double-stranded DNA
  • a heterogeneous population of nucleic acids may be partitioned based on nucleic acid length (e.g., molecules of up to 160 bp and molecules having a length of greater than 160 bp).
  • the DNA of at least one partition is subjected to an end repair and sequencing procedure described herein. In some embodiments at least one partition is not subjected to the end repair and sequencing procedure described herein.
  • the method comprises a conversion procedure
  • corresponding sequences from the converted and non-converted partitions can be compared to identify single nucleotides that have undergone conversion and therefore identify corresponding modified nucleosides in the initial sample.
  • partition tagging comprises tagging molecules in each partition with a partition tag.
  • partition tags identify the source partition.
  • different partitions are tagged with different sets of molecular tags, e.g., comprised of a pair of barcodes.
  • each molecular barcode indicates the source partition as well as being useful to distinguish molecules within a partition. For example, a first set of 35 barcodes can be used to tag molecules in a first partition, while a second set of 35 barcodes can be used tag molecules in a second partition.
  • the molecules may be pooled for sequencing in a single run.
  • a sample tag is added to the molecules, e.g., in a step subsequent to addition of partition tags and pooling. Sample tags can facilitate pooling material generated from multiple samples for sequencing in a single sequencing run.
  • tags may be attached to molecules already partitioned based on one or more characteristics, the final tagged molecules in the library may no longer possess that characteristic. For example, while single stranded DNA molecules may be partitioned and tagged, the final tagged molecules in the library are likely to be double stranded. Similarly, while DNA may be subject to partition based on different levels of methylation, in the final library, tagged molecules derived from these molecules are likely to be unmethylated. Accordingly, the tag attached to a molecule in the library typically indicates the characteristic of the “parent molecule” from which the ultimate tagged molecule is derived, not necessarily to characteristic of the tagged molecule, itself. [0329] As an example, barcodes 1, 2, 3, 4, etc.
  • Differentially tagged partitions can be pooled prior to sequencing. Differentially tagged partitions can be separately sequenced or sequenced together concurrently, e.g., in the same flow cell of an Illumina sequencer.
  • analysis of reads can be performed on a partition-by-partition level, as well as a whole DNA population level. Tags are used to sort reads from different partitions. Analysis can include in silico analysis to determine genetic and epigenetic variation (one or more of methylation, chromatin structure, etc.) using sequence information, genomic coordinates length, coverage, and/or copy number. In some embodiments, higher coverage can correlate with higher nucleosome occupancy in genomic region while lower coverage can correlate with lower nucleosome occupancy or a nucleosome depleted region (NDR).
  • NDR nucleosome depleted region
  • Disclosed methods herein comprise analyzing DNA in a sample.
  • the disclosed methods comprise partitioning DNA.
  • different forms of DNA e.g., hypermethylated and hypom ethylated DNA
  • This approach can be used to determine, for example, whether certain sequences are hypermethylated or hypomethylated.
  • a first subsample or aliquot of a sample is subjected to steps for making capture probes as described elsewhere herein and a second subsample or aliquot of a sample is subjected to partitioning.
  • a sample or subsample or aliquot thereof is subjected to partitioning and differential tagging, followed by a capture step using capture probes for rearranged sequences and optionally additional capture probes, e.g., for sequence-variable and/or epigenetic target regions.
  • Methylation profiling can involve determining methylation patterns across different regions of the genome. For example, after partitioning molecules based on extent of methylation (e.g., relative number of methylated nucleobases per molecule) and sequencing, the sequences of molecules in the different partitions can be mapped to a reference genome. This can show regions of the genome that, compared with other regions, are more highly methylated or are less highly methylated. In this way, genomic regions, in contrast to individual molecules, may differ in their extent of methylation.
  • the partitioning comprises contacting the DNA with an agent that recognizes a modification associated with (e.g., in) the DNA.
  • the agent that recognizes the modification is an antibody.
  • the agent is immobilized on a solid support.
  • the partitioning comprises immunoprecipitation, e.g., using the antibody agent, such as an antibody, immobilized on solid support.
  • the modification is methylation
  • the partitioning comprises partitioning on the basis of methylation level.
  • the agent is a methyl binding reagent.
  • the methyl binding reagent specifically recognizes 5-methylcytosine.
  • the agent is a hydroxymethyl binding reagent.
  • the methyl binding reagent specifically recognizes 5-hydroxymethylcytosine, biotinylated 5-hydroxymethylcytosine, glucosylated 5- hydroxymethylcytosine, or sulfonylated 5-hydroxymethylcytosine.
  • the partitioning comprises partitioning on the basis of binding to a protein comprising contacting the sample comprising the DNA with a binding reagent specific for the protein.
  • binding reagent specifically binds a methylated protein, an acetylated protein, such as a methylated or acetylated histone.
  • the binding reagent specifically binds an unmethylated or unacetylated protein epitope.
  • the modification is hydroxymethylation
  • the partitioning comprises partitioning on the basis of hydroxymethylation level.
  • the agent is a hydroxymethyl binding reagent, such as an antibody.
  • the hydroxymethyl binding reagent e.g., antibody
  • the hydroxymethyl binding reagent specifically recognizes 5-hydroxymethylcytosine (5-hmC).
  • a modification such as hydroxymethylation is labeled (e.g., biotinylated, glucosylated, or sulfonated) before being contacted with an agent that recognizes the labeled form of the modification.
  • 5- hmC can be enzymatically glucosylated and then partitioned based on binding to J-binding protein 1.
  • Exemplary methods of labeling and/or partitioning 5-hmC are provided, e.g., in Song et al., Nat. Biotech. 29:68-72 (2010); Ko et al., Nature 468:839-843 (2010); and Robertson et al., Nucleic Acids Res. 39:e55 (2011).
  • the DNA may be converted to double-stranded form by complementary strand synthesis before a subsequent step. Such synthesis may use an adapter as a primer binding site, or can use random priming.
  • Partitioning nucleic acid molecules in a sample can increase a rare signal, e.g., by enriching rare nucleic acid molecules that are more prevalent in one partition of the sample. For example, a genetic variation present in hypermethylated DNA but less (or not) present in hypomethylated DNA can be more easily detected by partitioning a sample into hypermethylated and hypomethylated nucleic acid molecules.
  • Partitioning may include physically partitioning nucleic acid molecules into partitions or subsamples based on the presence or absence of one or more methylated nucleobases.
  • a sample may be partitioned into partitions or subsamples based on a characteristic that is indicative of differential gene expression or a disease state.
  • a sample may be partitioned based on a characteristic, or combination thereof that provides a difference in signal between a normal and diseased state during analysis of nucleic acids, e.g., cell free DNA (cfDNA), non- cfDNA, tumor DNA, circulating tumor DNA (ctDNA) and cell free nucleic acids (cfNA).
  • cfDNA cell free DNA
  • ctDNA circulating tumor DNA
  • cfNA cell free nucleic acids
  • hypermethylation and/or hypomethylation variable epigenetic target regions are analyzed to determine whether they show differential methylation characteristic of tumor cells or cells of a type that does not normally contribute to the DNA sample being analyzed (such as cfDNA), and/or particular immune cell types.
  • heterogeneous DNA in a sample is partitioned into two or more partitions (e.g., at least 3, 4, 5, 6 or 7 partitions).
  • each partition is differentially tagged.
  • Tagged partitions can then be pooled together for collective sample prep and/or sequencing.
  • the partitioning-tagging-pooling steps can occur more than once, with each round of partitioning occurring based on a different characteristic (examples provided herein), and tagged using differential tags that are distinguished from other partitions and partitioning means.
  • the differentially tagged partitions are separately sequenced.
  • sequence reads from differentially tagged and pooled DNA are obtained and analyzed in silico. After sequencing, analysis of reads can be performed on a partition-by-partition level, as well as a whole DNA population level. Tags are used to sort reads from different partitions. Analysis to detect genetic variants can be performed on a partition-by- partition level, as well as whole nucleic acid population level. For example, analysis can include in silico analysis to determine genetic variants, such as copy number variations (CNVs), single nucleotide variations (SNVs), insertions/deletions (indels), and/or fusions in nucleic acids in each partition. In some instances, in silico analysis can include analysis to determine epigenetic
  • I l l variation (one or more of methylation, chromatin structure, etc.).
  • Analysis can include in silico using sequence information, genomic coordinates length, coverage, and/or copy number. For example, coverage of sequence reads can be used to determine nucleosome positioning in chromatin. Tags are used to sort reads from different partitions. Higher coverage can correlate with higher nucleosome occupancy in genomic region while lower coverage can correlate with lower nucleosome occupancy or nucleosome depleted region (NDR).
  • NDR nucleosome depleted region
  • the agents used to partition populations of nucleic acids within a sample can be affinity agents, such as antibodies with the desired specificity, natural binding partners or variants thereof (Bock et al., Nat Biotech 28: 1106-1114 (2010); Song et al., Nat Biotech 29: 68-72 (2011)), or artificial peptides selected e.g., by phage display to have specificity to a given target.
  • the agent used in the partitioning is an agent that recognizes a modified nucleobase.
  • the modified nucleobase recognized by the agent is a modified cytosine, such as a methylcytosine (e.g., 5-methylcytosine).
  • the modified nucleobase recognized by the agent is a product of a procedure that affects the first nucleobase in the DNA differently from the second nucleobase in the DNA of the sample.
  • the modified nucleobase may be a “converted nucleobase,” meaning that its base pairing specificity was changed by a procedure. For example, certain procedures convert unmethylated or unmodified cytosine to dihydrouracil, or more generally, at least one modified or unmodified form of cytosine undergoes deamination, resulting in uracil (considered a modified nucleobase in the context of DNA) or a further modified form of uracil.
  • partitioning agents include antibodies, such as antibodies that recognize a modified nucleobase, which may be a modified cytosine, such as a methylcytosine (e.g., 5-methylcytosine).
  • the partitioning agent is an antibody that recognizes a modified cytosine other than 5-methylcytosine, such as 5-carboxylcytosine (5-caC).
  • Alternative partitioning agents include methyl binding domain (MBDs) and methyl binding proteins (MBPs) as described herein, including proteins such as MeCP2, MBD2, and antibodies preferentially binding to 5- methylcytosine. Where an antibody is used to immunoprecipitate methylated DNA, the methylated DNA may be recovered in single- stranded form.
  • a second strand can be synthesized.
  • Hypermethylated (and optionally intermediately methylated) subsamples may then be contacted with a methylation sensitive nuclease that does not cleave hemi-methylated DNA, such as Hpall, BstUI, or Hin6i.
  • hypomethylated (and optionally intermediately methylated) subsamples may then be contacted with a methylation dependent nuclease that cleaves hemi-methylated DNA.
  • partitioning can comprise both binary partitioning and partitioning based on degree/level of modifications.
  • methylated fragments can be partitioned by methylated DNA immunoprecipitation (MeDIP), or all methylated fragments can be partitioned from unmethylated fragments using methyl binding domain proteins (e.g., MethylMinder Methylated DNA Enrichment Kit (ThermoFisher Scientific).
  • MethylMinder Methylated DNA Enrichment Kit ThermoFisher Scientific.
  • additional partitioning may involve eluting fragments having different levels of methylation by adjusting the salt concentration in a solution with the methyl binding domain and bound fragments. As salt concentration increases, fragments having greater methylation levels are eluted.
  • Analyzing DNA may comprise detecting or quantifying DNA of interest.
  • Analyzing DNA can comprise detecting genetic variants and/or epigenetic features (e.g., DNA methylation and/or DNA fragmentation).
  • the DNA of interest is one or more differentially methylated regions of the DNA.
  • the detecting or quantifying the DNA of interest comprises quantifying and/or detecting a level of methylation at one or more differentially methylated regions of the DNA.
  • quantifying and/or detecting the level of methylation at one or more differentially methylated regions of the DNA comprises sequencing at least a portion of the amplified DNA or quantitative PCR (qPCR).
  • methylation levels can be determined using partitioning, modification-sensitive conversion such as direct detection during sequencing, methylationsensitive restriction enzyme digestion, methylation-dependent restriction enzyme digestion, or any other suitable approach.
  • different forms of DNA e.g., hypermethylated and hypomethylated DNA
  • a methylated DNA binding protein e.g., an MBD such as MBD2, MBD4, or MeCP2
  • an antibody specific for 5-methylcytosine as in MeDIP
  • a DNA fragmentation pattern can be determined based on endpoints and/or centerpoints of DNA molecules, such as cfDNA molecules.
  • the final partitions are enriched in nucleic acids having different extents of modifications (overrepresentative or underrepresentative of modifications).
  • Overrepresentation and underrepresentation can be defined by the number of modifications bom by a nucleic acid relative to the median number of modifications per strand in a population. For example, if the median number of 5-methylcytosine residues in nucleic acid in a sample is 2, a nucleic acid including more than two 5-methylcytosine residues is overrepresented in this modification and a nucleic acid with 1 or zero 5-methylcytosine residues is underrepresented.
  • the effect of affinity separation is to enrich for nucleic acids overrepresented in a modification in a bound phase and for nucleic acids underrepresented in a modification in an unbound phase (i.e. in solution).
  • the nucleic acids in the bound phase can be eluted before subsequent processing.
  • methylation When using MeDIP or Methyl Miner “Methylated DNA Enrichment Kit (ThermoFisher Scientific) various levels of methylation can be partitioned using sequential elutions. For example, a hypomethylated partition (no methylation) can be separated from a methylated partition by contacting the nucleic acid population with the MBD from the kit, which is attached to magnetic beads. The beads are used to separate out the methylated nucleic acids from the nonmethylated nucleic acids. Subsequently, one or more elution steps are performed sequentially to elute nucleic acids having different levels of methylation.
  • a first set of methylated nucleic acids can be eluted at a salt concentration of 160 mM or higher, e.g., at least 150 mM, at least 200 mM, 300 mM, 400 mM, 500 mM, 600 mM, 700 mM, 800 mM, 900 mM, 1000 mM, or 2000 mM.
  • a salt concentration 160 mM or higher, e.g., at least 150 mM, at least 200 mM, 300 mM, 400 mM, 500 mM, 600 mM, 700 mM, 800 mM, 900 mM, 1000 mM, or 2000 mM.
  • the elution and magnetic separation steps can be repeated to create various partitions such as a hypomethylated partition (enriched in nucleic acids comprising no methylation), a methylated partition (enriched in nucleic acids comprising low levels of methylation), and a hyper methylated partition (enriched in nucleic acids comprising high levels of methylation).
  • a hypomethylated partition enriched in nucleic acids comprising no methylation
  • a methylated partition enriched in nucleic acids comprising low levels of methylation
  • a hyper methylated partition enriched in nucleic acids comprising high levels of methylation
  • nucleic acids bound to an agent used for affinity separation based partitioning are subjected to a wash step.
  • the wash step washes off nucleic acids weakly bound to the affinity agent.
  • nucleic acids can be enriched in nucleic acids having the modification to an extent close to the mean or median (i.e., intermediate between nucleic acids remaining bound to the solid phase and nucleic acids not binding to the solid phase on initial contacting of the sample with the agent).
  • the affinity separation results in at least two, and sometimes three or more partitions of nucleic acids with different extents of a modification. While the partitions are still separate, the nucleic acids of at least one partition, and usually two or three (or more) partitions are linked to nucleic acid tags, usually provided as components of adapters, with the nucleic acids in different partitions receiving different tags that distinguish members of one partition from another.
  • the tags linked to nucleic acid molecules of the same partition can be the same or different from one another. But if different from one another, the tags may have part of their code in common so as to identify the molecules to which they are attached as being of a particular partition.
  • the nucleic acid molecules can be partitioned into different partitions based on the nucleic acid molecules that are bound to a specific protein or a fragment thereof and those that are not bound to that specific protein or fragment thereof.
  • Nucleic acid molecules can be partitioned based on DNA-protein binding.
  • Protein-DNA complexes can be partitioned based on a specific property of a protein. Examples of such properties include various epitopes, modifications (e.g., histone methylation or acetylation) or enzymatic activity. Examples of proteins which may bind to DNA and serve as a basis for fractionation may include, but are not limited to, protein A and protein G. Any suitable method can be used to partition the nucleic acid molecules based on protein bound regions.
  • Examples of methods used to partition nucleic acid molecules based on protein bound regions include, but are not limited to, SDS-PAGE, chromatin-immuno-precipitation (ChIP), heparin chromatography, and asymmetrical field flow fractionation (AF4).
  • ChIP chromatin-immuno-precipitation
  • AF4 asymmetrical field flow fractionation
  • the partitioning comprises contacting the DNA with a methylation sensitive restriction enzyme (MSRE) and/or a methylation dependent restriction enzyme (MDRE). Following the treatment of the DNA with a MSRE or a MDRE, the DNA may be partitioned based on size to generate hypermethylated (longest DNA molecules following MSRE treatment and shortest DNA fragments following MDRE treatment), intermediate (intermediate length DNA molecules following MSRE or MDRE treatment), and hypomethylated (shortest DNA molecules following MSRE treatment and longest DNA fragments following MDRE treatment) subsamples.
  • the partitioning is performed by contacting the nucleic acids with a methyl binding domain (“MBD”) of a methyl binding protein (“MBP”).
  • an MBD binds to 5-methylcytosine (5mC), and an MBP comprises an MBD and is referred to interchangeably herein as a methyl binding protein or a methyl binding domain protein.
  • MBD is coupled to paramagnetic beads, such as Dynabeads® M-280 Streptavidin via a biotin linker. Partitioning into fractions with different extents of methylation can be performed by eluting fractions by increasing the NaCl concentration.
  • bound DNA is eluted by contacting the antibody or MBD with a protease, such as proteinase K. This may be performed instead of or in addition to elution steps using NaCl as discussed above.
  • a protease such as proteinase K. This may be performed instead of or in addition to elution steps using NaCl as discussed above.
  • agents that recognize a modified nucleobase contemplated herein include, but are not limited to:
  • MeCP2 is a protein that preferentially binds to 5-methyl-cytosine over unmodified cytosine.
  • RPL26, PRP8 and the DNA mismatch repair protein MHS6 preferentially bind to 5- hydroxymethyl-cytosine over unmodified cytosine.
  • FOXK1, FOXK2, FOXP1, FOXP4 and FOXI3 preferably bind to 5-formyl-cytosine over unmodified cytosine (lurlaro et al., Genome Biol. 14: R119 (2013)).
  • elution is a function of the number of modifications, such as the number of methylated sites per molecule, with molecules having more methylation eluting under increased salt concentrations.
  • a series of elution buffers of increasing NaCl concentration can range from about 100 nm to about 2500 mM NaCl.
  • the process results in three (3) partitions. Molecules are contacted with a solution at a first salt concentration and comprising a molecule comprising an agent that recognizes a modified nucleobase, which molecule can be attached to a capture moiety, such as streptavidin.
  • a population of molecules will bind to the agent and a population will remain unbound.
  • the unbound population can be separated as a “hypom ethylated” population.
  • a first partition enriched in hypomethylated form of DNA is that which remains unbound at a low salt concentration, e.g., 100 mM or 160 mM.
  • a second partition enriched in intermediate methylated DNA is eluted using an intermediate salt concentration, e g., between 100 mM and 2000 mM concentration. This is also separated from the sample.
  • a third partition enriched in hypermethylated form of DNA is eluted using a high salt concentration, e.g., at least about 2000 mM.
  • a monoclonal antibody raised against 5-methylcytidine (5mC) is used to purify methylated DNA.
  • DNA is denatured, e.g., at 95°C in order to yield single-stranded DNA fragments.
  • Protein G coupled to standard or magnetic beads as well as washes following incubation with the anti-5mC antibody are used to immunoprecipitate DNA bound to the antibody.
  • DNA may then be eluted.
  • Partitions may comprise unprecipitated DNA and one or more partitions eluted from the beads.
  • the partitions of DNA are desalted and concentrated in preparation for enzymatic steps of library preparation.
  • Sequences that comprise aberrantly high copy numbers may tend to be hypermethylated.
  • the DNA contacted with capture probes specific for members of an epigenetic target region set comprising a plurality of target regions that are both type-specific differentially methylated regions and copy number variants comprises at least a portion of a hypermethylated partition.
  • the DNA from or comprising at least a portion of the hypermethylated partition may or may not be combined with DNA from or comprising at least a portion of one or more other partitions, such as an intermediate partition or a hypomethylated partition.
  • the DNA of at least one partition is subjected to an end repair and sequencing procedure described herein. In some embodiments at least one partition is not subjected to the end repair and sequencing procedure according to the methods of the disclosure described herein. In cases where the sequencing procedure comprises a conversion procedure, corresponding sequences from the converted and non-converted partitions can be compared to identify single nucleotides that have undergone conversion and therefore identify corresponding modified nucleosides in the initial sample.
  • Disclosed methods herein can comprise analyzing DNA in a sample. In some embodiments described herein, the disclosed methods comprise partitioning DNA.
  • different forms of DNA can be physically partitioned based on one or more characteristics of the DNA. This approach can be used to determine, for example, whether certain sequences are hypermethylated or hypomethylated.
  • a first subsample or aliquot of a sample is subjected to steps for making capture probes as described elsewhere herein and a second subsample or aliquot of a sample is subjected to partitioning.
  • a sample or subsample or aliquot thereof is subjected to partitioning and differential tagging, followed by a capture step using capture probes for rearranged sequences and optionally additional capture probes, e.g., for sequence-variable and/or epigenetic target regions.
  • Methylation profiling can involve determining methylation patterns across different regions of the genome. For example, after partitioning molecules based on extent of methylation (e.g., relative number of methylated nucleobases per molecule) and sequencing, the sequences of molecules in the different partitions can be mapped to a reference genome. This can show regions of the genome that, compared with other regions, are more highly methylated or are less highly methylated. In this way, genomic regions, in contrast to individual molecules, may differ in their extent of methylation.
  • extent of methylation e.g., relative number of methylated nucleobases per molecule
  • the adapters are added to the DNA to yield DNA flanked by adapters.
  • DNA flanked by adapters, as described herein, can be selectively amplified and, optionally, be subjected to methylation-preserving amplification.
  • the adapters are added to the DNA before methylation-preserving amplification, before contacting the DNA in the sample with a deaminase, and/or before selective amplification of the DNA in the converted sample.
  • the adapters are added to the DNA after methylation-preserving amplification, after contacting the DNA in the sample with a deaminase, and/or after selective amplification of the DNA in the converted sample.
  • the selective amplification of the DNA in the converted sample comprises amplifying using a uracil-intolerant DNA polymerase.
  • the selective amplification of the DNA in the converted sample comprises contacting the DNA with a uracil-DNA glycosylase (UDG) and amplifying the DNA using an AP site-intolerant DNA polymerase, a uracil-intolerant DNA polymerase, or a DNA polymerase that is an AP site-intolerant DNA polymerase and a uracil-intolerant DNA polymerase.
  • UDG uracil-DNA glycosylase
  • the contacting the DNA with a UDG converts uracils in the DNA to apyrimidinic sites (AP sites).
  • the UDG is an E. coli UDG.
  • the selective amplification of the DNA in the converted sample comprises contacting the DNA with a UDG; cutting DNA comprising AP sites using an AP lyase; and amplifying DNA that was not cut by the AP lyase using a DNA polymerase.
  • contacting the DNA with a UDG converts uracils in the DNA to AP sites.
  • the DNA polymerase is an AP-site intolerant DNA polymerase and/or a uracil- intolerant DNA polymerase.
  • DNA can be amplified by methylation-preserving amplification.
  • the methylation-preserving amplification can occur before the selective amplification of the DNA in a converted sample. In some embodiments, the methylationpreserving amplification can occur after the selective amplification of the DNA in a converted sample.
  • Amplification including methylation-preserving amplification
  • Amplification methods can involve cycles of denaturation, annealing and extension, resulting from thermocycling or can be isothermal as in transcription-mediated amplification.
  • DNA flanked by adapters added to the DNA as described herein can be amplified by PCR or other amplification methods.
  • Amplification methods of use herein, including methylation-preserving amplification can include any suitable methods, such as known to those of ordinary skill in the art.
  • amplification is primed by primers binding to primer binding sites in adapters flanking a DNA molecule to be amplified.
  • DNMT1 is used at a concentration of about 50-10000 U/mL, such as about 50-2000, about 50-5000, about 2500-7500, or about 5000- 10000 U/mL. In some embodiments, DNMT1 is used at a concentration of about 100-500, about 500-1000, about 100-1000, about 1000-1500, about 500-1500, about 600-1400, about 700-1300, about 800-1200, about 900-1100, or about 950-1050 U/mL.
  • DNMT1 is used at a concentration of about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, or about 2000 U/mL. In some embodiments, DNMT1 is used at a concentration of about 1,000 U/ml.
  • enriching methylated DNA in a sample comprises amplification, such as embodiments comprising quantitative PCR (qPCR) or digital PCR.
  • qPCR quantitative PCR
  • digital PCR digital PCR.
  • Some such embodiments comprising targeted detection of DNA sequences using qPCR or digital PCR do not comprise standard DNA library preparation steps, such as adapter ligation or tagging.
  • adapted DNA is amplified before sequencing. This may be an additional amplification step subsequent to an earlier amplification step, such as selective amplification as described elsewhere herein.
  • amplification of adapted DNA comprises RCA, e.g., as described above.
  • RCA comprises copying the circularized DNA template using a rolling circle polymerase to generate a plurality of circularized DNA templates.
  • the rolling circle polymerase is a phi29 DNA polymerase.
  • Amplification may in some cases be before one or more capture steps.
  • the ligation step occurs after the conversion step. In some embodiments, the ligation occurs before or simultaneously with amplification.
  • sequencing DNA that was amplified using RCA provides sequence reads comprising multiple copies of the sequence of an original sample molecule or converted molecule and the copies are used to determine a consensus sequence of the original sample molecule or converted molecule.
  • DNA molecules in a sample can be subjected to a capture step, in which molecules having target sequences are captured for subsequent analysis.
  • methods disclosed herein comprise a step of capturing one or more sets of target regions of DNA, such as cfDNA.
  • the capture step (also referred to herein as an “enriching” or “enrichment” step) is performed prior to a step of subjecting the end-repaired DNA molecules to sequencing, prior to a step of selectively amplifying DNA in a converted sample, prior to a step of subjecting a DNA sample to sequencing, and/or prior to a step of subjecting a DNA sample comprising a plurality of DNA molecules to sequencing. Capture may be performed using any suitable approach known in the art.
  • Target capture can involve use of a bait set comprising oligonucleotide baits (a type of probe useful herein) labeled with a capture moiety, such as biotin or the other examples noted below.
  • the probes can have sequences selected to tile across a panel of regions, such as genes.
  • Such bait sets are combined with a sample under conditions that allow hybridization of the target molecules with the baits. Then, captured molecules are isolated using the capture moiety. For example, a biotin capture moiety by bead-based streptavidin.
  • a biotin capture moiety by bead-based streptavidin.
  • Capture moieties include, without limitation, biotin, avidin, streptavidin, a nucleic acid comprising a particular nucleotide sequence, a hapten recognized by an antibody, and magnetically attractable particles.
  • the extraction moiety can be a member of a binding pair, such as biotin/ streptavidin or hapten/antibody.
  • a capture moiety that is attached to an analyte is captured by its binding pair which is attached to an isolatable moiety, such as a magnetically attractable particle or a large particle that can be sedimented through centrifugation.
  • a panel of regions targeted for enrichment can be selected such that they do not contain regions known to include the base modification used in the end repair reaction.
  • a panel of regions targeted for enrichment may be selected such that they do not contain CpH dinucleotides which are known to be naturally methylated in the subject (e.g. humans).
  • CpH dinucleotides can be identified through the use of publicly available resources (e.g. MethBank3.0: a database ofDNA methylomes across a variety of species Nucleic Acids Res 2018). Such an approach has the advantage that any detected methylated CpH dinucleotides can unambiguously be attributed to regions synthesized in the end repair.
  • capturing comprises contacting the DNA to be captured with a set of target-specific probes.
  • the set of target-specific probes may have any of the features described herein for sets of target-specific probes, including but not limited to in the embodiments set forth above and the sections relating to probes below.
  • Capturing may be performed on one or more subsamples prepared during methods disclosed herein.
  • DNA is captured from at least the first subsample or the second subsample, e.g., at least the first subsample and the second subsample.
  • the subsamples are differentially tagged (e.g., as described herein) and then pooled before undergoing capture.
  • a method described herein comprises contacting cfDNA obtained from a subject with a set of target-specific probes, wherein the set of target-specific probes is configured to capture cfDNA corresponding to the sequence-variable target region set at a greater capture yield than cfDNA corresponding to the epigenetic target region set.
  • cfDNA corresponding to the sequence-variable target region set can be beneficial to capture cfDNA corresponding to the sequence-variable target region set at a greater capture yield than cfDNA corresponding to the epigenetic target region set because a greater depth of sequencing may be necessary to analyze the sequence-variable target regions with sufficient confidence or accuracy than may be necessary to analyze the epigenetic target regions.
  • the volume of data needed to determine fragmentation patterns (e.g., to test fsor perturbation of transcription start sites or CTCF binding sites) or fragment abundance (e.g., in hypermethylated and hypomethylated partitions) is generally less than the volume of data needed to determine the presence or absence of cancer-related sequence mutations.
  • Capturing the target region sets at different yields can facilitate sequencing the target regions to different depths of sequencing in the same sequencing run (e.g., using a pooled mixture and/or in the same sequencing cell).
  • the capturing step is performed with the sequence-variable target region probe set in a first vessel and with the epigenetic target region probe set in a second vessel, or the contacting step is performed with the sequence-variable target region probe set at a first time and a first vessel and the epigenetic target region probe set at a second time before or after the first time.
  • This approach allows for preparation of separate first and second compositions comprising captured DNA corresponding to the sequence-variable target region set and captured DNA corresponding to the epigenetic target region set.
  • the compositions can be processed separately as desired (e.g., to fractionate based on methylation as described elsewhere herein) and recombined in appropriate proportions to provide material for further processing and analysis such as sequencing.
  • a captured set of DNA (e.g., cfDNA) is provided.
  • the captured set of DNA may be provided, e g., by performing a capturing step prior to a sequencing step as described herein.
  • the captured set may comprise DNA corresponding to a sequence-variable target region set, an epigenetic target region set, or a combination thereof.
  • a capture step is performed prior to a conversion step or after a conversion step.
  • an increase in the level of hypomethylation variable target regions in the second subsample can be an indicator of the presence (or recurrence, depending on the history of the subject) of cancer.
  • first and second captured sets may be provided, comprising, respectively, DNA corresponding to a sequence-variable target region set and DNA corresponding to an epigenetic target region set.
  • the first and second captured sets may be combined to provide a combined captured set.
  • the unmethylated molecules comprise thymines as a result of the conversion of methylated cytosines.
  • the uracils are in UpG dinucleotides.
  • the thymines are in TpG dinucleotides.
  • a probe e.g., a capture probe captures both unmethylated and methylated DNA molecules.
  • the intronic target region set has a footprint in the range of 30 bp- 1000 kb, e.g., 30 bp-100 bp, 100 bp-200 bp, 200 bp-500 bp, 500 bp-lkb, 1 kb-2 kb, 2 kb-5 kb, 5 kb-10 kb, 10 kb- 20 kb, 20 kb-50 kb, 50 kb-100 kb, 100-200 kb, 200-300 kb, 300-400 kb, 400-500 kb, 500-600 kb, 600-700 kb, 700-800 kb, 800-900 kb, and 900-1,000 kb.
  • 30 bp-1000 kb e.g., 30 bp-100 bp, 100 bp-200 bp, 200 bp-500 bp, 500 bp-lkb, 1 kb-2 kb,
  • Exemplary rearrangements, such as intronic translocations that can be detected using the methods described herein include but are not limited to translocations wherein at least one of the two genes involved in the translocation is a receptor tyrosine kinase.
  • Exemplary translocation products are the BCR-ABL fusion, and fusions comprising any of ALK, FGFR2, FGFR3, NTRK1, RET, or ROSE
  • the DNA that is captured comprises target regions having a typespecific epigenetic variation.
  • an epigenetic target region set consists of target regions having a type-specific epigenetic variation.
  • the typespecific epigenetic variations e.g., differential methylation or a type-specific fragmentation pattern, are likely to differentiate DNA from one or more related cell or tissue types cells from DNA from other cell or tissue types present in a sample or in a subject.
  • nucleic acids captured or enriched using a method described herein comprise captured DNA, such as one or more captured sets of DNA.
  • the captured DNA comprise target regions that are differentially methylated in different immune cell types.
  • the immune cell types comprise rare or closely related immune cell types, such as activated and naive lymphocytes or myeloid cells at different stages of differentiation.
  • a captured epigenetic target region set captured from a sample or a subsample comprises genomic regions that show no or negligible methylation signal for a particular cell or tissue type (e.g., lung tissue) when analyzing cell-free DNA (cfDNA) from healthy individuals (e.g. in blood) but exhibit detectable methylation when analyzing cfDNA from individuals with disease associated with that particular cell or tissue type (e.g., if the tissue type is lung, then the disease can be lung cancer or pulmonary disorder).
  • a particular cell or tissue type e.g., lung tissue
  • cfDNA cell-free DNA
  • the hypermethylation variable target regions show lower methylation in healthy cfDNA than in at least one other tissue type. In some embodiments, the hypermethylation variable target regions show even higher methylation in cfDNA from a diseased cell of the one or more related cell or tissue types. In some embodiments, target regions comprise hypermethylated regions with aberrantly high copy number. In some such embodiments, the target regions are hypermethylated in healthy and diseased colon tissue and have aberrantly high copy number in pre-cancerous or cancerous colon tissue. Examples of such target regions are shown in Table 2 below.
  • hypomethylation variable target regions may be hypomethylated in other cell or tissue types but not to the extent observed in the one or more cell or tissue types.
  • the hypomethylation variable target regions show higher methylation in healthy cfDNA than in at least one other tissue type.
  • proliferating or activated immune cells and/or dying cancer cells may shed more DNA into the bloodstream than immune cells in a healthy individual and/or healthy cells of the same tissue type, respectively.
  • the distribution of cell type and/or tissue of origin of cfDNA may change upon carcinogenesis.
  • the presence and/or levels of cfDNA originating from certain cell or tissue types can be an indicator of disease.
  • Variations in hypermethylation and/or hypomethylation can be an indicator of disease.
  • an increase in the level of hypermethylation variable target regions and/or hypomethylation variable target regions in a subsample following a partitioning step can be an indicator of the presence (or recurrence, depending on the history of the subject) of cancer.
  • first and second captured target region sets comprise, respectively, DNA corresponding to a sequence-variable target region set and DNA corresponding to an epigenetic target region set, for example, as described in WO 2020/160414.
  • the first and second captured sets may be combined to provide a combined captured set.
  • the sequence-variable target region set and epigenetic target region set may have any of the features described for such sets in WO 2020/160414, which is incorporated by reference herein in its entirety.
  • the epigenetic target region set comprises a hypermethylation variable target region set.
  • the epigenetic target region set comprises a hypomethylation variable target region set.
  • the epigenetic target region set comprises CTCF binding regions.
  • Probes for detecting the panel of regions can include those for detecting genomic regions of interest (hotspot regions). Information about chromatin structure can be taken into account in designing probes, and/or probes can be designed to maximize the likelihood that particular sites (e.g., KRAS codons 12 and 13) can be captured, and may be designed to optimize capture based on analysis of cfDNA coverage and fragment size variation impacted by nucleosome binding patterns and GC sequence composition. Regions used herein can also include non-hotspot regions optimized based on nucleosome positions and GC models.
  • a sequence-variable target region set used in the methods of the present disclosure comprises at least a portion of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, or 70 of the genes of Table 3 of WO 2020/160414.
  • These 35 targets are AKT1, ALK, BRAF, CCND1, CDK2A, CTNNB1, EGFR, ERBB2, ESRI, FGFR1, FGFR2, FGFR3, FOXL2, GAT A3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MED 12, MET, MYC, NFE2L2, NRAS, PDGFRA, PIK3CA, PPP2R1A, PTEN, RET, STK11, TP53, and U2AF1.
  • the capture yield of the target-binding probes specific for the sequence-variable target region set is at least 1.25-, 1.5-, 1.75-, 2-, 2.25-, 2.5-, 2.75-, 3-, 3.5-, 4-,
  • the capture yield of the target-binding probes specific for the sequence-variable target region set is 1.25- to 1.5-, 1.5- to 1.75-, 1.75- to 2-, 2- to 2.25-, 2.25- to 2.5-, 2.5- to 2.75-, 2.75- to 3-, 3- to
  • the collection of capture probes is configured to have a capture yield specific for the sequence-variable target region set is 1.25- to 1.5-, 1.5- to 1.75-, 1.75- to 2-, 2- to 2.25-, 2.25- to 2.5-, 2.5- to 2.75-, 2.75- to 3-, 3- to 3.5-,
  • the collection of probes can be configured to provide higher capture yields for the sequence-variable target region set in various ways, including concentration, different lengths and/or chemistries (e.g., that affect affinity), and combinations thereof. Affinity can be modulated by adjusting probe length and/or including nucleotide modifications as discussed below.
  • the concentration of the target-binding probes specific for the sequence-variable target region set is 1.25- to 1.5-, 1.5- to 1.75-, 1.75- to 2-, 2- to 2.25-, 2.25- to 2.5-, 2.5- to 2.75-, 2.75- to 3-, 3- to
  • concentration may refer to the average mass per volume concentration of individual probes in each set.
  • the capture probes specific for the sequencevariable target region set have modifications that increase their affinity for their targets. In some embodiments, alternatively or additionally, the capture probes specific for the epigenetic target region set have modifications that decrease their affinity for their targets.
  • the capture probes comprise a capture moiety.
  • the capture moiety may be any of the capture moieties described herein, e.g., biotin.
  • the capture probes are linked to a solid support, e.g., covalently or non-covalently such as through the interaction of a binding pair of capture moieties.
  • the solid support is a bead, such as a magnetic bead.
  • the capture probes specific for the sequence-variable target region set and/or the capture probes specific for the epigenetic target region set are a capture probe set as discussed above, e.g., probes comprising capture moieties and sequences selected to tile across a panel of regions, such as genes.
  • the capture probes are provided in a single composition.
  • the single composition may be a solution (liquid or frozen). Alternatively, it may be a lyophilizate.
  • the capture probes may be provided as a plurality of compositions, e.g., comprising a first composition comprising probes specific for the epigenetic target region set and a second composition comprising probes specific for the sequence-variable target region set.
  • probes may be mixed in appropriate proportions to provide a combined probe composition with any of the foregoing fold differences in concentration and/or capture yield. Alternatively, they may be used in separate capture procedures (e.g., with aliquots of a sample or sequentially with the same sample) to provide first and second compositions comprising captured epigenetic target regions and sequence-variable target regions, respectively.
  • the probes for the epigenetic target region set may comprise probes specific for one or more types of target regions likely to differentiate DNA from neoplastic (e.g., tumor or cancer) cells from healthy cells, e.g., non-neoplastic circulating cells. Exemplary types of such regions are discussed in detail herein, e.g., in the sections above concerning captured sets.
  • the probes for the epigenetic target region set may also comprise probes for one or more control regions, e.g., as described herein.
  • the epigenetic target region set has a footprint in the range of 100-20 Mbp, e.g., 100-200 kbp, 200-300 kbp, 300-400 kbp, 400-500 kbp, 500-600 kbp, 600-700 kbp, 700-800 kbp, 800-900 kbp, 900-1,000 kbp, 1-1.5 Mbp, 1.5-2 Mbp, 2-3 Mbp, 3-4 Mbp, 4-5 Mbp, 5-6 Mbp, 6-7 Mbp, 7-8 Mbp, 8-9 Mbp, 9-10 Mbp, or 10-20 Mbp.
  • the epigenetic target region set has a footprint of at least 20 Mbp. a. Hypermethylation variable target regions
  • the probes for the epigenetic target region set comprise probes specific for one or more hypermethylation variable target regions.
  • Hypermethylation variable target regions may also be referred to herein as hypermethylated DMRs (differentially methylated regions).
  • the hypermethylation variable target regions may be any of those set forth above.
  • the probes specific for hypermethylation variable target regions comprise probes specific for a plurality of loci listed in Table 2, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the loci listed in Table 2.
  • the probes specific for hypermethylation variable target regions comprise probes specific for a plurality of loci listed in Table 3, e g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the loci listed in Table 3.
  • the probes specific for hypermethylation variable target regions comprise probes specific for a plurality of loci listed in Table 2 or Table 3, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the loci listed in Table 2 or Table 3.
  • each locus included as a target region there may be one or more probes with a hybridization site that binds between the transcription start site and the stop codon (the last stop codon for genes that are alternatively spliced) of the gene.
  • the one or more probes bind within 300 bp of the listed position, e.g., within 200 or 100 bp.
  • a probe has a hybridization site overlapping the position listed above.
  • the probes for the epigenetic target region set comprise probes specific for one or more hypomethylation variable target regions.
  • Hypomethylation variable target regions may also be referred to herein as hypomethylated DMRs (differentially methylated regions).
  • the hypomethylation variable target regions may be any of those set forth above.
  • the probes specific for one or more hypomethylation variable target regions may include probes for regions such as repeated elements, e.g., LINE1 elements, Alu elements, centromeric tandem repeats, peri centromeric tandem repeats, and satellite DNA, and intergenic regions that are ordinarily methylated in healthy cells may show reduced methylation in tumor cells.
  • probes specific for hypomethylation variable target regions include probes specific for repeated elements and/or intergenic regions.
  • probes specific for repeated elements include probes specific for one, two, three, four, or five of LINE1 elements, Alu elements, centromeric tandem repeats, pericentromeric tandem repeats, and/or satellite DNA.
  • Exemplary probes specific for genomic regions that show cancer-associated hypomethylation include probes specific for nucleotides 8403565-8953708 and/or 151104701- 151106035 of human chromosome 1.
  • the probes specific for hypomethylation variable target regions include probes specific for regions overlapping or comprising nucleotides 8403565-8953708 and/or 151104701-151106035 of human chromosome 1.
  • the probes for the epigenetic target region set include probes specific for CTCF binding regions.
  • the probes specific for CTCF binding regions comprise probes specific for at least 10, 20, 50, 100, 200, or 500 CTCF binding regions, or 10-20, 20-50, 50-100, 100-200, 200-500, or 500-1000 CTCF binding regions, e g., such as CTCF binding regions described above or in one or more of CTCFBSDB or the Cuddapah et al., Martin et al., or Rhee et al. articles cited above.
  • the probes for the epigenetic target region set comprise at least 100 bp, at least 200 bp at least 300 bp, at least 400 bp, at least 500 bp, at least 750 bp, or at least 1000 bp upstream and downstream regions of the CTCF binding sites. d. Transcription start sites
  • the probes for the epigenetic target region set include probes specific for transcriptional start sites.
  • the probes specific for transcriptional start sites comprise probes specific for at least 10, 20, 50, 100, 200, or 500 transcriptional start sites, or 10-20, 20-50, 50-100, 100-200, 200-500, or 500-1000 transcriptional start sites, e.g., such as transcriptional start sites listed in DBTSS.
  • the probes for the epigenetic target region set comprise probes for sequences at least 100 bp, at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 750 bp, or at least 1000 bp upstream and downstream of the transcriptional start sites.
  • focal amplifications are somatic mutations, they can be detected by sequencing based on read frequency in a manner analogous to approaches for detecting certain epigenetic changes such as changes in methylation.
  • regions that may show focal amplifications in cancer can be included in the epigenetic target region set, as discussed above.
  • the probes specific for the epigenetic target region set include probes specific for focal amplifications.
  • the probes specific for focal amplifications include probes specific for one or more of AR, BRAF, CCND1, CCND2, CCNE1, CDK4, CDK6, EGFR, ERBB2, FGFR1, FGFR2, KIT, KRAS, MET, MYC, PDGFRA, PIK3CA, and RAFI.
  • the probes specific for focal amplifications include probes specific for one or more of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 of the foregoing targets. f. Control regions
  • the probes specific for the epigenetic target region set include probes specific for control methylated regions that are expected to be methylated in essentially all samples. In some embodiments, the probes specific for the epigenetic target region set include probes specific for control hypomethylated regions that are expected to be hypomethylated in essentially all samples.
  • the probes for the sequence-variable target region set may comprise probes specific for a plurality of regions known to undergo somatic mutations in cancer.
  • the probes may be specific for any sequence-variable target region set described herein. Exemplary sequence-variable target region sets are discussed in detail herein, e.g., in the sections above concerning captured sets.
  • the epigenetic target region probe set has a footprint in the range of 0.5-100 kb, e.g., 0.5-2 kb, 2-10 kb, 10-20 kb, 20-30 kb, 30-40 kb, 40-50 kb, 50-60 kb, 60-70 kb, 70-80 kb, 80-90 kb, and 90-100 kb.
  • the sequence-variable target region probe set has a footprint of at least 50 kbp, e.g., at least 100 kbp, at least 200 kbp, at least 300 kbp, or at least 400 kbp.
  • the sequence-variable target region probe set has a footprint in the range of 100-2000 kbp, e.g., 100-200 kbp, 200-300 kbp, 300-400 kbp, 400-500 kbp, 500-600 kbp, 600-700 kbp, 700-800 kbp, 800-900 kbp, 900-1,000 kbp, 1-1.5 Mbp or 1.5-2 Mbp. In some embodiments, the sequence-variable target region set has a footprint of at least 2 Mbp.
  • probes specific for the sequence-variable target region set comprise probes specific for at least a portion of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, or at 70 of the genes of Table 4.
  • probes specific for the sequencevariable target region set comprise probes specific for the at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, or 70 of the SNVs of Table 4.
  • probes specific for the sequence-variable target region set comprise probes specific for at least 1, at least 2, at least 3, at least 4, at least 5, or 6 of the fusions of Table 4. In some embodiments, probes specific for the sequence-variable target region set comprise probes specific for at least a portion of at least 1, at least 2, or 3 of the indels of Table 4. In some embodiments, probes specific for the sequencevariable target region set comprise probes specific for at least a portion of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, or 73 of the genes of Table 5.
  • probes specific for the sequence-variable target region set comprise probes specific for at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, or 73 of the SNVs of Table 5. In some embodiments, probes specific for the sequence-variable target region set comprise probes specific for at least 1 , at least 2, at least 3, at least 4, at least 5, or 6 of the fusions of Table 5.
  • probes specific for the sequence-variable target region set comprise probes specific for at least a portion of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, or 18 of the indels of Table 5.
  • probes specific for the sequence-variable target region set comprise probes specific for at least a portion of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 of the genes of Table 6.
  • the probes specific for the sequence-variable target region set comprise probes specific for target regions from at least 10, 20, 30, or 35 cancer-related genes, such as AKT1, ALK, BRAF, CCND1, CDK2A, CTNNB1, EGFR, ERBB2, ESRI, FGFR1, FGFR2, FGFR3, FOXL2, GATA3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MED12, MET, MYC, NFE2L2, NRAS, PDGFRA, PIK3CA, PPP2R1 A, PTEN, RET, STK11, TP53, and U2AFl.
  • cancer-related genes such as AKT1, ALK, BRAF, CCND1, CDK2A, CTNNB1, EGFR, ERBB2, ESRI, FGFR1, FGFR2, FGFR3, FOXL2, GATA3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2,
  • sample nucleic acids flanked by adapters with or without prior amplification can be subject to sequencing.
  • Sequencing methods include, for example, Sanger sequencing, high-throughput sequencing, pyrosequencing, sequencing-by-synthesis, long-read sequencing (also known as single-molecule sequencing or third generation sequencing), nanopore sequencing (a type of long-read sequencing), 5-letter sequencing or 6-letter sequencing, semiconductor sequencing, sequencing-by-ligation, sequencing-by-hybridization, Digital Gene Expression (Helicos), Next generation sequencing (NGS), Single Molecule Sequencing by Synthesis (SMSS) (Helicos), massively-parallel sequencing, Clonal Single Molecule Array (Solexa), shotgun sequencing, Ion Torrent, Oxford Nanopore, Roche Genia, Maxim-Gilbert sequencing, primer walking, and sequencing using PacBio, SOLiD, Ion Torrent, or Nanopore platforms. Sequencing reactions can be performed in a variety of sample processing units, which may include multiple lanes, multiple channels
  • sequencing comprises detecting and/or distinguishing unmodified and modified nucleobases.
  • long-read sequencing also referred to herein as third generation sequencing
  • third generation sequencing methods include those that can generate longer sequencing reads, such as reads in excess of 10 kilobases, as compared to short-read sequencing methods, which generally produce reads of up to about 600 bases in length.
  • long reads can improve de novo assembly, transcript isoform identification, and detection and/or mapping of structural variants.
  • long-read sequencing of native DNA or RNA molecules reduces amplification bias and preserves base modifications, such as methylation status.
  • Long- read sequencing technologies useful herein can include any suitable long-read sequencing methods, including, but not limited to, Pacific Biosciences (PacBio) single-molecule real-time (SMRT) sequencing, Oxford Nanopore Technologies (ONT) nanopore sequencing, and synthetic long-read sequencing approaches, such as linked reads, proximity ligation strategies, and optical mapping. Synthetic long-read approaches comprise assembly of short reads from the same DNA molecule to generate synthetic long reads, and may be used in conjunction with “true” long-read sequencing technologies, such as SMRT and nanopore sequencing methods.
  • Single-molecule real-time (SMRT) sequencing can facilitate direct detection of, e.g., 5- methylcytosine and 5-hydroxymethylcytosine as well as unmodified cytosine (Weirather JL, et al., “Comprehensive comparison of Pacific Biosciences and Oxford Nanopore Technologies and their applications to transcriptome analysis,” FlOOOResearch, 6:100, 2017).
  • nextgeneration sequencing methods detect augmented signals from a clonal population of amplified DNA fragments
  • SMRT sequencing captures a single DNA molecule, maintaining base modification during sequencing.
  • the error rate of raw PacBio SMRT sequencing-generated data is about 13-15%, as the signal -to-noise ratio from single DNA molecules not high.
  • this platform uses a circular DNA template by ligating hairpin adaptors to both ends of target double-stranded DNA.
  • the DNA template is sequenced multiple times to generate a continuous long read (CLR).
  • CLR can be split into multiple reads (“subreads”) by removing adapter sequences, and multiple subreads generate circular consensus sequence (“CCS”) reads with higher accuracy.
  • the average length of a CLR is >10 kb and up to 60 kb, with length depending on the polymerase lifetime. Thus, the length and accuracy of CCS reads depends on the fragment sizes.
  • PacBio sequencing has been utilized for genome (e.g., de novo assembly, detection of structural variants and haplotyping) and transcriptome (e.g., gene isoform reconstruction and novel gene/isoform discovery) studies.
  • SMRT sequencing relies on sequencing-by-synthesis, where the sequence of a circular DNA template is determined from the succession of fluorescence pulses, each resulting from the addition of one labelled nucleotide by a polymerase fixed to the bottom of a well. Base modifications do not affect the base-called sequence, but they affect the kinetics of the polymerase.
  • inter-pulse duration IPD
  • base modifications can be inferred from the comparison of a modified template to an in silico model or an unmodified template.
  • Such methods can therefore use the pulse width of a signal from sequencing bases, the interpulse duration (IPD) of bases, and the identity of the bases in order to detect a modification in a base or in a neighboring base.
  • SMRT sequencing can thus be used to detect base modifications such as 5-caC, 4mC, 5mC, 5hmC, 6mA, and 8oxoG (Gouil & Keniry Essays in Biochemistry (2019) 63 639-648).
  • the sequencing comprises SMRT sequencing.
  • the end repair may be performed using dNTPs, which comprise 5-caC, 4mC, 5mC, 5hmC, 6mA, and/or 8oxoG.
  • reaction data can include both kinetics and other behavior of the enzyme and fluctuations in current through the nanopore.
  • ratchet proteins, helicases, or motor proteins can be used to push or pull a nucleic acid molecule through a hole in a biological or synthetic membrane.
  • the kinetics of these proteins can vary depending on the sequence context of a nucleic acid on which they are acting. For example, they may slow down or pause at a modified base, and this behavior, captured as a part of the reaction data, is indicative of the presence of the modified base even where the modified base is not within the sensing portion of the nanopore.
  • Nanopore sequencing can be used to detect base modifications including 5-caC, 5mC, 5hmC, 6mA, BrdU, FldU, IdU, and EdU (see e.g., Gouil & Keniry Essays in Biochemistry (2019) 63 639-648; Kutyavin, Biochemistry (2008), 47, 51, 13666-1367; Muller et al., Nature Methods (2019), volume 16, pages 429-436; Hennion et al., Genome Biology (2020), volume 21, Article number: 125).
  • the sequencing comprises nanopore sequencing.
  • the end repair may be performed using dNTPs, which comprise 5-caC, 4mC, 5mC, 5hmC, 6mA, BrdU, FldU, IdU, and/or EdU.
  • the construct is then split to separate the sense and antisense sample strands.
  • a complementary copy strand is synthesized by DNA polymerase extension of the 3 ’-end to generate a hairpin construct with the original sample DNA strand connected to its complementary strand, lacking epigenetic modifications, via a synthetic loop.
  • Sequencing adapters are then ligated to the end. Modified cytosines are enzymatically protected. The unprotected Cs are then deaminated to uracil, which is subsequently read as thymine.
  • amplification methods may comprise uracil- and/or dihydrouracil-tolerant amplification methods, such as PCR using a uracil- and/or dihydrouracil-tolerant DNA polymerase (i.e., a DNA polymerase that can read and amplify templates comprising uracil and/or dihydrouracil bases).
  • a uracil- and/or dihydrouracil-tolerant DNA polymerase i.e., a DNA polymerase that can read and amplify templates comprising uracil and/or dihydrouracil bases.
  • the deaminated constructs are no longer fully complementary and have substantially reduced duplex stability, thus the hairpins can be readily opened and amplified by PCR.
  • the constructs can be sequenced in paired-end format whereby read 1 (Pl primed) is the original stand and read 2 (P2 primed) is the copy stand.
  • the read data is pairwise aligned so read 1 is aligned to its complementary read 2.
  • Cognate residues from both reads are computationally resolved to produce a single genetic or epigenetic letter. Pairings of cognate bases that differ from the permissible five are the result of incomplete fidelity at some stage(s) comprising sample preparation, amplification, or erroneous base calling during sequencing. As these errors occur independently to cognate bases on each strand, substitutions result in a non- permissible pair. Non-permissible pairs are masked (marked as N) within the resolved read and the read itself is retained, leading to minimal information loss and high accuracy at read-level. The resolved read is aligned to the reference genome. Genetic variants and methylation counts are produced by read-counting at base-level.
  • 5hmC has been shown to have value as a marker of biological states and disease which includes early cancer detection from cell-free DNA.
  • 5mC is disambiguated from 5hmC without compromising genetic base calling within the same sample fragment.
  • the first three steps of the workflow are identical to 5-letter sequencing described above, to generate the adapter ligated sample fragment with the synthetic copy strand.
  • Methylation at 5mC is enzymatically copied across the CpG unit to the C on the copy strand, whilst 5hmC is enzymatically protected from such a copy.
  • unmodified C, 5mC and 5hmC in each of the original CpG units are distinguished by unique 2-base combinations.
  • sequence coverage of the genome may be, for example, less than 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or 100%.
  • sequence reactions may provide for sequence coverage of, for example, at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, or 80% of the genome. Sequence coverage can be performed on, for example, at least 5, 10, 20, 70, 100, 200 or 500 different genes, or up to, for example, 5000, 2500, 1000, 500 or 100 different genes.
  • cell-free nucleic acids may be sequenced with at least, for example, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 50000, or 100,000 sequencing reactions. In other embodiments, cell-free nucleic acids may be sequenced with less than, for example, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 50000, or 100,000 sequencing reactions. Sequencing reactions may be performed sequentially or simultaneously. Subsequent data analysis may be performed on all or part of the sequencing reactions.
  • data analysis may be performed on at least, for example, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 50000, or 100,000 sequencing reactions. In other cases, data analysis may be performed on less than, for example, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 50000, or 100,000 sequencing reactions.
  • An exemplary read depth is 1000- 50000 or 1000-10000 or 1000-20000 reads per locus (base).
  • sequencing of epigenetic target regions requires a lesser depth of sequencing than sequencing of a sequence-variable target region, e.g. for analysis of mutations.
  • lesser sequencing depths may in some cases be adequate for the methods described herein.
  • sequencing DNA that was amplified using RCA provides sequence reads comprising multiple copies of the sequence of an original sample molecule or converted molecule and the copies are used to determine a consensus sequence of the original sample molecule or converted molecule.
  • the captured cfDNA corresponding to the sequence-variable target region set and the captured cfDNA corresponding to the epigenetic target region set are sequenced concurrently, e.g., in the same sequencing cell (such as the flow cell of an Illumina sequencer) and/or in the same composition, which may be a pooled composition resulting from recombining separately captured sets or a composition obtained by capturing the cfDNA corresponding to the sequence-variable target region set and the captured cfDNA corresponding to the epigenetic target region set in the same vessel.
  • the captured cfDNA corresponding to the hydroxymethylation variable target region set and the captured cfDNA corresponding to the at least one other target region set are sequenced concurrently, e.g., in the same sequencing cell (such as the flow cell of an Illumina sequencer) and/or in the same composition, which may be a pooled composition resulting from recombining separately captured sets or a composition obtained by capturing the cfDNA corresponding to the hydroxymethylation variable target region set and the captured cfDNA corresponding to the at least one other target region set in the same vessel.
  • DNA or a subsample thereof e.g., a first, second, or third subsample prepared by partitioning a sample as described herein, such as on the basis of a level of a cytosine modification, such as methylation, e.g., 5 -methylation
  • a methylation-dependent nuclease or methylation-sensitive nuclease is contacted with a methylation-dependent nuclease or methylation-sensitive nuclease.
  • the contacting can be performed using a sample that has been divided into a plurality of subsamples as disclosed herein, and/or using a sample that has been partitioned into a plurality of subsamples as disclosed herein.
  • the first subsample is the subsample with a higher level of the modification; the second subsample is the subsample with a lower level of the modification; and, when present, the third subsample has a level of the modification intermediate between the first and second subsamples.
  • methods herein comprise contacting DNA with a methylationsensitive nuclease, thereby degrading DNA comprising unmethylated sequences or sequences having low levels of methylation.
  • the methylation-sensitive nuclease is a methylation-sensitive restriction enzyme (MSRE), thereby degrading DNA comprising an unmethylated recognition site of the MSRE.
  • MSRE methylation-sensitive restriction enzyme
  • Methylation-sensitive nucleases can thus be used in methods herein comprising one or more steps that deplete unmodified or unmethylated sequences, such as those that are prevalent in cfDNA from a subject.
  • methods herein comprise contacting DNA with a methylationdependent nuclease, thereby degrading DNA comprising methylated sequences or sequences having high levels of methylation.
  • the methylation-dependent nuclease is a methylation-dependent restriction enzyme (MORE), thereby degrading DNA comprising an methylated recognition site of the MSRE.
  • MORE methylation-dependent restriction enzyme
  • Methylation-dependent nucleases can thus be used in methods herein comprising one or more steps that deplete modified or methylated sequences, such as those that are prevalent in cfDNA from a subject.
  • partitioning procedures may result in imperfect sorting of DNA molecules among the subsamples.
  • the choice of a methylation-dependent nuclease or methylation-sensitive nuclease can be made so as to degrade nonspecifically partitioned DNA.
  • the second subsample can be contacted with a methylation-dependent nuclease, such as a methylation-dependent restriction enzyme. This can degrade nonspecifically partitioned DNA in the second subsample (e.g., methylated DNA) to produce a treated second subsample.
  • the first subsample can be contacted with a methylationsensitive endonuclease, such as a methylation-sensitive restriction enzyme, thereby degrading nonspecifically partitioned DNA in the first subsample to produce a treated first subsample.
  • a methylationsensitive endonuclease such as a methylation-sensitive restriction enzyme
  • Degradation of nonspecifically partitioned DNA in either or both of the first or second subsamples is proposed as an improvement to the performance of methods that rely on accurate partitioning of DNA on the basis of a cytosine modification, e.g., to detect the presence of aberrantly modified DNA in a sample, to determine the tissue of origin of DNA, and/or to determine whether a subject has cancer.
  • such degradation may provide improved sensitivity and/or simplify downstream analyses.
  • the present disclosure provides methods of enriching methylated DNA in a sample.
  • DNA in the sample is contacted with a deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs.
  • DNA in the converted sample that comprises methylated CpGs or conversion products of methylated CpGs is then selectively amplified.
  • the methods disclosed herein further comprise sequencing the selectively amplified DNA, and analyzing at least some of the sequence data to detect the presence or absence of base modifications and/or mutations present in the DNA sample.
  • analyzing the sequence data further comprises filtering out one or more repaired regions of end-repaired DNA such that the one or more repaired regions are not used to determine the methylation status of cytosines in the DNA sample.
  • analyzing the sequence data further comprises classifying all base calls within the one or more repaired regions as not having double stranded support.
  • the method further comprises quantifying DNA damage in the DNA sample through the identification of the one or more regions of the end-repaired DNA that were synthesized during the end repair.
  • Genetic data can be used for characterizing a specific form of cancer. Cancers are often heterogeneous in both composition and staging. Genetic profile data may allow characterization of specific sub-types of cancer that may be useful in the diagnosis or treatment of that specific sub-type. This information may also provide a subject or practitioner clues regarding the prognosis of a specific type of cancer and allow either a subject or practitioner to adapt treatment options in accord with the progress of the disease. Some cancers progress, becoming more aggressive and genetically unstable. Other cancers may remain benign, inactive or dormant. The system and methods of this disclosure may be useful in determining disease progression.
  • the present methods can thus be used to generate_or profile, fingerprint or set of data that is a summation of epigenetic, and optionally genetic, information derived from different cells in a heterogeneous disease.
  • This set of data may comprise epigenetic information, copy number variation, and/or rare mutation analyses alone or in combination.
  • detecting the presence, levels, or absence of DNA sequences and/or modifications facilitates disease diagnosis or identification of appropriate treatments.
  • the presence of or a change in the levels of one or more sequences and/or modifications is indicative of the presence or absence of a disease or disorder in a subject, such as cancer or precancer, or other disorder that causes changes in nucleic acids relative to a healthy subject.
  • the methods of the disclosure may be used to characterize the heterogeneity of a condition in a subject.
  • Such methods can include, e.g., generating an aggregate profile of extracellular nucleic acids derived from the subject, wherein the aggregate profile comprises a plurality of data resulting from various nucleic acid analyses.
  • the aggregate profile comprises epigenetic and mutation analyses.
  • an aggregate profile comprises a summation of information derived from different cells in a heterogeneous disease. This summation may comprise structural variation identities and levels, copy number variation, epigenetic variation, or other mutation analyses.
  • An exemplary method for analyzing DNA comprises the following steps (e.g., in the order listed below), which is illustrated in FIG. 1A:
  • Conversion of DNA in the sample using a methyl-sensitive, CpG specific deaminase provides a converted sample in which the methylated CpGs in the DNA remain as CpGs and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs.
  • Another exemplary method for analyzing DNA comprises the following steps (e.g., in the order listed below), which is illustrated in FIG. IB:
  • Conversion of DNA in the sample using a methyl -insensitive, CpG specific deaminase provides a converted sample in which at least a portion of the methylated CpGs in the DNA are converted to TpGs, and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs.
  • Conversion of DNA in the sample using a methyl-sensitive, CpG specific deaminase provides a converted sample in which the methylated CpGs in the DNA remain as CpGs and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs.
  • Another exemplary method for analyzing DNA comprises the following steps (e.g., in the order listed below), which is illustrated in FIG. 1C:
  • an extracted DNA sample e.g., extracting DNA, such as cfDNA, from a human, such as a blood sample.
  • Conversion of DNA in the sample using a methyl -insensitive, CpG specific deaminase provides a converted sample in which at least a portion of the methylated CpGs in the DNA are converted to TpGs, and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs.
  • Conversion of DNA in the sample using a methyl -sensitive, CpG specific deaminase provides a converted sample in which the methylated CpGs in the DNA remain as CpGs and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs.
  • Another exemplary method for analyzing DNA comprises the following steps (e.g., in the order listed below), which is illustrated in FIG. ID:
  • an extracted DNA sample e.g., extracting DNA, such as cfDNA, from a human, such as a blood sample.
  • Another exemplary method for analyzing DNA comprises the following steps (e.g., in the order listed below), which is illustrated in FIG. 2:
  • an extracted DNA sample e.g., extracting DNA, such as cfDNA, from a human, such as a blood sample.
  • NGS next-generation sequencing
  • the amplified DNA can be subjected to library preparation, including attaching adapters (which may comprise barcodes) to the selectively amplified DNA molecules.
  • the methods disclosed herein allow for enrichment and optionally detection of methylated cytosines in DNA of a sample. This information has utility in a wide range of contexts, including determining the methylation status of DNA in the DNA sample and optionally in the detection of mutations in the DNA.
  • the methods presented herein may be used as part of any method that benefits from obtaining an accurate modified nucleoside profile of DNA in any DNA sample and/or accurate mutation calling of DNA in any DNA sample. This is because the methods disclosed herein allow for enrichment of methylated DNA from a sample, which can improve the efficiency of methylation analysis by reducing or avoiding subsequent amplification and sequencing of CpG sites containing unmethylated cytosines.
  • One useful exemplary application of the methods of the disclosure is using the resulting sequencing data in diagnosing and prognosing cancer or other genetic diseases or conditions.
  • methods described herein comprise identifying or predicting the presence or absence of DNA produced by a tumor (or neoplastic cells, or cancer cells), determining the probability that a test subject has a tumor or cancer, and/or characterizing a tumor, neoplastic cells or cancer as described herein.
  • the present disclosure can also be useful in determining the efficacy of a particular treatment option.
  • Successful treatment options may increase the amount of rare mutations detected in subject's blood if the treatment is successful as more cancers may die and shed DNA. In other examples, this may not occur.
  • certain treatment options may be correlated with genetic profiles of cancers over time. This correlation may be useful in selecting a therapy.
  • target regions are analyzed to determine whether they show methylation characteristics of tumor cells or cells that do not ordinarily contribute significantly to cfDNA and/or target regions are analyzed to determine whether they show methylation characteristic of tumor cells or cells that do not ordinarily contribute significantly to cfDNA.
  • successful treatment options may result in changes in levels of different immune cell types (including rare immune cell types), and/or increases in the amount of target proteins, copy number variation, rare mutations, and/or cancer-related epigenetic signatures (such as hypermethylated regions or hypom ethylated regions) detected in, e.g., a sample from a subject, such as detected in a subject's blood (such as in DNA isolated from a buffy coat sample or any other sample comprising cells, such as in a blood sample (e.g., a whole blood sample, a leukapheresis sample, or a PBMC sample) from the subject) if the treatment is successful as more cancer cells may die and shed DNA, or, e.g., if a successful treatment results in an increase or decrease in the quantity of a specific protein in the blood and an unsuccessful treatment results in no change.
  • a sample from a subject such as detected in a subject's blood (such as in DNA isolated from a buffy coat sample or any other sample comprising cells
  • the present methods can be used to monitor the likelihood of residual disease or the likelihood of recurrence of disease.
  • the present methods are used for screening for a cancer, such as a metastasis, or in a method for screening cancer, such as in a method of detecting the presence or absence of a metastasis.
  • the sample can be a sample from a subject who has or has not been previously diagnosed with cancer.
  • one or more, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more samples are collected from a subject as described herein, such as before and/or after the subject is diagnosed with a cancer.
  • the subject may or may not have cancer.
  • the subject may or may not have an early-stage cancer.
  • the subject has one or more risk factors for cancer, such as tobacco use (e.g., smoking), being overweight or obese, having a high body mass index (BMI), being of advanced age, poor nutrition, high alcohol consumption, or a family history of cancer.
  • tobacco use e.g., smoking
  • BMI body mass index
  • the subject has used tobacco, e.g., for at least 1, 5, 10, or 15 years.
  • the subject has a high BMI, e.g., a BMI of 25 or greater, 26 or greater, 27 or greater, 28 or greater, 29 or greater, or 30 or greater.
  • the subject is at least 40, 45, 50, 55, 60, 65, 70, 75, or 80 years old.
  • the subject has high alcohol consumption, e.g., at least three, four, or five drinks per day on average (where a drink is about one ounce or 30 mL of 80-proof hard liquor or the equivalent).
  • the subject has a family history of cancer, e.g., at least one, two, or three blood relatives were previously diagnosed with cancer.
  • the methods and systems disclosed herein may be used to identify customized or targeted therapies to treat a given disease or condition in patients based on the classification of a nucleic acid variant as being of somatic or germline origin.
  • the disease under consideration is a type of cancer.
  • Non-limiting examples of such cancers include biliary tract cancer, bladder cancer, transitional cell carcinoma, urothelial carcinoma, brain cancer, gliomas, astrocytomas, breast cancer, metaplastic carcinoma, cervical cancer, cervical squamous cell carcinoma, rectal cancer, colorectal carcinoma, colon cancer, hereditary nonpolyposis colorectal cancer, colorectal adenocarcinomas, gastrointestinal stromal tumors (GISTs), endometrial carcinoma, endometrial stromal sarcomas, esophageal cancer, esophageal squamous cell carcinoma, esophageal adenocarcinoma, ocular melanoma, uveal melanoma, gallbladder carcinomas, gallbladder adenocarcinoma, renal cell carcinoma, clear cell renal cell carcinoma, transitional cell carcinoma, urothelial carcinomas, Wilms tumor, leukemia, acute lymphocytic leukemia (ALL
  • the cancer is a type of cancer that is not a hematological cancer, e.g., a solid tumor cancer such as a carcinoma, adenocarcinoma, or sarcoma.
  • Type and/or stage of cancer can be detected from genetic variations including mutations, rare mutations, indels, rearrangements, copy number variations, transversions, translocations, recombinations, inversion, deletions, aneuploidy, partial aneuploidy, polyploidy, chromosomal instability, chromosomal structure alterations, gene fusions, chromosome fusions, gene truncations, gene amplification, gene duplications, chromosomal lesions, DNA lesions, abnormal changes in nucleic acid chemical modifications, abnormal changes in epigenetic patterns, such as 5mC and 5mC profiles.
  • the present methods can in some cases be used in combination with methods used to detect other gen etic/epi genetic variations, e g.
  • a method described herein comprises identifying the presence of target regions and/or DNA produced by a tumor (or neoplastic cells, or cancer cells) or by precancer cells. In some embodiments, a method described herein comprises determining the level of target regions and/or identifying the presence of DNA produced by a tumor (or neoplastic cells, or cancer cells) or by precancer cells. In some embodiments, determining the level of target regions comprises determining either an increased level or decreased level of target regions, wherein the increased or decreased level of target regions is determined by comparing the level of target regions with a threshold level/value.
  • Genetic and/or epigenetic data can also be used for characterizing a specific form of cancer. Cancers are often heterogeneous in both composition and staging. Genetic and/or epigenetic profile data may allow characterization of specific sub-types of cancer that may be important in the diagnosis or treatment of that specific sub-type. This information may also provide a subject or practitioner clues regarding the prognosis of a specific type of cancer and allow either a subject or practitioner to adapt treatment options in accord with the progress of the disease. Some cancers can progress to become more aggressive and genetically unstable. Other cancers may remain benign, inactive or dormant. The system and methods of this disclosure may be useful in determining disease progression.
  • an abnormal condition is cancer, e.g. as described herein.
  • the abnormal condition may be one resulting in a heterogeneous genomic population.
  • some tumors are known to comprise tumor cells in different stages of the cancer.
  • heterogeneity may comprise multiple foci of disease such as where one or more foci (such as one or more tumor foci) are the result of metastases that have spread from a primary site of a cancer.
  • the tissue(s) of origin can be useful for identifying organs affected by the cancer, including the primary cancer and/or metastatic tumors.
  • the present methods can also be used to quantify levels of different cell types, such as immune cell types, including rare immune cell types, such as activated lymphocytes and myeloid cells at particular stages of differentiation. Such quantification can be based on the numbers of molecules corresponding to a given cell type in a sample.
  • Sequence information obtained in the present methods may comprise sequence reads of the nucleic acids generated by a nucleic acid sequencer.
  • the nucleic acid sequencer performs pyrosequencing, singlemolecule sequencing, nanopore sequencing, semiconductor sequencing, sequencing-by- synthesis, 5-letter sequencing, 6-letter sequencing, sequencing-by -ligation or sequencing-by- hybridization on the nucleic acids to generate sequencing reads.
  • the method further comprises grouping the sequence reads into families of sequence reads, each family comprising sequence reads generated from a nucleic acid in the sample.
  • the methods comprise determining the likelihood that the subject from which the sample was obtained has cancer or precancer, or has a metastasis, that is related to changes in proportions of types of immune cells.
  • the present methods can be used to generate or profile, fingerprint or set of data that is a summation of genetic and/or epigenetic information derived from different cells in a heterogeneous disease.
  • This set of data may comprise copy number variation, epigenetic variation, and mutation analyses alone or in combination.
  • the present methods can be used to diagnose, prognose, monitor or observe cancers, or other diseases.
  • the methods herein do not involve the diagnosing, prognosing or monitoring a fetus and as such are not directed to non-invasive prenatal testing.
  • these methodologies may be employed in a pregnant subject to diagnose, prognose, monitor or observe cancers or other diseases in an unborn subject whose DNA and other polynucleotides may co-circulate with maternal molecules.
  • Non-limiting examples of other genetic-based diseases, disorders, or conditions that are optionally evaluated using the methods and systems disclosed herein include achondroplasia, alpha- 1 antitrypsin deficiency, antiphospholipid syndrome, autism, autosomal dominant polycystic kidney disease, Charcot-Mari e-Tooth (CMT), cri du chat, Crohn's disease, cystic fibrosis, Dercum disease, down syndrome, Duane syndrome, Duchenne muscular dystrophy, Factor V Leiden thrombophilia, familial hypercholesterolemia, familial mediterranean fever, fragile X syndrome, Gaucher disease, hemochromatosis, hemophilia, holoprosencephaly, Huntington's disease, Klinefelter syndrome, Marfan syndrome, myotonic dystrophy, neurofibromatosis, Noonan syndrome, osteogenesis imperfecta, Parkinson's disease, phenylketonuria, Poland anomaly, porphyria, progeria,
  • the methods can provide a measure of the extent of DNA damage through the quantification of the methylated cytosines of CpG sites, the methods disclosed herein can also be used to quantify the level of DNA damage present in the original DNA sample.
  • the method further comprises calculating a synthesis index which is a quantitative measure of the regions synthesized in the end repair.
  • the synthesis index may be on a molecule level and/or a sample level.
  • the synthesis index may be the proportion of sequencing data which corresponds to synthesized regions.
  • the method further comprises comparing the synthesis index to one or more reference values to classify the DNA sample. The classification may be whether the DNA sample derives from a subject with or without cancer.
  • the reference values may be derived from one or more control DNA samples which are known to have a specific properties, such as being derived from a subject known to have cancer, e.g. a specific type of cancer.
  • the reference values may be obtained by performing the method used to obtain the synthesis index on control samples (i.e. using the same end repair, deamination, amplification, ligation and/or sequencing methods).
  • a method described herein comprises detecting a presence or absence of DNA originating or derived from a tumor cell at a preselected timepoint following a previous cancer treatment of a subject previously diagnosed with cancer using a set of sequence information obtained as described herein.
  • the method may further comprise determining a cancer recurrence score that is indicative of the presence or absence of the DNA originating or derived from the tumor cell for the subject.
  • a cancer recurrence score may further be used to determine a cancer recurrence status.
  • the cancer recurrence status may be at risk for cancer recurrence, e.g., when the cancer recurrence score is above a predetermined threshold.
  • the cancer recurrence status may be at low or lower risk for cancer recurrence, e.g., when the cancer recurrence score is above a predetermined threshold.
  • a cancer recurrence score equal to the predetermined threshold may result in a cancer recurrence status of either at risk for cancer recurrence or at low or lower risk for cancer recurrence.
  • a cancer recurrence score is compared with a predetermined cancer recurrence threshold, and the subject is classified as a candidate for a subsequent cancer treatment when the cancer recurrence score is above the cancer recurrence threshold or not a candidate for therapy when the cancer recurrence score is below the cancer recurrence threshold.
  • a cancer recurrence score equal to the cancer recurrence threshold may result in classification as either a candidate for a subsequent cancer treatment or not a candidate for therapy.
  • the present methods can also be used to quantify levels of different cell types, such as immune cell types, including rare immune cell types, such as activated lymphocytes and myeloid cells at particular stages of differentiation.
  • Sequence information obtained in the present methods may comprise sequence reads of the nucleic acids generated by a nucleic acid sequencer.
  • the nucleic acid sequencer performs pyrosequencing, singlemolecule sequencing, nanopore sequencing, semiconductor sequencing, sequencing-by- synthesis, 5-letter sequencing, 6-letter sequencing, sequencing-by-ligation or sequencing-by- hybridization on the nucleic acids to generate sequencing reads.
  • the method further comprises grouping the sequence reads into families of sequence reads, each family comprising sequence reads generated from a nucleic acid in the sample.
  • the methods comprise determining the likelihood that the subject from which the sample was obtained has cancer, precancer, an infection, transplant rejection, or other diseases or disorder that is related to changes in proportions of types of immune cells.
  • Comparisons of immune cell identities and/or immune cell quantities/proportions between two or more samples collected from a subject at two different time points can allow for monitoring of one or more aspects of a condition in the subject over time, such as a response of the subject to a treatment, the severity of the condition (such as a cancer stage) in the subject, a recurrence of the condition (such as a cancer), and/or the subject’s risk of developing the condition (such as a cancer).
  • the methods discussed above may further comprise any compatible feature or features set forth elsewhere herein, including in the section regarding methods of determining a risk of cancer recurrence in a subject and/or classifying a subject as being a candidate for a subsequent cancer treatment.
  • a method provided herein is or comprises a method of determining a risk of cancer recurrence in a subject. In some embodiments, a method provided herein is or comprises a method of detecting the presence of absence of a metastasis in a subject. In some embodiments, a method provided herein is or comprises a method of classifying a subject as being a candidate for a subsequent cancer treatment. [0523] Any of such methods may comprise collecting a sample (such as DNA, such as DNA originating or derived from a tumor cell) from the subject diagnosed with the cancer at one or more preselected timepoints following one or more previous cancer treatments to the subject. The subject may be any of the subjects described herein.
  • the sample may comprise chromatin, cfDNA, or other cell materials.
  • the sample such as the DNA sample, may be a tissue sample.
  • the DNA may be DNA, such as cfDNA, from a blood sample (e.g., a whole blood sample, a buffy coat sample, a leukapheresis sample, or a PBMC sample).
  • the DNA may comprise DNA obtained from a tissue sample.
  • Any of such methods may comprise capturing a plurality of sets of target regions from DNA from the subject, wherein the plurality of target region sets comprises a sequence-variable target region set and an epigenetic target region set, whereby a captured set of DNA molecules is produced.
  • the capturing step may be performed according to any of the embodiments described elsewhere herein.
  • the previous cancer treatment may comprise surgery, administration of a therapeutic composition, and/or chemotherapy.
  • Any of such methods may comprise sequencing the captured DNA molecules, whereby a set of sequence information is produced.
  • the captured DNA molecules of the sequence-variable target region set may be sequenced to a greater depth of sequencing than the captured DNA molecules of the epigenetic target region set.
  • the detection of the presence or absence of DNA, such as cfDNA, originating or derived from a tumor cell may be performed according to any of the embodiments thereof described elsewhere herein.
  • Methods of determining a risk of cancer recurrence in a subject may comprise determining a cancer recurrence score that is indicative of the presence or absence, or amount, of the DNA, such as genomic regions of interest and target regions, originating or derived from the tumor cell for the subject.
  • the cancer recurrence score may further be used to determine a cancer recurrence status.
  • the cancer recurrence status may be at risk for cancer recurrence, e.g., when the cancer recurrence score is above a predetermined threshold.
  • the cancer recurrence status may be at low or lower risk for cancer recurrence, e.g., when the cancer recurrence score is above a predetermined threshold.
  • a cancer recurrence score equal to the predetermined threshold may result in a cancer recurrence status of either at risk for cancer recurrence or at low or lower risk for cancer recurrence.
  • Methods of classifying a subject as being a candidate for a subsequent cancer treatment may comprise comparing the cancer recurrence score of the subject with a predetermined cancer recurrence threshold, thereby classifying the subject as a candidate for the subsequent cancer treatment when the cancer recurrence score is above the cancer recurrence threshold or not a candidate for therapy when the cancer recurrence score is below the cancer recurrence threshold.
  • a cancer recurrence score equal to the cancer recurrence threshold may result in classification as either a candidate for a subsequent cancer treatment or not a candidate for therapy.
  • the subsequent cancer treatment comprises chemotherapy or administration of a therapeutic composition.
  • sequence-variable target region sequences are obtained, and determining the cancer recurrence score may comprise determining at least a first subscore indicative of the amount of the levels of particular immune cell types, SNVs, insertions/deletions, CNVs and/or fusions present in sequence-variable target region sequences.
  • a number of mutations in the sequence-variable target regions chosen from 1, 2, 3, 4, or 5 is sufficient for the first subscore to result in a cancer recurrence score classified as positive for cancer recurrence.
  • the number of mutations is chosen from 1, 2, or 3.
  • abnormal molecules i.e., molecules with an epigenetic state different from DNA found in a corresponding sample from a healthy subject
  • epigenetic changes associated with cancer such as with a metastasis
  • methylation of hypermethylation variable target regions and/or perturbed fragmentation of fragmentation variable target regions where “perturbed” means different from DNA found in a corresponding sample from a healthy subject.
  • a proportion of molecules corresponding to the hypermethylation variable target region set and/or fragmentation variable target region set that indicate hypermethylation in the hypermethylation variable target region set and/or abnormal fragmentation in the fragmentation variable target region set greater than or equal to a value in the range of 0.001%-10% is sufficient for the subscore to be classified as positive for cancer recurrence.
  • the range may be 0.001%-l%, 0.005%-!%, 0.01%-5%, 0.01%-2%, or 0.01%-!%.
  • any of such methods may comprise determining a fraction of tumor DNA from the fraction of molecules in the set of sequence information that indicate one or more features indicative of origination from a tumor cell.
  • a fraction of tumor DNA greater than or equal to a threshold in the range of 10 10 to 10 9 , 10 9 to 10 8 , 10 8 to 10 7 , 10 7 to I O 6 , 10 6 to 10 5 , I 0 5 to I O 4 , 10 ⁇ to I O 3 , I O 3 to I O 2 , or 10 2 to I 0 1 is sufficient for the cancer recurrence score to be classified as positive for cancer recurrence.
  • the fraction of tumor DNA greater than a threshold of at least 10' 7 is sufficient for the cancer recurrence score to be classified as positive for cancer recurrence.
  • the set of sequence information comprises sequence-variable target region sequences and epigenetic target region sequences
  • determining the cancer recurrence score comprises determining a first subscore indicative of the levels of particular immune cell types, a second subscore indicative of the amount of SNVs, insertions/deletions, CNVs and/or fusions present in sequence-variable target region sequences and a third subscore indicative of the amount of abnormal molecules in epigenetic target region sequences, and combining the first, second, and third subscores to provide the cancer recurrence score.
  • a value for the combined score in the range of -4 to 2 or -3 to 1 is sufficient for the cancer recurrence score to be classified as positive for cancer recurrence.
  • the cancer recurrence status of the subject may be at risk for cancer recurrence and/or the subject may be classified as a candidate for a subsequent cancer treatment.
  • the cancer is any one of the types of cancer described elsewhere herein, e.g., colorectal cancer.
  • the present methods can be used to monitor one or more aspects of a condition in a subject over time, such as a subject’s response to receiving a treatment for a condition (such as a response to a chemotherapeutic or immunotherapeutic), the severity of the condition (such as a cancer stage) in the subject, a recurrence of the condition (such as a cancer), and/or the subject’s risk of developing the condition (such as a cancer) and/or to monitor a subject’s health as part of a preventative health monitoring program (such as to determine whether and/or when a subject is in need of further diagnostic screening).
  • monitoring comprises analysis of at least two samples collected from a subject at at least two different time points as described herein.
  • successful treatment options may result in an increase or decrease in the levels of different immune cell types (including rare immune cell types), and/or an increase or decrease in the levels of a specific protein or proteins and/or a specific DNA sequence (e.g., of a CDR3), such as in the blood, and an unsuccessful treatment may result in no change. In other examples, this may not occur.
  • quantities of each of a plurality of cell types are determined based on sequencing and analysis (such as determination of epigenetic and/or genomic signatures) of DNA isolated from at least one sample comprising cells (such as a tissue sample or a blood sample, e.g., a whole blood sample, a huffy coat sample, a leukapheresis sample, or a PBMC sample) from a subject.
  • a tissue sample or a blood sample e.g., a whole blood sample, a huffy coat sample, a leukapheresis sample, or a PBMC sample
  • differences in levels and/or presence of particular genetic and/or epigenetic signatures in DNA isolated from blood samples from a subject can be used to quantify cell types, such as immune cell types, within the sample.
  • a comparison of the disclosed genetic and/or epigenetic signatures in DNA isolated from blood samples collected from a subject at two or more time points can be used to monitor changes in cell type quantities in the subject under different conditions (such as prior to and after a treatment), or over time (e.g., as part of a preventative health monitoring program).
  • the disclosed methods can include evaluating (such as quantifying) and/or interpreting cell types (such as immune cell types) present in one or more samples (such as a tissue sample or a blood sample, e.g., a whole blood sample, a buffy coat sample, a leukapheresis sample, or a PBMC sample) collected from a subject at one or more timepoints in comparison to a selected baseline value or reference standard (or a selected set of baseline values or reference standards).
  • samples such as a tissue sample or a blood sample, e.g., a whole blood sample, a buffy coat sample, a leukapheresis sample, or a PBMC sample
  • a baseline value or reference standard may be a quantity of cell types measured in one or more samples (such as an average quantity or range of quantities of cell types present in at least two samples) collected from the subject at one or more time points, such as prior to receiving a treatment, prior to diagnosis of a condition (such as a cancer), or as part of a preventative health monitoring program.
  • a baseline value or reference standard may be a quantity of cell types measured in one or more samples (such as an average quantity or range of quantities of cell types present in at least two samples) collected at one or more timepoints from one or more subjects that do not have the condition (such as a healthy subject that does not have a cancer), one or more subjects that responded favorably to the treatment, or one or more subjects that have not received the treatment.
  • the baseline value or reference standard utilized is a standard or profile derived from a single reference subject. In other embodiments, the baseline value or reference standard utilized is a standard or profile derived from averaged data from multiple reference subjects.
  • the reference standard in various embodiments, can be a single value, a mean, an average, a numerical mean or range of numerical means, a numerical pattern, or a graphical pattern created from the cell type quantity data derived from a single reference subject or from multiple reference subjects. Selection of the particular baseline values or reference standards, or selection of the one or more reference subjects, depends upon the use to which the methods described herein are to be put by, for example, a research scientist or a clinician (such as a physician).
  • one or more samples may be collected from a subject at two or more timepoints, to assess changes in cell types (such as changes in quantities of cell types) between the two or more timepoints.
  • a sample collected at a first time point is a tissue sample or a blood sample
  • a sample collected at a subsequent time point is a blood sample.
  • a sample collected at a first time point is a tissue sample and a sample collected at a subsequent time point (such as a second time point) is a blood sample.
  • a condition such as a cancer
  • a response of the subject to a treatment one or more characteristic of a condition (such as a cancer stage) in the subject, recurrence of a condition (such as a cancer), and/or a subject’s risk of developing a condition (such as a cancer).
  • methods are provided wherein quantities of cell types present in at least one sample (such as at least one tissue sample and/or at least one blood sample, e.g., a whole blood sample, buffy coat sample, leukapheresis sample, or PBMC sample) collected from a subject at one or more timepoints (such as prior to receiving a treatment) are compared to quantities of cell types present in at least one sample collected from the subject at one or more different time points (such as after receiving the treatment).
  • tissue sample such as at least one tissue sample and/or at least one blood sample, e.g., a whole blood sample, buffy coat sample, leukapheresis sample, or PBMC sample
  • the disclosed methods can allow for patient-specific monitoring, such that, for example, differences in cell type quantities between samples collected from the subject at different timepoints may indicate changes (such as presence or absence of a condition, response to a treatment, a prognosis, or the like) that are significant with respect to the subject but may yet fall within a normal range of a general healthy population.
  • methods are provided for monitoring one or more aspects of a condition in a subject over time, such as but not limited to, a subject’s response to receiving a treatment for a condition (such as a response to a chemotherapeutic or immunotherapeutic).
  • a condition such as a response to a chemotherapeutic or immunotherapeutic.
  • one or more samples is collected from the subject at at least 1-10, at least 1-5, at least 2-5, or at least 1, at least 2, least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, or at least 20 time points prior to the subject receiving the treatment.
  • one or more samples is collected from the subject at at least
  • Sample collection from a subject can be ongoing during and/or after treatment to monitor the subject’s response to the treatment.
  • samples are not collected from a subject prior to diagnosis of a condition (such as a cancer) or prior to receiving a treatment.
  • a condition such as a cancer
  • cell types are compared between samples taken at at least
  • Sample collection from a subject can be ongoing during and/or after treatment to monitor the subject’s response to the treatment.
  • one or more samples is collected from a subject at least once per year, such as about 1-12 times or about 2-6 times, such as about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 times per year. In other embodiments, one or more samples is collected from the subject less than once per year, such as about once every 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 months. In some embodiments, one or more samples is collected from the subject about once every 1-5 years or about once every 1-2 years, such as about every 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5 years.
  • one or more samples is collected from the subject every month, every 2 months, every 3 months, every 4 months, every 5 months, every 6 months, every 7 months, every 8 months, every 9 months, every 10 months, every 11 months, or every 12 months.
  • one or more samples is collected from the subject at least once per day, such as 1, 2, 3, 4, 5, or 6 times per day. Selection of the one or more sample collection timepoints (e.g., the frequency of sample collection), or of the number of samples to be collected at each timepoint, depends upon the use to which the methods described herein are to be put by, for example, a research scientist or a clinician (such as a physician).
  • the methods disclosed herein relate to identifying and administering customized therapies, such as customized therapies to patients.
  • determination of the levels of particular immune cell types, including rare immune cell types facilitates selection of appropriate treatment.
  • the patient or subject has a given disease, disorder or condition, e.g., any of the cancers or other conditions described elsewhere herein.
  • any cancer therapy e g., surgical therapy, radiation therapy, chemotherapy, immunotherapy, and/or the like
  • the therapy administered to a subject comprises at least one chemotherapy drug.
  • the chemotherapy drug may comprise alkylating agents (for example, but not limited to, Chlorambucil, Cyclophosphamide, Cisplatin and Carboplatin), nitrosoureas (for example, but not limited to, Carmustine and Lomustine), antimetabolites (for example, but not limited to, Fluorauracil, Methotrexate and Fludarabine), plant alkaloids and natural products (for example, but not limited to, Vincristine, Paclitaxel and Topotecan), anti- tumor antibiotics (for example, but not limited to, Bleomycin, Doxorubicin and Mitoxantrone), hormonal agents (for example, but not limited to, Prednisone, Dexamethasone, Tamoxifen and Leuprolide) and biological response modifiers (for example, but not limited to, Herceptin and Avastin, Erbitux and Rituxan).
  • alkylating agents for example, but not limited to, Chlorambucil, Cyclophospham
  • the chemotherapy administered to a subject may comprise FOLFOX or FOLFIRI.
  • a therapy may be administered to a subject that comprises at least one PARP inhibitor.
  • the therapies are PARP inhibitors, such as Olaparib (LYNPARZA®), Rucaparib (RUBRACA®), Niraparib (ZEJULA®), and Talazoparib (TALZENNA®). These may be used for treating mutations in BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L alterations, and/or for genes associated Homologous Recombination Repair (HRR).
  • HRR Homologous Recombination Repair
  • therapies include at least one immunotherapy (or an immunotherapeutic agent).
  • Immunotherapy refers generally to methods of enhancing an immune response against a given cancer type.
  • immunotherapy refers to methods of enhancing a T cell response against a tumor or cancer.
  • Therapies can function by helping the immune system destroy cancer cells.
  • certain targeted therapies may mark cancer cells for the immune system to destroy them.
  • Other targeted therapies may support the immune system to work more effectively against cancer.
  • Yet other therapies may stop cancer cells from growing, for example, by interfering with cancer cell surface markers preventing them from dividing.
  • therapies can inhibit signals that promote angiogenesis.
  • Such angiogenesis inhibitors prevent blood supply into the tumor thereby, preventing tumor growth.
  • Other targeted therapies can deliver toxic substances to the tumor. Examples include monoclonal antibodies combined with toxins, chemotherapy, or radiation.
  • Some targeted therapies induce apoptosis or deplete cancer of hormones.
  • therapy is customized based on the status of a nucleic acid variant as being of somatic or germline origin.
  • essentially any cancer therapy e.g., surgical therapy, radiation therapy, chemotherapy, immunotherapy, and/or the like
  • Customized therapies can include at least one immunotherapy (or an immunotherapeutic agent).
  • Immunotherapy refers generally to methods of enhancing an immune response against a given cancer type.
  • immunotherapy refers to methods of enhancing a T cell response against a tumor or cancer.
  • the immunotherapy or immunotherapeutic agent targets an immune checkpoint molecule.
  • Certain tumors are able to evade the immune system by co-opting an immune checkpoint pathway.
  • targeting immune checkpoints has emerged as an effective approach for countering a tumor’s ability to evade the immune system and activating anti-tumor immunity against certain cancers. Pardoll, Nature Reviews Cancer, 2012, 12:252-264.
  • the treatment comprises immunotherapies and/or immune checkpoint inhibitors (ICTS).
  • Immunotherapies are treatments with one or more agents that act to stimulate the immune system so as to kill or at least to inhibit growth of cancer cells, and preferably to reduce further growth of the cancer, reduce the size of the cancer and/or eliminate the cancer.
  • Some such agents bind to a target present on cancer cells; some bind to a target present on immune cells and not on cancer cells; some bind to a target present on both cancer cells and immune cells.
  • Such agents include, but are not limited to, checkpoint inhibitors and/or antibodies.
  • Checkpoint inhibitors are inhibitors of pathways of the immune system that maintain self-tolerance and modulate the duration and amplitude of physiological immune responses in peripheral tissues to minimize collateral tissue damage (see, e.g., Pardoll, Nature Reviews Cancer 12, 252-264 (2012)).
  • Exemplary agents include antibodies against any of PD-1, PD-2, PD-L1, PD-L2, CTLA-4, 0X40, B7.1, B7He, LAG3, CD137, KIR, CCR5, CD27, CD40, or CD47.
  • Other exemplary agents include proinflammatory cytokines, such as IL-ip, IL-6, and TNF-a.
  • Other exemplary agents are T-cells activated against a tumor, such as T-cells activated by expressing a chimeric antigen targeting a tumor antigen recognized by the T-cell.
  • anti-PD-1 or anti-PD-Ll therapies comprise pembrolizumab (KEYTRUDA®), nivolumab (OPDIVO®), and cemiplimab (LIBTAYO®), atezolizumab (TECENTRIQ®), durvalumab (INFINZI®), and avelumab (BAVENCIO®). These therapies may be used to treat patients identified as having high microsatehite instability (MSI) status or high tumor mutational burden (TMB).
  • MSI microsatehite instability
  • TMB tumor mutational burden
  • the immune checkpoint molecule is an inhibitory molecule that reduces a signal involved in the T cell response to antigen.
  • CTLA4 is expressed on T cells and plays a role in downregulating T cell activation by binding to CD80 (aka B7.1) or CD86 (aka B7.2) on antigen presenting cells.
  • PD-1 is another inhibitory checkpoint molecule that is expressed on T cells. PD-1 limits the activity of T cells in peripheral tissues during an inflammatory response.
  • the ligand for PD-1 (PD-L1 or PD-L2) is commonly upregulated on the surface of many different tumors, resulting in the downregulation of antitumor immune responses in the tumor microenvironment.
  • the inhibitory immune checkpoint molecule is CTLA4 or PD-1.
  • the inhibitory immune checkpoint molecule is a ligand for PD-1, such as PD-L1 or PD-L2.
  • the inhibitory immune checkpoint molecule is a ligand for CTLA4, such as CD80 or CD86.
  • the inhibitory immune checkpoint molecule is lymphocyte activation gene 3 (LAG3), killer cell immunoglobulin like receptor (KIR), T cell membrane protein 3 (TTM3), gal ectin 9 (GAL9), or adenosine A2a receptor (A2aR).
  • the immunotherapy or immunotherapeutic agent is an antagonist of an inhibitory immune checkpoint molecule.
  • the inhibitory immune checkpoint molecule is PD-1.
  • the inhibitory immune checkpoint molecule is PD-L1.
  • the antagonist of the inhibitory immune checkpoint molecule is an antibody (e.g., a monoclonal antibody).
  • the antibody or monoclonal antibody is an anti- CTLA4, anti-PD-1, anti-PD-Ll, or anti-PD-L2 antibody.
  • the antibody is a monoclonal anti-PD-1 antibody.
  • the antibody is a monoclonal anti-PD- Ll antibody.
  • the monoclonal antibody is a combination of an anti- CTLA4 antibody and an anti-PD-1 antibody, an anti-CTLA4 antibody and an anti-PD-Ll antibody, or an anti-PD-Ll antibody and an anti-PD-1 antibody.
  • the anti-PD-1 antibody is one or more of pembrolizumab (Keytruda®) or nivolumab (Opdivo®).
  • the anti-CTLA4 antibody is ipilimumab (Yervoy®).
  • the anti-PD-Ll antibody is one or more of atezolizumab (Tecentriq®), avelumab (Bavencio®), or durvalumab (Imfinzi®).
  • the immunotherapy or immunotherapeutic agent is an antagonist (e.g., antibody) against CD80, CD86, LAG3, KIR, TIM3, GAL9, or A2aR.
  • the antagonist is a soluble version of the inhibitory immune checkpoint molecule, such as a soluble fusion protein comprising the extracellular domain of the inhibitory immune checkpoint molecule and an Fc domain of an antibody.
  • the soluble fusion protein comprises the extracellular domain of CTLA4, PD-1, PD-L1, or PD-L2.
  • the soluble fusion protein comprises the extracellular domain of CD80, CD86, LAG3, KIR, TIM3, GAL9, or A2aR.
  • the soluble fusion protein comprises the extracellular domain of PD-L2 or LAG3.
  • the therapies target mutated forms of the EGFR protein.
  • Such therapies can include osimertinib (TAGRISSO®), erlotinib (TARCEVA®), and gefmitib (IRESSA®).
  • Therapies can include one or more of treatments for target therapies, including abemaciclib (VERZENIO®), abiraterone acetate (ZYTIGA®), acalabrutinib (CALQUENCE®), adagrasib (KRAZATI®), ado-trastuzumab emtansine (KADCYLA®), afatinib dimaleate (GILOTRIF®), alectinib (ALCENSA®), alemtuzumab (CAMPATH®), alitretinoin (PANRETIN®), alpelisib (PIQRAY®), amivantamab- vmjw (RYBREVANT®), anastrozole (ARIMIDEX®), apalutamide (ERLEADA®), asciminib hydrochloride (SCEMBLIX®), atezolizumab (TECENTRIQ®), avapritinib (AYVAKIT®), avelumab
  • Table 7 provides an exemplary list of drugs used to treat cancers with mutations observed in target genes associated with certain cancer types.
  • the subject has a cancer of a type listed in Table 7 including a mutation in one or more target genes listed in Table 7 for that cancer type, and the therapy administered to the subject comprises the drug listed in Table 7 for that cancer type and mutation.
  • the methods described herein can be used to treat patients by (i) detecting one or more mutations in the one or more target genes listed in Table 7; and (ii) administering the corresponding one or more drugs listed in Table 7.
  • these therapies may be used alone or in combination with other therapies to treat a disease.
  • the immune checkpoint molecule is a co-stimulatory molecule that amplifies a signal involved in a T cell response to an antigen.
  • CD28 is a costimulatory receptor expressed on T cells.
  • CD80 aka B7.1
  • CD86 aka B7.2
  • CTLA4 is able to counteract or regulate the co-stimulatory signaling mediated by CD28.
  • the immune checkpoint molecule is a co- stimulatory molecule selected from CD28, inducible T cell co-stimulator (ICOS), CD137, 0X40, or CD27.
  • the immune checkpoint molecule is a ligand of a co-stimulatory molecule, including, for example, CD80, CD86, B7RP1, B7-H3, B7-H4, CD137L, OX40L, or CD70.
  • the immunotherapy or immunotherapeutic agent is an agonist of a co-stimulatory checkpoint molecule.
  • the agonist of the co-stimulatory checkpoint molecule is an agonist antibody and preferably is a monoclonal antibody.
  • the agonist antibody or monoclonal antibody is an anti-CD28 antibody.
  • the agonist antibody or monoclonal antibody is an anti-ICOS, anti-CD137, anti -0X40, or anti-CD27 antibody.
  • the agonist antibody or monoclonal antibody is an anti-CD80, anti-CD86, anti-B7RPl, anti-B7-H3, anti-B7-H4, anti-CD137L, anti-OX40L, or anti-CD70 antibody.
  • the biomarker may include an epigenetic signature, such as a methylation state, methylation score and/or DNA fragmentation pattem/score.
  • the epigenetic signature can be determined for one or more regions that include, but not limited to, transcription start sites, promoter regions, CTCF binding regions and regulatory protein binding regions.
  • the epigenetic signature is determined for one or more regions that include, but not limited to, transcription start sites, promoter regions, intergenic regions and/or intronic regions that are associated with at least one or more genes listed in Table 7.
  • Such treatments may include small-molecule drugs or monoclonal antibodies.
  • the methods may also improve biomarker testing in individuals suffering from disease and help determine if the individual is a candidate for a certain drug or combination of drugs based on the presence or absence of the biomarker. Additionally, the methods can improve identification of mutations that contribute to the development of resistance to targeted therapy. Consequently, the analysis techniques may reduce unnecessary or untimely therapeutic interventions, patient suffering, and patient mortality.
  • the status of a nucleic acid variant from a sample from a subject as being of somatic or germline origin may be compared with a database of comparator results from a reference population to identify customized or targeted therapies for that subject.
  • the reference population includes patients with the same cancer or disease type as the subject and/or patients who are receiving, or who have received, the same therapy as the subject.
  • a customized or targeted therapy (or therapies) may be identified when the nucleic variant and the comparator results satisfy certain classification criteria (e.g., are a substantial or an approximate match).
  • the customized therapies described herein are typically administered parenterally (e.g., intravenously or subcutaneously).
  • Pharmaceutical compositions containing an immunotherapeutic agent are typically administered intravenously.
  • Certain therapeutic agents are administered orally.
  • customized therapies e.g., immunotherapeutic agents, etc.
  • therapy is customized based on the status of a nucleic acid variant as being of somatic or germline origin.
  • determination of the levels of particular cell types e.g., immune cell types, including rare immune cell types, facilitates selection of appropriate treatment.
  • the present methods can be used to diagnose the presence of a condition, e.g., cancer or precancer, in a subject, to characterize a condition (such as to determine a cancer stage or heterogeneity of a cancer), to monitor a subject’s response to receiving a treatment for a condition (such as a response to a chemotherapeutic or immunotherapeutic), assess prognosis of a subject (such as to predict a survival outcome in a subject having a cancer), to determine a subject’s risk of developing a condition, to predict a subsequent course of a condition in a subject, to determine metastasis or recurrence of a cancer in a subject (or a risk of cancer metastasis or recurrence), and/or to monitor a subject’s health as part of a preventative health monitoring program (such as to determine whether and/or when a subject is in need of further diagnostic screening).
  • a condition e.g., cancer or precancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The disclosure relates to enrichment and analysis of methylated DNA through CpG-specific deamination. Specifically, the disclosure provides methods of enriching methylated DNA in a sample by contacting the DNA with a deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs, and selectively amplifying DNA in the converted sample that comprises methylated CpGs or conversion products of methylated CpGs.

Description

METHODS FOR METHYLATION ENRICHMENT USING CpG-SPECIFIC DEAMINATION
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority of US Provisional Patent Application No. 63/570,986, filed March 28, 2024, US Provisional Patent Application No. 63/667,401, filed July 3, 2024, US Provisional Patent Application No. 63/669,078, filed July 9, 2024, US Provisional Patent Application No. 63/669,082, filed July 9, 2024, US Provisional Patent Application No. 63/670,034, filed July 11, 2024, and US Provisional Patent Application No. 63/670,035, filed July 11, 2024, each of which is incorporated by reference herein in its entirety for all purposes.
FIELD OF THE INVENTION
[0002] The disclosure relates to methods for enrichment of methylated DNA using CpG-specific deamination, e g., including differential processing of the uracil product of CpG-specific deamination. Such methods can be useful for accurately detecting the methylation status and variants present in DNA, which, in turn, can be used to infer information about the cells and subject from which the DNA sample is derived. In some embodiments, the DNA molecule is from a subject having or suspected of having a disease or disorder, such as cancer.
SEQUENCE LISTING
[0003] The present application is filed with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled “GH0195WO.xml” created on March 26, 2025, which is 191,363 bytes in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.
INTRODUCTION AND SUMMARY
[0004] Cancer is responsible for millions of deaths per year worldwide. Early cancer detection may result in improved outcomes because early-stage cancer tends to be more susceptible to treatment.
[0005] Improperly controlled cell growth is a hallmark of cancer. Cancer is usually caused by the accumulation of mutations within an individual's normal cells, at least some resulting in improperly regulated cell division. Such mutations commonly include single nucleotide variations (SNVs), gene fusions, insertions and deletions (indels), transversions, translocations, and inversions. Cancers may also exhibit an accumulation of epigenetic changes, including modification of cytosine (e.g., 5-methylcytosine, 5 -hydroxymethylcytosine, and other more oxidized forms) and association of DNA with chromatin proteins and transcription factors. Thus, cancer can be indicated by non-sequence modifications, such as methylation. Examples of methylation changes in cancer include local gains of DNA methylation, e.g., in the CpG islands at the transcription start sites of genes involved in normal growth control, DNA repair, cell cycle regulation, and/or cell differentiation. Hypermethylation can be associated with an aberrant loss of transcriptional capacity of involved genes and occurs at least as frequently as point mutations and deletions as a cause of altered gene expression. Furthermore, without wishing to be bound by any particular theory, cells in or around a cancer or neoplasm may shed more DNA than cells of the same tissue type in a healthy subject. The DNA from such cells may differ epigenetically from shed DNA in a healthy subject. As such, the distribution of epigenetically modified (e.g., methylated) DNA in certain DNA samples, such as cell-free DNA (cfDNA), may change upon carcinogenesis. Thus, sufficiently sensitive epigenetic (e.g., DNA methylation) profiling can be used to detect aberrant methylation in DNA of a sample.
[0006] Biopsies represent a traditional approach for detecting or diagnosing cancer in which cells or tissue are extracted from a possible cancer site and analyzed for relevant phenotypic and/or genotypic features. Biopsies have the drawback of being invasive. Cancer detection based on analysis of body fluids (“liquid biopsies”), such as blood, is an intriguing alternative based on the observation that DNA from cancer cells is released into body fluids. A liquid biopsy is noninvasive (sometimes requiring only a blood draw). However, it has been challenging to develop accurate and sensitive methods for analyzing liquid biopsy material in part because the amount of nucleic acids released into body fluids is low and variable, as is recovery of nucleic acids from such fluids in analyzable form. Further, the contribution of DNA from cells in or around a cancer or neoplasm to a sample may be relatively small relative to the contribution from other cells, and the DNA contributed from other cells may be uninformative as to cancer status. Isolating and processing cell-free DNA useful for further analysis in liquid biopsy procedures can be a useful part of these methods.
[0007] Current methods of cancer diagnostic assays of cell-free nucleic acids (e.g., cell-free DNA or cell-free RNA) may focus on the detection of tumor-related somatic variants, including single nucleotide variants (SNVs), copy number variations (CNVs), fusions, and indels (i.e., insertions or deletions), which are all mainstream targets for liquid biopsy. There is growing evidence that non-sequence modifications like methylation status and fragmentomic signal in cell-free DNA can provide information on the source of cell-free DNA and disease level. Detailed knowledge of the non-sequence modifications of the cell-free DNA (e.g., when combined with somatic mutation calling) can improve assessments of tumor status.
[0008] Accordingly, there is a continued need for improved methods and compositions for analyzing non-sequence modifications (such as methylation status) in DNA, including cell-free DNA, e.g., in liquid biopsies.
[0009] The present disclosure aims to meet the need for improved analysis of methylated DNA, such as in a cfDNA sample, provide other benefits, or at least provide the public with a useful choice. In some embodiments, the present disclosure provides methods for enriching methylated DNA in a sample through differential processing of uracil products of CpG-specific deamination. In some embodiments, the disclosed methods can improve enrichment and analysis of methylated DNA in a sample by deaminating DNA in the sample with a CpG-specific deaminase and amplifying methylated CpGs or conversion products of methylated CpGs.
[0010] Accordingly, the embodiments described herein are provided, which include, but are not limited to, the following.
[0011] Embodiment l is a method of enriching methylated DNA in a sample comprising:
(a) contacting the DNA in the sample with a deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs; and
(b) selectively amplifying DNA in the converted sample that comprises methylated CpGs or conversion products of methylated CpGs.
[0012] Embodiment 2 is the method of embodiment 1, wherein selectively amplifying DNA in the converted sample comprises amplifying the DNA using a uracil-intolerant DNA polymerase. [0013] Embodiment 3 is the method of embodiment 1, wherein selectively amplifying DNA in the converted sample comprises:
(i) contacting the DNA with a uracil-DNA glycosylase (UDG), thereby converting uracils in the DNA to apyrimidinic sites (AP sites); and
(ii) amplifying the DNA using an AP site-intolerant DNA polymerase and/or a uracil-intolerant DNA polymerase.
[0014] Embodiment 4 is the method of embodiment 1, wherein selectively amplifying DNA in the converted sample comprises:
(i) contacting the DNA with a UDG, thereby converting uracils in the DNA to AP sites;
(ii) cutting DNA comprising the AP sites using an AP lyase; and (iii) amplifying DNA that was not cut by the AP lyase using a DNA polymerase.
[0015] Embodiment 5 is the method of the immediately preceding embodiment, wherein the AP lyase is an endonuclease VIII.
[0016] Embodiment 6 is the method of embodiment 4 or 5, wherein the DNA comprises adapters and amplifying DNA that was not cut by the AP lyase using the DNA polymerase comprises amplification using primers that bind sites in the adapters.
[0017] Embodiment 7 is the method of embodiment 1, wherein selectively amplifying DNA in the converted sample comprises:
(i) contacting the DNA with a uracil-specific excision reagent enzyme, thereby converting uracils in the DNA to AP sites;
(ii) cutting the DNA; and
(iii) amplifying DNA that was not cut by the uracil-specific excision reagent enzyme using a DNA polymerase.
[0018] Embodiment 8 is the method of the immediately preceding embodiment, wherein the DNA comprises adapters and amplifying DNA that was not cut comprises amplification using primers that bind sites in the adapters.
[0019] Embodiment 9 is the method of embodiment 4 or 7, wherein the DNA polymerase is an AP site-intolerant DNA polymerase or a uracil-intolerant DNA polymerase.
[0020] Embodiment 10 is the method of embodiment 1, wherein the deaminase is a dsDNA deaminase, and wherein selectively amplifying DNA in the converted sample comprises:
(i) cutting DNA comprising UpGs using a mismatch endonuclease (MME); and
(ii) amplifying DNA that was not cut by the MME using a DNA polymerase.
[0021] Embodiment 11 is the method of the immediately preceding embodiment, wherein the MME is mismatch endonuclease I.
[0022] Embodiment 12 is the method of embodiment 10 or 11, wherein the DNA comprises adapters and amplifying DNA that was not cut comprises amplification using primers that bind sites in the adapters.
[0023] Embodiment 13 is the method of any one of the preceding embodiments, wherein the DNA comprises barcodes.
[0024] Embodiment 14 is the method of any one of the preceding embodiments, wherein the method comprises ligating adapters comprising barcodes to the DNA. [0025] Embodiment 15 is the method of any one of embodiments 1-14, wherein the method comprises ligating adapters comprising barcodes to the DNA prior to the amplifying.
[0026] Embodiment 16 is the method of any one of embodiments 1-15, wherein the method comprises ligating adapters comprising barcodes to the DNA prior to the contacting the DNA with the deaminase.
[0027] Embodiment 17 is the method of any one of embodiments 4-12, wherein the method comprises ligating adapters to the DNA after cutting the DNA.
[0028] Embodiment 18 is the method of any one of embodiments 12 or 14-17, wherein the adapters are Y-shaped adapters.
[0029] Embodiment 19 is the method of any one of the preceding embodiments, wherein the deaminase is thermally inactivated after step (a).
[0030] Embodiment 20 is the method of any one of embodiments 4-6, wherein the steps of contacting the DNA with the UDG and cutting DNA comprising the AP sites using the AP lyase are in the same reaction mixture.
[0031] Embodiment 21 is the method of any one of the preceding embodiments, wherein the deaminase is a dsDNA deaminase.
[0032] Embodiment 22 is the method of any one of embodiments 1-9, wherein the deaminase is a ssDNA deaminase.
[0033] Embodiment 23 is the method of any one of embodiments 1-9, wherein the deaminase is a methyl insensitive deaminase.
[0034] Embodiment 24 is the method of the immediately preceding embodiment, wherein the methyl insensitive deaminase is A3 A.
[0035] Embodiment 25 is the method of any one of embodiments 1-22, wherein the deaminase is a methyl sensitive deaminase.
[0036] Embodiment 26 is the method of the immediately preceding embodiment, wherein the methyl sensitive deaminase is MsddA.
[0037] Embodiment 27 is the method of any one of embodiments 1-26, further comprising, prior to step (a): subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules, wherein the end repair is performed using deoxynucleotide triphosphates (dNTPs), wherein at least one type of dNTP comprises a modified base, and the at least one dNTP comprising a modified base is incorporated into a repaired region of the end-repaired DNA molecules at one or more locations.
[0038] Embodiment 28 is the method of embodiment 27, wherein the end repair is performed using a DNA polymerase that does not have 5’-3’ exonuclease activity and/or is not a strand displacing DNA polymerase.
[0039] Embodiment 29 is the method of embodiment 27, wherein the end repair is performed using a DNA polymerase that has 5 ’-3’ exonuclease activity and/or is a strand displacing DNA polymerase.
[0040] Embodiment 30 is the method of any one of embodiments 27-29, wherein the at least one type of dNTP which comprises a modified base, wherein the modified base includes a dNTP comprising 5-caryboxylcytosine (5-caC), 4-methylcytosine (4mC), a dNTP comprising 5- methylcytosine (5mC), a dNTP comprising 5-hydroxymethyl-cytosine (5hmC), a dNTP comprising N6-methyladenosine (6mA), a dNTP comprising bromodeoxyuridine (BrdU) and/or a dNTP comprising 8-oxoguanine (8oxoG).
[0041] Embodiment 31 is the method of any one of embodiments 1-30, further comprising performing an A-tailing reaction, optionally after a step of subjecting a DNA sample to end repair.
[0042] Embodiment 32 is the method of embodiment 31, wherein the end-repair and the A- tailing reaction are performed in the same reaction mixture, optionally wherein the end-repair and the A-tailing reaction are performed a single tube and/or optionally wherein the end-repair and the A-tailing reaction are performed without an intervening clean-up step.
[0043] Embodiment 33 is the method of embodiment 31 or 32, wherein the A-tailing is performed using a DNA polymerase that does not possess 5’-3’ exonuclease activity and/or is not a strand displacing DNA polymerase, optionally wherein the DNA polymerase is HemoKlen Taq.
[0044] Embodiment 34 is the method of any one of embodiments 31-33, wherein the A-tailing is performed using a thermostable DNA polymerase.
[0045] Embodiment 35 is the method of any one of embodiments 1-34, prior to step (a), performing a methylation-preserving amplification of the DNA of the sample.
[0046] Embodiment 36 is the method of the immediately preceding embodiment, wherein the methylation-preserving amplification is a linear, methylation-preserving amplification. [0047] Embodiment 37 is the method of any one of embodiments 35-36, wherein the methylation-preserving amplification comprises contacting the DNA with a methyltransferase. [0048] Embodiment 38 is the method of any one of embodiments 35-37, wherein the methylation-preserving amplification comprises one or more of polymerase chain reaction, linear amplification, rolling circle amplification, ligase chain reaction, strand displacement amplification, nucleic acid sequence-based amplification, and self-sustained sequence-based replication.
[0049] Embodiment 39 is the method of any one of embodiments35-37, wherein the methylation-preserving amplification comprises thermocycled amplification.
[0050] Embodiment 40 is the method of any one of embodiments 35-37, wherein the methylation-preserving amplification comprises isothermal amplification.
[0051] Embodiment 41 is the method of any one of embodiments 1-40, wherein the step of contacting the DNA in the sample with a deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs, comprises APOBEC-coupled epigenetic (ACE) conversion, enzymatic methyl-seq (EM-seq) or single-enzyme 5- methylcytosine sequencing (SEM-seq) method.
[0052] Embodiment 42 is the method of any one of the preceding embodiments, further comprising sequencing at least a portion of the amplified DNA.
[0053] Embodiment 43 is the method of any one of embodiments 1-42, further comprising quantifying a level of methylation at one or more differentially methylated regions of the DNA. [0054] Embodiment 44 is the method of the immediately preceding embodiment, wherein quantifying the level of methylation at one or more differentially methylated regions of the DNA comprises sequencing at least a portion of the amplified DNA or quantitative PCR.
[0055] Embodiment 45 is the method of embodiment 42 or 44, wherein the sequencing is nextgeneration sequencing (NGS).
[0056] Embodiment 46 is the method of the immediately preceding embodiment, wherein the NGS is pyrosequencing, sequencing-by-synthesis, semiconductor sequencing, sequencing-by- ligation, or sequencing-by-hybridization.
[0057] Embodiment 47 is the method of embodiment 42 or 44, wherein the sequencing comprises nanopore-based sequencing or single-molecule real time (SMRT) sequencing. [0058] Embodiment 48 is the method of embodiment 42, 44, or 47, wherein the sequencing comprises nanopore-based sequencing and the method further comprises subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules, wherein the end repair is performed using at least one type of dNTP which comprises a modified base including a dNTP comprising 5-caryboxylcytosine (5-caC), a dNTP comprising 4mC, a dNTP comprising 5mC, a dNTP comprising 5hmC, a dNTP comprising 6mA, a dNTP comprising BrdU, dUTP, a dNTP comprising fluorodeoxyuridine (FldU), a dNTP comprising 5-iododeoxyuridine (IdU), and/or a dNTP comprising 5-ethynyldeoxyuridine (EdU), and the at least one type of dNTP comprising a modified base is incorporated into a repaired region of the end-repaired DNA molecules at one or more locations.
[0059] Embodiment 49 is the method of embodiment 42, 44, or 47, wherein the sequencing comprises single-molecule real time (SMRT) sequencing and the method further comprises subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules, wherein the end repair is performed using at least one type of dNTP which comprises a modified base including a dNTP comprising a 4mC, a dNTP comprising 5mC, a dNTP comprising 5hmC, a dNTP comprising 6mA, and/or a dNTP comprising 8oxoG, and the at least one type of dNTP comprising a modified base is incorporated into a repaired region of the end-repaired DNA molecules at one or more locations.
[0060] Embodiment 50 is the method of any one of embodiments 42-49, wherein the DNA sample comprises cell-free DNA (cfDNA).
[0061] Embodiment 51 is the method of the immediately preceding embodiment, further comprising analyzing the sequence data to determine a level of measured artifacts in the cfDNA. [0062] Embodiment 52 is the method of any one of embodiments 1-51, further comprising subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules, wherein the end repair is performed using at least one type of dNTP which comprises a modified base, wherein the modified base is other than 5mC or 5hmC, and the at least one type of dNTP comprising a modified base is incorporated into a repaired region of the end-repaired DNA molecules at one or more locations.
[0063] Embodiment 53 is the method of any one of embodiments 1-51, further comprising subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules, wherein the end repair is performed using at least one type of dNTP which comprises a modified base, wherein the modified base is a methylated cytosine, optionally wherein the methylated base is 5mC or 5hmC, and the at least one type of dNTP comprising a modified base is incorporated into a repaired region of the end-repaired DNA molecules at one or more locations. [0064] Embodiment 54 is the method of any one of embodiments 1-51, further comprising subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules, wherein the end repair is performed using at least one type of dNTP which comprises a modified base, wherein the modified base is a methylated cytosine, optionally wherein the methylated base is 5mC or 5hmC, wherein the at least one type of dNTP comprising a modified base is incorporated into a repaired region of the end-repaired DNA molecules at one or more locations, and the repaired region is defined as:
(i) the sequence between two non-methylated cytosines which span one or more methylated CpH cytosines; and/or
(ii) the sequence between a methylated CpH cytosine and an end of a sequence read, wherein the methylated CpH cytosine is the CpH cytosine most distant from the end of the sequence read, or a subsequence thereof comprising one or more methylated CpH cytosines.
[0065] Embodiment 55 is the method of any one of embodiments 27-34 or 52-54 , wherein adapters are ligated to the end-repaired DNA molecules or the adapters are ligated to the DNA molecules.
[0066] Embodiment 56 is the method of the immediately preceding embodiment, wherein the adapters comprise molecular barcodes.
[0067] Embodiment 57 is the method of any one of the preceding embodiments, further comprising enriching the DNA for a plurality of target regions, optionally prior to the step of selectively amplifying DNA in the converted sample, or optionally prior to a step of sequencing the DNA.
[0068] Embodiment 58 is the method of embodiment 57, wherein the plurality of target regions comprises epigenetic target regions.
[0069] Embodiment 59 is the method of embodiment 58, wherein the epigenetic target regions comprise hypermethylation variable target regions.
[0070] Embodiment 60 is the method of embodiment 58 or 59, wherein the epigenetic target regions comprise hypomethylation variable target regions.
[0071] Embodiment 61 is the method of any one of embodiments 57-60, wherein the plurality of target regions comprise sequence-variable target regions.
[0072] Embodiment 62 is the method of any one of the preceding embodiments, wherein the DNA sample comprises cell-free DNA (cfDNA) or DNA from formalin fixed paraffin embedded samples. [0073] Embodiment 63 is the method of the immediately preceding embodiment, wherein the DNA sample comprises cell-free DNA.
[0074] Embodiment 64 is the method of any one of the preceding embodiments, wherein the DNA sample is from a subject.
[0075] Embodiment 65 is the method of any one of the preceding embodiments, wherein the DNA sample is from a subject and the method further comprises determining the presence or absence of cancer in the subject based at least in part on the sequencing data.
[0076] Embodiment 66 is the method of any one of embodiments 64-65, wherein the subject is an animal.
[0077] Embodiment 67 is the method of the immediately preceding embodiment, wherein the subject is a human.
[0078] Embodiment 68 is the method of any one of embodiments 64-67, wherein the subject has or is at risk of having a cancer.
[0079] Embodiment 69 is the method of any one of embodiments 64-68, further comprising determining the presence or status of a cancer in the subject.
[0080] In some embodiments, the results of the methods disclosed herein are used as an input to generate a report. The report may be in a paper or electronic format. For example, the true methylation status of cytosines or variants, as obtained by the methods disclosed herein, or information derived therefrom, can be displayed directly in such a report. Alternatively or additionally, diagnostic information or therapeutic recommendations which are at least in part based on the methods disclosed herein can be included in the report.
[0081] The various steps of the methods disclosed herein may be carried out at the same or different times, in the same or different geographical locations, e.g. countries, and/or by the same or different people.
[0082] Additional advantages will be set forth in part in the description which follows or may be learned by practice. The advantages will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0083] FIGS. 1A-1D illustrate exemplary workflows according to certain embodiments of the disclosure. FIG. 1A is a schematic which shows a methylation enrichment method using a methyl-insensitive CpG-specific deaminase (labeled as “CpG deaminase”) or a methyl -sensitive CpG deaminase, followed by amplification using a uracil-intolerant DNA polymerase. FIG. IB is a schematic which shows a methylation enrichment method using a methyl -insensitive CpG- specific deaminase (labeled as “CpG deaminase”) or a methyl -sensitive CpG deaminase, followed by a uracil-DNA glycosylase (UDG), and amplification using an apyrimidinic (AP) site-intolerant DNA polymerase. FIG. 1C is a schematic which shows a methylation enrichment method using a methyl-insensitive CpG-specific deaminase (labeled as “CpG deaminase”) or a methyl-sensitive CpG deaminase, followed by a UDG, an AP lyase, and amplification using a DNA polymerase. FIG. ID is a schematic which shows a methylation enrichment method using a methyl-sensitive CpG deaminase followed by a mismatch endonuclease and amplification using a DNA polymerase (e.g., a uracil-intolerant DNA polymerase).
[0084] FIG. 2 is a schematic which shows an exemplary methylation enrichment method that uses differential processing of the uracil product of CpG-specific deamination for identifying methylated CpG sites and retaining end-repair resynthesized CpGs. End-repair and A-tailing reactions are performed on a DNA sample, followed by ligation of next-generation sequencing (NGS) adapters to the DNA, deamination of the DNA using a methyl -insensitive CpG-specific deaminase, and uracil-intolerant amplification of the DNA. The sequences in the figure are: mCGmCGmCGmCGmCG (SEQ ID NO: 90), mCGmCGmCGCGCG (SEQ ID NO: 91), CGCGmCGmCGmCG (SEQ ID NO: 92), mCGmCGCGCGCG (SEQ ID NO: 96), CGCGCGmCGmCG (SEQ ID NO: 97), mCGCGCGCGCG (SEQ ID NO: 98), CGCGCGCGmCG (SEQ ID NO: 99), CGCGCGCGCG (SEQ ID NO: 93), mCGmCGmCGcaCGcaCG (SEQ ID NO: 100), TGTGTGTGTG (SEQ ID NO: 95), TGTGTGcaCGcaCG (SEQ ID NO: 101), TGTGTGUGUG (SEQ ID NO: 102), UGUGTGTGTG (SEQ ID NO: 103), TGTGUGUGUG (SEQ ID NO: 104), UGUGUGTGTG (SEQ ID NO: 105), TGUGUGUGUG (SEQ ID NO: 106), UGUGUGUGTG (SEQ ID NO: 107), UGUGUGUGUG (SEQ ID NO: 108), wherein “mC” denotes a methylated cytosine and “caC” denotes a CpG- deaminase resistant modified cytosine (e.g., 5-caryboxylcytosine (5-caC)).
[0085] FIG. 3 is a schematic diagram of an example of a system suitable for use with some embodiments of the disclosure.
DETAILED DESCRIPTION
[0086] Reference will now be made in detail to certain embodiments of the disclosure. While the disclosure will be described in conjunction with such embodiments, it will be understood that they are not intended to limit the disclosure to those embodiments. On the contrary, the disclosure is intended to cover all alternatives, modifications, and equivalents, which may be included within the disclosure as defined by the appended claims.
[0087] Before describing the present teachings in detail, it is to be understood that the disclosure is not limited to specific compositions or process steps, as such may vary. It should be noted that, as used in this specification and the appended claims, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, reference to “a nucleic acid” includes a plurality of nucleic acids.
[0088] Numeric ranges are inclusive of the numbers defining the range. Measured and measurable values are understood to be approximate, taking into account significant digits and the error associated with the measurement.
[0089] Unless specifically noted in the above specification, embodiments in the specification that recite “comprising” various components are also contemplated as “consisting of’ or “consisting essentially of’ the recited components.
[0090] The section headings used herein are for organizational purposes and are not to be construed as limiting the disclosed subject matter in any way.
[0091] All patents, patent applications, websites, other publications or documents and the like cited herein whether supra or infra, are expressly incorporated by reference in their entirety for all purposes to the same extent as if each individual item were specifically and individually indicated to be so incorporated by reference. If different versions of a publication, website or the like are published at different times, the version most recently published at the effective filing date of the application is meant, unless otherwise indicated.
I. Definitions
[0092] A “reaction cleanup” refers to the removal of contaminants such as salts, enzymes, unincorporated dNTPs, primers, ethidium bromide, and other impurities that can interfere with downstream analysis. For example, when a reaction cleanup is performed between end repair and an A-tailing reaction, it removes unincorporated dNTPs such that the A-tailing reaction can be performed solely in the presence of dATP (i.e. not dCTP, dGTP and dCTP, as used in the end tailing reaction). Reaction cleanups can be performed using commercially available kits such as MinElute Reaction Cleanup Kit (Qiagen)
[0093] “Repaired regions”, also referred to as “synthesized regions” or “regions of the end- repaired DNA that were synthesized during the end repair” refer to regions of the DNA that were not present in the DNA prior to the end repair and A-tailing reactions. They are regions which have been synthesized by the polymerases used in the end repair and/or A tailing reactions, if present. In instances where the A-tailing is performed in the same tube as the end repair reaction, all four types of dNTPs will be present, and thus the polymerases used for A-tailing may generate synthesized regions, e g. through nick translation. In instances where the A-tailing is performed separately to the end repair reaction, and these steps are separated by a reaction cleanup, only dATP will be present in the A-tailing reaction, and thus the polymerases used for A-tailing will not typically generate synthesized regions because the dNTP components are not all present in the A-tailing reaction mix.
[0094] As used herein, “base pairing specificity” refers to the standard DNA base (A, C, G, or T) for which a given base most preferentially pairs. Thus, for example, unmodified cytosine and 5- methylcytosine have the same base pairing specificity (i.e., specificity for G) whereas uracil and cytosine have different base pairing specificity because uracil has base pairing specificity for A while cytosine has base pairing specificity for G. The ability of uracil to form a wobble pair with G, for example, is irrelevant because uracil nonetheless most preferentially pairs with A among the four standard DNA bases.
[0095] A “type of dNTP” refers to a dNTP comprising a specific base, including A, T, G or C. Accordingly, wherein an end repair reaction is performed with dNTPs, wherein at least one type of dNTP comprises a modified base, the end repair reaction may be performed using dCTP comprising 5mC, and dATP, dTTP and dGTP all comprising non-modified bases.
[0096] “Capable of identifying the base modification in the at least one type of dNTP” refers to the ability of a modification-sensitive sequencing method to detect the presence or absence of the base modification in the at least one type of dNTP comprising a modified base used in the end repair. This detection of the base modification may be direct, such as in nanopore sequencing or single molecule real time sequencing, wherein the sequencing data itself indicates the presence or absence of a base modification. Alternatively, the detection of the base modification may be indirect, for example wherein the method involves a conversion procedure which alters the base pairing specificity dependent on the base modification status. It is these changes in base pairing specificity which can be detected by the sequencing method, e.g. through the comparison of the sequencing data to a reference sequence. Moreover, a modification-sensitive sequencing method is capable of identifying the base modification in the at least one type of dNTP regardless of whether it can distinguish one base modification from all other base modifications. For example, one form of modification-sensitive sequencing is sequencing after bisulfite conversion. This method is capable of distinguishing 5hmC and 5mC from unmethylated cytosine, but cannot distinguish 5hmC from 5mC.
[0097] Bases of the “same identity” refer to the same base, regardless of modification status of that base. For example, cytosine is considered to be the “same identity” as 5-methylcytosine (5mC) and/or 5-hydroxymethyl-cytosine (5hmC), despite them having different modification statuses.
[0098] “ Cell-free DNA,” “cfDNA molecules,” or simply “cfDNA” include DNA molecules that naturally occur in a subject in extracellular form (e.g., in blood, serum, plasma, or other bodily fluids such as lymph, cerebrospinal fluid, urine, or sputum). While the cfDNA originally existed in a cell or cells in a large complex biological organism, e.g., a mammal, it has undergone release from the cell(s) into a fluid found in the organism, and may be obtained from a sample of the fluid without the need to perform an in vitro cell lysis step.
[0099] As used herein, “cellular nucleic acids” means nucleic acids that are disposed within one or more cells from which the nucleic acids have originated, at least at the point a sample is taken or collected from a subject, even if those nucleic acids are subsequently removed (e.g., via cell lysis) as part of a given analytical process.
[0100] DNA is “derived from cancerous cells” if it originated from a tumor cell. Cell free DNA derived from cancerous cells includes ctDNA or circulating tumor DNA. Tumor cells are neoplastic cells that originated from a tumor, regardless of whether they remain in the tumor or become separated from the tumor (as in the cases, e.g., of metastatic cancer cells and circulating tumor cells).
[0101] The term “methylation” or “DNA methylation” refers to addition of a methyl group to a nucleotide base in a nucleic acid molecule. In some embodiments, methylation refers to addition of a methyl group to a cytosine at a CpG site (cytosine-phosphate-guanine site (i .e., a cytosine followed by a guanine in a 5’ -> 3’ direction of the nucleic acid sequence)). In some embodiments, DNA methylation refers to addition of a methyl group to adenine, such as in N6- methyladenine (6mA). In some embodiments, DNA methylation is 5-methylation (modification of the carbon in the 5th position of the cytosine ring). In some embodiments, 5-methylation refers to addition of a methyl group to the 5C position of the cytosine to create 5-methylcytosine (5mC). In some embodiments, methylation comprises a derivative of 5mC. Derivatives of 5mC include, but are not limited to, 5-hydroxymethylcytosine (5-hmC), 5-formylcytosine (5-fC), and 5-caryboxylcytosine (5-caC). In some embodiments, DNA methylation is 3C methylation (modification of the carbon in the 3rd position of the cytosine ring). In some embodiments, 3C methylation comprises addition of a methyl group to the 3C position of the cytosine to generate 3 -methylcytosine (3mC). Methylation can also occur at non-CpG sites, for example, methylation can occur at a CpA, CpT, or CpC site. DNA methylation can change the activity of methylated DNA region. For example, when DNA in a promoter region is methylated, transcription of the gene may be repressed. DNA methylation is critical for normal development and abnormality in methylation may disrupt epigenetic regulation. The disruption, e.g., repression, in epigenetic regulation may cause diseases, such as cancer. Promoter methylation in DNA may be indicative of cancer.
[0102] The “modified nucleoside profile of DNA” means the position and identity of the nucleoside and the modification status of the nucleoside, such as methylations, within a DNA sequence. As described above, different modification sensitive sequencing methods can be used to detect such modifications. This includes methods which involve conversion followed by sequencing detect one or more different types of modified or unmodified nucleoside. For example, the TAPS method detects, but does not distinguish between, 5-methylcytosine (5mC) and 5-hydroxymethyl-cytosine (5hmC). Hence, a method for analyzing the modified nucleoside profile of DNA in a sample typically means identifying particular modifications or groups of modification, such as 5mC and/or 5hmC. Modified nucleosides are identified according to the specific method/conversion procedure being used as described above. This generally involves comparing sequence data obtained from DNA that has been subjected to a conversion procedure to a reference sequence. Typically, the method involves (i) comparing the sequence data with (A) one or more pre-determined reference sequence; or (B) sequence data obtained by sequencing a sub-sample of the DNA that was not subjected to the conversion procedure, for example a subsample that was separated before subjecting a separate subsample to the conversion procedure, for example as described herein; and (ii) identifying point differences between the converted DNA sequences and the reference sequence(s) (A) or non-converted DNA sequences (B) as nucleosides (in the initial sample) having a modification status that permits a change in base pairing specificity on exposure to the conversion procedure.
[0103] As used herein, a modification or other feature is present in “a greater proportion” in a first sample or population of nucleic acid than in a second sample or population when the fraction of nucleotides with the modification or other feature is higher in the first sample or population than in the second population. For example, if in a first sample, one tenth of the nucleotides are mC, and in a second sample, one twentieth of the nucleotides are mC, then the first sample comprises the cytosine modification of 5-methylation in a greater proportion than the second sample.
[0104] As used herein, “without substantially altering base-pairing specificity” of a given nucleobase means that a majority of molecules comprising that nucleobase that can be sequenced do not have alterations of the base pairing specificity of the second nucleobase relative to its base pairing specificity as it was in the originally isolated sample. In some embodiments, 75%, 90%, 95%>, or 99% of molecules comprising that nucleobase that can be sequenced do not have alterations of the base pairing specificity of the second nucleobase relative to its base pairing specificity as it was in the originally isolated sample.
[0105] As used herein, “base pairing specificity” refers to the standard DNA base (A, C, G, or T) for which a given base most preferentially pairs. Thus, for example, unmodified cytosine and 5- methylcytosine have the same base pairing specificity (i.e., specificity for G) whereas uracil and cytosine have different base pairing specificity because uracil has base pairing specificity for A while cytosine has base pairing specificity for G. The ability of uracil to form a wobble pair with G is irrelevant because uracil nonetheless most preferentially pairs with A among the four standard DNA bases.
[0106] As used herein, “modified cytosine” refers to a cytosine in which at least one position of the cytosine has been substituted with a chemical moiety, such as a methyl or hydroxymethyl, that is different from the substituent at that position in unmodified cytosine. For the avoidance of doubt, “modified cytosine” does not include unmodified cytosine.
[0107] As used herein, a “combination” comprising a plurality of members refers to either of a single composition comprising the members or a set of compositions in proximity, e.g., in separate containers or compartments within a larger container, such as a multiwell plate, tube rack, refrigerator, freezer, incubator, water bath, ice bucket, machine, or other form of storage. [0108] The “capture yield” of a collection of probes for a given target set refers to the amount (e.g., amount relative to another target set or an absolute amount) of nucleic acid corresponding to the target set that the collection of probes captures under typical conditions. Exemplary typical capture conditions are an incubation of the sample nucleic acid and probes at 65°C for 10-18 hours in a small reaction volume (about 20 pL) containing stringent hybridization buffer. The capture yield may be expressed in absolute terms or, for a plurality of collections of probes, relative terms. When capture yields for a plurality of sets of target regions are compared, they are normalized for the footprint size of the target region set (e.g., on a per-kilobase basis). Thus, for example, if the footprint sizes of first and second target regions are 50 kb and 500 kb, respectively (giving a normalization factor of 0.1), then the DNA corresponding to the first target region set is captured with a higher yield than DNA corresponding to the second target region set when the mass per volume concentration of the captured DNA corresponding to the first target region set is more than 0.1 times the mass per volume concentration of the captured DNA corresponding to the second target region set. As a further example, using the same footprint sizes, if the captured DNA corresponding to the first target region set has a mass per volume concentration of 0.2 times the mass per volume concentration of the captured DNA corresponding to the second target region set, then the DNA corresponding to the first target region set was captured with a two-fold greater capture yield than the DNA corresponding to the second target region set.
[0109] “Capturing” one or more target nucleic acids refers to preferentially isolating or separating the one or more target nucleic acids from non-target nucleic acids.
[0110] A “captured set” of nucleic acids refers to nucleic acids that have undergone capture. [0U1] A “target-region set” or “set of target regions” refers to a plurality of genomic loci targeted for capture and/or targeted by a set of probes (e.g., through sequence complementarity). [0112] “Corresponding to a target region set” means that a nucleic acid, such as cfDNA, originated from a locus in the target region set or specifically binds one or more probes for the target-region set.
[0113] As used herein, a “differentially methylated region” (DMR) refers to a region of DNA having a detectably different degree of methylation in at least one cell or tissue type relative to the degree of methylation in the same region of DNA from at least one other cell or tissue type; or having a detectably different degree of methylation in at least one cell or tissue type obtained from a subject having a disease or disorder relative to the degree of methylation in the same region of DNA in the same cell or tissue type obtained from a healthy subject. In some embodiments, a DMR has a detectably higher degree of methylation (e.g., a hypermethylated region) in at least one cell or tissue type relative to the degree of methylation in the same region of DNA from at least one other cell or tissue type or from the same cell or tissue type from a healthy subject. In some embodiments, a DMR has a detectably lower degree of methylation (e.g., a hypomethylated region) in at least one cell or tissue type relative to the degree of methylation in the same region of DNA from at least one other cell or tissue type or from the same cell or tissue type from a healthy subject.
[0114] “Specifically binds” in the context of a probe or other oligonucleotide and a target sequence means that under appropriate hybridization conditions, the oligonucleotide or probe hybridizes to its target sequence, or replicates thereof, to form a stable probe:target hybrid, while at the same time formation of stable probemon-target hybrids is minimized. Thus, a probe hybridizes to a target sequence or replicate thereof to a sufficiently greater extent than to a nontarget sequence, to enable capture or detection of the target sequence. Appropriate hybridization conditions are well-known in the art, may be predicted based on sequence composition, or can be determined by using routine testing methods (see, e.g., Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) at §§ 1.90-1.91, 7.37-7.57, 9.47-9.51 and 11.47-11.57, particularly §§ 9.50-9.51, 11.12- 11.13, 11.45-11.47 and 11.55-11.57, incorporated by reference herein).
[0115] “Sequence-variable target region set” refers to a set of target regions that may exhibit changes in sequence such as nucleotide substitutions (i.e., single nucleotide variations), insertions, deletions, or gene fusions or transpositions in neoplastic cells (e g., tumor cells and cancer cells).
[0116] “Epigenetic target region set” refers to a set of target regions that may show sequenceindependent changes in neoplastic cells (e.g., tumor cells and cancer cells) or that may show sequence-independent changes in cfDNA from subjects having cancer relative to cfDNA from healthy subjects. Examples of sequence-independent changes include, but not limited to, changes in methylation (increases or decreases), nucleosome distribution, CTCF binding, transcription start sites, and regulatory protein binding regions. For present purposes, loci susceptible to neoplasia-, tumor-, or cancer-associated focal amplifications and/or gene fusions may also be included in an epigenetic target region set because detection of a change in copy number by sequencing or a fused sequence that maps to more than one locus in a reference genome tends to be more similar to detection of exemplary epigenetic changes discussed above than detection of nucleotide substitutions, insertions, or deletions, e.g., in that the focal amplifications and/or gene fusions can be detected at a relatively shallow depth of sequencing because their detection does not depend on the accuracy of base calls at one or a few individual positions.
[0117] The term “hypermethylation” refers to an increased level or degree of methylation of nucleic acid molecule(s) relative to the other nucleic acid molecules within a population (e.g., sample) of nucleic acid molecules. In some embodiments, hypermethylated DNA can include DNA molecules comprising at least 1 methylated residue, at least 2 methylated residues, at least 3 methylated residues, at least 5 methylated residues, or at least 10 methylated residues.
[0118] The term “hypomethylation” refers to a decreased level or degree of methylation of nucleic acid molecule(s) relative to the other nucleic acid molecules within a population (e.g., sample) of nucleic acid molecules. In some embodiments, hypomethylated DNA includes unmethylated DNA molecules. In some embodiments, hypomethylated DNA can include DNA molecules comprising 0 methylated residues, at most 1 methylated residue, at most 2 methylated residues, at most 3 methylated residues, at most 4 methylated residues, or at most 5 methylated residues.
[0119] As used herein, “methylation status” can refer to the presence or absence of methyl group on a DNA base (e.g. cytosine) at a particular genomic position in a nucleic acid molecule. It can also refer to the degree of methylation in a nucleic acid sequence (e.g., highly methylated, low methylated, intermediately methylated or unmethylated nucleic acid molecules). The methylation status can also refer to the number of nucleotides methylated in a particular nucleic acid molecule.
[0120] As used herein, “mutation” refers to a variation from a known reference sequence and includes mutations such as, for example, single nucleotide variants (SNVs), and insertions or deletions (indels). A mutation can be a germline or somatic mutation. In some embodiments, a reference sequence for purposes of comparison is a wildtype genomic sequence of the species of the subject providing a test sample, typically the human genome.
[0121] As used herein, the terms “neoplasm” and “tumor” are used interchangeably. They refer to abnormal growth of cells in a subject. A neoplasm or tumor can be benign, potentially malignant, or malignant. A malignant tumor is referred to as a cancer or a cancerous tumor. [0122] As used herein, “next-generation sequencing” or “NGS” refers to sequencing technologies having increased throughput as compared to traditional Sanger- and capillary electrophoresis-based approaches, for example, with the ability to generate hundreds of thousands of relatively small sequence reads at a time. Some examples of next-generation sequencing techniques include, but are not limited to, sequencing by synthesis, sequencing by ligation, and sequencing by hybridization. In some embodiments, next-generation sequencing includes the use of instruments capable of sequencing single molecules. Examples of commercially available instruments for performing next-generation sequencing include, but are not limited to, NextSeq, HiSeq, NovaSeq, MiSeq, Ion PGM and Ion GeneStudio S5.
[0123] As used herein, “nucleic acid tag” refers to a short nucleic acid (e.g., less than about 500 nucleotides, about 100 nucleotides, about 50 nucleotides, or about 10 nucleotides in length), used to distinguish nucleic acids from different samples (e g., representing a sample index), distinguish nucleic acids from different partitions (e.g., representing a partition tag) or different nucleic acid molecules in the same sample (e.g., representing a molecular barcode), of different types, or which have undergone different processing. The nucleic acid tag comprises a predetermined, fixed, non-random, random or semi-random oligonucleotide sequence. Such nucleic acid tags may be used to label different nucleic acid molecules or different nucleic acid samples or sub-samples. Nucleic acid tags can be single-stranded, double-stranded, or at least partially double-stranded. Nucleic acid tags optionally have the same length or varied lengths. Nucleic acid tags can also include double-stranded molecules having one or more blunt-ends, include 5’ or 3’ single-stranded regions (e.g., an overhang), and/or include one or more other single- stranded regions at other locations within a given molecule. Nucleic acid tags can be attached to one end or to both ends of the other nucleic acids (e.g., sample nucleic acids to be amplified and/or sequenced). Nucleic acid tags can be decoded to reveal information such as the sample of origin, form, or processing of a given nucleic acid. For example, nucleic acid tags can also be used to enable pooling and/or parallel processing of multiple samples comprising nucleic acids bearing different molecular barcodes and/or sample indexes in which the nucleic acids are subsequently being deconvolved by detecting (e.g., reading) the nucleic acid tags. Nucleic acid tags can also be referred to as identifiers (e.g. molecular identifier, sample identifier).
Additionally, or alternatively, nucleic acid tags can be used as molecular identifiers (e.g., to distinguish between different molecules or amplicons of different parent molecules in the same sample or sub-sample). This includes, for example, uniquely tagging different nucleic acid molecules in a given sample, or non-uniquely tagging such molecules. In the case of non-unique tagging applications, a limited number of tags (i.e., molecular barcodes) may be used to tag each nucleic acid molecule such that different molecules can be distinguished based on their endogenous sequence information (for example, start and/or stop positions where they map to a selected reference genome, a sub-sequence of one or both ends of a sequence, and/or length of a sequence) in combination with at least one molecular barcode. Typically, a sufficient number of different molecular barcodes are used such that there is a low probability (e.g., less than about a 10%, less than about a 5%, less than about a 1%, or less than about a 0.1% chance) that any two molecules may have the same endogenous sequence information (e.g., start and/or stop positions, subsequences of one or both ends of a sequence, and/or lengths) and also have the same molecular barcode. Terms such as “library adaptors having distinct molecular barcodes” encompass library adaptors for uniquely or non-uniquely tagging molecules, in that regardless of whether the adaptors are for unique or non-unique tagging, distinct barcodes will be present in the population of adaptors.
[0124] As used herein, DNA that is “not immobilized” or that is “free in solution” refers to DNA that is not bound covalently or non-covalently to a solid support, such as a bead. Such DNA may be free in solution during any step (such as all steps) of the disclosed methods.
[0125] As used herein, “partitioning” refers to physically separating or fractionating a mixture of nucleic acid molecules in a sample based on a characteristic of the nucleic acid molecules. The partitioning can be physical partitioning of molecules. Partitioning can involve separating the nucleic acid molecules into groups or sets based on the level of epigenetic feature (for e g., methylation). For example, the nucleic acid molecules can be partitioned based on the level of methylation of the nucleic acid molecules. In some embodiments, the methods and systems used for partitioning may be found in PCT Patent Application No. PCT/US2017/068329, which is hereby incorporated by reference in its entirety.
[0126] As used herein, “partitioned set” or “partition” refers to a set of nucleic acid molecules partitioned into a set or group based on the differential binding affinity of the nucleic acid molecules or proteins associated with the nucleic acid molecules to a binding agent. A partitioned set may also be referred to as a subsample. The binding agent binds preferentially to the nucleic acid molecules comprising nucleotides with epigenetic modification. For example, if the epigenetic modification is methylation, the binding agent can be a methyl binding domain (MBD) protein. In some embodiments, a partitioned set can comprise nucleic acid molecules belonging to a particular level or degree of epigenetic feature (for e.g., methylation). For example, the nucleic acid molecules can be partitioned into three sets - one set for highly methylated nucleic acid molecules (first subsample, hyper partition, hyper partitioned set or hypermethylated partitioned set), a second set for low methylated nucleic acid molecules (second subsample, hypo partition, hypo partitioned set or hypom ethylated partitioned set), and a third set for intermediate methylated nucleic acid molecules (third subsample, intermediate partitioned set, intermediately methylated partitioned set, residual partitioned set, or residual partition). In another example, the nucleic acid molecules can be partitioned based on the number of methylated nucleotides - one partitioned set can have nucleic acid molecules with nine methylated nucleotides, and another partitioned set can have unmethylated nucleic acid molecules (zero methylated nucleotides).
[0127] As used herein, “polynucleotide”, “nucleic acid”, “nucleic acid molecule”, or “oligonucleotide” refers to a linear polymer of nucleosides (including deoxyribonucleosides, ribonucleosides, or analogs thereof) joined by inter-nucleosidic linkages. Typically, a polynucleotide comprises at least three nucleosides. Oligonucleotides often range in size from a few monomeric units, e.g., 3-4, to hundreds of monomeric units. Whenever a polynucleotide is represented by a sequence of letters, such as “ATGCCTG”, the nucleotides are in 5’ -> 3’ order from left to right, and in the case of DNA, “A” denotes deoxyadenosine, “C” denotes deoxycytidine, “G” denotes deoxy guanosine, and “T” denotes deoxythymidine, unless otherwise noted. The letters A, C, G, and T may be used to refer to the bases themselves, to nucleosides, or to nucleotides comprising the bases.
[0128] As used herein, “processing” refers to a set of steps used to generate a library of nucleic acids that is suitable for sequencing. The set of steps can include, but are not limited to, partitioning, end repairing, addition of sequencing adapters, tagging, and/or PCR amplification of nucleic acids.
[0129] As used herein, “quantitative measure” refers to an absolute or relative measure. A quantitative measure can be, without limitation, a number, a statistical measurement (e.g., frequency, mean, median, standard deviation, or quantile), or a degree or a relative quantity (e.g., high, medium, and low). A quantitative measure can be a ratio of two quantitative measures. A quantitative measure can be a linear combination of quantitative measures. A quantitative measure may be a normalized measure.
[0130] As used herein, “reference sequence” refers to a known sequence used for purposes of comparison with experimentally determined sequences. For example, a known sequence can be an entire genome, a chromosome, or any segment thereof. A reference sequence can align with a single contiguous sequence of a genome or chromosome or chromosome arm or can include noncontiguous segments that align with different regions of a genome or chromosome. Examples of reference sequences include, for example, human genomes, such as, hgl9 and hg38.
[0131] As used herein, “sample” means anything capable of being analyzed by the methods and/or systems disclosed herein. [0132] As used herein, “sequencing” refers to any of a number of technologies used to determine the sequence (e.g., the identity and order of monomer units) of a biomolecule, e.g., a nucleic acid such as DNA or RNA. Examples of sequencing methods include, but are not limited to, targeted sequencing, single molecule real-time sequencing, exon or exome sequencing, intron sequencing, electron microscopy -based sequencing, panel sequencing, transistor-mediated sequencing, direct sequencing, random shotgun sequencing, Sanger dideoxy termination sequencing, wholegenome sequencing, sequencing by hybridization, pyrosequencing, duplex sequencing, cycle sequencing, single-base extension sequencing, solid-phase sequencing, high-throughput sequencing, massively parallel signature sequencing, emulsion PCR, co-amplification at lower denaturation temperature-PCR (COLD-PCR), multiplex PCR, sequencing by reversible dye terminator, paired-end sequencing, near-term sequencing, exonuclease sequencing, sequencing by ligation, short-read sequencing, single-molecule sequencing, sequencing-by-synthesis, realtime sequencing, reverse-terminator sequencing, nanopore sequencing, 454 sequencing, Solexa Genome Analyzer sequencing, SOLiD™ sequencing, MS-PET sequencing, and a combination thereof. In some embodiments, sequencing can be performed by a gene analyzer such as, for example, gene analyzers commercially available from Illumina, Inc., Pacific Biosciences, Inc., or Applied Biosystems/Thermo Fisher Scientific, among many others.
[0133] As used herein, “sequence information” in the context of a nucleic acid polymer means the order and identity of monomer units (e.g., nucleotides, etc.) in that polymer.
[0134] As used herein “sequence-variable target region set” refers to a set of target regions that may exhibit changes in sequence such as nucleotide substitutions, insertions, deletions, or gene fusions or transpositions in neoplastic cells (e.g., tumor cells and cancer cells).
[0135] As used herein, the terms “somatic mutation” or “somatic variation” are used interchangeably. They refer to a mutation in the genome that occurs after conception. Somatic mutations can occur in any cell of the body except germ cells and accordingly, are not passed on to progeny.
[0136] As used herein, “subject” refers to an animal, such as a mammalian species (e.g., human) or avian (e.g., bird) species, or other organism, such as a plant. More specifically, a subject can be a vertebrate, e.g., a mammal such as a mouse, a primate, a simian or a human. Animals include farm animals (e.g., production cattle, dairy cattle, poultry, horses, pigs, and the like), sport animals, and companion animals (e.g., pets or support animals). A subject can be a healthy individual, an individual that has or is suspected of having a disease or a predisposition to the disease, or an individual in need of therapy or suspected of needing therapy. The terms “individual” or “patient” are intended to be interchangeable with “subject”. For example, a subject can be an individual who has been diagnosed with having a cancer, is going to receive a cancer therapy, and/or has received at least one cancer therapy. The subject can be in remission of a cancer. As another example, the subject can be an individual who is diagnosed of having an autoimmune disease. As another example, the subject can be a female individual who is pregnant or who is planning on getting pregnant, who may have been diagnosed of or suspected of having a disease, e.g., a cancer, an auto-immune disease.
[0137] As used herein, “target-region set” or “set of target regions” or “target regions” or “target regions of interest” or “regions of interest” or “genomic regions of interest” refers to a plurality of genomic loci or a plurality of genomic regions targeted for capture and/or targeted by a set of probes (e.g., through sequence complementarity).
[0138] As used herein, “tumor fraction” refers to the proportion of cfDNA molecules that originated from tumor cells for a given sample, or sample-region pair.
[0139] As used herein, an “asymmetric adapter” is a double stranded adapter in which the two strands are not completely complementary or are otherwise distinguishable such that synthesis of a complementary sequence of one strand of the adapter results in a sequence that is distinguishable from the sequence of the other strand of the adapter. Examples of asymmetric adapters are Y-shaped adapters and bubble adapters.
[0140] As used herein, a “Y-shaped adapter” refers to an adapter comprising two DNA strands comprising complementary and non-complementary parts, wherein the non-complementary parts form single-stranded arms. The adapter can be attached to a sample or insert DNA molecule, e.g., by ligation, such that the complementary (double-stranded) part of the adapter is proximal to the sample or insert DNA molecule. Prior to attachment, the double stranded portion of the Y- shaped adapter may have a blunt end or an overhang, e.g., of one to three nucleotides. The single stranded arms may or may not be of identical length.
[0141] As used herein, a “bubble adapter” refers to an adapter comprising two DNA strands comprising a non-complementary part flanked by complementary parts, such that the adapter has a single stranded region located between double-stranded regions. The adapter can be attached to a sample or insert DNA molecule, e.g., by ligation, such that one of the complementary (doublestranded) parts of the adapter is proximal to the sample or insert DNA molecule. Prior to attachment, the double stranded portion of the Y-shaped adapter that would be attached to the insert or sample molecule may have a blunt end or an overhang, e.g., of one to three nucleotides. The single stranded portions of the two strands may or may not be of identical length.
[0142] The terms “or a combination thereof’ and “or combinations thereof’ as used herein refers to any and all permutations and combinations of the listed terms preceding the term. For example, “A, B, C, or combinations thereof’ is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, ACB, CBA, BCA, BAC, or CAB. Continuing with this example, expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, AAB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth. The skilled artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context.
[0143] “Buffy coat” refers to the portion of a blood (such as whole blood) or bone marrow sample that contains all or most of the white blood cells and platelets of the sample. The buffy coat fraction of a sample can be prepared from the sample using centrifugation, which separates sample components by density. For example, following centrifugation of a whole blood sample, the buffy coat fraction is situated between the plasma and erythrocyte (red blood cell) layers. The huffy coat can contain both mononuclear (e.g., T cells, B cells, NK cells, dendritic cells, and monocytes) and polymorphonuclear (e.g., granulocytes such as neutrophils and eosinophils) white blood cells.
[0144] As used herein, “leukapheresis” refers to a procedure in which white blood cells (leukocytes) are isolated from a sample of blood collected from a subject. Leukapheresis may be performed, e.g., obtain cells for research, diagnostic, prognostic, or monitoring purposes, such as those described herein. Thus, as used herein, a “leukapheresis sample” refers to a sample comprising leukocytes collected from a subject using leukapheresis.
[0145] As used herein, “peripheral blood mononuclear cells” or “PBMCs” refers to immune cells having a single, round nucleus that originate in bone marrow and are found in the peripheral circulation. Such cells include, e.g., lymphocytes (T cells, B cells, and NK cells) as well as monocytes, and are isolated from blood samples (such as from a whole blood sample collected from a subject) using density gradient centrifugation.
[0146] As used herein, “amplify,” “amplifying,” or “amplification” refers to a process by which extra or multiple copies of a particular polynucleotide are formed. Amplification methods can include any suitable methods known in the art. As used herein, a nucleic acid molecule amplified using “methylation-preserving amplification” substantially maintains its methylation status postamplification.
[0147] A “X1///7//X2 mutation” in a specified polypeptide as used herein, where Xi and X2 are amino acids and nnn is a position in an amino acid sequence, refers to a substitution in the polypeptide of amino acid Xi present at position nnn of the full-length wild-type polypeptide with amino acid X2. The polypeptide is the human polypeptide unless indicated otherwise. The polypeptide comprising the XinnnXz mutation may, but does not necessarily, comprise additional differences from the wild-type sequence, including but not limited to truncations and deletions as well as other substitutions. For example, a “T1372S mutation” in TET2 refers to a substitution in a TET2 enzyme of the threonine present at position 1372 of the full-length wildtype human TET2 enzyme with a serine. Position 1372 of wild-type human TET2 aligns to position 258 and 248, respectively, of the truncated TET2 sequences disclosed as SEQ ID NOs: 23 and 24 of US Patent 10,961,525. Similarly, a “V1900X2 mutation” where X2 is A, C, G, I, or P in TET2 refers to a substitution in a TET2 enzyme of the valine present at position 1900 of the full-length wild-type human TET2 enzyme with an alanine, cysteine, glycine, isoleucine, or proline.
[0148] “Or” is used in the inclusive sense, i.e., equivalent to “and/or,” unless the context requires otherwise.
IL Exemplary methods
A. Overview
[0149] Cancer formation and progression may arise from both genetic modification and epigenetic features of deoxyribonucleic acid (DNA). The present disclosure provides methods and systems for analyzing DNA, such as cell-free DNA (cfDNA). The present disclosure provides methods for analyzing epigenetic and/or sequence-variable target regions.
[0150] Without wishing to be bound by any particular theory, cells in or around a cancer or neoplasm may shed more DNA than cells of the same tissue type in a healthy subject. As such, the distribution of tissue of origin of certain DNA samples, such as cfDNA, may change upon carcinogenesis. Thus, for example, an increase in the level of hypermethylation variable target regions that show lower methylation in healthy cfDNA than in at least one other tissue type can be an indicator of the presence (or recurrence, depending on the history of the subject) of cancer. Similarly, an increase in the level of hypomethylation variable target regions in the sample can be an indicator of the presence (or recurrence, depending on the history of the subject) of cancer. [0151] Thus, DNA methylation profiling can be used to detect aberrant methylation in DNA of a sample. The DNA can correspond to certain genomic regions (“differentially methylated regions” or “DMRs”) that are normally hypermethylated or hypomethylated in a given sample type (e.g., cfDNA from the bloodstream) but which may show an abnormal degree of methylation that correlates to a neoplasm or cancer, e.g., because of unusually increased contributions of tissues to the type of sample (e.g., due to increased shedding of DNA in or around the neoplasm or cancer) and/or from extents of methylation of the genome that are altered during development or that are perturbed by disease, for example, cancer or any cancer- associated disease.
[0152] In some embodiments, DNA methylation comprises addition of a methyl group to a cytosine residue at a CpG site (cytosine-phosphate-guanine site (i.e., a cytosine followed by a guanine in a 5’ -> 3’ direction of the nucleic acid sequence). In some embodiments, DNA methylation comprises addition of a methyl group to an adenine residue, such as in N6- methyladenine. In some embodiments, DNA methylation is 5-methylation (modification of the carbon in the 5th position of the cytosine ring). In some embodiments, 5-methylation comprises addition of a methyl group to the 5C position of the cytosine residue to create 5-methylcytosine (m5c or 5-mC or 5mC). In some embodiments, methylation comprises a derivative of m5c. Derivatives of m5c include, but are not limited to, 5-hydroxymethylcytosine (5-hmC or 5hmC), 5-formylcytosine (5-fC), and 5-caryboxylcytosine (5-caC). In some embodiments, DNA methylation is 3C methylation (modification of the carbon in the 3rd position of the cytosine ring). In some embodiments, 3C methylation comprises addition of a methyl group to the 3C position of the cytosine residue to generate 3 -methylcytosine (3mC). Methylation can also occur at non-CpG sites, for example, methylation can occur at a CpA, CpT, or CpC site. DNA methylation can change the activity of methylated DNA region. For example, when DNA in a promoter region is methylated, transcription of the gene may be repressed. DNA methylation is critical for normal development and abnormality in methylation may disrupt epigenetic regulation. The disruption, e.g., repression, in epigenetic regulation may cause diseases, such as cancer. Promoter methylation in DNA may be indicative of cancer.
[0153] Many commercialized methods and methods undergoing development target specific cancer changes that occur in early stage cancers and pre-cancers. However, the methylation detection accuracy, molecular recovery, coverage uniformity, and methylation-specific enrichment efficacy can be improved in these methods (e.g., single-site methylation assays), which would lead to improved clinical assay performance and/or assay cost reduction.
[0154] The present disclosure provides methods and systems for enriching methylated DNA, such as cell-free DNA (cfDNA), in a sample. The disclosed methods enrich methylated DNA in a sample by deaminating DNA in the sample using a CpG deaminase and selectively amplifying DNA molecules comprising the methylated CpGs or conversion products of the methylated CpGs. Selectively amplifying DNA molecules comprising the methylated CpGs or conversion products of the methylated CpGs can improve the efficiency of downstream analyses, such as library preparation, sequencing, and subsequent data analysis, e.g., analyzing the sequencing data to quantify a level of methylation at one or more differentially methylated regions of the DNA. In some embodiments, conversion products of methylated CpGs are TpGs. In some such embodiments, methylated cytosines of CpGs have been converted into thymines using a methylinsensitive CpG-deaminase. Selective amplification of DNA that comprises methylated CpGs or conversion products of methylated CpGs (e.g., TpGs) means that DNA not comprising methylated CpGs or conversion products of methylated CpGs (e.g., TpGs) is amplified to a lesser extent (which includes no amplification), such that resources used downstream, e.g., during sequencing and analysis, can be more efficiently focused on methylated DNA.
[0155] Some embodiments of the disclosed methods of enriching methylated DNA in a sample comprise: (a) contacting the DNA in the sample with a deaminase; and (b) selectively amplifying DNA in a converted sample that comprises methylated CpGs or conversion products of methylated CpGs. In some embodiments, the contacting the DNA in the sample with the deaminase provides a converted sample in which unmethylated CpGs in the DNA are converted to UpGs.
[0156] In some embodiments, the selective amplification of the DNA in the converted sample comprises amplifying using a uracil-intolerant DNA polymerase.
[0157] In some embodiments, the uracil-intolerant DNA polymerase used in the amplification reaction may be Q5® High-Fidelity DNA Polymerase, Phusion® High-Fidelity DNA Polymerase, Vent® DNA Polymerase, Vent® (exo-) DNA Polymerase, Deep Vent® DNA Polymerase, Deep Vent® (exo-) DNA Polymerase, or any combination thereof. In some embodiments, the uracil -intolerant DNA polymerase used in the amplification reaction may be an Archaeal uracil-intolerant DNA polymerase, such as a uracil-intolerant DNA polymerase from Pyrococcus furiosus or Methanosarcina acetivorans (see, e.g., Wardle J, Burgers PM, Cann IK, Darley K, Heslop P, Johansson E, Lin LJ, McGlynn P, Sanvoisin J, Stith CM, Connolly BA. Uracil recognition by replicative DNA polymerases is limited to the archaea, not occurring with bacteria and eukarya. Nucleic Acids Res. 2008 Feb;36(3):705-l L). In some embodiments, the Archaeal uracil-intolerant DNA polymerase is a Family B DNA polymerase, such as Pfu-Pol or Mac-Pol.
[0158] In some embodiments, the selective amplification of the DNA in the converted sample comprises: (i) contacting the DNA with a uracil-DNA glycosylase (UDG); and (ii) amplifying the DNA using an apyrimidinic (AP) site-intolerant DNA polymerase, a uracil-intolerant DNA polymerase, or a DNA polymerase that is an AP site-intolerant DNA polymerase and a uracil- intolerant DNA polymerase. In some embodiments, the contacting the DNA with a UDG converts uracils in the DNA to AP sites.
[0159] In some embodiments, the AP site-intolerant DNA polymerase may be Q5® High- Fidelity DNA Polymerase, Q5U® Hot Start High-Fidelity DNA Polymerase, Phusion® High- Fidelity DNA Polymerase, One/aq" DNA Polymerase, Taq DNA Polymerase, LongAmp® Taq DNA Polymerase, Hemo KlenT , Epimark® Hot Start Taq DNA Polymerase, Bst DNA Polymerase, Full Length, Bst DNA Polymerase, Large Fragment, Bst 2.0 DNA Polymerase, Bst 3.0 DNA Polymerase, Bsu DNA Polymerase, Large Fragment, phi29 DNA Polymerase, phi29-XT DNA Polymerase, Sulfolobus DNA Polymerase IV, Therminator™ DNA Polymerase, T7 DNA Polymerase, DNA Polymerase I (E. coli), DNA Polymerase I, Large (KI enow) Fragment (“KI enow fragment”), KI enow Fragment (3 '— 5' exo-), T4 DNA Polymerase, Vent® DNA Polymerase, Vent® (exo-) DNA Polymerase, Deep Vent® DNA Polymerase, Deep Vent® (exo-) DNA Polymerase, or any combination thereof.
[0160] In some embodiments, the selective amplification of the DNA in the converted sample comprises: (i) contacting the DNA with a UDG; (ii) cutting DNA comprising AP sites using an AP lyase; and (iii) amplifying DNA that was not cut by the AP lyase using a DNA polymerase. In some embodiments, contacting the DNA with a UDG converts uracils in the DNA to AP sites. In some embodiments, the AP lyase is endonuclease VIII, formamidopyrimidine (fpg) DNA Glycosylase, thermostable oxoguanine glycosylase (OGG), or any combination thereof. In some embodiments, the DNA in the converted sample comprises adapters. In some embodiments, the amplifying DNA that was not cut by the AP lyase using a DNA polymerase comprises amplification using primers (e.g., amplification primers) that bind sites in the adapters. [0161] In some embodiments, the DNA polymerase may be Q5® High-Fidelity DNA Polymerase, Q5U® Hot Start High-Fidelity DNA Polymerase, Phusion® High-Fidelity DNA Polymerase, One aq® DNA Polymerase, Taq DNA Polymerase, LongAmp® Taq DNA Polymerase, Hemo Klen 7i«/, Epimark® Hot Start Taq DNA Polymerase, Bst DNA Polymerase, Full Length, Bst DNA Polymerase, Large Fragment, Bst 2.0 DNA Polymerase, Bst 3.0 DNA Polymerase, Bsu DNA Polymerase, Large Fragment, phi29 DNA Polymerase, phi29-XT DNA Polymerase, Sulfolobus DNA Polymerase IV, Therminator™ DNA Polymerase, T7 DNA Polymerase, DNA Polymerase I (E. coli), DNA Polymerase I, Large (Klenow) Fragment (“Klenow fragment”), Klenow Fragment (3 ' — >5' exo-), T4 DNA Polymerase, Vent® DNA Polymerase, Vent® (exo-) DNA Polymerase, Deep Vent® DNA Polymerase, Deep Vent® (exo-) DNA Polymerase, or any combination thereof.
[0162] In some embodiments, the selective amplification of the DNA in the converted sample comprises: (i) contacting the DNA with a uracil-specific excision reagent enzyme; (ii) cutting the DNA; and (iii) amplifying DNA that was not cut by the uracil-specific excision reagent enzyme using a DNA polymerase. In some embodiments, the contacting the DNA with a uracil-specific excision reagent enzyme converts uracils in the DNA to AP sites. In some embodiments, the DNA comprises adapters. In some embodiments, the amplifying DNA that was not cut by the uracil -specific excision reagent enzyme using a DNA polymerase comprises amplification using primers (e.g., amplification primers) that bind sites in the adapters. In some embodiments, the uracil -specific excision reagent enzyme is USER® (New England Biolabs, Massachusetts, United States).
[0163] In some embodiments, the DNA polymerase is an AP-site intolerant DNA polymerase or a uracil-intolerant DNA polymerase.
[0164] In some embodiments, the deaminase is a dsDNA deaminase and the selective amplification of the DNA in the converted sample comprises: cutting DNA comprising UpGs using a mismatch endonuclease (MME); and (ii) amplifying DNA that was not cut by the MME using a DNA polymerase. In some embodiments, the MME is endonuclease I or Authenticase®. In some embodiments, the DNA in the converted sample comprises adapters. In some embodiments, the amplifying DNA that was not cut by the MME using a DNA polymerase comprises amplification using primers (e.g., amplification primers) that bind sites in the adapters. [0165] In some embodiments, the DNA comprises barcodes. In some embodiments, the adapters comprise barcodes. In some embodiments, the method comprises ligating adapters comprising barcodes to the DNA. In some embodiments, the ligation of the adapters comprising barcodes occurs prior to amplifying the DNA (e.g., the selective amplification of the DNA in the converted sample). In some embodiments, the ligation of the adapters comprising barcodes occurs prior to contacting the DNA with the deaminase. In some embodiments, the method comprises ligating adapters to the DNA after cutting the DNA. In some embodiments, the adapters are Y-shaped adapters.
[0166] In some embodiments, the deaminase is thermally inactivated after deamination of the DNA in the sample. In some embodiments, the thermal inactivation comprises heating or cooling of the deaminase to a temperature at which the deaminase has reduced or inhibited activity relative to a deaminase that has not been subjected to heating or cooling. In some embodiments, the thermal inactivation completely inhibits the activity of the deaminase or reduces the activity of the deaminase by at least about 5%, about 10%, about 15%, about 20%, about 25%, about 50%, about 75%, about 90%, about 95%, about 98%, about 99%, or 100% relative to a deaminase that has not been subjected to heating or cooling.
[0167] In some embodiments, the steps of contacting the DNA with the UDG and cutting DNA comprising the AP sites using the AP lyase are in the same reaction mixture.
[0168] In some embodiments, the deaminase is a double-stranded DNA (dsDNA) deaminase. In some embodiments, the deaminase is a single-stranded DNA (ssDNA) deaminase. In some embodiments, the deaminase is a methyl -insensitive deaminase, including e.g., APOBEC3A (A3 A). In some embodiments, the deaminase is a methyl -sensitive deaminase, including e.g., modification-sensitive DNA deaminase A (MsddA) or a modification-sensitive DNA deaminase A (MsddA)-like deaminase.
[0169] The disclosed methods can be combined with analysis of one or more additional biomarkers. In some embodiments, the disclosed methods are combined with one or more methods, such as but not limited to, methods for assessing DNA methylation patterns, DNA mutations (such as somatic mutations), nucleic acid fragmentation patterns, non-coding RNA (such as micro RNAs (miRNAs), ribosomal RNAs, transfer RNAs, small nucleolar RNAs (snow RNAs), and/or small nuclear RNAs (snRNAs)) levels, and/or cell type proportions/levels, cellular locations, and/or structural modifications of one or more proteins (such as in a sample from a subject). In some embodiments, the disclosed methods are combined with one or more analyses of genetic variations including mutations, rare mutations, indels, rearrangements, copy number variations, transversions, translocations, recombinations, inversion, deletions, aneuploidy, partial aneuploidy, polyploidy, chromosomal instability, chromosomal structure alterations, gene fusions, chromosome fusions, gene truncations, gene amplification, gene duplications, chromosomal lesions, DNA lesions, abnormal changes in nucleic acid chemical modifications, abnormal changes in epigenetic patterns, and/or abnormal changes in nucleic acid 5-methylcytosine.
B. Samples and Subjects
[0170] The disclosure relates to methods of enriching methylated DNA in a sample, comprising contacting the DNA of the sample with a deaminase (e.g., a methyl sensitive CpG-specific deaminase or a methyl-insensitive CpG-specific deaminase) to yield a converted sample, and selectively amplifying the DNA of the converted sample. In some cases, the DNA sample is obtained or has been obtained from a subject. In some embodiments, the DNA sample may comprise or consist of DNA from a biological sample obtained from a subject. The subject may be a human, a mammal, an animal, a primate, rodent (including mice and rats), or other common laboratory, domestic, companion, service or agricultural animal, for example a rabbit, dog, cat, horse, cow, sheep, goat or pig. Preferably, the DNA sample is from a human. The subject may in some cases have or be suspected of having a cancer, tumor, or neoplasm. In other cases, the subject may not have cancer or a detectable cancer symptom. The subject may have been treated with one or more cancer therapy, e g., any one or more of chemotherapies, antibodies, vaccines or biologies. The subject may be in remission, e.g. from a tumor, cancer, or neoplasia (e.g., following treatment such as chemotherapy, surgical resection, radiation, or a combination thereof). The subject may or may not be diagnosed as being susceptible to cancer or any cancer- associated genetic mutations/disorders. In some embodiments, the sample is a DNA sample obtained from a tumor tissue biopsy. The cancer, tumor, or neoplasm may generally be of any type, for example a cancer tumor or neoplasm of the lung, colon, rectum (or colorectum), kidney, breast, prostate, or liver, or other type of cancer as described herein. In some embodiments, the sample is obtained from a subject in remission from a tumor, cancer, or neoplasia (e.g., following chemotherapy, surgical resection, radiation, or a combination thereof). In any of the foregoing embodiments, the pre-cancer, cancer, tumor, or neoplasia or suspected pre-cancer, cancer, tumor, or neoplasia may be of the bladder, head and neck, lung, colon, rectum, kidney, breast, prostate, skin, or liver. In some embodiments, the pre-cancer, cancer, tumor, or neoplasia or suspected pre-cancer, cancer, tumor, or neoplasia is of the lung. In some embodiments, the pre-cancer, cancer, tumor, or neoplasia or suspected pre-cancer, cancer, tumor, or neoplasia is of the colon or rectum. In some embodiments, the pre-cancer, cancer, tumor, or neoplasia or suspected precancer, cancer, tumor, or neoplasia is of the breast. In some embodiments, the pre-cancer, cancer, tumor, or neoplasia or suspected pre-cancer, cancer, tumor, or neoplasia is of the prostate. In any of the foregoing embodiments, the subject may be a human subject. In some embodiments, the sample is obtained from a subject having a stage I cancer, stage II cancer, stage III cancer or stage IV cancer.
[0171] In some embodiments, the subject may have an infection, a transplant rejection, or other disease or disorder related to changes in the immune system. The subject may not have cancer or a detectable cancer symptom. The subject may have been treated with one or more cancer therapy, e.g., any one or more of chemotherapies, antibodies, vaccines or biologies. The subject may be in remission. The subject may or may not be diagnosed as being susceptible to cancer or any cancer-associated genetic mutations/disorders.
[0172] The biological sample can be any biological sample isolated from a subject. Biological samples can include body tissues, such as known or suspected solid tumors (such as carcinomas, adenocarcinomas, or sarcomas), whole blood, platelets, serum, plasma, stool, red blood cells, white blood cells or leucocytes, endothelial cells, tissue biopsies, cerebrospinal fluid synovial fluid, lymphatic fluid, ascites fluid, interstitial or extracellular fluid, the fluid in spaces between cells, including gingival crevicular fluid, bone marrow, pleural effusions, cerebrospinal fluid, saliva, mucous, sputum, semen, sweat, urine. In some embodiments, biological samples are body fluids, particularly blood and fractions thereof (e.g., plasma and/or serum), or urine. A sample can be in the form originally isolated from a subject or can have been subjected to further processing to remove or add components, such as cells, or enrich for one component relative to another.
[0173] In some embodiments, a population of nucleic acids is obtained from a serum, plasma or blood sample from a subject having or suspected of having neoplasia, a tumor, precancer, or cancer or previously diagnosed with neoplasia, a tumor, precancer, or cancer. The population includes nucleic acids having varying levels of sequence variation and/or epigenetic variation, such as post-translation modifications (PTMs) of chromatin and/or nucleobase modifications, e.g., modifications of cytosine, particularly at the 5-position of the nucleobase, e.g., 5- methylcytosine, 5-hydroxymethylcytosine, 5-formylcytosine and 5-carboxylcytosine. [0174] A sample can be isolated or obtained from a subject and transported to a site of sample analysis. The sample may be preserved and shipped at a desirable temperature, e.g., room temperature, 4°C, -20°C, and/or -80°C. A sample can be isolated or obtained from a subject at the site of the sample analysis.
[0175] In a particular embodiment, the DNA sample comprises cell-free DNA. In another particular embodiment the DNA sample is a DNA sample from a formalin fixed paraffin embedded (FFPE) sample.
[0176] In some embodiments, a population of nucleic acids is obtained from a serum, plasma or blood sample from a subject suspected of having neoplasia, a tumor, precancer, or cancer or previously diagnosed with neoplasia, a tumor, precancer, or cancer. The population includes nucleic acids having varying levels of sequence variation, epigenetic variation, and/or postreplication or transcriptional modifications. Post-replication modifications include modifications of cytosine, particularly at the 5-position of the nucleobase, e.g., 5-methylcytosine, 5- hydroxymethylcytosine, 5-formylcytosine and 5-carboxylcytosine.
[0177] In some embodiments, the DNA sample is from plasma. The volume of plasma used to obtain the DNA sample can depend on the desired read depth for sequenced regions. Exemplary volumes are 0.4-40 ml, 5-20 ml, 10-20 ml. For example, the volume can be 0.5 mL, 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, 10 mL, 20 mL, 30 mL, or 40 mL. A volume of sampled plasma may be 5 to 20 mL. In some embodiments, the sample volume is 3-5 mL of plasma, such as 4 mL of plasma, per 10 mL whole blood.
[0178] In some embodiments, the sample comprises whole blood. Exemplary volumes of sampled whole blood are 0.4-40 mL, 5-20 mL, 10-20 mL, 1-6 mL, 1-3 mL, and 3-5 mL. For example, the volume can be 0.5 mL, 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, 10 mL, 20 mL, 30 mL, or 40 mL. A volume of sampled whole blood may be 5 to 20 mL. In some embodiments, the sample volume is 1-5 mL of whole blood, such as 2.5 mL of whole blood.
[0179] In some embodiments, the sample comprises buffy coat separated from whole blood. Exemplary volumes of sampled buffy coat are 0.1-20 mL, 1-10 mL, 1-5 mL, 0.2-0.6 mL, and 0.3-0.5 mL. For example, the volume can be 0.1 mL, 0.2 mL, 0.3 mL, 0.4 mL, 0.5 mL, 0.6 mL, 0.7 mL, 0.8 mL, 0.9 mL, 1 mL, 2 mL, 3 mL, 4 mL, 5 mL 10 mL, or 20 mL. A volume of sampled buffy coat may be 1 to 10 mL. In some embodiments, the sample volume is 0.1-0.5 mL of buffy coat, such as 0.3 mL of buffy coat, per 10 mL whole blood. [0180] In some embodiments, the sample comprises PBMCs separated from whole blood. Exemplary volumes of sampled PBMCs are 0.1-20 mL, 1-10 mL, 1-5 mL, 0.2-0.6 mL, and 0.3- 0.5 mL. For example, the volume can be 0.1 mL, 0.2 mL, 0.3 mL, 0.4 mL, 0.5 mL, 0.6 mL, 0.7 mL, 0.8 mL, 0.9 mL, 1 mL, 2 mL, 3 mL, 4 mL, 5 mL 10 mL, or 20 mL. A volume of sampled PBMCs may be 1 to 10 mL. In some embodiments, the sample volume is 0.1-0.5 mL of PBMCs, such as 0.3 mL of PBMCs, per 10 mL whole blood.
[0181] In some embodiments, the sample comprises leukocytes separated from subject blood using leukapheresis. Exemplary volumes of sampled leukocytes from leukapheresis are 0.1-20 mL, 1-10 mL, 1-5 mL, 0.2-0.6 mL, and 0.3-0.5 mL. For example, the volume can be 0.1 mL, 0.2 mL, 0.3 mL, 0.4 mL, 0.5 mL, 0.6 mL, 0.7 mL, 0.8 mL, 0.9 mL, 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 10 mL, or 20 mL. A volume of sampled leukocytes from leukapheresis may be 1 to 10 mL. In some embodiments, the sample volume is 0.1-0.6 mL of leukocytes from leukapheresis, such as 0.4 mL of leukocytes, per 10 mL whole blood.
[0182] A sample can comprise various amounts of DNA that contain genome equivalents. For example, a sample of about 30 ng DNA can contain about 10,000 (104) haploid human genome equivalents and, in the case of cell free DNA (cfDNA), about 200 billion (2xlOn) individual polynucleotide molecules. Similarly, a sample of about 100 ng of DNA can contain about 30,000 haploid human genome equivalents and, in the case of cfDNA, about 600 billion individual molecules.
[0183] A sample can comprise nucleic acids from different sources, e.g., nucleic acids from cells and cell-free nucleic acids of the same subject, and nucleic acids from cells and cell-free nucleic acids of different subjects. In some embodiments, the nucleic acid may be DNA. A sample can comprise DNA carrying mutations. For example, a sample can comprise DNA carrying germline mutations and/or somatic mutations. Germline mutations refer to mutations existing in germline DNA of a subject. Somatic mutations refer to mutations originating in somatic cells of a subject, e.g., cancer cells. A sample can comprise DNA carrying cancer-associated mutations (e.g., cancer-associated somatic mutations). A sample can comprise an epigenetic variant, wherein the epigenetic variant associated with the presence of a genetic variant such as a cancer-associated mutation. In some embodiments, the sample comprises an epigenetic variant associated with the presence of a genetic variant, wherein the sample does not comprise the genetic variant.
[0184] The DNA sample may be or comprise cell free nucleic acids or cfDNA. The cfDNA may be obtained from a test subject, for example as described above. For example, the sample for analysis may be plasma or serum containing cell-free nucleic acids. “Cell-free DNA” “cfDNA molecules,” or “cfDNA”, for example, include DNA molecules that naturally occur in a subject in extracellular form (e.g., in blood, serum, plasma, or other bodily fluids such as lymph, cerebrospinal fluid, urine, or sputum). While the cfDNA originally existed in a cell or cells in a large complex biological organism, e.g., a mammal, it has undergone release from the cell(s) in vivo into a fluid found in the organism, and may be obtained by obtaining a sample of the fluid without the need to perform an in vitro cell lysis step. In other words, cell-free nucleic acids or cfDNA are nucleic acids or DNA not contained within or otherwise bound to a cell, or the nucleic acids or DNA remaining in a sample after removing intact cells. Cell-free nucleic acids include DNA, RNA, and hybrids thereof, including genomic DNA, mitochondrial DNA, siRNA, miRNA, circulating RNA (cRNA), tRNA, rRNA, small nucleolar RNA (snoRNA), Piwi- interacting RNA (piRNA), long non-coding RNA (long ncRNA), or fragments of any of these. Cell-free nucleic acids can be double-stranded, single-stranded, or a hybrid thereof. A cell-free nucleic acid can be released into bodily fluid through secretion or cell death processes, e.g., cellular necrosis and apoptosis. Some cell-free nucleic acids are released into bodily fluid from cancer cells e.g., circulating tumor DNA, (ctDNA). Others are released from healthy cells. In some embodiments, cfDNA is cell-free fetal DNA (cffDNA). In some embodiments, cell free nucleic acids are produced by tumor cells. In some embodiments, cell free nucleic acids are produced by a mixture of tumor cells and non-tumor cells.
[0185] Exemplary amounts of cell-free nucleic acids (e.g. cfDNA) in a sample before amplification range from about 1 fg to about 1 pg, e.g., 1 pg to 200 ng, 1 ng to 100 ng, 10 ng to 1000 ng. For example, the amount can be up to about 600 ng, up to about 500 ng, up to about 400 ng, up to about 300 ng, up to about 200 ng, up to about 100 ng, up to about 50 ng, or up to about 20 ng of cell-free nucleic acid molecules. The amount can be at least 1 fg, at least 10 fg, at least 100 fg, at least 1 pg, at least 10 pg, at least 100 pg, at least 1 ng, at least 10 ng, at least 100 ng, at least 150 ng, or at least 200 ng of cell-free nucleic acid molecules. The amount can be up to 1 femtogram (fg), 10 fg, 100 fg, 1 picogram (pg), 10 pg, 100 pg, 1 ng, 10 ng, 100 ng, 150 ng, or 200 ng of cell-free nucleic acid molecules. The method can comprise obtaining 1 femtogram (fg) to 200 ng cell-free nucleic acid molecules from samples.
[0186] Cell-free nucleic acids have an exemplary size distribution of about 100-500 nucleotides, with molecules of 110 to about 230 nucleotides representing about 90% of molecules, with a mode of about 168 nucleotides and a second minor peak in a range between 240 to 440 nucleotides.
[0187] Cell-free nucleic acids can be isolated from bodily fluids through a fractionation or partitioning step in which cell-free nucleic acids, as found in solution, are separated from intact cells and other non-soluble components of the bodily fluid. Partitioning may include techniques such as centrifugation or filtration. Alternatively, cells in bodily fluids can be lysed and cell-free and cellular nucleic acids processed together. Generally, after addition of buffers and wash steps, nucleic acids can be precipitated with an alcohol. Further clean up steps may be used such as silica-based columns to remove contaminants or salts. Non-specific bulk carrier nucleic acids, DNA or protein for sequencing, hybridization, and/or ligation, may be added throughout the reaction to optimize certain aspects of the procedure such as yield.
[0188] After such processing, samples can include various forms of nucleic acid including double stranded DNA, single stranded DNA and single stranded RNA. In some embodiments, single stranded DNA and RNA can be converted to double stranded forms so they are included in subsequent processing and analysis steps.
[0189] The methods disclosed herein are also particularly suited for the analysis of DNA from formalin-fixed paraffin-embedded (FFPE) tissue samples. While the formalin fixation process adequately preserves the ultrastructure of the tissues, it results in various types of damage to the DNA within the tissues, such as nicks in the DNA. As explained elsewhere herein, these nicks can lead to synthesis of regions of the DNA molecule in the end repair process. The methods disclosed herein allow for these regions to be identified and the sequence data to be interpreted accordingly.
[0190] Reference or control molecules can be added to or spiked into a sample as a control or normalization standard. For example, a certain amount of modified DNA from a species other than the species of the subject from which the sample was obtained or synthetic nucleic acids comprising certain modifications may be added to the sample. In some embodiments, the reference or control molecules are distinguishable from the molecules originally present in the sample. In some embodiments, the detected DNA sequences are normalized to the reference or control molecules.
C. End repair and A-tailing
[0191] In some embodiments, the disclosed methods comprise subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules. In some embodiments, the end repair is performed before contacting the DNA in the sample with a deaminase. In some embodiments, the end repair is performed using deoxynucleotide triphosphates (dNTPs). In some embodiments, at least one type of dNTP comprises a modified base, and the at least one dNTP comprising a modified base is incorporated into repaired regions of the end-repaired DNA molecules at one or more locations.
[0192] End repair refers to methods for repairing DNA by the conversion of non-blunt ended DNA into blunt ended DNA. Sequencing workflows typically use end repair to make ends of DNA molecules compatible with adapters, which are subsequently ligated onto the DNA. Fragmented and/or damaged DNA (e.g. cfDNA or DNA from FFPE samples) often contain nonblunt ends, which contain 3’overhangs and/or 5’overhangs. A 3’overhang refers to the 3’ end of a DNA strand which extends beyond the 5 ’end of the paired strand, resulting in one or more unpaired nucleotides at the 3 ’end of the DNA strand. Conversely, a 5 ’overhang refers to the 5’ end of a DNA strand which extends beyond the 3 ’end of the paired strand, resulting in one or more unpaired nucleotides at the 5 ’end of the DNA strand.
[0193] The process of end repair involves the conversion of double-stranded DNA with 3’overhangs and/or 5’overhangs to double-stranded DNA without overhangs. This can be done using one or more enzymes such as T4 DNA polymerase and/or Klenow fragment. The 3’ to 5’ exonuclease activity of these enzymes removes the 3 ’ends at 3’overhangs and the 5’ to 3’ polymerase activity of these enzymes extends the 3’ ends at 5’ overhangs to remove the 5’ overhang, thereby generating a blunt-ended DNA molecule. In order to fill in these 5’ overhangs, end repair is conducted in the presence of dATP, dCTP, dGTP and dTTP. End repair can also include a second step, which involves the addition of a phosphate group to the 5' ends of DNA, by an enzyme such as polynucleotide kinase. This makes the 5’ends of the end-repaired DNA molecules compatible with the subsequent action of DNA polymerases and DNA ligases.
[0194] As used herein, the term “A-tailing” refers to the addition of a single deoxyadenosine residue to the end of a blunt-ended double-stranded DNA fragment to form a 3' deoxyadenosine single-base overhang. Such A tailing reactions are conducted with polymerases which have the ability to add a non-templated A to the 3' end of a blunt, double-stranded DNA molecule. Polymerases capable of A-tailing typically do not possess 3 ’-5’ exonuclease activity. When A- tailing is performed as a separate reaction to end repair, it is typically conducted in the presence of dATP, but the absence of dCTP, dTTP and dGTP. A-tailed fragments are not compatible for self-ligation (i.e., self-circularizatian and concantenation of the DNA), but they are compatible with 3' T-overhangs, which can be used on adapters. Methods comprising end repair, A-tailing and ligation to adapters with 3' T-overhangs can result in higher efficiency ligation, compared to blunt ended ligation, as blunt ligation can lead to self-ligation of the adapters and/or DNA molecules.
[0195] In some embodiments, the methods disclosed herein comprise end repair of the DNA molecules followed by blunt end ligation of adapters. In other embodiments, the methods disclosed herein comprise end repair of the DNA molecules followed by A-tailing and sticky-end ligation of T-tailed adapters. When the methods disclosed herein comprise an A-tailing step, it may be performed separately from the end repair with an intervening reaction clean-up step or it may be performed in the same reaction as the end repair (e.g. using NEBNext® Ultra™ II End Repair/dA-Tailing Module (E7546)). In some embodiments, the reaction clean-up step removes unincorporated dNTPs. In instances wherein the A-tailing reaction is performed in the same reaction as end repair, the sticky-end ligation may be performed with a mixture of T-tailed adapters and C-tailed adapters.
[0196] End repair and A tailing reactions can have varying impacts on the composition of the DNA molecule, dependent on the exact workflow and reaction components used. These reactions can lead to the synthesis of regions at the 3 ’ends of DNA strands, but also the synthesis of internal regions through nick translation and through gap filling followed by ligation.
[0197] . In some embodiments, end repair can lead to 3 ’fill in with unmethylated cytosines, which may not reflect the true methylation status of that position in the DNA molecule prior to the generation of the 5 ’overhang. In nicked DNA, polymerases which contain 5’ to 3’ exonuclease activity and/or strand displacement activity can lead to the synthesis of internal regions of the DNA molecule through nick translation. If the end repair reaction is conducted with non-methylated deoxy cytidine triphosphate (dCTP), the synthesized regions will incorporate the non-methylated dCTP, potentially at positions which initially comprised methylated cytosines. In gapped DNA, both the DNA polymerases used in end repair and A tailing can lead to the generation of synthesized regions. The gaps can be fdled in with DNA polymerases used in the end repair reaction, regardless of whether they possess 5’ to 3’ exonuclease activity or strand displacement activity. After this gap filling, a nick will still exist between the synthesized region and the region of the original DNA molecule 3’ of the gap. The A-tailing enzymes may then introduce further synthesized regions through nick translation, as described for the nicked DNA. This synthesized region may extend to the 3 ’end of the DNA molecule.
[0198] In some embodiments, the end-repair and the A-tailing reactions are performed in a single tube. In such cases, the A tailing reaction can be performed at a higher temperature than the end repair. Optionally, end repair is performed at ambient temperature (e.g. 15-35°C) and A tailing is performed at a temperature over 60°C, including e.g., about 60°C-75°C. The A tailing reaction can be performed using a thermostable polymerase (e g. Taq DNA polymerase, TH DNA polymerase, Bst DNA Polymerase, Large Fragment or Tth DNA polymerase) and the method further comprises increasing temperature of the sample after the end repair to inactivate the polymerase used in end repair (e.g. T4 DNA polymerase or Klenow fragment). In some embodiments the A-tailing is performed using a DNA polymerase that: (i) does not possess 5 ’-3’ exonuclease activity; and/or (ii) is not a strand displacing DNA polymerase. These properties reduce the ability of the DNA polymerase to extend from nick. This reduces the level of synthesis which may occur during the end repair and A-tailing reactions thus reducing the proportion of sequencing data that may be fdtered out as potentially containing artifactual data. Accordingly, in some embodiments, the A-tailing is performed using a DNA polymerase that cannot extend from a nick in the DNA such as HemoKlen Taq. In other embodiments, the A- tailing is performed using Taq DNA polymerase. In other embodiments, the A-tailing is performed using Tfl polymerase, Bst DNA Polymerase, Large Fragment or Tth polymerase. [0199] . In order to reduce the level of synthesized regions, the end repair reaction can be performed using DNA polymerases can be used which lack 5 ’to 3’ exonuclease activity and/or strand displacement activity (e.g. T4 DNA polymerase or Klenow fragment).
[0200] In nicked DNA and gapped DNA, nick translation is reduced in end repair through the use of polymerases which lack 5’to 3’ exonuclease activity and/or strand displacement activity. The separation of the end repair and A tailing reaction by a reaction clean-up means that only dATP (not dCTP, dTTP or dGTP) is present in the A tailing reaction. This means that efficient nick translation cannot occur in the A tailing reaction because the three of the four nucleotide components are not present in the reaction mixture. In gapped DNA, the gaps can be filled in with DNA polymerases used in the end repair reaction, regardless of whether they possess 5’ to 3’ exonuclease activity or strand displacement activity. These filled gaps thereby generate synthesized regions. [0201] In some embodiments, the end-repair is performed with a polymerase which lacks 5’to 3’ exonuclease activity and/or strand displacement activity. In some cases, the polymerase used in the end repair reaction may be Q5® High-Fidelity DNA Polymerase, Q5U® Hot Start High- Fidelity DNA Polymerase, Phusion® High-Fidelity DNA Polymerase, Hemo Klen aq, phi29 DNA Polymerase, T7 DNA Polymerase, DNA Polymerase I (E. coli), DNA Polymerase I, Large (Klenow) Fragment (“KI enow fragment”) or T4 DNA Polymerase. In some embodiments, the polymerase used in the end repair is T4 DNA Polymerase or Klenow fragment. In some embodiments, the end repair is performed with a DNA polymerase which has 5 ’-3’ exonuclease activity and/or is a strand displacing DNA polymerase.
[0202] In some embodiments, the methods disclosed herein comprise an A tailing reaction after the end repair and before the ligation reaction, wherein the end repair and A tailing reactions are separated by a reaction cleanup. The A tailing reaction is typically performed in the presence of dATP, but in the absence of dCTP, dTTP and dGTP. In some embodiments, the A tailing reaction is performed using Klenow Fragment lacking 3'-5' exonuclease activity.
[0203] In some embodiments, a dNTP that comprises a modified base is used in end repair, which may be any modified base wherein the presence or the absence of the modification can be detected by a type of sequencing. In some embodiments, a dNTP comprising a modified base can be used in a combined end repair and A-tailing reaction. In some embodiments, the modified base is incorporated in the synthesized regions at both CpG sites and CpH sites (i.e. CpA, CpC and CpT sites). While methylation of cytosines in non-CpG contexts has been described, it is thought to comprise 0.02% of total methyl-cytosine in differentiated somatic cells (Jang et al. Genes (Basel). 2017 Jun; 8(6): 148). The presence of methylated cytosine in non-CpG contexts in the end-repaired DNA can therefore be interpreted as being introduced during the end repair and/or A-tailing reactions. Using a dNTP comprising a modified base can therefore be used to effectively label the synthesized regions of the end repaired DNA.
[0204] In some embodiments, a dNTP that comprises a modified base may comprise any modified base wherein the presence or the absence of the modification can be detected by a type of sequencing. The modified base may be 5-caryboxylcytosine (5-caC), 4-methylcytosine (4mC), 5-methylcytosine (5mC), 5-hydroxymethyl-cytosine (5hmC), N6-methyladenosine (6mA), bromodeoxyuridine (BrdU), 5-fluorodeoxyuridine (FldU), 5 -iododeoxyuridine (IdU), 5- ethynyldeoxyuridine (EdU) and/or 8-oxoguanine (8oxoG). [0205] When a dNTP comprising a modified base is used, it may be used in place of the equivalent unmodified base in the end repair reaction. For instance, if a dCTP comprising 5mC is used in the end repair reaction, there may be no dCTP comprising an unmodified cytosine. This would ensure that dCTPs incorporated into the DNA molecule during the end repair reaction contain 5mC. In some embodiments, multiple types of dNTP comprising a modified base are used in the end repair. For example, dATP comprising 6mA and dCTP comprising 5mC can be used in the end repair reaction in place of dATP comprising unmodified adenine and dCTP comprising unmodified cytosine. The use of multiple types of dNTP comprising a modified base is advantageous because it provides increased resolution in defining the regions of the end- repaired DNA molecule which have been synthesized during the end repair reaction. This is because, in this example, the end of a synthesized region can be defined as the first unmodified adenine or unmodified cytosine after a stretch of containing 6mAs and/or 5mCs, rather than relying on the detection of solely an unmodified adenine or solely an unmodified cytosine.
[0206] The sequencing method used will depend on the type of modified base used in the endrepair reaction such that the specific modification can be detected. Exemplary conversion-based methods are described above alongside the base modification which they can detect. Moreover, nanopore-based sequencing can be used to detect 5-caC, 4mC, 5mC, 5hmC, 6mA, BrdU, FldU, IdU, and EdU. and single-molecule real time (SMRT) sequencing from Pacific Biosciences can be used to detect 5-caC, 4mC, 5mC, 5hmC, 6mA, and 8oxoG.
[0207] The disclosed methods use at least one type of dNTP which comprises a modified base (e.g. a methylated deoxy cytidine triphosphate, such as deoxycytidine triphosphate comprising 5- methylcytosine (5mC) and/or 5 -hydroxymethyl -cytosine (5hmC)) in the end repair reaction. In particular embodiments, the dNTP is 5mC. During end repair reactions, the methylated deoxycytidine triphosphate will be incorporated into the synthesized regions regardless of the sequence context. This will result in methylated cytosines in non-CpG positions (i.e., methylated cytosines in a CpH context), which are very rare in nature. These methylated non-CpG cytosines can therefore be used as labels for identifying synthesized regions in the end repaired DNA molecule. Similarly, other types of dNTP which comprise a modified base uncommon or absent in nature can be used. The identification of such modified bases can be performed using sequencing, and regions comprising these modifications can be interpreted as defining regions which were synthesized in the end repair reaction. [0208] In other embodiments of the disclosed methods, the modified base is a methylated cytosine, such as 5mC or 5hmC. In some embodiments, the methylated cytosine is 5mCpH (where H = A, T, or C). In other embodiments, the modified base is other than 5mC or 5hmC. In some embodiments wherein the modified base is other than 5mC or 5hmC, a repaired region is defined as (i) the sequence between two non-modified bases spanning a modified base, wherein the bases are of the same identity to the modified bases present in the at least one type of dNTP; and/or (ii) the sequence between a non-modified base and the end of a sequence read, wherein there is no additional non-modified bases between the non-modified base and the end of the sequence read, where the non-modified bases are the same identity as the modified base present in the at least one type of dNTP. In some embodiments wherein the modified base is a methylated cytosine, such as 5mC or 5hmC, a repaired region is defined as (i) the sequence between two non-methylated cytosines which span one or more methylated CpH cytosines; and/or (ii) the sequence between a methylated CpH cytosine and an end of a sequence read, wherein the methylated CpH cytosine is the CpH cytosine most distant from the end of the sequence read, or a subsequence thereof comprising one or more methylated CpH cytosines.
D. Ligation to Adapters
[0209] In some embodiments, the methods comprise ligating adapters to DNA. In some embodiments, DNA molecules can be subjected to blunt-end ligation with blunt-ended adapters. In some embodiments, DNA molecules can be subjected to sticky-end ligation with sticky-ended adapters. In some embodiments, once the DNA has been end-repaired it can be subjected to blunt-end ligation with blunt-ended adapters, in cases where A-tailing is not performed, or sticky end ligation with T-tailed adapters, when A tailing is performed. DNA molecules can be ligated to adapters at either one end or both ends. DNA molecules can be ligated with at least partially double stranded adapter (e.g., a Y shaped or bell-shaped adapter). In some embodiments, the ligation step can take place before or after the conversion step. In general, “conversion step” or “conversion procedure” refers to any step or procedure that changes the base pairing specificity of one or more nucleotides. In some embodiments, the conversion step comprises contacting DNA (e.g., DNA in a sample) with a deaminase. In some embodiments, the conversion step of contacting DNA (e.g., DNA in a sample) with a deaminase provides a converted sample in which unmethylated CpGs in the DNA are converted to UpGs. In some embodiments, the ligation step is performed after the conversion step. In some embodiments, the ligation step occurs before contacting the DNA with a deaminase. In some embodiments, the ligation step occurs before selectively amplifying the DNA in the converted sample. In some embodiments, the ligation step occurs after contacting the DNA with a deaminase and before selectively amplifying the DNA in the converted sample. In some embodiments, adapters are ligated to end-repaired DNA molecules or the adapters are ligated to the DNA molecule or a plurality of DNA molecules. In some such embodiments, the ligation reaction also seals nicks present in the end-repaired DNA. [0210] DNA ligase and adapters are added to ligate DNA molecules in the sample with an adapter on one or both ends, i.e. to form adapted DNA. As used herein, “adapter” refers to short nucleic acids (e.g., less than about 500, less than about 100 or less than about 50 nucleotides in length, or be 20-30, 20-40, 30-50, 30-60, 40-60, 40-70, 50-60, 50-70, 20-500, or 30-100 bases from end to end) that are typically at least partially double-stranded and can be ligated to the end of a given sample DNA molecule. In some instances, two adapters can be ligated to a single sample DNA molecule, with one adapter ligated to each end of the sample nucleic acid molecule. [0211] In some embodiments, the ligase used in ligation reactions can act on both single strand DNA nicks and double stranded DNA ends. In some cases, the ligase is T4 DNA ligase or T3 DNA ligase. Adapters can include nucleic acid primer binding sites to permit amplification of a sample DNA molecule flanked by adapters at both ends, and/or a sequencing primer binding site, including primer binding sites for sequencing applications, such as various next generation sequencing (NGS) applications. Adapters can include a sequence for hybridizing to a solid support, e.g., a flow cell sequence. Adapters can also include binding sites for capture probes, such as an oligonucleotide attached to a flow cell support or the like. Adapters can also include sample indexes and/or molecular barcodes. These are typically positioned relative to amplification primer and sequencing primer binding sites, such that the sample index and/or molecular barcode is included in amplicons and sequencing reads of a given DNA molecule.
Adapters of the same or different sequence can be linked to the respective ends of a sample DNA molecule. In some cases, adapters of the same or different sequence are linked to the respective ends of the DNA molecule except that the sample index and/or molecular barcode differs in its sequence. In some embodiments, the adapter is a Y-shaped adapter in which one end is blunt ended or tailed as described herein, for joining to a nucleic acid molecule, which is also blunt ended or tailed with one or more complementary nucleotides to those in the tail of the adapter. In another exemplary embodiment, an adapter is a bell-shaped adapter that includes a blunt or tailed end for joining to a DNA molecule to be analyzed. Other exemplary adapters include T-tailed, C- tailed or hairpin shaped adapters. For example, a hairpin shaped adaptor can comprise a complementary double stranded portion and a loop portion, where the double stranded portion can be attached (e.g. ligated) to a double-stranded polynucleotide. Hairpin shaped sequencing adaptors can be attached to both ends of a polynucleotide fragment to generate a circular molecule, which can be sequenced multiple times. The adapters used in the methods of the present disclosure comprise one or more known modified nucleosides, such as methylated nucleosides. In instances where two adapters are ligated to a sample nucleic acid (one at each end), either or both of the adapters may comprise one or more known modified nucleosides. Typically, the primer binding site(s), sequencing primer binding site(s), sample index(es) and/or molecular barcode(s), if present, do not comprise the known modified nucleosides that change base pairing specificity as a result of the conversion procedure.
[0212] In some embodiments, adapters may be added to the DNA or a subsample thereof. Adapters can be ligated to DNA at any point in the methods herein. In some embodiments, adapters are ligated to the DNA in a sample or DNA in a converted sample prior to amplification. In some embodiments, adapters are ligated to the DNA in the sample prior to contacting the DNA with a deaminase. In some embodiments, adapters are ligated to the DNA in a sample or DNA in a converted sample prior to cutting DNA (e.g., DNA comprising an AP site) using an AP lyase. In some embodiments, adapters are ligated to the DNA of a sample or subsample thereof prior to annealing primers to the DNA for capture probe generation. In some such embodiments, the adapter-ligated DNA is amplified prior to annealing primers to the DNA for capture probe generation. In some embodiments, adapters are ligated to the DNA of a sample or subsample thereof before the DNA is contacted with the capture probes. In some embodiments, the DNA to which the adapters are ligated is in the same sample or subsample as the DNA used as a template to generate capture probes. In some embodiments, the DNA to which the adapters are ligated is in a different sample or subsample, e.g., a second sample or a second subsample of a first sample, than the DNA used as a template to generate capture probes. In some embodiments, the adapters ligated to DNA captured by the capture probes.
[0213] In some embodiments, the primers used to generate capture probes are not complementary to adapters, and the resulting capture probes therefore do not comprise adapters. Adapter-ligated DNA can therefore be selectively amplified in the presence of capture probes that do not comprise adapters. Similarly, adapter-ligated DNA can be separated from DNA that does not comprise adapters. [0214] In some embodiments, the disclosed methods comprise analyzing DNA in a sample. In such methods, adapters may be added to the DNA. This may be done concurrently with an amplification procedure, e.g., by providing the adapters in a 5’ portion of a primer (where PCR is used, this can be referred to as library prep-PCR or LP-PCR), before, or after an amplification step. In some embodiments, adapters are added by other approaches, such as ligation. In some such methods, first adapters are added to the 3’ ends of the nucleic acids by ligation, which may include ligation to single-stranded DNA. In some embodiments, prior to any partitioning or capturing steps, first adapters are added to the nucleic acids by ligation, which may include ligation to single-stranded DNA (e.g., to the 3’ ends thereof). In some embodiments, the capture probes can be isolated after partitioning and ligation. For example, the hypomethylated partition can be ligated with adapters and a portion of the ligated hypomethylated partition can then be used to generate the capture probes for rearrangements. The adapter can be used as a priming site for second-strand synthesis, e.g., using a universal primer and a DNA polymerase. A second adapter can then be ligated to at least the 3’ end of the second strand of the now double-stranded molecule. In some embodiments, the first adapter comprises an affinity tag, such as biotin, and nucleic acid ligated to the first adapter is bound to a solid support (e.g., bead), which may comprise a binding partner for the affinity tag such as streptavidin. For further discussion of a related procedure, see Gansauge et al., Nature Protocols 8:737-748 (2013). Commercial kits for sequencing library preparation compatible with single- stranded nucleic acids are available, e.g., the Accel-NGS® Methyl-Seq DNA Library Kit from Swift Biosciences. In some embodiments, after adapter ligation, nucleic acids are amplified.
[0215] In some embodiments, the single-stranded DNA library preparation is performed in a one-step combined phosphorylation/ligation reaction, e.g., as described in Troll et al., BMC Genomics, 20: 1023 (2019), available at https://doi.org/10.1186/sl2864-019-6355-0. This method, called Single Reaction Single- stranded LibrarY (“SRSLY,”) can be performed without end-polishing. SRSLY may be useful for converting short and fragmented DNA molecules, e.g., cfDNA fragments, into sequencing libraries while retaining native lengths and ends. The SRSLY method can create sequencing libraries (e.g., Illumina sequencing libraries) from fragmented or degraded template (input) DNA. In particular embodiments, template DNA is first heat denatured and then immediately cold shocked to render the template DNA molecules singlestranded. The DNA can be maintained as single-stranded throughout the ligation reaction by the inclusion of a thermostable single-stranded binding protein (SSB). Next, the template DNA, which at this point can be single- stranded and coated with SSB, is placed in a phosphorylation/ligation dual reaction with directional dsDNA NGS adapters that contain singlestranded overhangs. Both the forward and reverse sequencing adapters can share similar structures but differ in which termini is unblocked in order to facilitate proper ligations. Both sequencing adapters can comprise a dsDNA portion and a single-stranded splint overhang of random nucleotides that occurs on the 3 -prime terminus of the bottom strand of the forward adapter and the 5-prime terminus of the bottom strand of the reverse adapter. In this way, the forward adapter (e.g., (P5) Illumina adapter) can be delivered to the 5-prime end of template molecules and the reverse adapter (e.g., (P7) Illumina adapter) is delivered to the 3-prime end of template molecules. Thus, the native polarity of input DNA molecules can be retained.
[0216] During the dual phosphorylation/ligation reaction, T4 Polynucleotide Kinase (PNK) can be used to prepare template DNA termini for ligation by phosphorylating 5-prime termini and dephosphorylating 3-prime termini. T4 PNK works on both ssDNA and dsDNA molecules and has no activity on the phosphorylation state of proteins. Simultaneously, the random nucleotides of the splint adapter can be annealed to the single-stranded template molecule. This creates a short, localized dsDNA molecule, enabling ligation of template to adapter with a ligase such as T4 DNA ligase, which has high ligation efficiency on dsDNA templates but low efficiency on ssDNA. After the single phosphorylation/ligation reaction is complete, the library DNA can be, e.g., purified and placed directly into standard NGS indexing PCR, compatible with both traditional single or dual index primers.
[0217] In some embodiments, the adapters include different tags of sufficient numbers that the number of combinations of tags results in a low probability e.g., 95, 99 or 99.9% of two nucleic acids with the same start and stop points receiving the same combination of tags. Adapters, whether bearing the same or different tags, can include the same or different primer binding sites, but preferably adapters include the same primer binding site.
[0218] In some embodiments, following attachment of adapters, the nucleic acids are subject to amplification. The amplification can use, e.g., universal primers that recognize primer binding sites in the adapters.
[0219] In some embodiments, following attachment of adapters, the DNA or a sub sample or portion of the DNA is partitioned, comprising contacting the DNA with an agent that preferentially binds to nucleic acids bearing an epigenetic modification. The nucleic acids are partitioned into at least two partitioned subsamples differing in the extent to which the nucleic acids bear the modification from binding to the agents. For example, if the agent has affinity for nucleic acids bearing the modification, nucleic acids overrepresented in the modification (compared with median representation in the population) preferentially bind to the agent, whereas nucleic acids underrepresented for the modification do not bind or are more easily eluted from the agent. The nucleic acids can then be amplified from primers binding to the primer binding sites within the adapters. Partitioning may be performed instead before adapter attachment, in which case the adapters may comprise differential tags that include a component that identifies which partition a molecule occurred in.
[0220] In some embodiments, the nucleic acids are linked at both ends to Y-shaped adapters including primer binding sites and tags. The molecules are amplified.
E. Molecular Tagging
[0221] In some embodiments, the DNA molecules of the sample may be tagged with sample indexes and/or molecular barcodes (referred to generally as “tags”). In some embodiments, the DNA molecules of the sample comprise barcodes.
[0222] Tags can be molecules, such as nucleic acids, containing information that indicates a feature of the molecule with which the tag is associated. For example, DNA molecules can bear a sample tag or sample index (which distinguishes molecules in one sample from those in a different sample), a partition tag (which distinguishes molecules in one partition from those in a different partition) and/or a molecular tag/molecular barcode (which distinguishes different molecules from one another (in both unique and non-unique tagging scenarios)).
[0223] Tagging strategies can be divided into unique tagging and non-unique tagging strategies. In unique tagging, all or substantially all of the molecules in a sample bear a different tag, so that reads can be assigned to original molecules based on tag information alone. Tags used in such methods are sometimes referred to as “unique tags”. In non-unique tagging, different molecules in the same sample can bear the same tag, so that other information in addition to tag information is used to assign a sequence read to an original molecule. Such information may include start and stop coordinate, coordinate to which the molecule maps, start or stop coordinate alone, etc. Tags used in such methods are sometimes referred to as “non-unique tags”. Accordingly, it is not necessary to uniquely tag every molecule in a sample. It suffices to uniquely tag molecules falling within an identifiable class within a sample. Thus, molecules in different identifiable families can bear the same tag without loss of information about the identity of the tagged molecule. [0224] In certain embodiments, a tag can comprise one or a combination of barcodes. As used herein, the term “barcode” refers to a nucleic acid molecule having a particular nucleotide sequence, or to the nucleotide sequence, itself, depending on context. A barcode can have, for example, between 10 and 100 nucleotides. A collection of barcodes can have degenerate sequences or can have sequences having a certain Hamming distance, as desired for the specific purpose. So, for example, a molecular barcode can be comprised of one barcode or a combination of two barcodes, each attached to different ends of a molecule. Additionally or alternatively, for different partitions and/or samples, different sets of molecular barcodes, molecular tags, or molecular indexes can be used such that the barcodes serve as a molecular tag through their individual sequences and also serve to identify the partition and/or sample to which they correspond based the set of which they are a member. For example, barcodes can be used to allow the origin of the DNA (e.g., the subject, biological sample (e.g., samples collected at various time points), enriched DNA sample (e.g., enriched DNA comprising an epigenetic target region set or enriched DNA comprising a sequence-variable target region set), partition, or similar) to be identified, e.g., following pooling of a plurality of samples for parallel sequencing. Tags comprising barcodes can be incorporated into or otherwise joined to adapters. Tags can be incorporated by ligation, overlap extension PCR among other methods. Tags can be used to label the individual polynucleotide population partitions so as to correlate the tag (or tags) with a specific partition. Alternatively, tags can be used in embodiments of the disclosure that do not employ a partitioning step. In some embodiments, a single tag can be used to label a specific partition. In some embodiments, multiple different tags can be used to label a specific partition. In embodiments employing multiple different tags to label a specific partition, the set of tags used to label one partition can be readily differentiated for the set of tags used to label other partitions. In some embodiments, the tags may have additional functions, for example the tags can be used to index sample sources or used as unique molecular identifiers (which can be used to improve the quality of sequencing data by differentiating sequencing errors from mutations, for example as in Kinde et al., Proc Nat’l Acad Sci USA 108: 9530-9535 (2011), Kou et al., PLoS ONE, 11 : eO 146638 (2016)) or used as non-unique molecule identifiers, for example as described in US Pat. No. 9,598,731. Similarly, in some embodiments, the tags may have additional functions, for example the tags can be used to index sample sources or used as nonunique molecular identifiers (which can be used to improve the quality of sequencing data by differentiating sequencing errors from mutations). [0225] Tags may be incorporated into or otherwise joined to adapters by chemical synthesis, ligation (e.g., as described above, e.g. by blunt-end ligation or sticky-end ligation), or overlap extension polymerase chain reaction (PCR), among other methods. Such adapters are ultimately joined to the sample DNA molecule. In other embodiments, one or more rounds of amplification cycles (e.g., PCR amplification) may be applied to introduce sample indexes to a nucleic acid molecule using conventional nucleic acid amplification methods. The amplifications may be conducted in one or more reaction mixtures (e.g., a plurality of microwells in an array). Molecular barcodes and/or sample indexes may be introduced simultaneously, or in any sequential order. In some embodiments, molecular barcodes and/or sample indexes are introduced prior to and/or after any conversion procedure. In the case of molecular barcodes and/or sample indexes being introduced through amplification processes, the conversion step will occur before the molecular barcodes and/or sample indexes are introduced. In some embodiments, molecular barcodes and/or sample indexes are introduced prior to and/or after sequence capturing steps, if present, are performed. In some embodiments, only the molecular barcodes are introduced prior to probe capturing and the sample indexes are introduced after sequence capturing steps are performed. In some embodiments, both the molecular barcodes and the sample indexes are introduced prior to performing probe-based capturing steps, if present. In some embodiments, the sample indexes are introduced after sequence capturing steps are performed, if present. In some embodiments, sample indexes are incorporated through overlap extension polymerase chain reaction (PCR).
[0226] In some embodiments, the tags may be located at one end or at both ends of the sample DNA molecule. In some embodiments, tags are predetermined or random or semi -random sequence oligonucleotides. In some embodiments, the tag(s) may together be less than about 500, 200, 100, 50, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 nucleotides in length. Typically tags are about 5 to 20 or 6 to 15 nucleotides in length. The tags may be linked to sample DNA molecules randomly or non-randomly.
[0227] In some embodiments, each sample or partition (discussed below) is uniquely tagged with a sample index or a combination of sample indexes. In some embodiments, each nucleic acid molecule of a sample or sub-sample is uniquely tagged with a molecular barcode or a combination of molecular barcodes. In other embodiments, a plurality of molecular barcodes may be used such that molecular barcodes are not necessarily unique to one another in the plurality (e.g., non-unique molecular barcodes). In these embodiments, molecular barcodes are generally attached (e.g., by ligation as part of an adapter) to individual molecules such that the combination of the molecular barcode and the sequence it may be attached to creates a unique sequence that may be individually tracked. Detection of non-unique molecular barcodes in combination with endogenous sequence information (e.g., the beginning (start) and/or end (stop) genomic location/position corresponding to the sequence of the original DNA molecule in the sample, start and stop genomic positions corresponding to the sequence of the original DNA molecule in the sample, the beginning (start) and/or end (stop) genomic location/position of the sequence read that is mapped to the reference sequence, start and stop genomic positions of the sequence read that is mapped to the reference sequence, sub-sequences of sequence reads at one or both ends, length of sequence reads, and/or length of the original DNA molecule in the sample) typically allows for the assignment of a unique identity to a particular molecule. In some embodiments, beginning region comprises the first 1, first 2, the first 5, the first 10, the first 15, the first 20, the first 25, the first 30 or at least the first 30 base positions at the 5' end of the sequencing read that align to the reference sequence. In some embodiments, the end region comprises the last 1, last 2, the last 5, the last 10, the last 15, the last 20, the last 25, the last 30 or at least the last 30 base positions at the 3' end of the sequencing read that align to the reference sequence. The length, or number of base pairs, of an individual sequence read are also optionally used to assign a unique identity to a given molecule. As described herein, fragments from a single strand of nucleic acid having been assigned a unique identity, may thereby permit subsequent identification of fragments from the parent strand, and/or a complementary strand. [0228] In certain embodiments of non-unique tagging, the number of different tags used can be sufficient that there is a very high likelihood (e.g., at least 99%, at least 99.9%, at least 99.99% or at least 99.999% that all DNA molecules of a particular group bear a different tag. It is to be noted that when barcodes are used as tags, and when barcodes are attached, e.g., randomly, to both ends of a molecule, the combination of barcodes, together, can constitute a tag. This number, in term, is a function of the number of molecules falling into the calls. For example, the class may be all molecules mapping to the same start-stop position on a reference genome. The class may be all molecules mapping across a particular genetic locus, e.g., a particular base or a particular region (e.g., up to 100 bases or a gene or an exon of a gene).
[0229] In certain embodiments, the number of different tags used to uniquely identify a number of molecules, z, in a class can be between any of 2*z, 3*z, 4*z, 5*z, 6*z, 7*z, 8*z, 9*z, 10*z, 11 *z, 12*z, 13*z, 14*z, 15*z, 16*z, 17*z, 18*z, 19*z, 20*z or 100*z (e.g., lower limit) and any of 100,000*z, 10,000*z, 1000*z or 100*z (e.g., upper limit). In some embodiments, molecular barcodes are introduced at an expected ratio of a set of identifiers (e.g., a combination of unique or non-unique molecular barcodes) to molecules in a sample. One example format uses from about 2 to about 1,000,000 different molecular barcode sequences, or from about 5 to about 150 different molecular barcode sequences, or from about 20 to about 50 different molecular barcode sequences, ligated to both ends of a target molecule. Alternatively, from about 25 to about 1,000,000 different molecular barcode sequences may be used. For example, 20-50 x 20-50 molecular barcode sequences (i.e., one of the 20-50 different molecular barcode sequences can be attached to each end of the target molecule) can be used. Such numbers of identifiers are typically sufficient for different molecules having the same start and stop points to have a high probability (e.g., at least 94%, 99.5%, 99.99%, or 99.999%) of receiving different combinations of identifiers. In some embodiments, about 80%, about 90%, about 95%, or about 99% of molecules have the same combinations of molecular barcodes. For example, in a sample of about 5 ng to 30 ng of cell free DNA, one expects around 3000 molecules to map to a particular nucleotide coordinate, and between about 3 and 10 molecules having any start coordinate to share the same stop coordinate. Accordingly, about 50 to about 50,000 different tags (e.g., between about 6 and 220 barcode combinations) can suffice to uniquely tag all such molecules. To uniquely tag all 3000 molecules mapping across a nucleotide coordinate, about 1 million to about 20 million different tags would be required.
[0230] In some embodiments, the assignment of unique or non-unique molecular barcodes in reactions is performed using methods and systems described in, for example, U.S. Patent Application Nos. 20010053519, 20030152490, and 20110160078, and U.S. Patent Nos. 6,582,908, 7,537,898, 9,598,731, and 9,902,992, each of which is hereby incorporated by reference in its entirety. Alternatively, in some embodiments, different nucleic acid molecules of a sample may be identified using only endogenous sequence information (e.g., start and/or stop positions, sub-sequences of one or both ends of a sequence, and/or lengths). Tags can be linked to sample nucleic acids randomly or non-randomly.
[0231] In some embodiments, the tagged nucleic acids are sequenced after loading into a microwell plate. The microwell plate can have 96, 384, or 1536 microwells. In some cases, they are introduced at an expected ratio of unique tags to microwells. For example, the unique tags may be loaded so that more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, 50,000, 100,000, 500,000, 1,000,000, 10,000,000, 50,000,000 or 1,000,000,000 unique tags are loaded per genome sample. In some cases, the unique tags may be loaded so that less than about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, 50,000, 100,000, 500,000, 1,000,000, 10,000,000, 50,000,000 or 1,000,000,000 unique tags are loaded per genome sample. In some cases, the average number of unique tags loaded per sample genome is less than, or greater than, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, 50,000, 100,000, 500,000, 1,000,000, 10,000,000, 50,000,000 or 1,000,000,000 unique tags per genome sample.
[0232] In some embodiments a format uses 20-50 different tags (e.g., barcodes) ligated to both ends of target nucleic acids. For example, 35 different tags (e.g., barcodes) ligated to both ends of target molecules creating 35 x 35 permutations, which equals 1225 for 35 tags. Such numbers of tags are sufficient so that different molecules having the same start and stop points have a high probability (e.g., at least 94%, 99.5%, 99.99%, 99.999%) of receiving different combinations of tags. Other barcode combinations include any number between 10 and 500, e.g., about 15x15, about 35x35, about 75x75, about 100x100, about 250x250, about 500x500.
[0233] In some cases, unique tags may be predetermined or random or semi-random sequence oligonucleotides. In other cases, a plurality of barcodes may be used such that barcodes are not necessarily unique to one another in the plurality. In this example, barcodes may be ligated to individual molecules such that the combination of the barcode and the sequence it may be ligated to creates a unique sequence that may be individually tracked. As described herein, detection of non-unique barcodes in combination with sequence data of beginning (start) and end (stop) portions of sequence reads may allow assignment of a unique identity to a particular molecule. The length or number of base pairs, of an individual sequence read may also be used to assign a unique identity to such a molecule. As described herein, fragments from a single strand of nucleic acid having been assigned a unique identity, may thereby permit subsequent identification of fragments from the parent strand.
[0234] In some embodiments, the method includes adding one or more internal control DNAs and forward and reverse primers for amplifying the internal control DNAs. The internal control DNAs may be added before amplification using the primers that anneal upstream and downstream of the rearrangement breakpoints. The forward and reverse primers for amplifying the internal control DNAs may be included with, or added at the same time as, the primers that anneal upstream and downstream of the rearrangement breakpoints. The internal control DNAs may comprise or consist of sequences that do not occur in the genome of the subject, or that do not occur in the genome of the species of which the subject is a member (e.g., the human genome). The forward and/or reverse primers for amplifying the internal control DNAs may comprise sequences that are not complementary to any sequence in the genome of the subject, e.g., the human genome. The internal control DNAs may be used to ensure that the amplification process proceeded as designed. As such, the method may comprise detecting (e.g., sequencing) molecules amplified from and/or captured by the one or more internal control DNAs. The method can comprise comparing an amount of internal control DNAs (e.g., number of molecules or reads detected that correspond to an internal control DNA sequence) to a predetermined threshold, and either rejecting sequencing results if the predetermined threshold is not met or accepting sequencing results if the predetermined threshold is met. The predetermined threshold may be established, e.g., based on historical data or by testing the method on samples of DNA from test subjects, such as healthy volunteers. For example, amplification and detection of the one or more internal control DNAs provides confirmation that the amplification process proceeded properly, thus reducing the likelihood of a false negative.
F. Conversion; Contacting the DNA with a Deaminase
[0235] The methods disclosed herein can comprise contacting DNA in a sample with a deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs. This step can be referred to as, or be included in, a conversion procedure, such as any of the conversion procedures described elsewhere herein. DNA in the converted sample that comprises methylated CpGs or conversion products of methylated CpGs is then selectively amplified. In some embodiments, the selectively amplified DNA is sequenced, and a level of methylation at one or more differentially methylated regions of the DNA is quantified. Such embodiments may also comprise a step of end-repair prior to the sequencing.
[0236] In some embodiments, the deaminase (e.g., the methyl-insensitive deaminase or the methyl-sensitive deaminase) comprises any one or more of the following deaminases or a truncated version thereof, such as any of the truncated versions disclosed in Vaisvila et al. (2023) Discovery of novel DNA cytosine deaminase activities enables a nondestructive single-enzyme methylation sequencing method for base resolution high-coverage methylome mapping of cell- free and ultra-low input DNA. bioRxiv; DOI: 10.1101/2023.06.29.547047, available at https://www.biorxiv.org/content/10. ! 101/2023.06.29.547047vl : MsddA, AshDaOl, MGYPDa21, PpDa03, SbDaOl, BlDaOl, PpDaO4, CsDaOl, MGYPDa22, FIDaOl, MGYPDa24, AaDaO2, MmgDaOl, PbDaOl, BcDaO2, LsfDaOl, SmgDaOl, XcDaOl, KsDaOl, PwDaOl, CaDaOl, SrDaOl, NgDaOl, NsDaOl, SzDaOl, SpDaOl, AdDaOl, MGYPDa23, WWTPDaO7, PdDaOl, MGYPDa25, MGYPDa26, DaDaOl, EcDaOl, EcDaO2, NgDaO2, PaDaOl, AsDaOl, HgmDaOl, MsDaO2, XinDaOl, XjaDaOl, RhDaOl, MGYPDaO4, MGYPDaO5, BaDaOl, WWTPDaO4, PbDaO2, CrDaOl, MGYPDal5, MGYPDal6, MGYPDal7, BaDaO2, VsDaOl, MGYPDal8, MGYPDal9, HmDaO6, MmgDaO2, HgmDaO2, CgmDaOl, FbiDaOl, PvmDaOl, MGYPDa408, MGYPDa687, MGYPDa917, MGYPDa624, DddA, StsDaOl, LbsDaOl, BpDaO2, AmDaO3, MsDaOl, KsDaO2, MGYPDa829, PaDaO2, RaDaOl, BadTF3,HmDaOl, HmDaO2, HmDaO3, AmDaOl, SjDaOl, MGYPDaOl, SqDaOl, TeDaOl, StsDaO3, SaDaO2, PpDaO2, EcDaO4, MGYPDaO2, MGYPDaO3, BcDaOl, IfDaOl, PcDaOl, StsDaO4,AmDaO4, AbDaO2, WWTPDaO5, WWTPDaO6, PeDaOl, SaDaO3, HgDaOl, AbcDaOl, HmDaO4, AmDaO2, AcDaOl, MGYPDal3, LbDaOl, CbDaOl, HcDaOl, MGYPDaO6, CseDaOl, AvDaOl, LbDaO2, MGYPDaO7, FbDaOl, IfDaO2, RsDaOl, NoDaOl, PfDaOl, ScDaO3, PsDaOl, PvDaOl, CdDaOl, AzDaOl, BdDaOl, MGYPDaO8, MGYPDaO9, AoDaOl, MGYPDalO, MGYPDal l, MGYPDal2, MGYPDal4, SsdA, gp317, xpl2da, APOBEC3A, KcDaOl, TuDaOl, BsDaOl, PpDaOl, SaDaOl, CpDaOl, EcDaO3, ScDaOl, BpDaOl, ScDaO2, StsDaO2, OTT-1508, NpDaOl, BmDaOl, BsDaO2, PIDaOl, BbDaOl, OlDaOl, WcDaOl, BbDaO2, PrDaOl, VRDaO2, VRDaO3, VRDaO4, VRDaO5, VRDaO6, AbDaOl, AaDaOl, WWTPDaOl, WWTPDaO2, WWTPDaO3, SoCaDaOl, SoCaDa02, SoCaDa03, SoCaDa04, SoCaDa05, SoCaDa06, SoCaDa07, SoCaDa08, or SoCaDa09. In some embodiments, the deaminase (e.g., the methyl -insensitive deaminase or the methyl -sensitive deaminase) comprises a mutant deaminase or an alternatively truncated deaminase. In some embodiments, the mutant deaminase or an alternatively truncated comprises any one or more a mutant StsDaOl comprising the C-terminus of MGYPDa829, in which the mutant StsDaOl comprises the amino acid sequence of
MLPCPSELEAGLEKAKNAS S SFERPGGMSGHAKLSDGTSHDLS SGGDGRNLRSDWEAPP GTTDENFHHLENQTAALMRQSGSHEAYLYLHKAEGAAYGACKYCVSAMREMLPQGS KLMVIWRNEEGAIRNRVFIGTSNDPKMSSRYKGN (SEQ ID NO: 78); an alternatively truncated MGYPDa829 with 11 amino acids at the C terminus deleted, in which the alternatively truncated MGYPDa829 comprises the amino acid sequence of MNLPEYDGKTTHGVLVLDNGTQVQLVSGNGDPRYTNYRNNGHVEQKAAIYMRENNIS NATVYHNNTNGTCGYCNTMTATFLPEGATLTVVPPKNAVANNSRAIAYVKTYTGTSN (SEQ ID NO: 79); an alternatively truncated HcDaOl with 21 amino acids at the N terminus deleted, in which the alternatively truncated HcDaOl comprises the amino acid sequence of MITDSNILSKLGTVAAENVPLARKSLSKASELSSMLGYGSKAIASDGTTNTLSGWAEITQ GAEYFNRAATPQDVIAKSNEIGHTLKTDIFDNGIPGQYNASHAEKQLSLLSNKALGVSRP MCSDCVEYFKKLAKFSNTEKVVSDSNITRIFMPDGITIIEIPH (SEQ ID NO: 80); an alternatively truncated HmDaO2 with 16 amino acids at the N terminus deleted, in which the alternatively truncated HmDaO2 comprises the amino acid sequence of MPRLGPRGVDPAHHNANIMVRDASGRLRHHERIVSGNMTPEEQALGFPRNTLASHTEA RAIRNIPLHRGETMIITGQRPPCPTCKGIMNQAARESGATIIYRWRENGVTRTWTAGN (SEQ ID NO: 81); an alternatively truncated MGYPDal7 with 18 amino acids at the N terminus deleted, in which the alternatively truncated MGYPDal7 comprises the amino acid sequence of MNYDVNSAEQYLRAVLDYENLSPEAWKSIDQFRESHGLNTLGNGLPKKGDGTV AFINA NGEKIFGINSSLLSEDKKMLGKKYYESMKEAGYFDNVTSYGNGSGQVFTHAEGNSLMN VYDLYGKSIGKDITIFCDRTTCGICKNNLGYFKDYFGIDSLTVLNKNGDIVIINKGTYIKIK S (SEQ ID NO: 82); an alternatively truncated MGYPDal7 with 16 amino acid-extension at the N terminus, in which the alternatively truncated MGYPDal7 comprises the amino acid sequence of
MWCKKKFKQKVKEYLEKGYSKKDAKVMANYEQIRENYDVNSAEQYLRAVLDYENLS PEAWKSIDQFRESHGLNTLGNGLPKKGDGTVAFINANGEKIFGINSSLLSEDKKMLGKK YYESMKEAGYFDNVTSYGNGSGQVFTHAEGNSLMNVYDLYGKSIGKDITIFCDRTTCGI CKNNLGYFKDYFGIDSLTVLNKNGDIVIINKGTYIKIKS (SEQ ID NO: 83); an alternatively truncated MGYPDal8 with 28 amino acid-extension at the N terminus, in which the alternatively truncated MGYPDal8 comprises the amino acid sequence of MNYMPDKAATEAQAAAKANLYIALQKMFPTASKRAIDEVAKTILEKRAKIARFREIAGL QP YSED SGDT VAMTEVGGHAIFGVNS SITKE SHEATKELRQKWFKMVKWCPPKKKEPK HLGHVQSLTHAESHALIRAYERLGKLPKRIIMYVDRKTCNMCKGEMPALLKHLGVDEL TIFSGDSLEPLVLKAVK (SEQ ID NO: 84); an alternatively truncated PaDaO2 with 28 amino acid-extension at the N terminus, in which the alternatively truncated PeDaO2 comprises the amino acid sequence of MGLLGGASGAAGHGLSTTGKNVLGHFEPTPTTPQGTSSDTIAEMLNSASQPGRTAGVLD IDGELTPLTSGRPSLPNYIASGHVEGQAAMIMRQQQVQSATVYHDNPNGTCGYCYSQLP TLLPEGAALDVVPPAGTVPPSNRWHNGGPSFIGNSSEPKPWPR (SEQ ID NO: 85); an alternatively truncated PeDaOl with 21 amino acid-extension at the N terminus and 4 amino acids at the C terminus deleted, in which the alternatively truncated PeDaOl comprises the amino acid sequence of MYAGGTNLFAYAPNPIWWIDPLGLNKFGSGKGVHTAVVNVHDSDGEHTVVSCILHSGN MTEEERALGFPRSSLATHTEARAVKQIPLQQGDVMVIDGQYPPCPSCKGKMNRASTETG AKIQYTWPENGETKTWTAGQK (SEQ ID NO: 86); an alternatively truncated PeDaOl with 4 amino acids at the C terminus deleted, in which the alternatively truncated PeDaOl comprises the amino acid sequence of
MGLNKFGSGKGVHTAVVNVHDSDGEHTVVSCILHSGNMTEEERALGFPRSSLATHTEA RAVKQIPLQQGDVMVIDGQYPPCPSCKGKMNRASTETGAKIQYTWPENGETKTWTAGQ K (SEQ ID NO: 87); an alternatively truncated PeDaOl with a 21 amino acid-extension at the N terminus, in which the alternatively truncated PeDaOl comprises the amino acid sequence of MYAGGTNLFAYAPNPIWWIDPLGLNKFGSGKGVHTAVVNVHDSDGEHTVVSCILHSGN MTEEERALGFPRSSLATHTEARAVKQIPLQQGDVMVIDGQYPPCPSCKGKMNRASTETG AKIQYTWPENGETKTWTAGQKRRRR (SEQ ID NO: 88); or an alternatively truncated RhDaOl with a 10 amino acid-extension at the N terminus, in which the alternatively truncated RhDaOl comprises the amino acid sequence of
MVTAGVGEAGKKEPWEAIDRFRKSNGLEPLGDRIPVRGDGLETVALMEVSGNKVFGVN SSLLSDELKNLGRDFFKVIKEKGLLGNAKHYGSGEAQVLTHAEAHALMKARKEAGGHL GDSVVLYVDRLTCPNCQKYLPEVRAAMGIKTLKVITKGGIELIL (SEQ ID NO: 89). [0237] Table 1 summarizes exemplary methods of deamination with the type of modified bases detectable with these methods. These are described in more detail below.
Table 1 - Exemplary deamination methods
[0238] As outlined below, there are various methods of detecting and/or identifying modified nucleosides that rely on a conversion procedure that changes the base-pairing specificity of a nucleoside, based on the modification status of the nucleosides. These changes of base-pairing specificity can then be detected, and thus the modification status of the nucleoside inferred, by sequencing.
[0239] In some embodiments, the conversion procedure used in the methods of the disclosure is one that changes the base pairing specificity of an unmodified nucleoside (e.g. cytosine), but does not change the base pairing specificity of the corresponding modified nucleoside (e.g. methylated cytosine, such as 5hmC and/or 5mC) or does not change the base pairing specificity of any modified nucleoside (e.g. modified cytosine, adenosine, guanosine and thymidine (or uracil)). In methods that require denaturation for conversion, failure to denature a DNA molecule will result in non-conversion of all bases in the DNA molecule. As biological changes in methylation are predominantly concerted to a localized regions of interest, these non-random (localized) non-conversion events can appear as false negatives (non -methylated regions). Random non-conversion methods can maximally affect a low percent of bases within a region, and thus the specificity of methylation change detection can be maximized (reduce false positives) by placing a threshold on percentage of bases within a region that are methylated/non- methylated. Hence, in some cases, a conversion procedure that does not involve denaturation is preferred.
[0240] The skilled person can select a suitable method according to their needs, including which nucleoside modifications are to be detected and/or identified and which type of modified base is used in the end repair reaction.
[0241] The methods described herein could in principle use any suitable enzymatic conversion procedure that changes the base-pairing specificity of the modified cytosine and thereby allows the modified base to be distinguished from the corresponding unmodified cytosine and/or other types of modification when sequenced. For example, any enzymatic conversion procedure could be used allowing 5-methylcytosine (m5c or 5-mC or 5mC) to be distinguished from unmodified cytosine. In particular embodiments, the conversion procedure converts unmodified (e.g., unmethylated) cytosines to uracils using a deaminase.
[0242] In some embodiments, the conversion procedure which converts unmodified cytosines comprises APOBEC-coupled epigenetic (ACE) conversion. In ACE conversion, an AID/APOBEC family DNA deaminase enzyme such as APOBEC3A (A3 A) is used to deaminate an unmodified cytosine and 5mC without deaminating 5hmC, 5fC, or 5-caC. Sequencing of ACE-converted DNA identifies positions that are read as cytosine as being 5hmC, 5fC, or 5-caC positions. Meanwhile, positions that are read as T are identified as being T, unmodified C, or 5mC. Performing ACE conversion as described herein thus facilitates distinguishing positions containing 5hmC from positions containing 5mC or unmodified C using the sequence reads obtained from the first subsample. In some embodiments, the end repair reaction can be performed with dNTPs, wherein at least one type of dNTP comprises a 5hmC, and regions synthesized during the end repair reaction can be identified as those regions comprising 5hmC (via C being called at these positions) at non-CpG positions. For an exemplary description of ACE conversion, see, e.g., Schutsky et al., Nature Biotechnology 2018; 36: 1083-1090.
[0243] In some embodiments, the conversion procedure comprises enzymatic conversion of a nucleobase, e.g., as in EM-Seq. See, e.g., Vaisvila R, et al. (2019) EM-seq: Detection of DNA methylation at single base resolution from picograms of DNA. bioRxiv, DOI: 10.1101/2019.12.20.884692, available at www.biorxiv.org/content/10.1101/2019.12.20.884692vl . For example, TET2 and T4-[3GT or 5-hydroxymethylcytosine carbamoyltransferase (described in Yang et al., Bio-protocol, 2023; 12(17): e4496) can be used to convert 5mC and 5hmC into substrates that cannot be deaminated by a deaminase (e.g., APOBEC3A), and then a deaminase (e.g., APOBEC3A) can be used to deaminate unmodified cytosines, converting them to uracils.
[0244] In some embodiments, the conversion procedure comprises enzymatic conversion of the nucleobase using a non-specific, modification-sensitive double-stranded DNA deaminase, e.g., as in SEM-seq. See, e.g., Vaisvila et al. (2023) Discovery of novel DNA cytosine deaminase activities enables a nondestructive single-enzyme methylation sequencing method for base resolution high-coverage methylome mapping of cell-free and ultra-low input DNA. bioRxiv; DOI: 10.1101/2023.06.29.547047, available at https://www.biorxiv.org/content/10.1101/2023.06.29.547047vl. SEM-Seq employs a nonspecific, modification-sensitive double-stranded DNA deaminase (MsddA) in a nondestructive single-enzyme 5-methylctyosine sequencing (SEM-seq) method that deaminates unmodified cytosines. Accordingly, SEM-seq does not require the TET2 and T4-PGT or 5- hydroxymethylcytosine carbamoyltransferase protection and denaturing steps that are of use, e.g., in APOBEC3A-based protocols. Additionally, MsddA does not deaminate 5-formylated cytosines (5fC) or 5-carboxylated cytosines (5-caC). In SEM-seq, unmodified cytosines in the DNA are deaminated to uracil and is read as “T” during sequencing. Modified cytosines (e.g., 5mC) are not converted and are read as “C” during sequencing. Cytosines that are read as thymines are identified as unmodified (e.g., unmethylated) cytosines or as thymines in the DNA. Performing SEM-seq conversion thus facilitates identifying positions containing 5mC using the sequence reads obtained. In some embodiments, the conversion procedure comprises enzymatic conversion of unmodified cytosine using MsddA or a modification-sensitive DNA deaminase A (MsddA)-like deaminase. For an exemplary description of MsddA and MsddA-like deaminases, see, e.g., Vaisvila et al. Mol Cell. 2024 Mar 7;84(5):854-866.e7, which illustrates in Fig. 2A-C that MsddA-like deaminases have reduced activity on each of 5mC, 5hmC, and 5gmC relative to unmodified cytosine in dsDNA, e.g., a reduction of about 75%, 80%, or more on each of 5mC, 5hmC, and 5gmC relative to unmodified cytosine (e.g., using assay conditions as described in Vaisvila et al., such as analysis of deamination of C in E. coli or lambda dem- DNA, deamination of 5mC in XP12 phage DNA, deamination of 5hmC in a C -hydroxy methylated adenovirus PCR fragment or fully C-hydroxymethylated T4147 phage DNA, and deamination of 5gmC in alpha-glucosyltransferase knockout (AGT-) T4 phage DNA). Deamination can be performed by contacting substrate DNA with deaminase and analyzed using NGS as follows: 50 ng of unmodified E. coli C2566 genomic DNA can be combined with the control DNAs (about 1 ng of Lambda, XP12, and T4147, and 0.1 ng of the 5hmC Adenovirus PCR fragment), sheared to about 300 bp and ligated to pyrrolo-dC adapters with 1 uL of in vitro synthesized deaminase (e.g., synthesized using the PURExpress In Vitro Protein Synthesis kit (NEB, Ipswich, MA) following manufacturer’s recommendations with 100-400 ng of PCR fragment template DNA containing codon-optimized deaminase coding sequence and T7 promoter and terminator).
Exemplary deamination reaction conditions are 50 mM Bis-Tris pH 6.0, 0.1% Triton X-100 for 1 hour at 37 degrees C. After the deamination reaction, 1 uL of Thermolabile Proteinase K (NEB, Ipswich, MA) can be added and incubated for 30 min at 37 degrees C and then the Proteinase K can be heat inactivated at 60 degrees C for 10 minutes. The deaminated product can then be used for library amplification using the NEBNext Q5U Master Mix (New England Biolabs, Ipswich, MA, USA) with 5mMof NEBNext Unique Dual Index Primers. The resulting library can be purified using IX NEBNext Sample Purification Beads according to the manufacturer’s instructions and the purified library can be analyzed and quantified by an Agilent Bioanalyzer 2100 DNA Highsensitivity chip. The libraries can be sequenced using the Illumina NextSeq and NovaSeq platforms. Paired-end sequencing of 75 cycles (2 x 75 bp) can be performed for all the sequencing runs. Base calling and demultiplexing can be carried out with the standard Illumina pipeline. [0245] In some embodiments, the methyl-sensitive deaminase comprises MsddA. In some embodiments, the methyl-sensitive deaminase comprises any one or more of MsddA, AshDaOl, MGYPDa21, PpDaO3, SbDaOl, BlDaOl, PpDaO4, CsDaOl, MGYPDa22, FIDaOl, MGYPDa24, AaDaO2, MmgDaOl, PbDaOl, BcDaO2, LsfDaOl, SmgDaOl, XcDaOl, KsDaOl, PwDaOl, CaDaOl, SrDaOl, NgDaOl, NsDaOl, SzDaOl, SpDaOl, AdDaOl, MGYPDa23, WWTPDa07, PdDaOl, MGYPDa25, MGYPDa26, DaDaOl, EcDaOl, EcDaO2, NgDaO2, PaDaOl, AsDaOl, HgmDaOl, MsDaO2, XinDaOl, XjaDaOl, RhDaOl, MGYPDaO4, MGYPDa05, BaDaOl, WWTPDaO4, PbDaO2, CrDaOl, MGYPDal5, MGYPDal6, MGYPDal7, BaDaO2, VsDaOl, MGYPDal8, MGYPDal9, HmDaO6, MmgDaO2, HgmDaO2, CgmDaOl, FbiDaOl, PvmDaOl, SjDaOl, HmDaO2, DddA, RaDaOl, MGYPDa624, AvDaOl, CbDaOl, PfDaOl, NoDaO 1, or SsdA. In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1, which is the amino acid sequence of MsddA (Accession: MGYP001011792517; database: MGnify): QDPIGLLGGNNLYQFAPNAQGWVDWLGLSYGFNIKANRWTNFETGKFVQKPSTLSGQA QAVHNLAGGLKPSKISIEKSTVAIFEVQLRDGSKTLYAAGSSGVLNPRQRALLKQIGVPE KNILFGKGSVLPVTKVNSNINHAEQIILRNIPKDAKVTRKGISWSSKHKNAPCSKCQSSV DGAGGVYD (SEQ ID NO: 1).
[0246] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 7, which is the amino acid sequence of XcDaOl (Accession: B0RYS5; database: UniProt): MLKRIMRRAALLLALAWPAAGLAETVEYIHTDALGSPVAITDAAGNVIERTVYEPYGG MVNKAAVDGPGFTGHVADSATGLSYMQQRYYDPQVGRLLSVDPVMAHGNPLGAFNR YWYANDNPYRFTDPDGRQTIPSENKLGSSDPAVINDFHQAQGEHAAITLNVALDLFLSQ FGDGPGGAAAGVGGVVAKSAEAVSALTRAREIQGALKPITQSKVTTAVTETAEGVRVV TSSEGRLRPAQRAALQVGEVAGKGAARTHAEVNGVNAARDMGLTPTSVSPSRTACPGC QEAMKKLEIPIKDK (SEQ ID NO: 7).
[0247] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 8, which is the amino acid sequence of KsDaOl (Accession: E4NEH0; database: UniProt): MAVTGSLVGAPPAFAEKPPKVWVPPTTPLQEVKSVSGRSDNVTGTAAVGGVPREWKR AAVAPAKAGSATVDVTDVSAEQEAARRLGGGAAPAAGGKAKVKAGDLPVFLTDLGA ANDRDRAAGVPSVKVDLLDEGRAKAAGSTGPVVRLEGAGGAAKGGHKLQVSLDVKA LTGNAMWSDRARLVLLPECALTTPDAEQCRTSTPVPSTVDPLSGLLTADVQLPEAPAVP AGTATQAGFVQQAGFVQQASAASSGAMVLAAQAAPSGSSGSFAATAIAPSAAWSAGSG SGNFTYSYTFDMPTAVGGAAPSVVLGYDSSSVDGRTASTNSQSGWVGDGWDYSAGSIS RSYKACLKSGIDMSGDECWAGQALQLNLAGHSGTVVKDDTTGVLRLQGDDGTLVTPL TGLANGAWNGEGFKVTTTDGTQYYFGANHLPGGDNTDPASNSVNTVPVYHPHAGDPC YS S STGLASWCQMGWQWNLDYIVDLHGNLIKYQYAKESNS YARGGGQNNGTGTRTA YDRYSNVSSIQYGLRLSDQIASKGAGNPAAKIDFTTAERCFASGSITCSDAQRVVANQSS WPDTPLDQACTASGTCTNYGPSFWTSKRLTGIQTTVYVGGAARVVDSWALNQVFSDPG DGNAPTLWLSSIQRTGKNGQADIALPAVSFTAMQMANRVDGLVPAAPQFNRPRMKEIT TETGGRITVNYKPAECSRVNNTMPASEAGNTMACMPVKWVPPGSQAGTKPIDDWFHK YLVSSIVESSLVTSSIVAKETQYAYGGGAAWHRNDSEFADDDTRTYDNFRGYQSVTTTT GSGSDGPRTKSVSTFLRGMGGQVTDSWGSTITDAEELAGFVRETQNYESDAAGAKVIG GELTTPWLSKITATHTQSGNLPKVTARYINTANVKNRSLLSNGQWRTTERSATYDEDHA GRLVTMDVLGDTTLSGLPQRQCTAVTYASGSNPALVEFPSRMLTLAGACAQTPSATNTI SDALTYYDGQALGVIGDKGDQTETRVLESYGTGNTPNYKVTAKAQFDAYGRQTSTTDP NRTDTAHPNGATTSTAYTPATGELPSKVEVTNPLGWKSTTLVDPARGLPTKATDENGRT TLETYDALGRLTAVWLPGRDPNDLDGNDTPNRKFTYALNGSTSPSVVTSESIREDRTYA KSLQIYDGLGRVRQSQSIPVQGQVGRLISESFYDSHGWQIKSTPSYYNADSGPIATVYLPE DSEVPTQTWNEYDGLGRITASKFISYGQEQWRSTASYPGTERTDATPPPGGYATTTLTD ATGAAVEVRQYKAGTPTGPYDATTYGYDVAGKPTWVQDSSTPAHRWTYTYDLLGQRT GSTDPDTGTSATVYDKAGHAVTTTDARGKSTSITYDLLGRQVASYDGTSTTDASKKLIE WTYDSLALGKPAATTTYADVPNGTGKVAYVGAVTGYDIGYRPTGMSMTIPSVTGEEAL AKTYTWSTTYTPVLGLVKNTKLPAVGGLAAETVGNSYDVDGNFQTSSGLDYYVQDMQ YDAFGRPTRTTVGKAGKQVVSTQQYDPGTGNVVQSTLDKQTATTTHVDFTNYTYNKV GSMTSAKTIQDGTSTDLQCFTYDYLGRLSSAWTDKGTTTTAPAPSVQGIGNCTNATEPT ALTASARIGGPAPYWQTYSYDLTGNRTKLVQHDTTGAVVNDKQTDQTFAPGPNTATTD PTTGGGTGGPHALLTSKTSSNGTSKVTTSTYDATGNTTSLTSTSGTKTLTWNNQGKLAK
VHDTAAPANDTSYVYDADGNQLVRRVGGKTTINLGTDELTLDTATGKTTATRYYAAP GGLTITRTADAAGATTLYYQASDPHGTAGVQMDAANLGVTRRPTDPFGNARGTQPGN GAWAGDKGFVGGTIEGTGFTNLGARQYDPATARFLSVDPLFDNSDPQSWNGYAYANN NPVDGSDPNGTCRVLDDGYCHGAPFIPVNHNSGDDGSGTDTSTSTSATGKAAHDASQE ALRQKQAADEALAKAKQAREELISKIVDVVGDLIGFNDARDCFTKGDVMGCINTALNF VPWAKVFKAVKIGIKAFKLWREGEKAYTAIRSAERVAKEAQQAFSVARKTEKEVAEAE QQAAKAAEADAAKTAKEADAAKADSAGTSESSASCPAGNSFPAGTLVQLADGTTKPID QLEPGDTVLATDPQTGETRAEPVTATITGHNDTEFTQLTLQGTESGDSLTVTSTAHHPY WDETSHQWVDALDVKAGHQLRTADGTLITVTALRTYSTQPSSAHNLTVANLHTYYVL AGATPVLVHNCGGELLDRARELYGTRADEASTVAVARVRSTSNPDKVETWVATERTGL PDEWKGGNAPLRGERYISGQGHAEATIMNRLGSDWEIVGMASSTRMCPTCFAQATGPG VGLTPSPIGKGAGVSRTGNTPWRVVLGGGG (SEQ ID NO: 8).
[0248] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 9, which is the amino acid sequence of PwDaOl (Accession: UPI0001B0E918; database: UniParc):
MREEILSRIARVGAMHAGNRPKPPPDLPEPGQGKPPTSPGKAIKHSSFWGALAGAAVGA LIAAAAFTVAAAAVAGAVALTGITGGAGLALVVGVVKLAVGFGAVFALGDLIGGVTNR VSAMVDSASPSSGAVKDGSKTVFVEGNPVSRAEIDAVLCDKHSGPQLIAQGSATVFVEG YYAARVGDKTVCGATIKEGASTVFFGSGQESPLSVADEFSGWEKALILAVEFLMPPSRG LFRGLGKLFTKGPMAVLRGMKAGAAHALEGLRSAVQCAKNGFKESKGLARVTESIRGF LKDPVYIASGEVIEKRLDLELGQTVPLLFERTYRSGSPHSGLLGHGWHDSWSEVATVGR TEQGDIQVTLTLAQGYDIDFTFVVGATVVYCAEYPEFKLVKRHNGFHLWHRDSQTWRA FTAKQGDQLLLSAITDNHRNRIDFLRDPKGYLRKIRHSDGIELLLVWQGEFLRQVQRIDG GQKTVLAEYRQDEQGRLVEADAAHAYHLFYDYDSHHRLIRWHDNDQTWARYEYDPQ GRCVYTTCADGYLTANFEYLADRVVMIDGLGQRHEYGFNDLYLMAWEKSPLGHITHY EYDDVGNLLREISPAGRVVEFAYLDNSGLVSTFTDGSGHQWHYDYDHYERLIGITDPLG RSWAWQYDSKGNPLSLTGPDASEVRFAWNRYGLLTEVSDEQGRTQASLFYDHRHRLM
SATDAESRTRQLRYDQQDRLTSWTRPDGATYRLGYRRASWKLPEQLLRPDDKQEQRQ YDKHNNLLNYTDGNGAVWAQTYGPFDLLTSRTDAEGRTWQYEYDKESQQLVCVTAP DGNRWQWWLDADARVIRERDMAGTETHYGYDEDGHCIAVRNGEGETRHFLYDGRGL LIKETAPDDTLHYRYDAAGRLIEVTSSTSHIQLEYDERDRVVQERNSGTAIRRHYQDTSH TVTRSLHWEGEEDSAALTSTFRYSATGELRQVQLPDGAELTLAHDSAGRESSRQSQAGF MQHREYDAMGWLTREMSGQAVDGRLQPTQTREYLYDGAGNLTGTRRNREAAGYQLD ASGRVLSVLSGGAGRSVNTEEQYRYTRSGLPQDATRLTEWQAGRLTQQDNTHYQYDK AGRLIRKQVVQPGYRPQVWHYRWDSRNQLRVVDTPAGERWFYRYDPFGRRIGKRCDQ THEDIRYLWDGDQIAEVRHYRDDELVSRRHWIHNGWELLVQQRQNADGRWETDFMTS SHNGEPQAAFNLAGELRWQAPRTNLWGQRYTDNTENLDPGLAFAGQYRDAESSLCYN RFRYYDPNGGYYISPDPVSIFGGDVNYGYAHNPLGWVDPFGLASCEHLNRMAKEVHDL
AGGLKTPDTRAIRNSTVSIVEATVDGKKVLYAAGSGGRLNPRQVETLERLGVSRENIFK GARVTNEFSKLENHAERIILRNLPEGAVVNRWGISWGGLQRGIPCDHCAPFVRDAGGFF (SEQ ID NO: 9).
[0249] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 10, which is the amino acid sequence of CaDaOl (Accession: C7QJN3; database: UniProt):
MATFAIGGRLRRSVAAVATAALGLAAFVAPTTAQAQAAAGPGSAAQHPASALGRSGFA MADPAPPPALPAPLDSSGPAQVQALEQQYQTDAQNDQQKYDQLAAEKGTLEQRAGDV QNRESSLETQATNLEDQSNALNSQAETLNSEIDAHNAEPHTFELPDEEAEYAAYNEEKA NLDEQKANLQNQIDALTAQSKKLQSDQAQADADQTQLETDVQTHNDAVSALEGDVGK
LEAERQQILTQIDSLLQDYAGAEPGGEGAPLAAEGGDESEPAAAAAPSPGARALPSGGG DQSAPPRSTYAPVQNAPSGSGSGQAQAQAAPAPAPTQTPVTVTLAPSTVSGLPASEAEN LQPSETFDGLIPEANGDYAAEEIQPPAGESVPPAQKAFDNVVNKGGKASTRIGGRPATID KIVPEAAAPAENQGGDTPRPAKAAAPPARSSWVPAVNQPNPANGPPVSIDALKSLLDQQ
GLGSDADQFDLEYSPTVLGQDGEPAYAVAPTDAAGNPELGAEGKPILRFSNLGLQNPEV AQDAFENEGLDVEPAQDDSPCPHSFSGATRVLMADGSTKAIAEVGVGDLVENAEPGGR AEVHRVDQVHTTTTDAAFVDVVVASAAPGGGGTLTGTANHPYYDATAGGFVDAGALR AGDRLQSAGGGQATVSGVHARFGPLVTYDLTIDGLHTYFVVAGSAPVLVHNCDGDLLD IAKDSATRASGYQKLAGSDWEVKNKTTSVIRARFPSGDPKNPWVYKNVVSSSGSGLSPA QISAIEANGDVAVTDNLEGFTHAEYNGLRYIDSMGGQPIAGGASRSVCTTICGPFIRGTD GNISGPVYQLEHGTKIRTFYWPGSTPG (SEQ ID NO: 10).
[0250] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 11, which is the amino acid sequence of SrDaOl (Accession: D6Z8J1; database: UniProt):
MSRPSQLRSTIDS ATS SAKGQRPAEDAGVAGVRAATRDPF AEAS SLLVHLVINRVPPIKH VLDKVTLDEGAAMALAQQWSDEFPAALREQRDALVSTRESISQNWEGEGASKTYQDR QRELEDLADSLAAACEGAGFLTSAVNELMVGVREQIIEWIAQLVSMLMRRLISVVATFW IPIVGEINEAAFIFEGVARVVETIERITSLITRVEGILGEVSSVAQVLGGSTQQVQQLGSAL GEVPQGLGASPLRALGRVGSVRQSGLTGSHGAVIRSVVPRRSKSPGGSAHAQSAGTSTR
GLGSQTGATPSASSGTHPQGGAVNASTRSLSPDSGTRGPVTRSQTAAERAQSSNANAQA EQARLDARARDLHSRLVNARTGEPDTRAQNSRTSVAMSTREGRDVLAGGGRDLNPSQR QAAGPNDVVATQPGAHAEVTAINGARAAGLTPSQIAVSRPICDNCQDAIQQSGGTVHPD RMGATWP (SEQ ID NO: 11).
[0251] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 12, which is the amino acid sequence of NgDaOl (Accession: G3Z1X9; database:
UniProt):
MPNKEENARNGLPETDWRDAQYDMLYLPVTETVRYHYDFNGNRTATVLPDGRQINYL YYGSGHLHQISLDDEVITDIERDKLHREIYRTQGKLASRYELDPLGRLKRQIATLNDLTET GKGKTKVAAGYGQTAVKRSYGYDRTGNLTHSTDQRTGTTKFEYDKLGRITQAGNELF AFDPAHNILSDDLNTITDNRLKTYNGTTYYYDELGNLIHRELADGEVQNYFYDLHDQLV
KAEIFKKDGTKETWSYTYDALGRRIGKGRLKTSQKVSETSFPHDLSGNDLENQTRFVWD GSHLLQEIHPDGRYTYIYADQNSYEPLAQVRDWTTVEDENRQQTRYFHCDQIGIPREMT DKDGNLLWFGNYTGWGRLKEETKVTDSAYQPFRLQNQYADRETGLHYNFFRYYEPDA GRFVNQDPIGLWGGDNLYRFSSNIQIWIDPLGLACIPNPNRKNDEDLARRIDKLSDNLTE KNRDGFTTLALARVTLADGTSQIWIAQAGSSLSSKPSRRQQSLAGADEIIQNLHPAGRSR KDGNHLNDAERQLIREAKKRGAKIKSLGATKPMCGRCEKGARRAGILRRIITPIKSRHC (SEQ ID NO: 12).
[0252] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 13, which is the amino acid sequence of NsDaOl (Accession: D3A5B8; database: UniProt):
MAGGAVNRRYAYDKAGNLIQSADQRSGVLNYVYDKIGRIQEARNSQSGRSETFAFDPA HNILSDKAAEGKGNNLVSGNRLKEYNGIEYTYDALGNLIYRQLPNGENQYYQYDLENQ LVRAEIKKPAGNTEIWTYAYDPFGRRLSKERQDKLAWTSTDPKRTHFVWDGTRLLQEY TYKGSYTYIYTDQDSYEPLAQIFDNAKDSKQYLAYFHNDQISIPREMTDIHGNLLWYGE
YTAWGRLKKDERVYKNAHQPFRLQNQYFDEETGLHYNLMRYYEPEAGRFVNQDPIGL LGGINLYQFSPNVQTWIDPLGLNAKLSEMAQSVHNLAGGLKTPDARAIEKSTVAIFEVEL KNGSKTLYAAGSSGRLNPRQRSLLEKLGVPKENILSGKKYTLPKDVVKNINHAEQIILRN IPDDAKVTRKGISWGSKQRNAPCSRCKPSVDGAGGVYD (SEQ ID NO: 13).
[0253] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 14, which is the amino acid sequence of SzDaOl (Accession: G2GKN7; database: UniProt):
MYVDTTLPKIRYLAHVLVTLTIVVMVALMVSLIPGVNVAQATEQKSDPPGLRNEKSIPG EVFTPKQRERPNGADRDWKASEASWPAGKRTAPIAAAPAGGRSASVGTSPVSVYQASG ARTASGADAGLVDIEVLDRKAAEKAGVNGVLFTVTPTVPATAGRAGSATAVAPSGKAR VTFDYAKFEGNFGANWGSRLELIDTATGKSVTRSNDSSARQLTGEINLPEARAGKAEPL ALAAVAQAAGSGGDYSATSLSPSGSWMGGSSSGGFSWTYPVDAPAVPGGPEPEVALGY S SQAIDGRTASTNAQS SWIAEGWDYEPGFIERRYRSCADDQGTGANNPGQAGRTGDLCF GSDQMVMSLDGSSTELVKDDTSGTWRPADDDGSKLERKTGADNGARGGEYWVLTTT DGTQYHFGLNKLPGAAAQRTDSTLTVPVAGNQAGEPCYASAFADSFCDQGWRWMLD YVVDPRGDAMSLWWAKESNYYGGNNKPAGMKYDRGAYLKNIDYGQRADKLFTQSA AARIAFTVAERCIPGSGFTCAEADRTPANAKYWPDTPIDQQCNAGEQCKDRNSPTFWST KRLTKITTQVNNGGLRDVDSFALDQSFPATGDGTSPALWLKSVERTGYGQDGTTATLPK VTFRGEQMDNRVDGLEGLEPFSRYRVNAVDTENGGTVGVTYSPQECRRGGTMPAGPD TNTLRCYPQNWTPKGALEPITDYFHKYLVTQVREEDNVTDAVARVTSYEYLGGAAWA YDDSENTEARRRTWSQYRGYERVRTRLGSGTDVRQLTENRYFRGMHGDKLPSGTRSVE IEDSEGGKITDYPQYQGQLREEITYASDGGAIAAATKLTPAAVKTAERERAGTTPLQAY MVSPVTSETREHVKDSTWRRSSETTTYDSDGLPTQIEETTGSGRKACTRIEYARNTAQHI LDTESREVTTTGACGAPGGKVVDDTRSLYDGGAYKAAPTQGLVTEVQELNAAGDGYIT VDRTEYDTHGREIRTFDVEGNETRTAFTPATGAVPTKQVDTDPLGQTETTEFDHRGLPTA ELDANGKRVDMRYDPLGRLLKVWDIDRNQATQSASAEYDYTIRSDGPTVVTSKTLKGD GSYATSYEILDGLLRTRQTQDAAVGGEGRIVGDTFYDSAGRAYKSNDGYFNEQNAAPS
LLSVGDNAVPSQTRIDFNGLGEETAEVTYSYGDEKLRSTTVKDGDAVTVIPPKGETVTTT YQDADGRDTKLREYTEADRSAWQDTVYSYDDLDQLTKVTEPGGGEYTFTYDARGRQT S ATDPDGGTTRFE YDRGDNVTAT VNALGKKL VTTFDK AGRAT SLRED S ADGPKRAEWT YDTLGKGLPVASVRYDKDGNAYRDEVTEYDANYRPRTTKTTIPAAAGKVAGEYTYTYS YTSTGNLAWVELPKVGPMAKERLVFRYNRDDLPISLSGAANYVTDITYSKYGEILRSEA GPAGRKLFSTYFYDDFTRRTDRVVHDRSVQPGRIDDTTYAYDEAGNVTAISRTPGEGMP D AQ YGTDTQCF A YDQLRRMT S AWTAGEKC APDGP SKET VGGPEP YWQ S YEFD ASGNR TKLVEHDPAGNVAEDITRTYSYGGDAGGPNRLREITSAGADGTTKTTFGYDKAGNTTTR QNGGTTQSLSWDIEGNLESVTEPRAGGGEKKTSYFYDASGERLLRTGSDGATTLYLGET ELTVRADGTESVERSYAHPDGATTVRSSDGGREVLLADQQGSTQTSVDMTEAGMPVTR RLLTPFGEDRGAAPSTWPGQRGFVGGTRDADTGLTQLGARPYDPATGRFLSVDPMVDY QQPATINPYAYANNAPATFSDPDGLFFPVLVGIAARIAIQAAIRAAARRAAQIAARKAAE ALRKRILAEARKRAIAAARKKAVAKAKREAARKAAAAKRAAAQRAAQRAAAKRAVA RQAAARAKQRAQRAAAQRAQAARAAARKARPKPRPKPKSQPRPRTKPSQKAKPAQQR KASPKQSVGSRAREEIRSEARGQAEDAVAEQASCRTNSFVPGTLVVMADGTRKRIEDVK LGDKVLATDPKSGRTTAQPVVSTILGDGTKNLVKITIRTGEASPENIRDAARPGGETDGG VPVDTGLLQAQPGDGDGNGATTGTGTGTVVATDGHPFWVPALGKWVDAGELEPGQW LQTSSGSWLQITAVQAWTQNATVRNLTVADTNTYYALAGTTPVLVHNCGGAQSLADR ASEIHAQAGSEIAMSKSTVAVVSAQTPKGVVNVVAGSGRGLNRAQKDMLSGVEFPARN IPGAHAEQNALLFINEMGWSPIAGGASRSVCSEVCAPLIRAGGGRITGRVYQNESGTKIR TFEW (SEQ ID NO: 14).
[0254] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 15, which is the amino acid sequence of SpDaOl (Accession: D6X696; database: UniProt):
MAPFLPVAPNVVLLDMLRLIFVTTRSRKASVERGETMFKRRTRRALVISCVVAVAATGV PQPAFAAPSGDGGTGIVRGLKNFFGVDDDKPAAEPPELPDTAVPSNEQIPKGRAAPAPKR VKELTDRRTPDARYWQLSDGRVQSEVSAVPTHYEAGKAWQAIDPTVKPTDRKGFTLAN TTNVARTYFGERPGELVRFELDEGHWAAIGVKGVTGSLKPQADGSTVTYKNALGAGTD LTYTVGNGTVKEGIVLDAAPRTAPSYEFTLTTGGLQAVRRAGGSIALYSESSGPTRPALV IPAPFMTDAKKDGESPYEAAGTDRVEQKLSGKGTSYTLTLRPDAKWLSAPERRYPVVV DPTISIAPTS SQSQDVMIS SDGPASNYDGNWRLS VGNTGSGS SRALLRFPLGAVPAGTKL DSADLKLYFDQTHTTGDSEVRLEAHRATAAWDETTATWNSASGITGELSGTSVLVDDR DSGTTAAKGSWPASGNTAFTQYAVNQDYLYNKDSVAGDTYTWQPNLPEDGDYQVEA HYVPASDRAANAPYTVTYSGGSKTYAVDQRAGTGGVWKTLGTHPFKAGTAGKIVLGD GPASTSTAVLADAVRFTKGGVVTKRPGESNTWHSFPVTRTVQSWIDGTHTNHGFVVKA GDESAGGPKGGPRYEAAEYAYKGEVANFPKLVLTWGRPGATLEAPQVIHATGAELKW SSYQDQDPISDRDDIVEYQVHRSVFQTFTPSPQTLIAPVPEGTTSYTDTTATPTPADSVDA FGNVFYYMVAVKTKDGQVVPAPTRIVKLPKAGRTTLVLQGDAADTTLSTTQPATGHDA LEDSGIGRPWLSVGNNSSTYGTTRALLKFPALSQVPSASRVIDAQLDLWGTTTTTGSDG AVYEVHALNKAFAEADASWNKANATTAWTTPGGDMDPAVADTVGTVTNDPARQSW NVTSLAQSWVSDPASDKGLAVRLKDESSTGPQERTIFLSSEAEEPQLRPQLVVTYLAKST DSTYFSPYTPARMTPGDRYTVDVTVTNTTTSAWKAADQALSYTWSLPDGTDATTGGN QLFTALPEDLLPGQSATVKAALQAPINSDSGNKRLDYVLKWDLRNKTAGTWLSATESIP PL AQNVRVEDPT SNQLGLEKF YS YAGKNTGAGS SMMTNLYAGNT VWQ YN AF SNPGRG LTTFARFAYNSQDTSDTVLGHGWSAQAAMPLRLGTALDFHPNPNPTEVTLPDGDGTEH TFRKQEDGTWKAPAGVHYLLRQGEGVDCTPNKDGDPKAWSLTRPDRSQFFFDCDGYL T SITDKNGNTQT YT YEERKSNNKP VKFLRYITDP AGRQ SLT VEYYTKADT S SPKIIDHVR SMTDISGRKVTFEYSDKGLMTKLTDGAGSSQPKVFGFVYDAEQGNKNAKLVKVTDPRG NAT SLD YY YP SEGDDPKFHWNTQTITDRLGGTTGYVYRDPD ATAGSFIETKVTD AENHT TTQSLDGYGRPNTITNAKSETTKLAWDADNNVTRLEEANGAFSTWVYDQKTGYPLEQK DAEANKNGTAAQTFTYSTGLNGHIADLFRKKSPEGRTWQFGYDTRGNVTSVTDPKGVA SATEGDYTSRSEYDTYGQLIKAIDANGHATANSDFQPVGYPGTITDAGGHTSAFRYDVR GNVTTVTNAKGAEVTQTYDAFGRPLEKKEPKDQAAGDFIVTPAPVYDANDNITKVTAP NGAVSTAGYDAADQVTESTVPGDLATDAPRRTTTTYDKVGNVLTTTSPKGNETATVGD HTTTTTYDAIYQPVAVVDANGGRATSEYDNVGNIVKETDPRTNATPDPDDYSTI<YEYD LNHRVTRTTDALGWTTSGRYDKDGLAIGRTDAEGNESLATYDERGALVESRVPVSKDA GGTIKYHTTRYEYDPVGNKTRTITPRGVATTDDTDDFASETVYDELNRVKEERSPFDKD TPGYTTPDTTVYAYDEVGNLESVSAPPSDGQTVRNTTRYTYYDNGWARTSTDPWDITT SYDYNQLGQQTKNTITSAGGSQQRTLSWDFYRSGNERAFFDNGVPVGRQAVLVDSSDF HNTATQGTWTRGQAEQQYGHDIASHPAGTGTAQFVWQLNIPQNGTYEVFVRHPKVSG AATDATFAVTHDGGTTSRSVDQTKDPGTWISLGKHAFVEDGPQKVTLTDKANGTVLAD AVKLVRDNTGESDTEQKDFTYAYDANANKVEVKDNSPGAKIDTYRIAYDGINRVSKVE ELAAGAVKNTSALTYDENGNPLTSTHDLTWSKIEYDARGLVAKVTNADSPTAGNQQIT
TLTYTGRGQLLRQTKPNGNTLDLTYFLDGSVKQSVEKTSGGTVVSQHDLEYSPNGHRS KDVLKLMNADDSTAYINNTYTFDYDPQDRVTKVGKAGDSPSTETYSYDANSNITEQSV AGVTTTHRYDRNRLLSSTTAGVASTYNYDPLGRLDTTSTGGQSLEKYYYDGFDRTVKT RSGTGAAATTTNYVFDPFDRTVSQSTSGTDPKTTAFTYLGLDSTLLREEVDGKADKSYQ YLASGKRATQIKHKDDGAKEYSQYTTSPRGDVEAITKEDGKTRSTYGYTAYGSDDESQ MTGEDKPDAQNPDKESYNAFRYNSSRWDKASGTYDMGFRNYDPGLNRFLTRDSYGGA LADMSLATDPFTGNRYAFAGGNPISFVELDGHLFGLSLSDIGHAALDVVGLIPVVGEVA DVANGIWYAAEGNYVDAALSMSSAIPLVGYGASAVKAGRYAKKGMDALDSANDARK TTDRAGDAADAGNDVRKADGDAPSTPAKTDAKTCKVNSFVPGTQVVLADGSSKAIED LREGDNVLATDVESGETRGRQVTDTRSHEGDKHLVTLTVDVDGTEGHATGEITSTAGH
HYWLPDSGRWAKAEQLEPGMWLRTSSGTWVQITAVDHDHAKKRVHNLTVAADHDYY VVAGGRSLLVHNECGPDYDQAASDKAGALHENLKVPGKKDGGYAYKNDTTAVVMAR DQAGNIRTIVASNRRYVPKAIKSKLDESAGEVFANGKGHAEMTALQYMDSQGWEFLGG AANRNVCAYCENAVRGRGLKLSGPTFPGFVQTLAGRFQFFGERMFRR (SEQ ID NO: 15). [0255] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 16, which is the amino acid sequence of AdDaOl (Accession: WP_203730777.1; database: GeneBank):
MLVSSRFRLLCHALIAAMIAAYLVSFPFTPASAAPVATAGAGPVNRPLPATAAANHGLP AGESAPPVPPAVATDGSKPRVPTAAEKAKRKLSAALAPTTKPIARGGFLLGDTSLVVYW DAEVNTGDPTSWGRWFATVTDTETGAEQRSIELGQADLSRCASPALLCRSFGAADGWV
LDPARTYTVTVTEIAADGTEQTSPPSDAAHPRKVDDVPTVAAGQVVGCGCSTVLGPTVT AQALRGATVNTATGQYLRVERDFTMPS YGIPFNHARYYS SGNTNVGMFGPGWS S S YDI RIVAADNGAVRVRAEDGSEAVYLARADGSFDAPAGIRATLSRNGTGWKLVPPDQRVLA FDADGRLLSIKNARGLGITLAYATAGPLSTVTDASGRVVRFEFRTDLRLITKIILPDGRST QFDYQDGRLLKTQDPRGYVTSYSYDAGGRLAEITDARGAKLIRNTYDANGRVTQQLDP EGGKTTFDWKPTEQIAVTVDPDGVTVSDGYKNNVLLYSQNGNSDTVNHRYTGKLNKN LVIDPKGNQEETKFDDAGNPISRTAPDPFLFTEVNTFDDRSNVTAVKDGRGNTWDYRYN QFNEMISQKDPKQGTGYEYTYDDKGQVSTRKDPRGKITEYEYDAYGDRTADVAPTGRR TEMFYDGTGRMTSVVDPRGTVAGASKDTYRTRFTYDQMNQVTETWQPGKGQPSRTTY DELGRVVVSTDPLSNSSRYTYDLASRLVEVKDPIGNVTATTWSAGGRRTSETDGEGNRT SWTYDNNGRVSTETSPRGNVTGADKALYTSVFHYDFNGNLIRTDRPYGTDGRRVEVDT AFDSLDRPTEQGDQFKNGTKVGYDNNGNVVSMTNERGEKLENFYDEANRRTGSSGGS GAAAVEYDDAGNVIKQTSPTGGVSTTSYDDDGRVVAVVEPRGNATGADPADFTTRYG YDLAGNPATETDALGNVAAAGYDPNNRVTSSTDANGNVTKYTYDAADRLASVIGPDA TGGQALTYGYNADGQVIKRTDPLGHTASLEYDRAGRTTVSTDGIGRRREYVYDADSNL VEEVTARIVELGRPDPNRPARTIFYAYDNLGRLISKQLGSGGTAYTYGYDAKNRLVSAA DPGGVLSYDYDVTDRLTTVTRGGEVFKYDYDSTDRIIGRTYPDGTKIGADYDDGDRITS LTATRGGTSANYGFHYDAADNLTGIDYPSATGITESRSYDRAGRMTRIAATKGDTTLSA FDLTLDKVGNPTKIIKATGEPGQPTITEAAAYTYDKANRITAECYGAQTCAGATAARTD YT YDLVGNRTTMKKVATGENTTTSYAYDAADQLTTETVSGTRS S SRAFTYDLEGNQTQ AGTDRFTYALDHTMTSASVNGTTTNYAYDAQGNRVSGTSGTGSSAITQTWSWDVNAS RPLLAQERQTGAAARDYLYDASGLPLGLIAADGTHSYLRDWLGGVSGVVSPAGAAEW EYAYDAFGVDRGTSKKADDAPDNPYQYAGTYQDTSQGDRYAMGVRSYDPSTGRFASA DPATQPATDQAVSTYSYTNARPTVLTDPSGADPDGMADTYADYYQAMACANYPPACA ATTDANTAAAGEGEQQVENPDWQNSKKLVDEAGSFVSKIGDEIVNLILDLVGFNDAKA CITEGDILACINTALQAVPWGKMFKAAKVAIKAIGVGRRLVDAYSRLKSAKNALAAIPR YIKKLTQTAEEAADSKKYADEAAKAAKGAKDAGGKAKATSQKAADNAKKAKKKEST TGESCEVAKGGTTRLASNSFAAGTPVLMADGSRKPIEKVQAGDTVMATEPSAALTAPS QVIATVAGTGEKSLVDLTLVGAGAGGGGPPAVITATTGHKFYSLDRDQWVPAGELKLG ETLRDNRGGKITLTGLSEHTAETTVYNLTVDDEHTYYVVAGDNPVLVHNCGAGADAES LAEAARYRADELHKALDPIARSKRTTAVISAYDHEGQIVDVVSASGRGLSRAQKELLGA GEYIAKSTGKRSHAEMNALAFIESKGWTPIAGGASRNVCGKCSAGLRASGARLFGGTFP GRGSRMRLFRWF (SEQ ID NO: 16).
[0256] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 17, which is the amino acid sequence of MGYPDa23 (Accession:
MGYP000056170311; database: MGnify):
QEDNTTQEVITWLFEGFVPVAKIVDDQKYSIVSDYLGKPFQAYDSEGELVWAAEHNIYG KVKTLKGDKTFIPFRQLGQYEDIEIDLYYNRFRYYDCHTGTYISQDPIGLAGNNPNIYAY VFDSNTEVDVFGLEVIFDETLANMARQAHDVLREKDKTKIKFNHSTVAIAEVEINGEKQ LFASGNGAVLSPAQRDKLKELGIPEENIFSGKRFKKILEDLEATKLANHAERVIIRNVPEG AIFTGKWGISWAGNQRNESCVNCLSFVEKVSNKHH (SEQ ID NO: 17).
[0257] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 18, which is the amino acid sequence of WWTPDaO7 (Accession: tigOOOOl 818- 10- 11279730_497; database: GeneBank):
VRSGEWDAAADQDSSGNFTEFTLPIEAYVSDFQVGWLLQPDINVAVYLPITSISGHSLTV SGSYGSLAPSSIGTHFRIHAPPGVERTGPFFSGFEAGTLSRFTSASSSRNLFGGYRYESPLA GVRDDLWMAVQGRQSGKNFTGLHYTLHRHYDPHLMRFTSTDPAAAPFFNLYAYCQGN PSRFFDPDGLDINTNATGCRLSPEDEEYFARSAGRTAALMDAMNCFGLFDRTKAAMRD QKSFSEVAGTFSNEVATTDWRTVTTSHFYNGANTLSGGWMGEVLDAETVAGWTGAKV NSREWRAGAASGSFAATTAAMLNPYSAMTVGLLTMTHGGYLAARIAAGDDSIDPFQA NAEMFGGAAMFGGGYVRLPSGSKGPKWKGDLYETPNLSVRARVRQLRESMLPDAANR VTLGAGILEDAQGVRRMVIATSEKRPYLRAGVRRNPGETMVPIVGKLHAEKKITLHAW ATRSKLVSVGATRPICGGCQDAILPTNASMATPLKRRRH (SEQ ID NO: 18).
[0258] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 19, which is the amino acid sequence of PdDaOl (Accession: JH605467.1; database: GeneBank):
MIDPNS SETE YKYDKLYRLIEQIDGE SGKTK YRYDKVGNVRF VTDPRDK VTEYQ YDRV YRLQKEIDANDETREYGYDLAGNLTSIQDRRDNTTIFEYDDVNRQTSRINPYGARFKIDY DKVGNVIKETDELGRSTKYDYDELNRLEVVTNAEDGTVVYGYDKVGNVISVQNERGKI TRYEYDEINRQIKITNALGFETIIDYTNDTDSNQLVVLVTEQVDADS SRS SEWRTDSRERL QTFTNADDTTTTYSYDGNNNLLTVVDELGRQTAYTYDELNREIRVTDAEGRTVETDYD ANGNVVK VVDELGYT VEYGYDQLNRLT SELDNLNRSLT YS YD SEGNQTK VTD SNGGE TKYKYDKLNRSLEITDAEGGKTTYTYDGVGNLKSVNDPNSNNGGNSNENGHTVTYSYD ARDRLIKEIDALNQETTYNYDEVGNLTSVSDRSGNQTIYKYDEINRQIERIDADGNSFKT EYDKVGNVTKETDELGRITTYS YDELNRLLEVTYP AIDGVVS SS S STYD AVGNLLTSTDE LGRTTEYKYDKINRNTEIKTPLGFITKFDYLDDTDNNLLVLTVTDAVGRETVSRTDGRG RLIEFVNADVSNVTYSYDGNDNLLTVVDELGRATAYTYDELNRETRVTTPLGNTTTTEY DSNSNVVKITDHLNNATRYTYNELDLLATETDARGFVTTYTYDEEENLASVQDPLDNV TTYTYDNLNRLFQETAVGVGTRTYSYDEVSNLTQLLDRNGRIVQFEYDDWNRQTAELW LNGDRIVNTIAYDYDAASQLVEVSDAVAKYSYKYDDDSRLTKEIRDTFGFTDGVVLDY THDGVGNVLTVTDTVGGIQLSTETYTYDAQDRVISISQTGNGVTPKTAVVTYDDAGQLE QLEVLNAFTTAQTFDLDGRPVTRTHTTAVGEVLAYGYEFDSLNRITAITSPNGESSFSYD STDQLTSASSDFQEDENYDYDETGNRLGNEIGPHNRLLNDGVYSYEYDDEGNRISRTEIA TGVVTD YEWDWRNRL VEVS S SNELGEVLS S SQ YQ YD AFDRRVAKLVD SNGDGIYELVE GF VYNGD S ILL VLNGDEVNQRYF YGPGID W VL AEETAGEGVE YALTNHLNS VEFILD S A GEVINEIVYDSFGGIVSETNPGVDVRYGFTGRDFDKETGLGYNRTRYYDFVTGTFLSVD RLGFEAGDVNLYRYVGNSPTIYVDPSGMFWEGFAEFIDENVNKPVGQFIADNPLVEDAV RIADSVAVGVSQTANLVGFDIREFREDIYGEGVNDNLNEAVVTASTVATLALGGYALSG LAAGSLGKVAATSINTGLFNTGFGLTTQLLFNGGDSRQLDYNSLRLDFAFGALGARLGF GVTARVGGGF ATQFA VSTAFEGTF AGFEQ VGRNLISGERLTQGVGENILS SILFQGF SEA L SNPRQ ALQ AGRRLLRGADNL ADDFLGVVRGPQL ATVDGVD SRLLRS VDEVPNVPKGG DNVFASIDDPKSRGELTKLIQQNGNVVDLSDRLIDVATSISNRSLHELAKDVHKLKGDKR AITQSAVAIVEARLVNGKKQLFASGSNATLSPRQRELLKQFGVPEENIFSGSKFRSSDKL KNHAERVILRHLPYRAKVLRWGISWASKHRNIPCPNCYPFVEKAGGIIE (SEQ ID NO: 19).
[0259] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 20, which is the amino acid sequence of MGYPDa25 (Accession:
MGYP00 1677015708; database: MGnify):
MVQSVHNLAGGLKTLDARAIEKSTVAILEVELRNGSKTLYAAGSSGWLNPRQRALLEK LGVPKENILSGKKYTLSKDVVKNINHVEQIILRNIPDNTKVTRKGISWGSKQRNAHCSRC KPSVDGAGGVYD (SEQ ID NO: 20).
[0260] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 21, which is the amino acid sequence of MGYPDa26 (Accession:
MGYP003599500301; database: MGnify):
GGEGHPASKTIAARASQTGATGQNHSKPAANDAEALYWASLNQQAEQKAQALAIEGW GTGTDGPQQQTAQAKIAEVYYFHTDQVGLPEELSNAQGQLVWQATYKTWGNTQAEE WKLVEADGSKTHPLDAGDQPESEAKHQNLRFQGQYLDRDTGLHYNTFRFYDPDIGRFIS PDPIGLEGGINLGSYSPNPIGWIDPWGWSCGELSSKARQVHNMAGGKVPDARSIRNSTV AIFEVKLPNGKTTLYAAGSSGKLNPRQRAELVKLGVPESNILHGKGVNLPKDGNPVNAN HAEQIIIRGIPDGSSVTRKGISWGGKQTNAPCIHCKPSVDGIGGIYD (SEQ ID NO: 21). [0261] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 22, which is the amino acid sequence of AshDaOl (Accession: A0A7H8HBT9; database: UniProt):
MRYHHVRVTDPGVTGGTVPGVALYAKKITYTGQGKIEGRYSITFTRDRDRGEPRRPDV VIDARNGFKQVTADLLRRVDILLDDKPIRAYELNYRTGAFAKTLLQSVTQFGEDGSPFTT HTFDYYDDIRSADGQYQAFGPAAGWSVPGDSLGESVPDGHASALSATTSRSTGGHLYV GFNPAVVSKSGSAGAKVGFNAGTSEGLLSLTDVNGDSLPDKVFRTGAGVFYRPSLSGPG GAPKFGDTPIRLPGLPGISEESTRSTTSGAEAYFGVAAQLDHVSTTTRTDRYLTDVNGDG IADLVTGGSVLFGHLDAQGNPVYSANSNDTPVPIGGGTVNGTIVGDQTAEIERQVDAFPL LDSVRRWVAPYDGTVRIAGGAKLTSDPGDDRAADGVRVAVQQEDTELWAQRITARDH NTYVPSGVDSVAVHRGDRLYFRVQSVADGRFDQVNWDPDVTYTGVTPATDVNSLDVY RYLASRDFTLGGRPSTVTAPVTGTLHLSGDVSKVGPTTDDVAVVITRNGTDVFSRTLPA AS ATTVPIDLDIP VS AGDTL S WRLKVD SPID AGTLHWVP S AHYT AAEGGVP VVDQQGNP TLVIDPPFDLDLYPVDTATAPQGTYTADRTGDLVVEPNLALAGDAHVVFTVKRRGALL AKRVIDVAGGQVPAPESLRVTVPVTAGDELFFDFSTLDPGLPAKVTGQSASVSTDGTTFT P VP S ALHAAAEQGAF AAP YRGWAAIGYQGNRDRAT APIKQ SDL VID AS YRDKIPGAPKE SDVPGFDGRVSKPNAVVLAPRPALERWGSDDGNTWVGAGSAASSRWGTDRIDVAQDA DIAGATGVSRVARIQQISTTFGASIPGVPIGAGASVARGRSSGQVDFLDLNGDRFPDVVG PAGIQYSDVTGGLGATRGSLGTGSVRESDSTAFTASANAGSPARTEPNGRGMSAPAADK PATTAQSGSELPSLGIGGSVGGGQSGAAFDLLDINGDTLPDRVYSDGTAALNLGYRFAA PEPWPGGPLADSNSRSSGVDLGFNTDFYGLAGGVSATSGQAKTEAGLQDVTGDGLPDR VFSRDGQPLSVAINTGSGFTAPTPLGGSQAGITTDTNAGLGAGAYFTFGFCLGILAGACV VFNPGADTSRGIGRSEVALRDVNGDGYADQVRSTRDDELVVAENRTGRTNLLRSVSRP LGARFELDYTRDGNTENLPQSRWVLSRTTLFDGHPGDGQDFQVSTFHYADGRFDRLER QFLGYGRVVSEQRDGDAVYRSTTSEYRTDSVYTRGLFTRTYTADGGGHLFTETLNSYV LRDVATGKVADPASTSATVFPLLAHTEQRFYEGGAAAGKTTATDNEYDQFGNLTRVLD TADTGTADDVETRMQYTAADAACRDRNIVGLPDVVDVVAAATKTTTRHRESTIDCATG EVRQVRAILADGSKAVTDMEYLGNGNLKAVVGPVNKAGQRYRLDYGYDPVVGVHIET IVDSYGYRTAITHNYKYGLPETTLDKNFQRVHTDYDRFGRVSFVAGPYEIPDNRVTVSF EYHPEAPVPYAVSRHIDTTAGGVRDDTIDTVQFTDGLGRVLQTKKDASVAPAPGVTPEA VMTVSGHTVYDFAGRAVEQYYPVTEPKGDKNYVFNPAVDSVAPTRLGYDILDRTTSTV IPDGSVSSTSFGFGADRSGTTRFETVSTDANGKQRRSYSDTRQLTTAVLEANPAGSQPVI WTSYDYDAMGQITSVVDDRGNTTKAAYDNFGRRTVVDSPDSGKVESGYDLADNIVSK
VTPTLRAQRKAIQYDYEFTRLTAIRYPVFSGNNVTYTYGALGAPENGAGRITSIHDAAGT VTRGYGPLGELTRETRTLGKDVGTWEDRGQSFTTTTRYDTWNRVLETTYPDGEELTYG YDTGGQVTTATGVKNGNQYKYLARMDYDKFNQKVLQETGNGVRTTYAYNDTDRRLA TLKSDQPDGREFQNLSYGYDKVGNVTTLTNDVAVPGAKELGGPSTQTYGYDDLYRLTS ATGSYRNDNDKLNHYQLDLTYDTLNNTTGKTQKHDLTTTSGVTQPQYNTSYTQKYTYS ALPHAPSKIGTDTQKYDAGGNLIAITAGRSTDAVVLAAADTSGGKRTQYVWDEENRLE CAFDDESSTVDQDPASCDGRHEQPTVRFVYDDAGNRVLKDGEETHVSIGTTYSRVDGK AVKHYFVGDTRLLSKKASDSGYEHDQFYFHPDQLGSATYVTDERGKLASHQEYFAYGE SWVEETRARKPVPYQYNGKEFDKETGFYFYGARYYNPRTDLWQSADPATGSYLDGTP NGGVTQPFNLSSYSYASDNPVRLADPDGLSTWNRVMGGLKLVGGFSEAATGAAFGTAT SWTGVGAVAGAVVFVHGADTAATGLRQLWTGEDESSLTSLAIQHTTGLSKETVDRGEA VVALGASLGMSAATKAPQVLGATAGGGGQTTRAVGSAGLIGGGLSQPGALRAAAVEV HDLALLEKGGEIRHTMSTVALHEARLADGTTQIFAAGSSGRLSAAQIEKLVELGVPRANI VRGGLHAERNILAAVPEGAEQVRWGIAWGARNKPIPCDKCAPFLKGVLEGAE (SEQ ID NO: 22).
[0262] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 23, which is the amino acid sequence of MGYPDa21 (Accession:
MGYP00 1278432191; database: MGnify):
DLIEQLAERLGNHANLTDELIAAELQAMGVAATDDIVARVWSGLNASALRQSGALRAV ALEVHNLAGSQIAINQSAIAVVEVTLADGSRQVFASGSGGRLTTEQVRRLIALGVPPENIL FGAAFTNGFTQAENHAERILLRNLPQGAVVNRWGISWAGSHRPIPCDVCRPFVAQAGGI LEGAQ (SEQ ID NO: 23).
[0263] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 24, which is the amino acid sequence of PpDa03 (Accession: A0A3S0YAN6; database: UniProt):
MAGTETHYGYDEDGNCVTVRNGEGEIRHFLHDGRGLLIRETAPDDILHYRYDAAGRLT EVTSATSHIQLAYDKRDRVLEEHNSGSVIRRHYQDASHTVTRSLLWEGEEDSAALTSSF CYSATGELRQVQLPDGAELMLAHDAAGRESIRHSNGGFTQQREYDAMGWLTREMSGQ QQDGRLHASQTREYLYDGAGNLAGVRHNRETWGYRLDATGRVLSVLSGGAGRAVET DEAYRYTRNGLPQDTTRLTEWQAGRLTQHDDTHYQYDKAGRLIRKQVIQPGYRPQVW HYRWDSRNQLRVVDTPTGERWFYRYDPFGRRTGKRCEQTQDDVRYLWDGDQIAEVR HYRNGERVARRHWVHNGWELLVQQRQNTDGRWETDFVTSSQNGEPQALYRPDGTLC WQAPKSTLWGQRPGSTEDPADPGLAFAGQYRDTESGLCYNRFRYYDPTGGCYVSPDPI SILGGESNYGYVQNPLGWVDPFGLASCEHLNKMAKEVHDLAGGLKTPDARAIRNSTVSI VEATIDGKKVLYAAGSGGRLNPRQVEALERLGVARGNIFKGARVTNDFTKLENHAERII LRNLPDGAVVNRWGISWGGLQRGIPCDHCAPFVRDAGGFF (SEQ ID NO: 24).
[0264] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 25, which is the amino acid sequence of SbDaOl (Accession: A0A7G6KCF9; database: UniProt):
MAQKVHDLAGGLHAPDLRAIRNSAVAIVEATVNGEKILFAAGSAGRLNPRQVALLKEY GVLEENIFRNSAVTKGFEQLENHAERIILRNLPEGATVERWGISWAGKQKNIPCPHCEPF VRDAGGFFDKIW (SEQ ID NO: 25).
[0265] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 26, which is the amino acid sequence of BlDaOl (Accession: A0A6P2WMK2; database: UniProt):
MWNGILLVQETYHDRWGEEALTYLYESNSYVPLARIDQGKAAANDANARDAVYYFHN DVSGLPEELTNAEGELIWQARYKVWGNAVQEEWIARAPQQPVPEWGELQVATATSVH MPRPQNLRFQGQYLDRETGLHYNTFRFYDPDIGRFINPDPIGLLGGTNLYRYAANPLVWI DPWGWACGELSGKAQEVHNLAGGGDARSIRNSTVSIVEAKVNGKPQLFAAGSGGRLSP
AQRQALMKMGVPEENIFYGKKSIDGFDKLENHAERIILRSLPEGAEVSRWGISWGGLQR NASCPSCQPHVDQAGGIFD (SEQ ID NO: 26).
[0266] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 27, which is the amino acid sequence of PpDaO4 (Accession: A0A5M9IK01; database: UniProt):
MSDALWAARMGDALTHTSMMADILGGVLEVAANVAITALATAAVAAAIGVTVATAGI GGCILGAVVGIVVGMAMSKTGADKGLSKMCESFANALFPPVVEATIAVGSADTFVNSIP AARAAGSIPSHVAPAGTELELPPPEPDTAPQAEPGFLDMAEGFFSQLWRPTVATPAPGVV PALTDMVLCARHPPMPPQLLAEGSDKVTINGQPAVRSGDRSMCDATVVSSGLISPNVTI
GGGTVVVQEIRSGKTPGVGLAIEVLMMLKGAKGKTLSDLPCMLLSGVTSYAVSQAMG AAANATMGSPNPVHAATGAKVLGGNTEMDFVLPGILPITWQRFYNSRDKRRNGMFGA GWSVSYEVCIEILPHPDGGEDLVYTDEQARRIHLGAMPLGTAMFSAGEGLSIRRHRNGQ VLIESEDGLYRLFDSAPGDSAFLRLSQLGDRNDNRIYLDYDERGQLVRLRDTFDLIQIELT
RERNRVCQIVRVYPDHRREPLALYSFDAAGDLAHVSDATGQTQRRFAYDSSQRMVEHQ LPTGLRCFYEWALIDQMEWRVIRHWTDEGDEYRFEYDLQAGITRITDSLQRVSTRLWNS QHQIVSYTDNLGQTWLFEWNDERQLLSATDPKGGRYAFSYDDSGNLIGEHDPLGRSDST VWLPHWALPRFQIDAAGNSWTYQYDSRGNCIRETDPLGYSTQYRYDAHGQIVEIIDAAG KSKRMRWNQFGQLIEYIDCSGYPTRFSYDERGFLQTITDALGERSHFSVDAKGRLLTSQS PDGQMDYFQRNANGQLVSHTNAAGHTTHYRRNRRGQVSQRTDAHGRTVEFGYDAFG RLQALTNENGERYLFTWDAGDRLEKQQDLDGSAKYYAYDALDNLASVESVPALYGTG LSVVPPTRAKPIVHRLERDAIGRLTAKVTDDGRTEYVYDVLNQLLAVTFTDHQGNSQAL GFSYDALGQLLEEASPAGSLRHHYDELGNLTQTQLPDGRWLNRLFYGSGHLHQINLDG VIISDFERDRLHREVMRTQGQISTYLGYDRSGRLRSRQRRYTQQASLLPSAEQSNFEYDL ANNLVVKRDQHAKGQRHQLLHYDATGRIIASQGDIQGQAEIFAYDAAANLLDGSQQGA GLVVHNKLITYQDKRFRYDGFGRVIEKRSSQRGLQSFRYDAEHRLIEVRNHGTAGDSVI CMKYDPLGRRQEKCEWRNGFQTNKTTFVWDGLKLLEEQHNSQKSLYLYATSGYEPLA RVDGRGHQQKIRYYHNDVNGSPLQLTEADGSPVWEATYKVWGNTLQEVQEPYYIEGQ NLRYQGQYLDRETGLHYNTFRFYDPDVGRFTTRDPIGLAGGLNLYQYAPNPIGWIDPLG LSCSLSAKARKIHDVARDPFAKRNSTVAIAEVTINGKTTHYVAGSGGTLSPAQRKLAAE MGIPPENILSGTKVRSSNADPTQAKLENHAERVIIRNLPEGAKVEKWGVSWGGKQTNAS CSNCQPHVDASGGIFD (SEQ ID NO: 27).
[0267] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 28, which is the amino acid sequence of CsDaOl (Accession: A0A3E1NUV0; database: UniProt):
MLISNKHFVPVIGLDIHIVILFGFPIPLPHPYLGFVLDPMDYIPFLGASTKVNHVPRGVSDT SGIIIILFHFPMGGPWLLAPLIGHD S VNF YGAKNTL VEGRML SPTGHMLMTCNDIGLPL SL KPGKKLIPMPGMYLPTSYSIPLSFGKPVIVGGPYVPDWAGVLMNLLMSFGFGALLKGIG KLGKKMMTKFNHALKGKLGSNKLSKFLCKHGFEPVDLVQGIVISEGLDFELSGPIPIVW ERTWNSDSAHKGLLGHGNHLFYDMRVQEFAAENATVVLLRDGRSAVFDALPYSGDKE YNRHEKMLLTRTDADEFVLYDYEDKLFYTFKKIRETDEQFRLFAIHNKMNFLVTLHYN QKGHLLRITDSAGRQLHIKNDFEGRITSVTAHHRGQEMLLVSYEYNEEGDLTAIADALG QATRISYRNHLMVSKTDRTGQTFYWEYDNKKRCIHTWGDGGLLEGFIEYHPSEGYNLV TNSLGETTTYYYSPDFVISQIRDPMGNSTFINYTEDFEIYQEIDEEGTVAGYTYDDMGNM TSVVQPDGSSYSFLYNEAGEMILGMDAEGNSSTYTYYPDNGLLHTNTRPDGSIQIMRYN EQLLLAS VEDTDDNITTMEYDEDFNLVKMVLPDGGEATWTYDVWGQCTS S SNPARQV QRFRYDALGRITDVETPDGNHISMEYDAYFQVLRAVDKHHDVKFSYTPLGNLRTREEN GAKVNYIYDTECRLRTIINEKGESYQFVRNAKGESIRETGFDGISYGFVRDATGKVIKVE RPGQKHSTYEYDYNGMLVRAEHSDGTWSSFAYDRNGLMIEATNENGTVSFKRDAMGN VIEERQNGHVVSTQYDENSRRMRVQTSLGAQVNLLRNRMGDITGMRANDSISRDPWTL QIQYDLAGMETERLLPGGISSSFTYDKAGMPASQTINSNKRTIRKTYYRWDANQRLREM VNALNNSSVKFAHDNFGNLAWAQYEDGHFDYRQPDKTGNLFRSVSQNDRKYGPGGQL QETPDARFEYDAEGFLIKKISSGLKVWEYEWTGRGTLQQVTRPDGKTVRFEYDALGRRT AKIYGNEITRWVWDGMNPVHEVVTYPVDERPQIRIDDMGNIMQQEEPVPAETLITWVFE GDSCIPVAKIINGKQYSILSDYLGVPFAAYDGSGGECWSCELDIYGKVRKLAGSKGFIPF RYQGQYEDVETGLYYNRFRYYSPDEGVYISKDPIGLDGGSRLYSFVNDPMSLFDLLGLH PIFDDALAEKARQAHNVLKRNIPGKPEIGFNQSTVSIGEGTLPSGEKQLFASGNGAKLTP AQRAKLIELGVPPENIYSGVAYMKKPVNKSKVKSVRKAYNLENHAERVIIRNAPKGTKF KKWGISWAKYQKNEPCSNCKPHVQCAS (SEQ ID NO: 28).
[0268] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 29, which is the amino acid sequence of MGYPDa22 (Accession:
MGYP00 1462196871; database: MGnify):
DEYVPPVGMPSPWLYGDTTNVSEEYIKKKFDRTFLLSKGFPVEFPDFLELLNSLGFAREA TEDEIIAHIYQYTHEYQALDYGYKVLRDRGEYSFIGSHSTPSEVWTGKEYSEEEVLQIGY ANIIYDEQQREIAKISLDLERNMEESRFADPEAKAVLDLGSTNPAYNFRALRFLIERLFNEI SLGVQQNQAILKNHLHRFPLLRMYVTNPLALPHLLGSSLPQNSWSRQIIDFDINFDEIIITD NISAENIPVNYSKLQTDVKSLEANIESTRDFAGFKAPLLDIYDEFHLEDSDSNPITAVAGG RTRTSANASAGLNSIELKLENTDPSQRKAALDELLMQNNEESWQALLMTYDSPHEDVR SKAQQTIKTRLKKDATFKKYVVNLVNTPQGLLSDFAFNLLTLYNSTEEINEDHYRKIVLQ NLHQANDLVGTFVSKVQLYFEYLHRNDAIDFQIDTTWINEGITNIEETYFHDLGSLGIRTT NFIEQLSIGLESIESMQEFIPTEISQRGKLKVEIHPQLINLITLSSKLGGEDAHEHFQSILTSL QAWPGKF AQAF SEDLYSTFTRVKAKLQS SLNSKALS SFKS AWATFKTDMITPLLTDTDV IILKLEQLKLTASSAPNKFFAELDTLSYQIESITEKAQYALSATDLMDTYSEFAWRNEVFK DEYLEEEQTIKNAWGLIALAAYNRDTDPEGARRQFNQVIESEVLKDVDEKIAELYKFQQ GELDTFMDIMILLVSIKTGGLAGGAARTGLGFLTRAGASTFARQATVAIATLGAEATAF HLTSRSLKTLANRGDFMDDTFWEDYLETFLMFGAMKGGGALFQKFLAPKAAKFMQST KFPNLAKATSFLGKQATVFSFFQAWTIGAHWIKTGEFISPTDKEFWQIAAQNAFFLGAIQ FGMAATRPLVMPKQSQVPKEWLETNNAEGGMLSRQMAAWKSNKQASNAEAMEIMKQ AKSILERRLGIFERIHANYPAELSKVEIIKIRSEINSLISSINNTLAFGNAKVKPSATHPGTY YYEGSFNQVAPSLREQGFVVAESTVPGQVNVVNSLTGEASTFLSLPSGSNPIPAGGISVA ERLNQLKAEGKSGGPRKQAIVENPDAYYFDLARKGGKGEYRLRPGLPKSPSSPGQIKFR TAKTALPRNLNEPLALYHLSRSVHNVAPKSMTTQGNITIEQSTVSIVKVKLADGTMTFY ASGNNAYLTPNQRVLLKLAGVPEKNILSGEEFRVNDKLENHAEKVILRNLPAGAVDLE WGISWAGGQKAASCSHCATVVDQTKIQRHRP (SEQ ID NO: 29).
[0269] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 30, which is the amino acid sequence of FIDaOl (Accession: A0A0Q4RZG0; database: UniProt):
MVYDKPEPIKNLITW VYEGGSF VP S AKIIGEHKF SI IND YIGRPIQ VYNEVGD VVWETD Y DIYGGLRNLKGDKSFIPFRQLGQYEDVETGLYYNRHRYYNPESGGYISQDPIGLLGGSAS YKYVHDCNNCVDIFGLNPVIFSEELSKIAQEAHNVLLEPGKSPRGFNNSTVSVAKVDVN GVSTLYASGNGASLSPAQRTKLVELGVPEENIFSGKRFKEIIDGDTGTLTKLSNHAERVIE RNIPKDASIKEWGISWASKQKNEMCNNCKTHFGCK (SEQ ID NO: 30).
[0270] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 31, which is the amino acid sequence of MGYPDa24 (Accession: MGYP000620945751; database: MGnify):
QETGFVEVSKGDIGVIGNAALARKIEPDPYLCPLRFQGQWEDEETGLYYNRFRYYEPMA GCYLSRDPMGIYGSYRPGAYVPNPALWIDPFGLQRQPASELSGCEELGEMARAVHDIID DPRAKANSTVEIFRGTDGQLYASGSGSRLRPAQREALMRMGIPASNIFSGVAFQGADKL ENHAERTILRNMPEGVKVQSFGVSWGSRQRNVCCTACAASMIPNLAN (SEQ ID NO: 31). [0271] In some embodiments, the amino acid sequence of the methyl -sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 32, which is the amino acid sequence of AaDaO2 (Accession: A0A2S8AG27; database: UniProt):
MAREVHNLARDERALRSQTVSIAKVEKDGVSSLYASGSGASLNPRQREKLEELGVPKE NIFSGKKFKVFIDGERGIQTKLANHAERVIERNIPLDSEIKEFGISWSSKQKNEMCPNCKE HFGHSH (SEQ ID NO: 32). [0272] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 33, which is the amino acid sequence of MmgDaOl (Accession:
JANFCGO 10307071; database: GeneBank):
SSTPVGSLRSIAMAAHSKAATPTALEKTAVALAEVRLKNGSVEYWAAGSGESLSGIQRN YLESLGFRVISGKAGFHAEEQIGYLLPEGSDVLRWGISWTTPQKGIPCIRCNPLLDTIGGVI EK (SEQ ID NO: 33).
[0273] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 34, which is the amino acid sequence of PbDaOl (Accession: MCL1918637.1; database: GeneBank):
YQNDPNGMPLRLLDENGIIKWEGHYSAFGLVDRVSVEAVGQPLRLQGQYFDDESGLCY NRHRYYDAVVGCFISSDPIGLDGGLNPYRFAPNVLGWIDPWGLSCAVLSARLARIARIV
HNLSGNPRAIRQSTVAIARVRINGKYQLFAAGSGGRLNPAQRAELVRLGVPEGNIFHGR GVTNGFSQIENHAERIVLRNIPEGSSVVHWGISWGGLQRNLPCVSCRPYVLGT (SEQ ID NO: 34).
[0274] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 35, which is the amino acid sequence of BcDaO2 (Accession: KVH32961.1; database: GeneBank):
MSSDHPGGYVEHNRLKMFEDKRFEYDVYGRLVRKLSGHGPAKELVLEYDDWNQLKA VVRKDRLGIGTTHFEYDAFGRRIRKFNGSYASTDFRWGGMRLVQETYHDRQGEEALTY LYEANSYVPLARIDQGKPAANDADARDAVYYFHNDVSGLPEELTDAGGELVWQARYK
VWGNVVQEEWIAPVRHQPALAWGEVRAVIESPDHVPRPQNLRFQGQYLDRETGLHYN TFRFYDPDIGRFISPDPIGLNGGRNLYRYTPNPLVWIDPWGWACGELSAKAREVHSLAR
DDFALRNSTVAIVEAKVGDKTELFASASGGKVTPAQREALERLGVPKENIFWGAKAVN GYERIENHAERIILRNLPDGSEVTRWGISWGGLQRNASCIYCQPHVDEAGGIFD (SEQ ID NO: 35).
[0275] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 36, which is the amino acid sequence of LsfDaOl (Accession: UHQ21442.1; database: GeneBank): MTTAAKHFDPQLGIDIHMYVFPPVPLPVPLPTPHIGIVLDPFDYLPFLGGTVHVNGIKRAT AGTGGLNLHIPMGAYHPAFLPKLPTGPQTDDELFMGSMTVSADGDPFSKLAMPVLDCN VVGMVPPFRLRKPKKPKLSLTLPTAVNLAIPTNVNVGGPPTISLMAMAMKGLFKLLGPV FKRGGKAFKKLRQKVFGNMKPGFLKCKVLRAEPVDIRTGSVSVTHEDFVVPGRLPLAW TREYGSNNDHVGACGYGWETPADIRLELDADGSVLFHSGEGVAVFPQAPEAPGLAHAV REFVDGARLYAQGDEWRVRSKDGLRYAFARPAANLVALTTQTLPIQRIEDASDNAWRF ERRGADLVRIVESGTVDPVSGQPLQGRFLQATSRQGRIEALELHDPATGRNHPLVRYEY NDAGDLVSAFDPLDAPRTFDYRQHRMVRHTDRLGLSFHYAYDEQWRVVHSWGDGGL YD YRF AYDDLLGD VEITD SLGHT SL VKFDE YRLPLCEIDPLGGVT VFEYDEAGRTTAVV DPAGLRTEFVYDERGNLLQLTRADGSTLQVQYDEEDRPVAVIDPLQASWQQRWDERGL L VEQ S SPLGARSTC S YDPHGQIIA YTD ALGA VTALHYDRHGQ VQ Al VDPLGTRS SFQHD ALGRLLEQANAAQQRTGYQYDAKGRLLNVVQPGGTTVRAAYDAEDQLIRYTDEAGAV TQLAYVGIGQIARRLQPDGHLVQYEYDREEQLIAVINQRGERYELKRDALGRIVEEVDY WGQARHYRYDAVGRLTGTTDPLGQVIAYATDPLGRITAKTLPAAERPGQQIKEIFRYDP RGQLIELRNEHRQVKRTFDSEGRLVEEDQDGFVIANTFDALGNRIVRTASAGNRVACEF DLRGQLSRVTINDDAPILIERDTLGRALTERLSPQVRRQLRYDERGLLTAQAVLKDEAPL FDTSYAYDAVGNLTQRHDSAHGADLYTYDPMGRILAHTDPRGKLTQFLNDPAGDRLRT RVHAKRQQQVVGGEPQPDEWTREGDYTGQHYVFDRAGNLVRRGDANSAGNDDERAL HLRWDANQRLLESTKDGATTRYGYDPLGRRVFKRNPTHTTWFYWDGDALLGEVSHDN DR. IE VP AL VNDG V V VDLF EARQRK R VF DGLHK R VR E Y V Y YP S SF VPL ALIDRQRD AAV NTSPAGTAAPEAATTTEVFHYHVDPNGCPTRLTDASGKVVWSVSYATWGEVTRVHVA EIDTPIRLQGQYSDVETGLHYNRHRLYMPELGDFASQDPLRFMAGENLYGIAPNTYAWI DPKGLSCQLSHIARQVHDLAGNHPKAKQMSTVAVVEAIVDGKKILYAAGSGARLSQMQ RELLEEYGVPASNIFHGAAVRANDQLANHAERVILRNLPPGAKVTRWGISWAGNQKNA SCPNCQPFVDAAGGVLD (SEQ ID NO: 36)
[0276] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 37, which is the amino acid sequence of SmgDaOl (Accession:
JAHZIMO 10172802.1; database: GeneBank):
VTSVVGGIAMVNGADDFLTGIRQMFTGRAERGATETFVTEAARLVPNLTRDQRENIGTG VSMGLGFISPVPGSNAPRMALAVAGGGQRMASGVTRAARIAEQARAAQIAANGVRVA MSTQDAPSSSTPDAPSSSTPDAPSSSTPDAPSSSTPDAPSSSTPDAPNSTSSSSAVARTPEQS AQAQLLPRSDIDYRLQPGGALRDTARSVHDLAHMSPSDIRTTRRLGSPMARTNRTVALV ELRVPGEDGSAVYASGSGGRLSPVQRGALEELGITIIGGIGHAEQNLSAAIPDGAEVLRW GISWGGTQNPNPCTGLCEPIVNRLGGVIER (SEQ ID NO: 37).
[0277] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 38, which is the amino acid sequence of DaDaOl (Accession: tr|A0A2T4Z6L8|A0A2T4Z6L8_9BACL; database: UniProt):
MKGREISKPSDTEQKRYNYTLYFLMILLLSIVFILLLPPDIAQAHNCGDFRDCYSTLRAAV AATLGLSMFAVMLSIGLDFVPIVGQTKGMIEAISGRDLITGEELEDHVRLLGILGPAGRIA GGAASVGRGASHFSKAESGYIEIQRFRRILNMPRYSLTNGRTGTVARVEVNGRRIFGVNT SL1KNS1<YAPRDMDLRRRWLREVNWVPP1<1<N1<PNHLGHAQSLSHAESHALIRAYERME RLGGQLPKKLTMVVDRPTCNICRGEMPALLKRLGIEELTIYSGGRDAIIIKAIK (SEQ ID NO: 38).
[0278] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 39, which is the amino acid sequence of EcDaOl (Accession: WP_001289064.1; database: GeneBank):
MSEGPGGPQGATAGGTLAMRMLSQQAMVASQMKRAANDKAIAQMLASKKSGPPAAR LGDEIQHKSFLGALAGAVLGAIVTIAEGCLIMAACATGPYALVLVPALMYASYKASDYV EEKQNQLESWINSFCDTDGAINTGSENVKINGELAARAAVTLPPPPPPGAIPEVPQGEPS WGDIATDLLESAAEKAVPLAKAWGNAVITLTDSNAGFMDRVSAGASLLFPAGPVLMEF ATMVGGRGEIKKEVDFPEAGEDTALCDKENKPPRIAQGSSNVFINNQPAARKGDKLECS AVIVGGSPDVFIGGEQVTYLDIQPEFPPWQRMILGGITIASYLLPPAGLLGKLKNLARLGK LGNLLGKSGKLLGAKLGALLGKTGKSLKSIANKVIRWVTDPVDPVTGAYCDERTDFTL GQTLPLSFTRFHSSVLPLHGLTGVGWSDSWSEYAWVREQGNRVDIISQGATLRFAFDGD SDTTVNP YHAQ YILRRRDD YLELFDRD AL S SRFF YD AFPGMRLRHP VTDDT SDDRL AHS PNDRMYMLGGMSDTASNRITFERDSQYRITGVSHTDGIRLKLTYHASGYLKAIHRTDNG IQTLATYEQDARGRLTEADARLDYHLFYEYDAADRIIRWSDNDQTWSRFTYDEQGRCV NVTGAEGYYNATLDYGDGCTTVTDGKGTHRYYYDPDGNILREEAPDGSTTTYEWDEF HHLLARHSPAGRVEKFEYNAALGQLSRYTAADGAEWLYRYDERGLLSNITDPAGQTWT QQCDERGLPVSLVSPQGEETRLAYTPQGLLSGIFRQDERRLGIEYDHHNRPETLTDVMG REHHTEYSGHDLPVKMRGPGGQSVRLQWQQHHKLSGIERAGTGAEGFRYDRHGNLLA YTDGNGVVWTMEYGPFDLPVARTDGEGHRWQYRYDKDTLQLTEVINPQGESYRYILD NCGRVTEERDWGGVVWRYRYDADGLCTARVNGLEETILYSRDAAGRLAEVITPEGKT
QYAYDKSGRLTGIFSPDGTSQRTGYDERGRVNVTTQGRRAIEYHYPDEHTVIRCILPPED ERDRHPDESLLKTTYRYNAAGELTEVILPGDETLTFSRDEAGREVFRHSNRGFACEQGW NAASQLVTQRAGFFPEETTWGGLLPSLVREYRYDSAGNVSAVTSREDYGRETRREYRL DRNGQVTAVTASGTGLGYGEGDESYGYDSCGYLKAQSAGRHRISEETDQYAGGHRLK QAGNTQYDYDAAGRMVSRTKHRDGYRPETERFRWDSRDQLTGYCSAQGEQWEYRHD ASGRRTEKRCDRKKIRFTYLWDGDSIAEIREYRDDKLYSVRHLVFNGFELISQQFSRVRQ PHPSVAPQWVTRTNHAVSDPTGRPLMLFNSEGKTVWRPGQTSLWGLALSLPADTDYPD PRGELDPEADPGLLYAGQWQDAESGLCYNRFRYYEPESGMYLVSDPLGLQGGEQTYRY VHNPNESIDPLGLAPCPWQIIDRFRSLKAGLSRLGEHIPHQGDGFGTVAYIEINGRKIFGV NSSVLSDKAKDLGRYWVDRLKLGRGVSQVAYHAEAHSLMRAFEKFRGKLPNEITMYV DRYTCPNCQKYLPLLMKEMGIDKLIIYSKNGKVVLLPK (SEQ ID NO: 39).
[0279] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 40, which is the amino acid sequence of EcDaO2 (Accession: ABG02915.1; database: GeneBank):
NTSSGGSVGVGVGVGSGGWGISVSASANQGKGSEKGNGTTHTETTVDAGKQLAIISGR DTTLTGAQAGGETVKVDAGRHLTLTSEQDSDRYDSKQQNASAGGSFTFGSMSGSASVN LSRDKMHSNYDSVQEQTGIFAGRGGFDVTTGQHTQLNGAVIASTATADKNRLDTGTLG FSDIENRADYKVEHQSVGISTGGSIGGQFAGNMANNLLVGANHEGHADSTTQSAVSAG NITIRDTKSQKQDVADLNRDAAHANQTLSPIFDREKEHQRLQQAQLIGEIGNQVADIART EGQIAGEKAKRDPAALNQARAELEAAGKPFTEQDVAQRAYNNGMAASGFGTGGKYRQ AIQAATAAVQGLGGGNLSAALAGGAAPYIAEIIKQTSPDGAGRVAAHAVVNAALSLAQ GKNALAGAAGAATGEVVGMIATQMYGKPVSELSETEKQTVSTLATVAAGLAGGLVGD SGASAVAGAQSGKTTVENNYLIVFEKTELEIAKQTLKNSKNPAEREAAQKKYNALREK DIASDKEVIDACANGNAGSSACAGARLKVFASKEGYEDGPYNSKYNQQYADAYGQIVN LLDITSVDAQNQQQVKDAMINYFMVTKGVDRQTAESYTETKQGLEIIAASVTPILGSVA AKQL SKIVD ANLKVVARGNVDGARF SDTNQGVRP SQL ADFNKPTLIND VVQ AKIDKRP DKNYPNGNMGTAHAEVGVIQQAFDKGMTQGREMAMSVGGKEVCNYCLSDVRIMAEK AGLKSLTIYEEATGNVLFWQQGMKKIENRGPAK (SEQ ID NO: 40). [0280] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 41, which is the amino acid sequence of NgDaO2 (Accession: WP_003703542.1; database: GeneBank):
MKPLRRLIKLLAACAVAAAALIQPALAADLAQDPFITDNTQRQHYEPGGKYHLFGDPRG SVSDRTGKINVIQDYTHQMGNLLIQQAAIQGNLGYTVRFSGHGHEEHAPFDNHAADSAS EEKGNVDDGFTVYRLNWEGHEHHPADAYDGPKGGNYPKPTGARDEYTYHVNGTARSI KLNPTDTRSIRQRISDNYNNLGSNFSDRADEANRKMFEHNAKLDRWGNSMEFINGVAA GALNPFISAGEALGIGDILYGTRYAIDKAAMRNIAPLPAEGKFAAIGGLGSVAGFEKNTR EAVDRWIQENPNAAETVEAVFNVAAAAKVAKLAKAAKPGKAAVSGDFSISYKNFSTV KPKVIAKGTINGKTFRD VNQ S AKIGSPD SPTLIAQRVNAKIQ ADGKPRPNATVANSHAEI GVIQQAYNAGETKGASMTMTVSGKDVCGYCKGDIAAAAQASGLKSLTVNATDNVTGK NKTYYWTPGMKSIKERK (SEQ ID NO: 41).
[0281] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 42, which is the amino acid sequence of PaDaOl (Accession: WP_006660219.1; database: GeneBank):
MNKLFYRLIFNAARQMLMVVSDITRSHRASPAGSGENRVENVAKSRVHWSVKLIVTSL WLTLGMVSFSASSSTIVADGNALGNQQPTVVNTQNGLPQVNIQAPNREGVSRNQYSQF DVDKNGAILNNSRTNTNTQLGGMIQGNYWLAKGEAKIILNEVNSRDPSQLNGFIEVAGK KADVIIANPAGITCNGCGFINADKALLSAGKTLIENGKIKGFEVDKGSINIVGQGYNGNG TNYTALIARSVNINAKLHAKDLAITTGKNTVAADGKTILKIDSTSTDDKSEFALDVAVLG GMYANTIKMRGTENGVGVRNAGHIGAEAGDITLSAEGKIGNAGVITASQHIALDSQQSI NNTGTVLAQNDILLNAKQTIINADKGQIVAGRDAVLRAEKINSDRTALLAAGVDSKGKL TNTGSLAVKGDKTVVLQGDILAKDELMATGSDLDLSHSNIQAKNMKLAASTADIRTQE AHLRATNNATLIAKRGIDNQKGEIVANQLTLSAPEFIDNQHGKLVQIENSKNTLNTKAFN NQQGEINLAGDTSITTQQLNNQSGQLFIREGKVDIQSQNLDNRQGTILAPGKQGLILKAD TLDGQKGEILTRGTLGLTAKSVNLDQGTTQAEQITLQANSLSLRQGNMLQTGDKAMTL NVVNGLDNTQGSVASKGDLNVQAGTVDNTDGKLLTSKNHRLDLMSTGELNNTRGVVQ TDKTLMINVDKLINQQGKISSLSGASLLTANHLAGEKGTIFAQTALRIESADINLNQGFTQ ANQVSIFANNFSHQGATLLQTGEGKTELHIQNQFDNQKGEISSNGQIDIVANGLNNQDG KIIAAKLGHLTLTIQQVLNNTQGTLLGNQGIQLAAERLINQSGKILASFGDNQLALKQLD GEKGEILSKGKLALTGEELNLNDAVTQADNIQIEGQNLSHQRGKMLQTGSEKGQIKLAH
TLDNQSGNISSQGTLRVNVDKLSNQQGVMVAAKVGALILNAKQHVDNTQGTLFAQQD
FTLNTQSFTNIDGKVISKQGDIRLATEDLQGQRGEIIAQGDLSLSGKDIDLTAANTQAQHI
QLTANRLTHQNGTMTQLSERQGTIEVSQQINNNAGDISGNGSWLIKTHALDNQQGKIFS
ARMGKLDLLIQQTLDNTGGTLTARQGVFVETQSLINRTGKVIASMGDVTFNSQLLESDD
GEILAANTLNIEGRTLSLNQAVTQADNIVITANSLEHQGGKLLQTGDKAGKITVQGALN
NQVGEIGSNGDLSLTANRLDNRDGQIITAKKSHLKVDLIHELLNQSGALIGEYGLNITAS
DIQNQQGKLVARHGDAKLDVAKGINNQAGLIAAEQLLQMSNQALKNQLGYIQANTIDI
NTNNQLLDNTQGSLLAKQQLTLNSGKLENQKGTIQSGSDMLIDTHGQQLNNTQSGDNK
GIYSQGGLTLTTGGLNNEQGRLVAKNTLALNNQELNNQQGLIGSQSANKMQTQQLDNS
QGTIKGQSVNLDTQGQRLTNLANKAEHGIFASQNLAMTVGELINRHGHIQANQITLNTQ
QNKIDNFQGEVLASETLQANSGEIDNQQGRMQASQQIAINTNGQLLNNNNTQQSDGILS
GGTLTLTTGKLDNQQGQIQSAGAQILNSQLLDNQKGSVYSGSSLSIDTQKNSVLNQEGV
LVSQAQLTLSARNLNNLQGTVQGKQGVNVHAETIDNQKGILLSQASAEVTGSSLNNRE
GTLQSQGKTNLTIAQHIENQQGKIQSESELVISGQNLDNTNGTVQGLKNIALTVVQQLQN
QQGWIKANETVDITALSIDNQNTSQTAKGIEGQNIALHTTYLNNQTGIVRASQTVETTIA
QKLNNEQGMISSENQITVTDGTNGKVLAISNQQGTIVSNGSANISANQLTGNGKLIAQKT
LTLNLKQTFENVGRLQAGEYLTANFAQGVTNRGLISSLGELVLTTSTIINQVPGEISGQST
RIQASGQISNTGLIDGSLTHLVANSLDNRGTGRIYGDFLAIHGNDLANDKQNDKAAVIAG
RKHVNLAVENLLNRDHALIYSDGDLVIGNTLDDQLQVTGHAKSVKNYSANIEAVGNLT
LKTALLENKDIHLQLTDDAMEVSREHFDWYDFGNGRRYKIQPRSGNQTRYAINDDGTL
NRNVGIHYEESNRWRMFVHGDWTKDFYEYVYDRIIYETQVIKRDAALITSGQHLTIDGQ
QLNNENSRVVAGKNLILTGYDLNNAEAQGVLRIVENGNTIYRYKGGGTWETYTSTSKY
QGVNSEEDLALHLLEVTENAGGINKTQLDSVKVNQLDGQAESVSDANSQENQGVNVTE
QALKEGKNTPLDLKPGQQMEVTQLPSISAKVDVQDDKSVDSSLHVDDTNIGKEADIQG
QVDAGQGKKITVEAEPQGKDNLDTVIRTVGPNTQLPDNSLFNLTPSSDSQFLIETDPRFT
NYKKWLSSIDIVTHEQLHKRLGDGYYEQRLVRNQLIETTGQRLLGNDKNDEEQYRALL
TNGVAFGHQFNLTPGIALSPEKMANLTTDIVWMVNKEVTLPDGRIEMVSVPQVYVRAR
QGDLNGNGALLAGRNISANMTGKFLNSGEISSRELTDLHAENIENSGRIQGKDVQLDAL
KDVKNIGGEIRGLDNVSLSVGRDILSETAQRGDGQSQWLDRPASIYVTGDNGQLTLKAV
HDISFIATDVGNLGVEGKTTIIAGRDISLETRDVS S AFDYTHNS SNYYRGANSTEVGIQIQ
TQGDLTLSAGQDLSARAANVTSDGELAINVGRDINVTSGIESSDYAKHTKNTEKGFLSST TTETHDEGHERIAISSILSGDRVNINAGRDVNVQGSNVLGTNGVSIDAGNQLTVSTSDET LYATHMNKTTKSGLMGTGGLGFTVGTHSQKVTTESDSNQKKGSVIGSTAGDVTLTAGG SANIHGSDVIAAKDIDMTGSDVTITAAENSRTDITTVESKSSGLTVSLGGAAGSMLDGMA QTAKSAKQEDDSQLAVLKGMKAGLQGVQAQQAGELAGLKEGGSTADAFGVNVSYGS SSSKSTTKTEQHTASGSSLSAGDNINLTATGKKDGSQGNLTVQCSQLDADKNVTLTAKN DINLTSATNTQTVDGKNESKGGSIGAGISTGGWNVNASVNKGSGFEKGDSQFYTDTKVT AGKQLTLNSGKDTTLIGAHASGETVKANVGGDLTLSSQQVTDKYDSKQQSGSVSGSIGS GLNTSASVSANKTEMHSDYQSVDKQTGINAGKGGFDITVGKHTQLDGAVISSTADANK NTLDTDILGFWDIKNKADYQVDSQSGGFSTGGASVGDQFVTNAAGSLLTNVNNKGKDS NTTHSAVSEGEIIIRDKANQNQDINNLSRDTDNAHEKLNTIFDKEQEQKRIEKTQLVGEL GKQITDIAVTNATINATKEVNANHPTLTGKAREEAIQAEINQSGWGVGGDNRRIVEAGT ALVQGLANGDVSKAVANASAPYIANTIAQHIGEENKAGRIAAHGIANVALALAKGENS GAQSLGAMTAEAVGMLSTELYGKDVSQLSEDEKATVSAFATLAAGIAGGLVGGDTSSA VNAAEAGKTTVENNFLSATKNEKLMKALDDQKEGKNLLQASQNIVYLTNEDRASNVL
LEQYRNDQLNESQQQDLANQLNQYGYELQTVYGFSETEAKAAIQNLVNGGAFVAAYA DAKAYNEALSYLKMYGVQSGQAAVGADALVALPGVPGSIIRNTLIAGGSYQTGTGVGQ VIEGNYTEGGINIGLGSLAVFGGIAGNKVVEKPTGSIVSPETTIVQESSKILDKKTHTSIPK VEAELIDKETGKIFKDTNQGNRPDYFLGDKSRPTLINDRIEAKVEKNPSKYLPNGNMASA HAEVGTIQQAFEDGITVGRDMNMKVTKEAVCGYCRGDIAAMADKAGLKSLTVYEEST GKTLYWNPGMKSLKEKK (SEQ ID NO: 42).
[0282] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 43, which is the amino acid sequence of AsDaOl (Accession: WP_005802165.1; database: GeneBank):
MNKNSYRIIYSKARQMFVAVAENVRSQTKASGQSEASAQSNIDNTESQAFHQLWQVKA LVASISLWMPLAPVYAGIVADSAANAANRAVIGAGKNSAGTVVPVVNIQTPKNGISHNI YKQFDVLAEGAVLNNSRQGATTKTVGNVAANPFLATGEARVILNEVNSSAASRFEGNL EVAGQMADVIIANPSGINIKGGGFINANKAIFTTGKPQLNADGSIKQFTIDQGKITVSANP NSKFGLGGNNNDANYVDLYARALELSAELRAKNDIQVIAGANNVSADLQDVTAKTGT GTAPTLAVDVKALGGMYANNIYLMGTEKGLGVTNAGTIQAVNNLVITSAGKIEHSGTIS STSKTQGLVNIQTTGTGAAADINSSGSINSNSMLNIDSGNNLNVNAKEIIINVGSLASSPLI VNAKGNINLAADTRIMDDSQGGDVYIDAANINLAAGSELKSNRGTATIQVQKDLVAAK GAKLIAAKDLNILSNGKLSLTENHIQASLGSINLQANSANTQNLIDLQGGTIYAGKDLNL YSSGDLNLKNLGFSLENAATRVKNIKAYSGRDLVWNNADKALPLITGLVQLDAANNLT VTAKEISNKDSIQLHANQIALNSALTSQKNIDVSSEIADLVLSQALKAQGDINLTALAGG VTANSLKATSSAGKISILANKNINLNSTQTSKAMPSADKDELTTDQTVISGLKGVTLGSIG DGTVNLQSVQVNANQGDILVSSNNGINLKANNDVVVTANKGQVKTVNNVLKGQTVSI ENSKSDIKVQNTDLGSTVGKLAVNSRAGMSTIIDSVLTSKGNTELYAKDLLTLQGVNAT SDQHLAVSSGRTVYSNAEYTPATKWIADKVTNLTSKGVTSVTATGNQVLQNTNLTGGA VLLEAGGFILGQTGLNLNAVGSDLLKNHTKLNSLNGDLTIQTNSNLTIDPKVYSLKAVG DIELVSKTGTLTLKGYGGTAGNGSEQVVKLDTANGGINLEGAKVELQGSNLKAAKDISI VSTNGDLVVDGVRNTITNQHTDEYKAKIIKLDEEIKILQKSSDYEAIIAFFMKEALKVYA RISSGELIEGSPEMDRELQKALQKTTKEFPEYVSKYGPLRDQKDFYSEMIKLFNVGYVNG EVHSGSKIISNTGNIQLVSNKGLSISGSSMDAKDGKVNLEAAGALDGEGYNIQGKYNNP TENSVKKGVIKGSIIIDANQDSYEQGSPSDNDYRWFSPVSPTTINGTKGVSIKVIGKQSTD NLILQGVAITSENDVNIEAYKNIIFDVAINNSFNKSQKTETKSKWYGKKKTITTTQTDEKS GGLSVDIDAKNINIKSQAKNTPAMSGQNRTSIDMYSSQLTAIDGKINIQAGGDLNFLTAD DVSLNTTDISKKSSFLGVKLNKSHTTNTRNVKSELPAELNADYIGTKSGFDTRLKGTVFN YLEGAEIQAGGTITLESASTTVTETLKKESNSVVWQSMQDKGSITETAQLPSFNGPVLPT FIAAGGLSVQVPISEKDVNKVELRNEILKLANQPGNAYLKELVNRKDVDWQTVLLTQK DWDYKSQGLTGAGAAIIVIIVTIVTMGSGTAAAAGAAGGAAASGTTVGLGASMLGAAG VTTT AAGAIVP S ALGAMAN AAIT SLA AQ AS VGLINNGGDIGKTLKDLGSKD SIKNLAAS VVTAGLMSQVGSALNLKPDSTLLPDRLANNFASSVGSTLVQTAIKGGDLGDNLQVALL AGLAGALQGELAQNLKGLEDVNYILHKIAHAAVGCAAAAATKQSCEAGAIGAGVGEII AQEMLHGRNPTFVSAEEKAKIEAYSKLIAGTISAYAGYDVNTAANSATIAIQNNAFKDK ALLKLEATRKYLDDKSKAALDGLINAYKKGDIEAAKKFKNQLDDS VTTWANS S S S YLNI ETKSALGEIVIVVSDLVIPTNYVEILPVGKLSKVAKILKIGEDGTKSAGRLAEELAELQKV DIKFGKTLPGAKAPITVTAESNIGGKHMFDTNQTARPEVNRTNTPTLAAGNAKIDPSNPN LTMKNAHAEIALIQRAYDAGLTKGETMQVLVRGKEVCDHCGQVMKTMYERSGLAKLII HDTTSGSTTTYYKVIDAKTNIATTKIVVSPIFGH (SEQ ID NO: 43).
[0283] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 44, which is the amino acid sequence of HgmDaOl (Accession:
JAEZY0010000802.1; database: GeneBank): MSAYEPLLKKPKAPPAPLRATVASKRPQPPIQTALEVSQPGDALELEADRVADHVLRSA APAPRMNAGSDARIDREADKEEQDTEEEYAPNHNSLVVQAMLQRMCAKCDAEEDREE ETPPGKLQRQALVVQRECGDC SEEEEEEQVQREAATPGPTAAAATPRFQAALS S ARASG GEALPSAVRGFMEPRFGQDFRGVRVHRDAAASELTERVHAKAFTVGKDVFFRRGHFEP NSEQGKRLIAHELTHVVQQREGMRSVQRELLQREELEAPPAQSAQAAPAEQAATEEEAL LANDEMYLEAHARGFKMAVNGTTYKSWKDPALEAFVLYFLRRYIGGSRDAALACLGD LRATGGIGFQSQLKPGQILNDKGIYGIEIDGALVQSSDAWVKQQRPGLRPVKPKLGIQKIP DIVSEGGGAADSAEEAVERFSPEGRILFPLGDGKIPTFVGGAEIKVAFQFTGAGAALGFN DFPHRINRVDFDWSISTETEGGKKEVDSGPLLEGGANQYSFDVEPGGYLVSVHLKSEHF QSGTELELKRPFE VIDEQ ARLGEAFDERFVGEGEAQPFELDQEGNLRLKPGAPEARSLKD QILELEFQIGQLEASRDGGGLPADEAAGYIEVFRERIEALKKLEQGSTSSSQYRIHGVFQS RED S S VREIVA VLHGLET SKEGQ S S YAF TLNDF TL SPGK A VQH VGA AP AP AGDDRNAAI ASAEGAALEALKERWRANNDYPDGHVRFVVPLKHGSGVKELTFDTHTLRKDARTALT VAAIGAGAVSIVLSGGTTAPVVLLVLEGVSLAAGAALAADEIARAIETNTLTKKQLVLN MLTLVPIAGSLARAGGITVRGMQLIQVSAGVAEGVLITAETQESLRAVMAEFAVQIAKA KTPEQRAQIERQRDQVIARLLGAAAVSGGISLVSTALGARGAIDDVRGPKPRAAVEGAE PHVRAGEVEGPTARPVEAEPAAPRRPAPDVETPEARRRGPVADPANGKAATAEATVLT ERHLTLAGETHTLSVVRKSDGRHLLTLCSPKPCGELANEIEDLLAQLATDHPARRELGRL HEAARKAQADLDTGQLALDAASIEANRIATALDTLSTKHPEVGKILATGGGRAETRQPA EASREPQAESLEPVGKTEGSGGSDRESLTPEGAWREIDRFRTKAKGFEALGDRVPQRGD GLGTVALVEGGGTRHVFGVNSSSLSESSKDLGRKVFSDMKSKGFFPDTKHYGQGAAQV LTHAETHALMRAWENSGRRLGKSVTLFVDRFTCANCRIALPDVMRYMGIEELTIVTKSG VVIPLRVGG (SEQ ID NO: 44).
[0284] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 45, which is the amino acid sequence of MsDaO2 (Accession: tr|A0A2G2M3J8|A0A2G2M3J8 9GAMM; database: UniProt):
MNNRRSHKQVAGTPHWTARLAVYGLSFLLASQPLMVSAQTIVAGTTVTTQTTAANGVP VINIATPSAKGVSHNQFQQYNIDQQGLVLNNAKAGTITQLGGAINANPHLRNSNAASLII NEVIAPNRSQLNGYSEVAGAAANVVIANPYGISCNGCGFINTPRATLTTGTINLHNGELT GFTVNGGQINIEGQGLNADNISQFDIISRAVTVNADIHAQKLTIVAGRNQIDYATLNATK LNSAASTTVDFALDSSVLGGMYANSIRLIGTEAGVGVRTLGNLATDSGDLTLSADGKIS VNKSQSAHNLTLISANNEIELNDRVHSNNVIELQSQTTVSNNAAVTAGQNINVTATNLE QQGTIASGVTVQGQNYQITQVGDLTLNISNTITNKGKLLSGGYTNITTNTLNNQNTALIH SGQTLNINADQLHNQKDISSVDKLTVQLSDTLTNSGSIESSANLAIDVAILTNNQGTISAV GTADSHITATAALNNNQGTIAANAGTLSLSGQTISNDSGQLLHSGDGALRLISSGIISNRN GNLASNNTLAIVSGTNKDQAFDNTTGIVAANEIKIESGDVSNQGGTIEGNTLELMTNGDL HNGSDAQLNTGFISALSTNDDSLKLNVQGQFNNSTGTTQTNAQSATITANSLSNNGNLIH AGNGTFNINSTNTIDNTAGTILSNGTLNLAASELNNTAGEVRTDGGDLNLTLAGDLSNTS GLIEAGEALAISADNLSNVDGHIKSIGTQDASISTTGQLDNNLGFIESNADNLTLSGNNFS NVNGHITHGGTGALLLNVGASIDNSQGNIASAGDFSQVGFTQFINTNGALINARTVSLVG DTIDNSNSEIVAGDIYIGVETLNNTDGIISSQNYLSIGGITNLINTGGWLQSSDTLDLTVYA DFTHEGNINALNYVGITADNIFIDTTSLEVDGDLNLTAWGDITNYASISSNQRLSINGGNL DNNGSINADLSVDLSLSNIVNNFEIGSYQNINIWAQLENYGGIAAGNDLEISGDIDNYGAL FSGNEJSRLYAYNLYNHEGANIFSWNNLTIADYDYYGSNTIIKSNSLINHAGTIEAFNGDIL IKTRTLENKTDLPTITSTRQVTNSNLIYHPQIGGAIYTGSVGMTQAQGYPVLQASQPDAL AIFETYGSNAAWNSFWTRGGSKRVKWFDVNVTRTRQQADLNITNPANLVAGNNLIIEA DDITNQLSLIGAEGDIHMTGNNLSNVAFSLTDTITGNWRLGREKKRRAVPRSEPSQNNY YEQAGSINTSTVIGTINSTIQAGGSLTGDFTHRIDNQNIKQNTAGLTHTEQFGMGGGGFG TGLTAITPQGVATISGSTTPAVLNGNLAALTPVSLQTPTFTLPTGSGLFVVNTQPNHPYLI ETNPTFLSNTNFTNNLTSTNHLFTGLGLQADQFTQRLGDGFYESRLLRDAIFAQTGRRYL TGQSNDQAQFKYLMDNAISARDSLNLVLGVALNAEQVARLTHDIVWLVEQNVQGHSV LVPRFYAATLNANDLNGQGALLVASTVELTGQGITNTGTIESDTNLQLTSNSDLLNRGTL KSGTNIELVARNNLFNTGGSIFAKGDIVLVASQGNIDIGRYTEQLTSTIDGRLQLTDTSTW VGDASTIQAGGTIDLHAGSDINIAGSTINADKSINANAGNNLNIQTVATTTDVHGQSANG RFSVDFKATTLDQLASQIQAGEDINLTAEEHIAIIGSTVTAAGDTNLNAGSDIQIAAAQQT SSYNYDSKSGGRTTKIEDRSTTHQQATIDAENININSGRDIAITGSDVNASNDINLQAHDN ITLASVENSEYHYYFHKAKKDFGRKKSETLETEQIRNLASSLNAGNDVLINVTKTEEDAE TNTVLSLNTQANDVHIIASDINAGNDIVIYAGDNLSAQTSTDYDYRFHEKTKTGLFGLTG SSESTTTKATRQQQANVKSEHDISLNAGNNIALISPTLDANNNIDIQADNQILLGTSKDSD YYHYEYSKTGAFKWEFGNEGHYDETVRHTEITAGGNINIDAGNGTIIEYKQNGTLEQSIN TLSQLPELAWMKDIQTQHNDTVQWQAIIEEHDKWQEHESGIGGPGVTLIAIAVAIAMPT FGADFLGYTGELTAIEAAQVAVIESLANQATVSLITNGGDISAVFEDLLSKEGLLNLATA
GATAGITNSLYTKLGLSTEAINLNDSLVANGAGLTLAENLQRNIIRAAVQSSVNTVAYG GDFEKNLFKAAANATVNTLAVQLTKDIGNLELTDGNISEGGLTKILAHAAVGCAAQSLT GGNC S AGALGAATAELL APHLSNS SLNNVS SEL S VLL ATGIAALVTGEDLEQTINAGLQ VERFNRQLHAGEIALAKKNAKLLQAAAAKRGEVISISEAEARIEKQLLRWVDADSNDGK VDELVISIIGFKGGNSDFDWDYKNYASLNPEQYTDSSINSENIPYYASELPVSEFGLTPEQI KERNDTLAAKVAKIGAFVVGVGSGAEIGIVLVRSASTLAAAAKVSIVTCLANIYLCGTQ ASIATGEIALGDAIGAASVLGTGAVATEKVGSKLIDELVEAGRKLKNDNAFDIIDTFRNH KQGMSELIDHIPVQGDKVGTVAVIDVNGQRTFGVNSTALVNDVDKNLARSWRERLGLN KGDAQALFHAEAHSLMRAYQKSDGKLPANVTMYSDRQTCSFCQKNIPALMKEMNIDK LTIFFKNGASMILRANN (SEQ ID NO: 45).
[0285] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 46, which is the amino acid sequence of XinDaOl (Accession: tr|A0AlN6MQY7|A0AlN6MQY7_9GAMM; database: UniProt):
MGLIDDIVTRSARVGAIHASQRGQGPKGPAAAREGDPIQHSSFWAALAGAVTGALISAA IFGAAALLVAGTGGAAAVVLTAALGTAGTMALGDLILGAS S AVTDMINSFC SPDGMLTS GSPNVLVEGKPAARATVDTAVCSKHPSPVPPLIAQGSETVFINGQPAARVDDKLVCGAA IKGGAGTVFIGSGQHAYLDVQEEFSLLERALLVAVEYLVPPTRGGLKLAGKLLTQQGRK VVTRAALKEAKAMARDAKSILAGAKQGAKKAQQWAKNAAKNPKALTQKAMAGAKA GAKKAAGNVKAGTQKVLKGAKTGATNAGKKIKDNYNDRVGCAKKAFHETKGAKRY WEATKRFFKGDPIDVTTGALFDQRTDVELGQTIALTFLRSWSPGESGLLGENWTDSFSG CAFVIGDRVEIRTTEGASLYFILMATDLNSVNPEHPQFTLSRANTGYVLHEKNNPVRQHF SVEVSDNKECQTWKLSSLSDRNGNAIDFHYSEQNQLIKVTHSDGPELVLLYRQDGLLKE IRRSDNDLNEVMARYDYHDNGWLAEADSTQQFHLFYEYNEQGLISHWSDGDQTAVDY lYDEQGRCTDSVGSGGYYPVHFEYEPGITRSMTPQGYTTIWHYNEEQLVTQVETPCGHIT HYEYDEWGNLRRQILPEGQIITLDYLADTGLVTAFTDATGATWQYRYDDLDRLSSMTD PLGRTWKQQYDDNGNAECFIAPDGSKTTLIRNEFGLVTAAEDDEGHKRTWEYDEHKRL TKLFDEENRSLKLGYDSHDRMQRLTSGSGALWLWEYDRHHRVSLSDRPNNSIERFRHD RHGNLTDWTDARGVKWHIEYGPFDLPMARIDGEGNRWQYRYDLDSLQLLEVVNPQGE SYSYILDADGRVITETDYAGTQWHYAYDGNGNCIEKRDALGNITRYEYDAAQRMTAM HTPEGTTTYRYDILGRLLEVIAPESAPLTFEYDDKDRIIKETQTHGKIERDYPDNATVERT LRNIDGQC WQ VK AE ANK VGELRLL SINGEHTLDLERDEDGHE WHRQ SDKGFILRQEHS
LMGQLTAQRAGRNTEFFASHEVADIPQPTLAGLDREYRYDAALNLVAANDERQWLRY VVNGNGQVTSVSEGERLREHYQYDASGYPARRFDGVNEVDGERLYQKGHRLRQLGQH LFEYDDAGRMTAMQLWQDGHRPQLTKFRWNSQNQLIGVQTPGGQQWDYRYDAFGRR TEKVCERAGSRTTYLWDGDVPAEIREYRHNRLYSIRHLVFDGWQLLAQQVQFFSLNPEN RQELIAGEIQTQYAVCAPTGEPLALFDAAGHRVWRQPPHSLYGLRLGRLGENAELNPGL QFAGQWLDDESGLVYNRFRYYSPVASCYLTPDPIGLAGGEKPYAYVGNPAQAVDPLGL
AGCEDPWKIVDRFRRSKNKMEPLGDRIPGAIDKDGLHTVAFFEMNGRRVFGVNSGTLY KKDKALGKQWNEKIDYLTKEEKGTSAFHAEGHALMRAHKKFGGVMPKEITMYVDRVT CNHCERFLPALMKEMGIEKLKLFSKNGTSSVLHAAR (SEQ ID NO: 46).
[0286] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 47, which is the amino acid sequence of XjaDaOl (Accession: tr|A0AlI5CFXl|A0AH5CFXl_9GAMM; database: UniProt):
MTALQLWQAGHRPQLTRFRWNSQNQLIGVQTPGGQQWEYRYDAFGRRTEKACERAGL RTTYLWDGDVPAEIREYQHNRLHCIRHLVFDGWQLLAQQVQFFSLNPENRHELLAGEV QMQYAVCAPTGEPLALFDAAGHRVWRQPPQSLYGLRLGVLGENAELNPGLQFAGQWL
DEESGLVYNRFRYYSPVAGQYLTPDPIGLMGGENPYAYVHNPSTWVDPMGLAGCPWE QIDRFRSRTRLPVLGNRVPAPNDGLQTVAFVSIGNRI<FFGMNRQAIPGLEYAAI<RI<EWF RKIYKSTGVEPSTISKAAADAEGLALVRAYERITKSGGKMPKEVTMFVDRPTCDFCKNY
LPLLRESMGIEKLVVYNKGVSNPLIF (SEQ ID NO: 47).
[0287] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 48, which is the amino acid sequence of RhDaOl (Accession: tr|A0AlV4SQ45|A0AlV4SQ45_RUMHU; database: UniProt):
MKPLEGPVNSVGGMIEQVTDQATGVVDNAEQSAMSSMGNGSKLLSGFAGSSGSQNRD AGKAGESKGQEKNSGKSGQEGGKSQGGGDFLGLLKSGVHTRLMTFGLMNIKKLGAKVI AAGAAKVTGVIKKMLTPKVKFRLGAEEHELWVEKGKNGNVVMMASKKPGPIKRKIEE
GEIPDNGEISNKRRKVEAEKDEQQVVQQNEAMASTIQAVTAGVGEAGKKEPWEAIDRF RKSNGLEPLGDRIPVRGDGLETVALMEVSGNKVFGVNSSLLSDELKNLGRDFFKVIKEK
GLLGNAKHYGSGEAQVLTHAEAHALMKARKEAGGHLGDSVVLYVDRLTCPNCQKYLP EVRAAMGIKTLKVITKGGIELIL (SEQ ID NO: 48).
[0288] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 49, which is the amino acid sequence of MGYPDaO4 (Accession:
MGYPOO 1129217467; database: MGnify):
TFTGAVPTNGSLSLGASEANRAWADVLSGLFASGSNDIFVGGETALIGAVLAAADGDLN LDTGSLRTEDLFDTDTSNSWGLSVAGGTGFGDGSASLSSIGGHYSTATREAETNATITSG NVT VRDL SEDETTELLASINRD VSNTQ VITRD SDFGTGQ VNLEVQ SILEIDDNLRAINDLR RIIAPPTSVDSDIKATFYRRLIANGIDADQAEKALKSQQFEEFSTVSQNWDRAIKAFGSAG DVPKNVRALIAMGKDVKLLFDEDGNVFVENENCAPTGDSGCRLRFGGNLSDQQVEEIA STALKNIKKLVEDLESIKTRMSETGKKLSELQYLCATYCDPRGDDRILEIEGLESDLNEFR IALLVGEIAVNNNLRYYALCSDPSESSTSAFAASISAALGKELGDDHGIGSNQIQEAANFG IAGDRAGQRADDSGQMLEMDFANAVFQRQDPLDELLNPSAAGSVIDAGIALRAAMYG GSRGGQYTEDLTSRSGARQVDPDNIVRAMVGYNIALNNLVDEVNGEDNLDRSTLFFSD FDDASHVGLSQNEDGTVGTDGNFFTRSSGDVGGEFRTNLLLAFDQNIRSAATGDTQLNG TIEGATGLFSLNNGENWNARTRENSYLQTLVEVLQAEVAGYGAFAALGYLGTGARTAL ALDNVGTITRLDGPATEITARAAGRTSPNPSSYTDEEAFDLINRFRDKKGGMDDLGDYIP IQ ADNTGT VSF VDLNGNP VFGVNS S ALDNT S S AYQGLMDE ARDWRKILIDEYPEDMAT RNVGSKPNDSLFHGESMALIRAHRKSGGNLPTEIDMFVDRATCNSCKTVLPLLAQQMG VQIRLTMKNGFKGVIKDGEFVPSPG (SEQ ID NO: 49).
[0289] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 50, which is the amino acid sequence of MGYPDa05 (Accession:
MGYPOO 1094202578; database: MGnify):
KSGFGSADEAFDAIAEFRSRTTITDTQGGRGTVAVTEINGQRYFGVNSSNLSGADKNLA RSWRDRLGLTRGQDQVVFHAEAHSLMRAYERTGENLPSNMTLYVDRNSCGTCQTYLP RMAQEMGIDNLNLSFTSGRTAAIRNGAFEWVN (SEQ ID NO: 50).
[0290] In some embodiments, the amino acid sequence of the methyl -sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 51, which is the amino acid sequence of BaDaOl (Accession: tr|A0A410KXF4|A0A410KXF4_9BACI; database: UniProt):
MDARAKHYQELREQMVDLKKALQGVANLGDDFTGKGADNIKSFYKELSGNVDMFISFI DKQIAFHDGVSGTLDDTSFGGDTFVEEHFLDNAVHMGIKNSKSIVKDQKKALKTIFEDID DLISLE VFD SKTFDEKIAD AEDERKKTVKDLIELDQNLKDEYAL SETEEKATMAL YAEMI NATNDGKSISPMNFDKKAFQDSEIYKAKSDIEKQTSEYLKIKKDQEEAREIAKEQEALAN RPWYEKALDYGGNIVNELTGVNDAKRAATGVDPITGEELTSGQRVAAGGMAAAGYIPI VGWAGRIFKGGKAIYKTSKATSAAVRAVDIYKTSQKSFDALKTSQKGLYGLTATNGFSE AITGRDMFGNKVSKEQQEASMNTALAILLPFGMKGPIKKTPGVIQKSNKQISESYDEIKR FREKAGLKPYAIDSGDTVAAVKVNDRTFFGVNSTITKESQQATRELRQKWLKEVQWVP PKKSSPKHLGHAQSLTHAESHSLIRAFEKEGQLPQKVTMFVDRKTCNICRGEMPALLKR LGVDELEVYSGGLEKPLVIKATK (SEQ ID NO: 51)
[0291] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 52, which is the amino acid sequence of WWTPDaO4 (Accession: tig00000754-10- 8122160_273; database: GeneBank):
VNWRVLTPADQFELHGYFQTNGNTDIDEIAEGFNLTGTGLLGVSVVPTPQTKAIGGIGA GLCFATSSGLNLYQRTSQGFNTRHDLLENGMDLAMIALSLSGAPRIAGNYLAKVHTGKL QVFGEGLESLFLHGKKVVVLAKLEVGAGRSLLCVCGIQAIQSVGSIVGRDDLSTDEKFH LLVETLGLFALQGLLMVVSRRTDKYVKYPTRSAESPPPPKAMGKTDHSPLENGKPLEGE SRSLKHEGEKPPDADGRGKVGEGEKTSDSENGAHPETEKQPEGESRALSEEERSSPNESK PKSMESETNLDEIPGQTGAERHETIVSRGKRGKGEPKEDARKPEEPPKPEPVVEPEPPKA WPRETDAPPPPFEKGKPAERSWNQWFQNERMPNVPNVKLGELKVVAYAEINGKQFVD YNQNARLKPLADEQTAIYEIIKRRASKLGKEISGFPNWKHLNLHAEGGLLYQLYRAGLT RGAKIVITVEGRKVCGFCLKDLIELAKALEIKELTVFEKNSFNELPPETLFWKEGENTWT DLN (SEQ ID NO: 52).
[0292] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 53, which is the amino acid sequence of PbDaO2 (Accession: A0A356KTR0; database: UniProt):
MSHATSPSGLVTRFTYRDPTTDPDPGDPDNRLRGPSLIESREGSGPAVWTIDHQRSSSPV GFVVTVSDSLGRSAIHSTPARAAINKGRYTSSWTTVAGDWSRKVDLFSDRQSVARRIPF NNFSFASTYRFFDEGRTHIRVLGFEEGGSRAHLALDGFWTTQVEPLQGPTQNYAIETKQ GGKVEGLIRNVSWEVAPGSLATVGITRNEDGEVEEVMNPVGVTTTTERYLSANKQGLPS AQIVAPGGTTYLPLGATPLREEFDYDLMGNVTSHRDTAGLATITAYTALDQIREVRLPSG LVQTNVYDQAGRLQSTSTNQGGRVTYVYNEFDQVIRVDQEGVGSTHYQRDEMGHLTQ VTTPRGEEVRYEYDNRWLVSATEHHAAEEVAGPLELQRRITYQRIARGNVLHETRTEGS AGANSYTTSYGYTAVGLVRSVVRPPMTLGESFRPQTTYHRGSNWLVNRVEQDVREDRE DKLASYVRDDADRVIAVRNGTAEATNPHRSQSEVLLDLAGNPNTFLSGDFLYDPSAPVG GTVLSDRPRSTVTRDGLARVKEVRNGSGCVIAELTYDSAGRVVVERRPNSNEQLEVVSR NVYDPLTGRLQSSEGYDYPGAGKAKREYYYDAEGRVKKTFVRDGGGNLITVNEVWYD AIGRVVRRQSRDKDTNPTEQRESRYEFHPQTGDVTRETQVVNGNSYTWVYTYGVGGRL ETTTDPLGKVSRLVYDAEGRLQKRIKKDGVEITYEYDGWDRVKTVTGPTETITYEYDAR NRVISEANALVKREFSYEDDLGRLESVKVTFLQVGLQVPKTFTYRYNAAEHRYGGLTEF VDPNGLETKYSYNRELDVERIEQRQGSAGPFSEVGSFAYDCSQRMTEWRTRGGSWERD YDATGRVLRQHGAQPNHSISYSHDAFGRRKTATYAHLQGLKFAWAYDGIGRMFDEQIS YGDGAPAYRETLTFDEAGNRSSRILNGQTTLYDYNEFNQLVRSRERVRTVANLTLSATT GPPASPGTDVLGPSYAPGLAVDGTIPTTSGANQAFVSGTADVEHLLEVSVTSGAVDLTG LEVHLPTDRNLPDKLHLEYFDGSAWVPLPVQSATGADVVMSGSDQDGLRARGARVFA
SVWPPINTSQVRVRQAQGEGPAQPTTHDNALAVNEVRLFTASSEVEVETSYVYDDNGN MKGVTRGAYERTYEYDQNDRLISIDDVGGAVPVNMRMAYCPSGKLTRQEVSGSVEHL LYQGDELYARYDASDALTKRYILGPGLDRKIGVVPYSGGVAENTRYFFPTPNGSVHQVT
EWDPLRNGGLGAAVLANTELTSAWGVPILQDRIPELLAGGGPPVVSIFAPDFGYTGRRK LGNSGLMDYRNRIYDPLLGRFLTSDPIGTKAGLNTYAYVNGDPVNLTDPFGLDPYDVHP
RPEEWYNQPGLYNKFQALRGEIGALWNRHVNPWGDAGAEVLEETLDEGEKLPGAMRT LGEAMQADPGGTTRIMLSQLPGVARNMVMQPIDQTAEAHYYHLLGDAVGERKAVIKS TTGFMALFGVAQGTRSLALRTTGVLRAIREVCFVAGTLVVTQEGRVPIEDVSVGDLVLS
RDPETGEIGFKRVTRLFSGKTTEIAEVRLFAPDLTDDSASVVVLTCTPTHLFRTRGRGWV EAKSLKPGDQLVTETGSLAVVAESPSIRQVEALSRFNLEVEDWHCYFVAPNESSASILVH NDCWDLINYYRRVHPNLPDLPSPDYVPGSQKIIPGSGVADKTLGTVAFVKIGERVFFGV
NPTAMSDAMKNLHRLFFDTVLKPGGYSGTRSARTGKALTAGQYGGMANLFHAEATAL LRAWKHNAIPKGGVLRMVVDRHTCRLCMKPLGEIVHALGLKGLEIVQKNGKVVRIKPI APGQ (SEQ ID NO: 53).
[0293] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 54, which is the amino acid sequence of CrDaOl (Accession: tr|AOA!S8L869|AOAlS8L869_9CLOT; database: UniProt):
MGAGAEAIYKASKDGFKEAKNALRTVKDEKNGFVDGVADTNAPWKAIDDYRNQRQG LEVLPEDYEFIKGDGKNTVAFNDTCDKRYFGVNSTLRTDAEKGLAKKYFNKLVEEGYF PKGSIYPRGKAQFITHAEGYTLIK AYEENGIDIGK S VTIYVDRPTC GFCQNNLPKLQ ASM GIDVLTVINKNGDVFRCDLRKYTSMTVSDVNAEKLIKIKSK (SEQ ID NO: 54).
[0294] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 55, which is the amino acid sequence of MGYPDal5 (Accession:
MGYP00 1492404292; database: MGnify):
DGRFSSRVEKDPLYTGTSLNSQQIAQHLTEKQMTAVAGSADLANALWFAGRQKKVLD
VDVPFTIPTEVLADPRDAVIIDGKLQSRKKYAEELRRDAKKSYSWAIGLTSDEEFGYRGL
FDRKKSLDSIFPSMLPEDESLVRRRAQERERTKEQAAVWSENSLELAEFLNNDEAFKKA SGSMIVTGKSGKPMLVPYRQASHSMLSRQINAQEKMSQSYYADQEGTLIGLGAVGVVA
APAIVFALPAAAVQAVAVGGVTGAAFEAGTQGLEGAFGYRSEFDWGALRDQTGAGMA LGGVLGKPATYLASRYPRATAAVSGSLGVGGGLYEWQVNGNPVRGATTAGLGLLPAP FLLRNRTPSSELVHVPGQGNQTFTHELTGAKFGTVEELRAYSKWLAAGKMGPPEPATPS STSALSPAKAFDAIDEFRRLGQGMQPLGAVVPVKGDDLGTVALIKYEGQSFFGVNSSILS
DESKNLGREVFSLMQQQGMLKGATGYGQGAAQVLTHAEAHSLMRLWKKLGSSMPSE VILYVDRYTCANCKRYLGEVAKALGVKSLSVVTKSGETIPITIP (SEQ ID NO: 55).
[0295] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 56, which is the amino acid sequence of MGYPDal6 (Accession:
MGYP001076701719; database: MGnify):
MFGCGHAMRGKAGTASCGLMNFLKYGTAALSVGTGGYDIYQIGKENYQKYVVNGEKF SWGDAALDTLRITLDATSIAGGIKLATETIPYCFVAGTLVETEYGQKPIEEIQAGDKVLSE NPETGEIAYKTVEETYINETDELIHVHVNDETISATPNHPFYVDKLGWTLAKNLRAGDIL
VLSNGEFVVVEWIQHEILENPIKVYNFEVQDFHTYFVGKSSVLVHNECTPEEAWKAIDE YRVKKDGLEPLGDSIPKRGDGKGTVAFVEVNGNKIFGINSSLLSKPEKELGKKMYEDMR
KAGYFSTVKSYGSGHAQVFTHGESNALFRAYNIYGDNIGKNVTIYCDRGTCGICQTNLG YIREFLGLEKLTVINKNGKKFEF (SEQ ID NO: 56).
[0296] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 57, which is the amino acid sequence of MGYPDal7 (Accession:
MGYP00 1100966096; database: MGnify):
ITSQYYLRARFYNPVIGRFLNEDTYYGDGLNLYTYCHNNPVEYVDPSGNWCKKKFKQK VKEYLEI<GYSI<I<DAI<VMANYEQIRENYDVNSAEQYLRAVLDYENLSPEAWI<SIDQFRE SHGLNTLGNGLPKKGDGTVAFINANGEKIFGINSSLLSEDKKMLGKKYYESMKEAGYFD NVTSYGNGSGQVFTHAEGNSLMNVYDLYGKSIGKDITIFCDRTTCGICKNNLGYFKDYF GIDSLTVLNI<NGDIVIINKGTYH<II<S (SEQ ID NO: 57).
[0297] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 58, which is the amino acid sequence of BaDaO2 (Accession: tr|A0A6B3Wl 13|AOA6B3W113_9BACI; database: UniProt):
TGYSSLPIVGMGTKPLGEIRPQMFSVKSKEGREMGNRKSINGYEGIGKFREKVGLKPYSI DSGDTVASITVNNKTYFGVNSTITKESQKASKALRQRWLREIEWVPPKRTAPKHLGHAQ SLAHAEAHSLIRAFERQGSLPKTVTMYVDRKTCNICRGELPALLKRLGIDELEVFSGGTT KPIIIKATK (SEQ ID NO: 58).
[0298] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 59, which is the amino acid sequence of VsDaOl (Accession: tr|A0AlN6M042|A0AlN6M042_9VIBR; database: UniProt):
MPAAARLGDNCAGHGCFPATPIMAGSGDVSINGKPAARKGDTVLLHACPCPQFPHGMH GRSISAGSSNVSINGKPAARVGDAIDCGGSVAAGSGNVLIGDTPYKSPTHKCGEGAAME QSPFLRIQPLAEAPPFDWASLPFVEEVYERSAKDKQKVVEKKSKKIRKGTNYNHKIQSPS DGYNVISSFRKKAGLQPYSSTSGDTVAFIEINGKKFFGVNSQITKTSQVSQKALREKWM KEVEWVPPKKNKPKHLGQVQSLTHGESHSLIRAYERLGNQLPKELSMYVDRKTCNMCR GEMPALLKRLGVDKLNIYSGGSTKPIVLESIKL (SEQ ID NO: 59).
[0299] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 60, which is the amino acid sequence of MGYPDal 8 (Accession:
MGYP000969250293; database: MGnify):
MNYMPDKAATEAQAAAKANLYIALQKMFPTASKRAIDEVAKTILEKRAKIARFREIAGL QPYSEDSGDTVAMTEVGGHAIFGVNSSITKESHEATKELRQKWFKMVKWCPPKKKEPK HLGHVQSLTHAESHALIRAYERLGKLPKRIIMYVDRKTCNMCKGEMPALLKHLGVDEL TIFSGDSLEPLVLKAVK (SEQ ID NO: 60).
[0300] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 61, which is the amino acid sequence of MGYPDal9 (Accession: MGYP000654575191; database: MGnify): GVSIGSNPEGKSKPGITVEGAYSNSETEGVARATIGEGEIIVRDGDGDGIKAADLEAEAD AAEAEGDTARAEALRTEADREAAEDKTTTETQLANINRDPDAVVVVTSRKEEGFELYLS DTSLEKAVEGIEVTGKALGEAFRALGEELAASGALTPSELDTAKTVAKAIDEGDLDLRA LVTCSGRRGFNLWDLVVSSAHAATGCVLFDENGREIAELTPREREACVQMLSRLLEEYA RDYLVGERGDTELPASITKTAETLREMASDEVLVAGAQSLGMSVSLIRDVSMRLALGEE KYAEYKEALKPLADAGELSSEAVARTVERFAKEQGLSNQEVKDLKLVAAVTTAAIVTA LGAI<RVLINGNRAPYTADVAFATIDEFRKHKGGLIELGDSIPLI<GDRI<GTVAFVDLDGK
PVFGVNSSVLVRDTDKELGRSWADTLGVKYGQGTGQYLTHGEAHSLMRAYEKSRGSM PSTVNMFVDRYSCSFCRDPKALPDLAQRMGIENLNLTFKDGSTAVINSGRFISK (SEQ ID NO: 61).
[0301] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 62, which is the amino acid sequence of HmDaO6 (Accession:
3300043543_Ga0453689_0082580_8_1099; database: IMG/M hot metagenome bin):
MKLQKGFCFLLRICNGQRWRVQETAGGITTGLYYNRARYLDPTTGRWTTQDPLGFAAG DANLYRYVGNTPTLLVDPSGNIWYPGKYIIQYFREWRRGRELDAQLDEIQRRRHDPLAA VMQAGSGPWSIHNTYAIADPAFDRNWWQGMGDAAVLAAVGANWLAAGTTWVSPGG QQLVWQSGRWWNRTANRAATAEEAAAATQAVAAARGAGAPAARTVNHFDEIARFRQ RAGLPAFRAEDSATGTVARAVVNDGTSRAYHGVNTGLSSNSIPSRMEVIQQLQTRGYFQ NVTNIGQAPMLAHAEAHALMRAVERTGARSITIYSDRTVCRACRTQLHLLAEHLGVTEL RVFEAGNPLPYIIMPRR (SEQ ID NO: 62).
[0302] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 63, which is the amino acid sequence of MmgDaO2 (Accession:
JANFCOO 10000966.1; database: GeneBank):
LTfDSVDGIGGIATSGDVFVSGVGLTVNSGINVGANTVRLQTSAGISQGFLGTITAGAVA VSNSGTAAVSLASSNSFGAFAATSSAAASISVTDSVSGGMTIGSVAAGGTLPAINGITTTN GTITIGSSTGVTVNQPILSGGAAVTIDADNQAINQSVNAGTAIVTLSPYNGNRAINLGAKP GGVLGLTNGDLSQITASVLRISNTASSGLTVSAAITAPLGWNALALLSSGPITETGSLAVA NLRVQSSNSSITLIGANAVSTVAVQNFFANTGPVAVVSTLPLTTGTVDGFSGVSAQSADI LLSGAGISVTQPIIAVNLRLLTSAGVSESGSGTISATGIGVRNTGSGSISLPLSNSFQTFAAT GAGEIVANAGGQPLTVGTITADSTGTFTPLSGITTSNSDVELYTSMFGSVAATQPINVGT GTVRVTGDGGFTESGSGAITAAALGVYINNNTVTLDGANNFATFAAAMGTFGSVVSIND AGHDLTIGTVGADSAGLFASVSGVTVSFFPSMTVSAQSLSVTQPIVVGIGNPVRFVTTNG VTQSGSGTITGNLGIRNSGSGNVSLTLGNSLGTVAIAQTVVAGTVSINDTAAATIGTIAAD AQSLFSATSGITTAGADILFTETSAIAINQPLNAGTGIVRLVTAGGISESGAGGVTASALG VINTFSGSVALPQANNVGVFATSNSVNGGAITFVNGTTALTIDSVSADASGAFAATSGIT AIGSGGVTLSSGALSITQPISDATGTVRLVAAGNVSQSGMGIITAATLGVRHSTAGAVNL NLANVGPTQFAATSSLSGASITFTSAQAVTVATVSSNTQFSTTTGIITSGGGNVILSSGALT ITQTINAGPGTVTINSAGGESELGGSITAATLAITNSGSLNVSLGVGNSVGSLSITNTVGNV SFTNAQSLAVTGISALNTSGTVSVTTTGAGHSLSTSGTVSAGTSSGSATLTSSGILTLGGD VAATTVTLS S VGGTS Q S AGVIT AAGSLGATNTT SGDIVLTQ SNLIP SFHATNAVGNVSFM TGQSLTITGITALSTTGTVSVRTTGAGHTLTANSAISAGTTSGSVSLLSAATLTLTANVTG ATVLLSSVGGMSQTNGAITAATSATATNATSGNIALAQANQAAAFTAANPVGNVTFLD NRTLVVTGITTLSTSGIITVTTTGAGHNLSTSGVISGGANSGSATLMSAGTVTLGANITAA TMAINSVGGSSQSASAIVSGGSLDTTNTGSGDVVLTQTNLVVSFHATNTVGNVSFVNGQ SLTVTGITAQSASGVATVTTTNAGNDLSTTGTITAGTTSGAVTLTSTGTLALGTITAATVT LNSVGGVNQTSGLITASGALSATNASSGDIRLTAINQIASLSATNSVGNVVLRDGRSLTIT
GITALVNTGTVSVTTTGAGSNLTNSGTISAGVTSGSATLTSAGTLTVSASLTAATVTLSSV GGMSQGGAITAATLTATNATSGDITLGQTNFVALLAATNPVGNVAFSDSQSLTVTGVTA LSTTGTAILTVSGAGHNLATSGAISGGTTSGSVVFTSAGTLTLGANVSAATVASSSVGGT NQTGGVITAATSAGATNTTSGDITLTQANLAAAFSATNLVGNVAFSNGQSLAVTGISAL GTTGTVSVTTIGAGSNLSTTGAISAGTTSGSATLASAGTSTLGASVTAATVTLSSIGGTSQ TAGVLTATTAGTTNTSSGNITLNQANLVNSFSATNLIGNVAFTNGQTLSVTGITALSTTG TVSVTTTGVGSNLSTSGAISAGTTSGSVTLTSAGTLSLGANVTGATVTLSSVGGMTQTAS LVSAASAGATNSGNGNITLSQPNSVASFSAMNTVGNVAFTDGQTLVIAGIIAQSTSGTVT ITTTSAGSNLSTSGAISAGASSGSVTLTSAGTLALGADVTAATVTLSSAGGTSQTSGVITA TTAGATNTTSGNITLNQANLVNSLSATNTVGNVAFTNGQALAVSGITALSTTGTVAVTTI GAGSNLSTGGAINAGLASGSVTLTSAGSLILAASISSATVTLNSATGASQTAGAISAATVG ATNTTSGDITLNQPNLAGSFSATAFVGNVAFTNGQTLVVTGVTTLSTSGNVNLTTVGTG SILSISGLISANATSGSIAIASSDVLILAANVTAATVTLSSATGTNQTAGVITAAGISAANST SGDIALGQTNSTAAFSATNLAGNVSFANGQLLAIGAAGITTSGGNIAIFAPILSINQPIAVG TGSVSLTTTAAGVTNTLAASITAASTTWTATAPSNLSVGGVSRLTDDEAFALIDKFRSKA NGLEPLGGRIPVKGDGLGTVAIVETPGRKFFGVNSSLLSDASKDLGRDFFQVMKSKGLL EGASAYGNGAAQVLTHAEAIALMRAWKFNGGKLGSEVTLFVDRYTCANCRKYLVEV MEAMGIKKLTIVTKSGEQIVL (SEQ ID NO: 63).
[0303] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 64, which is the amino acid sequence of HgmDaO2 (Accession:
JAEWLHO 10000049.1; database: GeneBank):
NLMTLGLINLKKLGMQILAAGAAKISGAIRKMLTPKVKFKLGSETHELWVEQDKTRNS VMMASTKGTEVEENSKASRILAESGELKDKLEKTKKKQNESQANANLQDLAQGIQAAG QGESKAANNGPWEEIDRFRSKTKGLEPLGDRIPERSDGLGTVAYVELNGTKVFGVNSSV LSDESKDLGRKFLKSMQAKGFLNEVKSYGQGHSQVLTHAEGHALMRVWKKTGGNLGS NVVIYVDRLTCGICQENLPKVKEFMNIKTLQVICKNGTKFTF (SEQ ID NO: 64).
[0304] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 65, which is the amino acid sequence of CgmDaOl (Accession:
J AEEGH011632547; database: GeneBank):
EDYYRFLPEFKKVPITAREPEKPAEKPTLAPTEQSGYTEKGFTGRVQDKITELRMWDSLD SFRETRGLPTTGTEPTKPGDGKGTTAVIMVNGEPVYGLNSGFRNAEEQQFIRECYEELIG SVFEQKENTHYGKGQSYFLTHAEGYALLQVWKNNGDLSGQDITIYCDRDTCGYCRGGL KELGKTLGMNSITIISKSGEAIYYEFGVGMTRWQPLS (SEQ ID NO: 65).
[0305] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 66, which is the amino acid sequence of FbiDaOl (Accession:
JAJXVD010000193.1 ; database: GeneBank):
MIIEGKTGTDEKTIPLFEWSMLPATDPNCYKEIVVEQTHEDVLLRRIKFSKAFVVDYSES HHDNVGYF SLHVRQF AGLDIEC SDGQPQ APPNT SEIVD VILNRRF AENIGD VEKVGILEN NVTQKGYGEKTEKYSTLWKEKQAYQSISTFREDRGLEVLEPNYEFQKSDGKNTVAFTQ EYDSKYFGVNSTIRTDDEKELAKKYFNLLVEDGYLKDEIYPRGKAQFLTHAEAFTLMKA YEENGGSIGKNVTVFVDRPTCSFCQNNLPKLQAAMGIDVLTVINENGDIYECDFTKYES NSKENIKKEKMKKMASKQRSI (SEQ ID NO: 66). [0306] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 67, which is the amino acid sequence of PvmDaOl (Accession: WFLX011519007; database: GeneBank):
INEKRKNNTPWEIIDNYRVEKGMTKLDDIVPSPGDGLNTVSYIDVGDQTIYGVNSSLLTD SEKDLGRHVFKEMQDMGLFGNPNLHYGQGGSQVLTHAEGNAIMKVCSEYKSQLNGKI VLYCDRKICPFCNANMSALKQYYGLDEIVIINKNGSVHKY (SEQ ID NO: 67).
[0307] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 68, which is the amino acid sequence of SjDaOl (Accession: tr|A0A7G8SQM7|A0A7G8SQM7_9GAMM; database: UniProt):
MSEAARVGDAIGHSHALAGMIGGTIVGGLIAAAGAVAAGALFVAGLAASCVGVGVLLV GASLAVGYLTGELATKARDGIAEAGAGSLTPAGKIVTGSSNVRINGKPAAIATVSQVAC DQDGPSMQMAQGSDI<VFINGQPAARVGDI<TNCDAQVMEGSPNVRIGGSTVTTLPII<PE VPDWLYKISDLTLLFAGLVGGVGGAASKLGALGKMLSKAPGINKLGRTACRFGTLMTA TTAAGIIARPIDIISGQKFLSGDDELDFVLPSRLPVEWQRYWRSGNPAQSVLGRGWSLFW ESSLKRYQDGLVWRAPSGDYVSFPMVPRGHKTYCEAEKCWLMHNSDGSWQVFDVSE QAWHYPALSDAPSRLQMLTDLTGNTISLFHDDHGRLTELVDSAGQRLACRYLTTANGL SRLSSVLLFTPDGELPLVHYGYDDEGQLVTVRNRAGEVTRRFGWQDGLMVSHQDQNG LLNEYRWQEIDGLPRVAAYHNSAGEQLALYYDFANGTRWAVRDDGTRALWQLDDDD NVAQFTDFDNRQSAFIYARGELCGVVLPGGAQRQSEWDRYGRLLSETDPLGRTTTYQY SRNSGRLFSVTYPDGSQAFQHWDSQGRPTQQIDALGNVTRYHYPDEEESLPASVIDALG GEVKLTWNAQGLLTRYTDCSGSVTAYAYDALGQLTHRTDAEGHLTRYHWDRAGRLQ TLLHPDGSEERFDWSAQGQLARHQDPLGSETRWQYNLLGQPVSITDRIQRTRHYHYNC RGWLTRLENGNGGDYQFSHDAVGRLTAERRPDRTDRYYRYGPAGQLSELRETGPLDPQ APPAQRLHQFRYDEAGQLTWHANDSAEWHYHYDAAGRMNRLMRTPTAAGSKLGIEP DSVQLRYDKAGNLLSEQGVNGELQYQWDALSNLQALTLPQGDQLQWLHYGSGHASAI
RFNQQLVSEFSRDRLHRETGRTQGALHQQRQYDVLGRRSGQSSAFGHISKPEEGVLWRT FRYTGRGELEGVSDALRGEIHYGYDAEGRLLQHREAQQGKPGHRLCYDLADNLIGEQR VSHDPDAFLPPAPVVDNRLEYWQRMFYRYDGWGNLTSRRNGIYQQHYVYDADNRLIK AHGRGPQGDFAAQYHYDALGRRTRKTVTYKGKAPETTRFLWEGYRLLQAQRDNGTRR TWSYDPANAWTPLAALEQAGDGQQADIYWLHTDLNSAPLEVTDAEGNLRWSGNYDTF GRLQGQTVTGAERRKGALVDQPLRYAGQYQDDESGLHYNLFRYYEPEVGRFTTQDPIG LRGGLNLYQYAPNPQGWVDPLGLAFGSGKGTHNAKATLFDSNGNVKATGVWQSGNM TPDEAALGFPQSTLATHTEARITRELHPQAAPGDRLVIDGEYPPCNSCKGKMNAFKTAT
GAEVEYI<VVPADTGDGTI<IWNAKSKGTRI<IPGADC (SEQ ID NO: 68).
[0308] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to
SEQ ID NO: 69, which is the amino acid sequence of HmDaO2 (Accession:
3300044995_Ga0484949_008810_2_589; database: IMG/M hot metagenome bin):
MFYVLGKGWTAAGELKPGDRIVGLDPRESVSVTALRLTGRQEKLYNLRVADYHTYFV GDAAWGFALWAHNEYNAPTSSPVPRLGPRGVDPAHHNANIMVRDASGRLRHHERIVS
GNMTPEEQALGFPRNTLASHTEARAIRNIPLHRGETMIITGQRPPCPTCKGIMNQAARES GATIIYRWRENGVTRTWTAGN (SEQ ID NO: 69).
[0309] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to
SEQ ID NO: 70, which is the amino acid sequence of DddA (Accession: P0DUH5; database: UniProt):
MYEAARVTDPIDHTSALAGFLVGAVLGIALIAAVAFATFTCGFGVALLAGMMAGIGAQ ALLSIGESIGKMFSSQSGNIITGSPDVYVNSLSAAYATLSGVACSKHNPIPLVAQGSTNIFI NGRPAARKDDKITCGATIGDGSHDTFFHGGTQTYLPVDDEVPPWLRTATDWAFTLAGL
VGGLGGLLKASGGLSRAVLPCAAKFIGGYVLGEAFGRYVAGPAINKAIGGLFGNPIDVT TGRKILLAESETDYVIPSPLPVAIKRFYSSGIDYAGTLGRGWVLPWEIRLHARDGRLWYT
DAQGRESGFPMLRAGQAAFSEADQRYLTRTPDGRYILHDLGERYYDFGQYDPESGRIA WVRRVEDQAGQWYQFERDSRGRVTEILTCGGLRAVLDYETVFGRLGTVTLVHEDERRL AVTYGYDENGQLASVTDANGAVVRQFAYTNGLMTSHMNALGFTSSYVWSKIEGEPRV VETHTSEGENWTFEYDVAGRQTRVRHADGRTAHWRFDAQSQIVEYTDLDGAFYRIKY
DAVGMPVMLMLPGDRTVMFEYDDAGRIIAETDPLGRTTRTRYDGNSLRPVEVVGPDGG AWRVEYDQQGRVVSNQD SLGRENRYEYPKALTALP S AHFD ALGGRKTLEWNSLGKL V GYTDCSGKTTRTSFDAFGRICSRENALGQRITYDVRPTGEPRRVTYPDGSSETFEYDAAG TLVRYIGLGGRVQELLRNARGQLIEAVDPAGRRVQYRYDVEGRLRELQQDHARYTFTY SAGGRLLTETRPDGILRRFEYGEAGELLGLDIVGAPDPHATGNRSVRTIRFERDRMGVLK VQRTPTEVTRYQHDKGDRLVKVERVPTPSGIALGIVPDAVEFEYDKGGRLVAEHGSNGS VIYTLDELDNVVSLGLPHDQTLQMLRYGSGHVHQIRFGDQVVADFERDDLHREVSRTQ GRLTQRSGYDPLGRKVWQSAGIDPEMLGRGSGQLWRNYGYDGAGDLIETSDSLRGSTR FSYDPAGRLISRANPLDRKFEEFAWDAAGNLLDDAQRKSRGYVEGNRLLMWQDLRFE YDPFGNLATKRRGANQTQRFTYDGQDRLITVHTQDVRGVVETRFAYDPLGRRIAKTDT AFDLRGMKLRAETKRFVWEGLRLVQEVRETGVSSYVYSPDAPYSPVARADTVMAEAL AATVIDSAKRAARIFHFHTDPVGAPQEVTDEAGEVAWAGQYAAWGKVEATNRGVTAA RTDQPLRFAGQYADDSTGLHYNTFRFYDPDVGRFINQDPIGLNGGANVYHYAPNPVGW VDPWGLAGSYALGPYQISAPQLPAYNGQTVGTFYYVNDAGGLESKVFSSGGPTPYPNY ANAGHVEGQSALFMRDNGISEGLVFHNNPEGTCGFCVNMTETLLPENAKMTVVPPEGA IPVKRGATGETKVFTGNSNSPKSPTKGGC (SEQ ID NO: 70).
[0310] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 71, which is the amino acid sequence of RaDaOl (Accession: A0A373WC03; database: UniProt):
MNKGFNSAVNKAGVKPSCFVAGTLVMAVAGMVAIEKIKSGDKVISTDPETFETAEKRV LETYIREDSKLIHLVINGEEIITTETPPFYVKNQGFIKAGELIVGDELLDVNGNVLLVENFD VELTDEPTTVYNFQVEDFHTYHVGKCRLLVHNANCNQEKPVLPKYDGKTTEGVMVTP DGKQISFKSGNSSTPSYPQYKAQSASHVEGKAALYMRENGINEATVFHNNPNGTCGFCD RQVPALLPKGAKLTVVPPSNSVANNVRAIPVPKTYIGNSTVPKIK (SEQ ID NO: 71). [0311] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 72, which is the amino acid sequence of MGYPDa624 (Accession:
MGYP00 1011623624; database: MGnify):
DPLGLEHGNMPRKGAGVGNGGSKYTLNKDFQGKFTLKRPELPVYDGKTTSGVLVTDD FKQIRFNSGNGDPRYTNYANNGHVEQKASLYMQDNNISKATLYHNNTNGTCGWCNNM TETFLPEGATLKVIPPSNAVANNSKAVAIPKVYTGNSNVPKVRKK (SEQ ID NO: 72). [0312] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 73, which is the amino acid sequence of AvDaOl (Accession: tr|A0A448PMLl|A0A448PMLl_ACTVI; database: UniProt):
MAGAISGGLTLASLAVRMVHDLVRDAISDIIGKIASKVTIGVLTAGLAAPWVVQSVISDV ASWVTRLTKEITDVVTSARNLKNLLDKATTLLDDVGEKFAGMAAMALGYGSKNTDNA AKGAKHADDAADAAKGADGAVPPSKGGGDGGGTPPGKGDKDGGGGGDDPAKKSQE AQQRAAEKAKEVNTKKAYKSKTVSSDHVKTLSGWSARRPEGFQDPNIDNVLTKCDEIG HTPEPHDFKDNGVPGQYHASHAEKQLSLTAKEPYIGVSKAMCPDCQGYFSKLAQHEGR DWYVTDPNNSWIFHADGTVTKQ (SEQ ID NO: 73).
[0313] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 74, which is the amino acid sequence of CbDaOl (Accession: NLK69555.1; database: GeneBank):
MEYKVTISDGTVLEKSIQHVSYIVYPPDDYDIRRNYPRNSMVISGIIDIGEGTVGLYKWAL IPGTNKECYKDVTVEHFYAGQLVSKVKFSKAFVVDYSESYSNSEGVGYFTIYLRQFAGM DIEHSNEISQEQQKKYQEQVQTNIEQTSELEKAEPKISSAVSLDNVNNVNSKPVMRITDR LKNQKDPDTLLTKEEVKLRYAKEIEASKEAYKRAIDMAKKKKVKGCVASNGKITLSGF DGKTTKAPEGFARVPLDTMFDYCKKIGHELPPKVPAFYDNGREGSYFACHAEKQLSLLT DEPIGISRDMCPDCVEYFKKHAAYTNQVKITADPKKTRIFFPDGRVEEF (SEQ ID NO: 74). [0314] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 75, which is the amino acid sequence of PfDaOl (Accession: tr|A0A0F4TG59|A0A0F4TG59_PSEFL; database: UniProt):
MSAAARLDDPIEHTGSLTGLLAGLAVGAIGAALIVGTGGLAAVAIVGAAAATGAGIGQL VGSLSFCSHEAGQIVSGSGNVHTNGKPAARAHLDKAKCDEHGSAPQIVAQGSSTVHING QPAARVGDCTVCDGKISSGSGNVFIGGGTDTTDPINPEVPEWLERAVLVVGLASAFVLA SPVVVVAGLVGAVAGGLAGNWAGGELFGQGSDGQKLMAFGGALLGGGLGAKGGKW FDARYEIKVQGVGSNLANVKIVPKGSEKVASIAESEAALGRANHAKTELPSSKEYKVKT VSSNDKKTLSGWGDKKPEGYEKVSAEHVKAKSEEIGHEVKSHPYDRDYKGQYYSSHA EKQMSIISPDHPIGVSKPMCNDCQGYFSKLAQYKNAEQVVADPKAVRIFKPDGTVETILR SE (SEQ ID NO: 75)
[0315] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 76, which is the amino acid sequence ofNoDaOl (Accession: WP_223985731.1; database: GeneBank):
MESEANLVRIAQSIQQSLNNPPNKKTIAGIESGELTVSGWKEIQGYTQATDIVIAKCQEIG HQLKPAGPLDKGVPGRYNASHAEKQISVLHPNQPIGVSSEMCADCQEYFKALVCHTGNI QVVADPKAVRIFRPDGSVDELANIPDI (SEQ ID NO: 76). [0316] In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 77, which is the amino acid sequence of SsdA (Accession: WP_046719483.1; database: GeneBank): MSAAARVNDPIEHTGSLTGLLAGLAIGAIGAALVVGTGGLAAVAIVGASAATGAGVGQ LIGSLSCCNHQTGQIVSGSSNVYINGEPAARAHADQAKCDEHSSRPQVIAQGSSNVYING HPAARVGDRTACDAKIVVGSSNVFIGGGTETTDPINPEVPELLERGILLVGLASAFVLASP VIVIAGLVGGIAGGTVGSMGGAQLFGEGTDGQKLMAFGGALLGGGLGAKGGKWFDTR YDIKVQGVGSNLGNLKITPKGAAKVSNIAESEAALGRASQARADLPQSKELKVKTVSSN DKKTLSGWGNKKPEGYERIS AEQVKAKSEEIGHEVKSHPYDRDYKGQYF S SHAEKQMS IASPNHPLGVSKPMCTDCQGYFSQLAKYSKVEQTVADPKAIRIFKTDGSVETIMRSE (SEQ ID NO: 77).
[0317] In some embodiments, the methyl-sensitive deaminase comprises the APOBEC3A protein containing a substitution mutation at Y130, such as Y130L, Y130W, or Y130H. In some embodiments, the methyl-sensitive deaminase comprises the APOBEC3A protein containing a substitution mutation at Y132, such as Y132P or Y132H, e.g., in addition to a substitution at Y130, e.g., Y132H and either Y130V or Y130W. In some embodiments, the methyl -sensitive deaminase comprises the APOBEC3A protein containing a substitution mutation at Y130 and Y132. In some embodiments, the Y130 substitution mutation is Y130L (e.g., SEQ ID NO: 2): MEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQHRGFLHNQ AKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQEN THVRLRIFAARILDYDPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGCPFQP WDGLDEHSQALSGRLRAILQNQGN). In some embodiments, the amino acid sequence of the methyl-sensitive deaminase comprises or has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 2 and contains the Y130L mutation. In some embodiments, the Y130 substitution mutation is Y130W (e.g., SEQ ID NO: 3):
MEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQHRGFLHNQ AKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQEN THVRLRIFAARIWDYDPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGCPFQP WDGLDEHSQALSGRLRAILQNQGN. In some embodiments, the Y132 substitution mutation is Y132P (e.g., SEQ ID NO: 4): MEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQHRGFLHNQ AKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQEN THVRLRIFAARIYDPDPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGCPFQP WDGLDEHSQALSGRLRAILQNQGN. In some embodiments, the methyl -sensitive deaminase has substitution mutations Y130V and Y132H substitution mutation (e.g., SEQ ID NO: 5): MEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQHRGFLHNQ AKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQEN THVRLRFFAARIVDHDPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGCPFQP WDGLDEHSQALSGRLRAILQNQGN. In some embodiments, the methyl -sensitive deaminase has substitution mutations Y130W and Y132H (e g., SEQ ID NO: 6): MEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQHRGFLHNQ AKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQEN THVRLRFFAARIWDHDPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGCPFQP WDGLDEHSQALSGRLRAILQNQGN. In some embodiments, the amino acid sequence of the methyl-sensitive deaminase has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 2 and contains the Y130L mutation. In some embodiments, the amino acid sequence of the methyl-sensitive deaminase has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 3 and contains the Y130W mutation. In some embodiments, the amino acid sequence of the methyl -sensitive deaminase has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 4 and contains the Y132P mutation. In some embodiments, the amino acid sequence of the methyl -sensitive deaminase has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 5 and contains the Y130V and Y132H mutations. In some embodiments, the amino acid sequence of the methyl -sensitive deaminase has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 6 and contains the Y130W and Y132H. In some embodiments, the deaminase (e.g., the methyl-insensitive deaminase or the methyl-sensitive deaminase) comprises any one or more of the following deaminases or a truncated version thereof, disclosed in WO 2024/073043, which is incorporated by reference herein in its entirety.
[0318] Exemplary cytosine deaminases for use herein include APOBEC enzymes, for example, APOBEC3A. Generally, AID/ APOBEC family DNA deaminase enzymes such as APOBEC3A (A3 A) are used to deaminate (unprotected) unmodified cytosine and 5mC. For an exemplary description of APOBEC conversion, see, e.g., Schutsky et al., Nature Biotechnology 2018; 36: 1083-1090. For an exemplary description of APOBEC enzymes, see, e.g., Gajula et al., Nucleic Acids Res. 2014 Sep;42(15):9964-75 and Schutsky et al., Nucleic Acids Res. 2017 Jul 27;45(13):7655-7665.
[0319] Optionally, the conversion procedure further includes enzymatic protection of 5hmCs, such as by glucosylation of the 5hmCs (e.g., using GT) or by carbamoylation of the 5hmCs (e.g., using 5-hydroxymethylcytosine carbamoyltransferase), in the DNA prior to the deamination of unprotected modified cytosines. In this method, 5hmC can be protected from conversion, for example through glucosylation using P-glucosyl transferase (PGT), forming (5- glucosylhydroxymethylcytosine) 5ghmC, or through carbamoylation using 5- hydroxymethylcytosine carbamoyltransferase, forming 5cmC. This is described, for example, in Yu et al., Cell 2012; 149: 1368-80, and in Yang et al., Bio-protocol, 2023; 12(17): e4496. Glucosylation or carbamoylation of 5hmC can reduce or eliminate deamination of 5hmC by a deaminase such as APOBEC3A.
[0320] As discussed above, in some embodiments, a TET protein can be used to convert 5mC and optionally 5hmC (but not unmodified C) into substrates (e.g., 5caC) that cannot be deaminated by a deaminase, and then a deaminase (e.g., APOBEC3A) can be used to deaminate unmodified cytosines, converting them to uracils. Various TET enzymes may be used in the disclosed methods as appropriate. In some embodiments of the disclosed methods, the DNA is not contacted with a glucosyltransferase (such as PGT), e.g., to protect 5hmC from conversion. In some embodiments, the one or more TET enzymes comprise TETv. TETv is described in US Patent 10,260,088 and its sequence is SEQ ID NO: 1 therein. In some embodiments, the one or more TET enzymes comprise TETcd. TETcd is described in US Patent 10,260,088 and its sequence is SEQ ID NO: 3 therein. In some embodiments, the one or more TET enzymes comprise TET1. In some embodiments, the one or more TET enzymes comprise TET2. TET2 may be expressed and used as a fragment comprising TET2 residues 1129-1480 joined to TET2 residues 1844-1936 by a linker as described, e.g., in US Patent 10,961,525. In some embodiments, the one or more TET enzymes comprise TET1 and TET2. In some embodiments, the one or more TET enzymes comprise a T1372 TET mutant, such as T1372S. In some embodiments, the one or more TET enzymes comprise a VI 900 TET mutant, such as a V1900A, V1900C, V1900G, VI 9001, or V1900P TET mutant. In some embodiments, the one or more TET enzymes comprise a VI 900 TET2 mutant, such as a V1900A, V1900C, V1900G, VI 9001, or V1900P TET2 mutant. It can be beneficial to use a TET enzyme that maximizes formation of 5-carboxylcytosine (5-caC) relative to less oxidized modified cytosines, particularly 5- formylcytosine, because 5-caC is not a substrate for enzymatic deamination, e.g., by APOBEC enzymes such as APOBEC3A. Maximizing formation of 5-caC thus reduces the risk of false calls in which a base is identified as unmethylated because it underwent deamination even though it was methylated (or hydroxymethylated) in the original sample. Accordingly, in some embodiments, the TET enzyme comprises a mutation that increases formation of 5-caC. Exemplary mutations are set forth above. “A mutation that increases formation of 5-caC” means that the TET enzyme having the mutation produces more 5-caC than a TET enzyme that lacks the mutation but is otherwise identical. 5-caC production can be measured as described, e.g., in Liu et al., Nat Chem Biol 13: 181-187 (2017) (see Online Methods section, TET reactions in vitro subsection, “driving” conditions). Any variants and/or mutants described in Liu et al. (2017) can be used in the disclosed methods as appropriate.
[0321] In some embodiments, the one or more TET enzymes comprise a TET2 enzyme comprising a T1372S mutation, such as TET2-CS-T1372S and TET2-CD-T1372S. A TET2 comprising a T1372S mutation is described in US Patent 10,961,525 and may be expressed and used as a fragment comprising TET2 residues 1129-1480 joined to TET2 residues 1844-1936 by a linker. Position 1372 of TET2 corresponds to position 258 of SEQ ID NO: 21 (wild type TET2 catalytic domain) of US Patent 10,961,525. Thus, the sequence of a T1372S TET2 catalytic domain may be obtained by changing the threonine at position 258 of SEQ ID NO: 21 of US Patent 10,961,525 to serine. TET2 comprising a T1372S mutation is also described in Liu et al., Nat Chem Biol. 2017 February; 13(2): 181-187. As demonstrated in Liu et al., TET2 comprising a T1372S mutation can more efficiently oxidize 5mC to produce 5-carboxylcytosine (5-caC) than other versions of TET2 such as TET2 lacking a T1372S mutation.
G. Partitioning
[0322] In some instances, a heterogeneous nucleic acid sample is partitioned into two or more partitions (sub-samples). In some embodiments, each partition is differentially tagged. Tagged partitions can then be pooled together for collective sample prep and/or sequencing. The partitioning-tagging-pooling steps can occur more than once, with each round of partitioning occurring based on a different characteristics, and tagged using differential tags that are distinguished from other partitions and partitioning means. The partitioning step can occur before or after contacting the DNA (e.g., DNA in a sample) with a deaminase. In some embodiments, the partitioning step occurs before contacting the DNA with a deaminase. In some embodiments, the partitioning step occurs after contacting the DNA with a deaminase In some embodiments, the partitioning step occurs before selectively amplifying the DNA in the converted sample. In some embodiments, the partitioning step occurs after contacting the DNA with a deaminase and before selectively amplifying the DNA in the converted sample. In some embodiments, the partitioning step occurs before or after a conversion step. In some embodiments, the conversion step comprises contacting DNA (e.g., DNA in a sample) with a deaminase. In some embodiments, the conversion step of contacting DNA (e.g., DNA in a sample) with a deaminase provides a converted sample in which unmethylated CpGs in the DNA are converted to UpGs. In some embodiments, the partitioning step occurs before a conversion step. In some embodiments, the partitioning step occurs after a conversion step.
[0323] Examples of characteristics that can be used for partitioning include sequence length, methylation level, nucleosome binding, sequence mismatch, immunoprecipitation, and/or proteins that bind to DNA. Resulting partitions can include one or more of the following nucleic acid forms: single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), shorter DNA fragments and longer DNA fragments. In some embodiments, partitioning based on a cytosine modification (e.g., cytosine methylation) or methylation generally is performed and is optionally combined with at least one additional partitioning step, which may be based on any of the foregoing characteristics or forms of DNA. In some embodiments, a heterogeneous population of nucleic acids is partitioned into nucleic acids with one or more base modifications and without the one or more base modifications. Examples of base modifications are described elsewhere herein. Alternatively or additionally, a heterogeneous population of nucleic acids can be partitioned into nucleic acid molecules associated with nucleosomes and nucleic acid molecules devoid of nucleosomes. Alternatively or additionally, a heterogeneous population of nucleic acids may be partitioned into single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA). Alternatively, or additionally, a heterogeneous population of nucleic acids may be partitioned based on nucleic acid length (e.g., molecules of up to 160 bp and molecules having a length of greater than 160 bp).
[0324] In some cases, different procedures are applied to different partitions to determine different characteristics of the initial sample. In some embodiments, the DNA of at least one partition is subjected to an end repair and sequencing procedure described herein. In some embodiments at least one partition is not subjected to the end repair and sequencing procedure described herein. In cases where the method comprises a conversion procedure, corresponding sequences from the converted and non-converted partitions can be compared to identify single nucleotides that have undergone conversion and therefore identify corresponding modified nucleosides in the initial sample.
[0325] In some embodiments, partition tagging comprises tagging molecules in each partition with a partition tag. After re-combining partitions (e.g., to reduce the number of sequencing runs needed and avoid unnecessary cost) and sequencing molecules, the partition tags identify the source partition. In another embodiment, different partitions are tagged with different sets of molecular tags, e.g., comprised of a pair of barcodes. In this way, each molecular barcode indicates the source partition as well as being useful to distinguish molecules within a partition. For example, a first set of 35 barcodes can be used to tag molecules in a first partition, while a second set of 35 barcodes can be used tag molecules in a second partition.
[0326] In some embodiments, after partitioning and tagging with partition tags, the molecules may be pooled for sequencing in a single run. In some embodiments, a sample tag is added to the molecules, e.g., in a step subsequent to addition of partition tags and pooling. Sample tags can facilitate pooling material generated from multiple samples for sequencing in a single sequencing run.
[0327] Alternatively, in some embodiments, partition tags may be correlated to the sample as well as the partition. As a simple example, a first tag can indicate a first partition of a first sample; a second tag can indicate a second partition of the first sample; a third tag can indicate a first partition of a second sample; and a fourth tag can indicate a second partition of the second sample.
[0328] While tags may be attached to molecules already partitioned based on one or more characteristics, the final tagged molecules in the library may no longer possess that characteristic. For example, while single stranded DNA molecules may be partitioned and tagged, the final tagged molecules in the library are likely to be double stranded. Similarly, while DNA may be subject to partition based on different levels of methylation, in the final library, tagged molecules derived from these molecules are likely to be unmethylated. Accordingly, the tag attached to a molecule in the library typically indicates the characteristic of the “parent molecule” from which the ultimate tagged molecule is derived, not necessarily to characteristic of the tagged molecule, itself. [0329] As an example, barcodes 1, 2, 3, 4, etc. are used to tag and label molecules in the first partition; barcodes A, B, C, D, etc. are used to tag and label molecules in the second partition; and barcodes a, b, c, d, etc. are used to tag and label molecules in the third partition. Differentially tagged partitions can be pooled prior to sequencing. Differentially tagged partitions can be separately sequenced or sequenced together concurrently, e.g., in the same flow cell of an Illumina sequencer.
[0330] After sequencing, analysis of reads can be performed on a partition-by-partition level, as well as a whole DNA population level. Tags are used to sort reads from different partitions. Analysis can include in silico analysis to determine genetic and epigenetic variation (one or more of methylation, chromatin structure, etc.) using sequence information, genomic coordinates length, coverage, and/or copy number. In some embodiments, higher coverage can correlate with higher nucleosome occupancy in genomic region while lower coverage can correlate with lower nucleosome occupancy or a nucleosome depleted region (NDR).
[0331] Disclosed methods herein comprise analyzing DNA in a sample. In some embodiments described herein, the disclosed methods comprise partitioning DNA. In such methods, different forms of DNA (e.g., hypermethylated and hypom ethylated DNA) can be physically partitioned based on one or more characteristics of the DNA. This approach can be used to determine, for example, whether certain sequences are hypermethylated or hypomethylated. In some embodiments, a first subsample or aliquot of a sample is subjected to steps for making capture probes as described elsewhere herein and a second subsample or aliquot of a sample is subjected to partitioning. In some embodiments, a sample or subsample or aliquot thereof is subjected to partitioning and differential tagging, followed by a capture step using capture probes for rearranged sequences and optionally additional capture probes, e.g., for sequence-variable and/or epigenetic target regions.
[0332] Methylation profiling can involve determining methylation patterns across different regions of the genome. For example, after partitioning molecules based on extent of methylation (e.g., relative number of methylated nucleobases per molecule) and sequencing, the sequences of molecules in the different partitions can be mapped to a reference genome. This can show regions of the genome that, compared with other regions, are more highly methylated or are less highly methylated. In this way, genomic regions, in contrast to individual molecules, may differ in their extent of methylation. [0333] In some embodiments, the partitioning comprises contacting the DNA with an agent that recognizes a modification associated with (e.g., in) the DNA. In some embodiments, the agent that recognizes the modification is an antibody. In some embodiments, the agent is immobilized on a solid support. In some embodiments, the partitioning comprises immunoprecipitation, e.g., using the antibody agent, such as an antibody, immobilized on solid support.
[0334] In some embodiments, the modification is methylation, and in some such embodiments, the partitioning comprises partitioning on the basis of methylation level. In some such embodiments, the agent is a methyl binding reagent. In some embodiments, the methyl binding reagent specifically recognizes 5-methylcytosine. In some such embodiments, the agent is a hydroxymethyl binding reagent. In some embodiments, the methyl binding reagent specifically recognizes 5-hydroxymethylcytosine, biotinylated 5-hydroxymethylcytosine, glucosylated 5- hydroxymethylcytosine, or sulfonylated 5-hydroxymethylcytosine. In some embodiments, the partitioning comprises partitioning on the basis of binding to a protein comprising contacting the sample comprising the DNA with a binding reagent specific for the protein. In some such embodiments, binding reagent specifically binds a methylated protein, an acetylated protein, such as a methylated or acetylated histone. In some embodiments, the binding reagent specifically binds an unmethylated or unacetylated protein epitope.
[0335] In some embodiments, the modification is hydroxymethylation, and in some such embodiments, the partitioning comprises partitioning on the basis of hydroxymethylation level. In some such embodiments, the agent is a hydroxymethyl binding reagent, such as an antibody. In some embodiments, the hydroxymethyl binding reagent (e.g., antibody) specifically recognizes 5-hydroxymethylcytosine (5-hmC). In some embodiments, a modification such as hydroxymethylation is labeled (e.g., biotinylated, glucosylated, or sulfonated) before being contacted with an agent that recognizes the labeled form of the modification. For example, 5- hmC can be enzymatically glucosylated and then partitioned based on binding to J-binding protein 1. Exemplary methods of labeling and/or partitioning 5-hmC are provided, e.g., in Song et al., Nat. Biotech. 29:68-72 (2010); Ko et al., Nature 468:839-843 (2010); and Robertson et al., Nucleic Acids Res. 39:e55 (2011).
[0336] Where immunoprecipitation is used and involves an antibody that recognizes singlestranded DNA, the DNA may be converted to double-stranded form by complementary strand synthesis before a subsequent step. Such synthesis may use an adapter as a primer binding site, or can use random priming. [0337] Partitioning nucleic acid molecules in a sample can increase a rare signal, e.g., by enriching rare nucleic acid molecules that are more prevalent in one partition of the sample. For example, a genetic variation present in hypermethylated DNA but less (or not) present in hypomethylated DNA can be more easily detected by partitioning a sample into hypermethylated and hypomethylated nucleic acid molecules. By analyzing multiple partitions of a sample, a multi-dimensional analysis of a single molecule can be performed and hence, greater sensitivity can be achieved. Partitioning may include physically partitioning nucleic acid molecules into partitions or subsamples based on the presence or absence of one or more methylated nucleobases. A sample may be partitioned into partitions or subsamples based on a characteristic that is indicative of differential gene expression or a disease state. A sample may be partitioned based on a characteristic, or combination thereof that provides a difference in signal between a normal and diseased state during analysis of nucleic acids, e.g., cell free DNA (cfDNA), non- cfDNA, tumor DNA, circulating tumor DNA (ctDNA) and cell free nucleic acids (cfNA).
[0338] In some embodiments, hypermethylation and/or hypomethylation variable epigenetic target regions are analyzed to determine whether they show differential methylation characteristic of tumor cells or cells of a type that does not normally contribute to the DNA sample being analyzed (such as cfDNA), and/or particular immune cell types.
[0339] In some instances, heterogeneous DNA in a sample is partitioned into two or more partitions (e.g., at least 3, 4, 5, 6 or 7 partitions). In some embodiments, each partition is differentially tagged. Tagged partitions can then be pooled together for collective sample prep and/or sequencing. The partitioning-tagging-pooling steps can occur more than once, with each round of partitioning occurring based on a different characteristic (examples provided herein), and tagged using differential tags that are distinguished from other partitions and partitioning means. In other instances, the differentially tagged partitions are separately sequenced.
[0340] In some embodiments, sequence reads from differentially tagged and pooled DNA are obtained and analyzed in silico. After sequencing, analysis of reads can be performed on a partition-by-partition level, as well as a whole DNA population level. Tags are used to sort reads from different partitions. Analysis to detect genetic variants can be performed on a partition-by- partition level, as well as whole nucleic acid population level. For example, analysis can include in silico analysis to determine genetic variants, such as copy number variations (CNVs), single nucleotide variations (SNVs), insertions/deletions (indels), and/or fusions in nucleic acids in each partition. In some instances, in silico analysis can include analysis to determine epigenetic
I l l variation (one or more of methylation, chromatin structure, etc.). Analysis can include in silico using sequence information, genomic coordinates length, coverage, and/or copy number. For example, coverage of sequence reads can be used to determine nucleosome positioning in chromatin. Tags are used to sort reads from different partitions. Higher coverage can correlate with higher nucleosome occupancy in genomic region while lower coverage can correlate with lower nucleosome occupancy or nucleosome depleted region (NDR).
[0341] The agents used to partition populations of nucleic acids within a sample can be affinity agents, such as antibodies with the desired specificity, natural binding partners or variants thereof (Bock et al., Nat Biotech 28: 1106-1114 (2010); Song et al., Nat Biotech 29: 68-72 (2011)), or artificial peptides selected e.g., by phage display to have specificity to a given target. In some embodiments, the agent used in the partitioning is an agent that recognizes a modified nucleobase. In some embodiments, the modified nucleobase recognized by the agent is a modified cytosine, such as a methylcytosine (e.g., 5-methylcytosine). In some embodiments, the modified nucleobase recognized by the agent is a product of a procedure that affects the first nucleobase in the DNA differently from the second nucleobase in the DNA of the sample. In some embodiments, the modified nucleobase may be a “converted nucleobase,” meaning that its base pairing specificity was changed by a procedure. For example, certain procedures convert unmethylated or unmodified cytosine to dihydrouracil, or more generally, at least one modified or unmodified form of cytosine undergoes deamination, resulting in uracil (considered a modified nucleobase in the context of DNA) or a further modified form of uracil. Examples of partitioning agents include antibodies, such as antibodies that recognize a modified nucleobase, which may be a modified cytosine, such as a methylcytosine (e.g., 5-methylcytosine). In some embodiments, the partitioning agent is an antibody that recognizes a modified cytosine other than 5-methylcytosine, such as 5-carboxylcytosine (5-caC). Alternative partitioning agents include methyl binding domain (MBDs) and methyl binding proteins (MBPs) as described herein, including proteins such as MeCP2, MBD2, and antibodies preferentially binding to 5- methylcytosine. Where an antibody is used to immunoprecipitate methylated DNA, the methylated DNA may be recovered in single- stranded form. In such embodiments, a second strand can be synthesized. Hypermethylated (and optionally intermediately methylated) subsamples may then be contacted with a methylation sensitive nuclease that does not cleave hemi-methylated DNA, such as Hpall, BstUI, or Hin6i. Alternatively or in addition, hypomethylated (and optionally intermediately methylated) subsamples may then be contacted with a methylation dependent nuclease that cleaves hemi-methylated DNA.
[0342] Additional, non-limiting examples of partitioning agents are histone binding proteins which can separate nucleic acids bound to histones from free or unbound nucleic acids. Examples of histone binding proteins that can be used in the methods disclosed herein include RBBP4, RbAp48 and SANT domain peptides.
[0343] In some embodiments, partitioning can comprise both binary partitioning and partitioning based on degree/level of modifications. For example, methylated fragments can be partitioned by methylated DNA immunoprecipitation (MeDIP), or all methylated fragments can be partitioned from unmethylated fragments using methyl binding domain proteins (e.g., MethylMinder Methylated DNA Enrichment Kit (ThermoFisher Scientific). Subsequently, additional partitioning may involve eluting fragments having different levels of methylation by adjusting the salt concentration in a solution with the methyl binding domain and bound fragments. As salt concentration increases, fragments having greater methylation levels are eluted.
[0344] Analyzing DNA may comprise detecting or quantifying DNA of interest. Analyzing DNA can comprise detecting genetic variants and/or epigenetic features (e.g., DNA methylation and/or DNA fragmentation). In some embodiments, the DNA of interest is one or more differentially methylated regions of the DNA. In some embodiments, the detecting or quantifying the DNA of interest comprises quantifying and/or detecting a level of methylation at one or more differentially methylated regions of the DNA. In some embodiments, quantifying and/or detecting the level of methylation at one or more differentially methylated regions of the DNA comprises sequencing at least a portion of the amplified DNA or quantitative PCR (qPCR).
[0345] In some embodiments, methylation levels can be determined using partitioning, modification-sensitive conversion such as direct detection during sequencing, methylationsensitive restriction enzyme digestion, methylation-dependent restriction enzyme digestion, or any other suitable approach. For example, different forms of DNA (e.g., hypermethylated and hypomethylated DNA) can be physically partitioned based on one or more characteristics of the DNA. For example, a methylated DNA binding protein (e.g., an MBD such as MBD2, MBD4, or MeCP2) or an antibody specific for 5-methylcytosine (as in MeDIP) can be used to partition the DNA. This approach can be used to determine, for example, whether certain sequences are hypermethylated or hypomethylated. In some embodiments, a DNA fragmentation pattern can be determined based on endpoints and/or centerpoints of DNA molecules, such as cfDNA molecules.
[0346] In some instances, the final partitions are enriched in nucleic acids having different extents of modifications (overrepresentative or underrepresentative of modifications). Overrepresentation and underrepresentation can be defined by the number of modifications bom by a nucleic acid relative to the median number of modifications per strand in a population. For example, if the median number of 5-methylcytosine residues in nucleic acid in a sample is 2, a nucleic acid including more than two 5-methylcytosine residues is overrepresented in this modification and a nucleic acid with 1 or zero 5-methylcytosine residues is underrepresented. The effect of affinity separation is to enrich for nucleic acids overrepresented in a modification in a bound phase and for nucleic acids underrepresented in a modification in an unbound phase (i.e. in solution). The nucleic acids in the bound phase can be eluted before subsequent processing.
[0347] When using MeDIP or Methyl Miner “Methylated DNA Enrichment Kit (ThermoFisher Scientific) various levels of methylation can be partitioned using sequential elutions. For example, a hypomethylated partition (no methylation) can be separated from a methylated partition by contacting the nucleic acid population with the MBD from the kit, which is attached to magnetic beads. The beads are used to separate out the methylated nucleic acids from the nonmethylated nucleic acids. Subsequently, one or more elution steps are performed sequentially to elute nucleic acids having different levels of methylation. For example, a first set of methylated nucleic acids can be eluted at a salt concentration of 160 mM or higher, e.g., at least 150 mM, at least 200 mM, 300 mM, 400 mM, 500 mM, 600 mM, 700 mM, 800 mM, 900 mM, 1000 mM, or 2000 mM. After such methylated nucleic acids are eluted, magnetic separation is once again used to separate higher level of methylated nucleic acids from those with lower level of methylation. The elution and magnetic separation steps can be repeated to create various partitions such as a hypomethylated partition (enriched in nucleic acids comprising no methylation), a methylated partition (enriched in nucleic acids comprising low levels of methylation), and a hyper methylated partition (enriched in nucleic acids comprising high levels of methylation).
[0348] In some methods, nucleic acids bound to an agent used for affinity separation based partitioning are subjected to a wash step. The wash step washes off nucleic acids weakly bound to the affinity agent. Such nucleic acids can be enriched in nucleic acids having the modification to an extent close to the mean or median (i.e., intermediate between nucleic acids remaining bound to the solid phase and nucleic acids not binding to the solid phase on initial contacting of the sample with the agent).
[0349] The affinity separation results in at least two, and sometimes three or more partitions of nucleic acids with different extents of a modification. While the partitions are still separate, the nucleic acids of at least one partition, and usually two or three (or more) partitions are linked to nucleic acid tags, usually provided as components of adapters, with the nucleic acids in different partitions receiving different tags that distinguish members of one partition from another. The tags linked to nucleic acid molecules of the same partition can be the same or different from one another. But if different from one another, the tags may have part of their code in common so as to identify the molecules to which they are attached as being of a particular partition.
[0350] For further details regarding portioning nucleic acid samples based on characteristics such as methylation, see WO2018/119452, which is incorporated herein by reference.
[0351] In some embodiments, the nucleic acid molecules can be partitioned into different partitions based on the nucleic acid molecules that are bound to a specific protein or a fragment thereof and those that are not bound to that specific protein or fragment thereof.
[0352] Nucleic acid molecules can be partitioned based on DNA-protein binding. Protein-DNA complexes can be partitioned based on a specific property of a protein. Examples of such properties include various epitopes, modifications (e.g., histone methylation or acetylation) or enzymatic activity. Examples of proteins which may bind to DNA and serve as a basis for fractionation may include, but are not limited to, protein A and protein G. Any suitable method can be used to partition the nucleic acid molecules based on protein bound regions. Examples of methods used to partition nucleic acid molecules based on protein bound regions include, but are not limited to, SDS-PAGE, chromatin-immuno-precipitation (ChIP), heparin chromatography, and asymmetrical field flow fractionation (AF4).
[0353] In some embodiments, the partitioning comprises contacting the DNA with a methylation sensitive restriction enzyme (MSRE) and/or a methylation dependent restriction enzyme (MDRE). Following the treatment of the DNA with a MSRE or a MDRE, the DNA may be partitioned based on size to generate hypermethylated (longest DNA molecules following MSRE treatment and shortest DNA fragments following MDRE treatment), intermediate (intermediate length DNA molecules following MSRE or MDRE treatment), and hypomethylated (shortest DNA molecules following MSRE treatment and longest DNA fragments following MDRE treatment) subsamples. [0354] In some embodiments, the partitioning is performed by contacting the nucleic acids with a methyl binding domain (“MBD”) of a methyl binding protein (“MBP”). In some such embodiments, the nucleic acids are contacted with an entire MBP. In some embodiments, an MBD binds to 5-methylcytosine (5mC), and an MBP comprises an MBD and is referred to interchangeably herein as a methyl binding protein or a methyl binding domain protein. In some embodiments, MBD is coupled to paramagnetic beads, such as Dynabeads® M-280 Streptavidin via a biotin linker. Partitioning into fractions with different extents of methylation can be performed by eluting fractions by increasing the NaCl concentration.
[0355] In some embodiments, bound DNA is eluted by contacting the antibody or MBD with a protease, such as proteinase K. This may be performed instead of or in addition to elution steps using NaCl as discussed above.
[0356] Examples of agents that recognize a modified nucleobase contemplated herein include, but are not limited to:
[0357] (a) MeCP2 is a protein that preferentially binds to 5-methyl-cytosine over unmodified cytosine.
[0358] (b) RPL26, PRP8 and the DNA mismatch repair protein MHS6 preferentially bind to 5- hydroxymethyl-cytosine over unmodified cytosine.
[0359] (c) FOXK1, FOXK2, FOXP1, FOXP4 and FOXI3 preferably bind to 5-formyl-cytosine over unmodified cytosine (lurlaro et al., Genome Biol. 14: R119 (2013)).
[0360] (d) Antibodies specific to one or more methylated or modified nucleobases or conversion products thereof, such as 5mC, 5-caC, or DHU.
[0361] In general, elution is a function of the number of modifications, such as the number of methylated sites per molecule, with molecules having more methylation eluting under increased salt concentrations. To elute the DNA into distinct populations based on the extent of methylation, one can use a series of elution buffers of increasing NaCl concentration. Salt concentration can range from about 100 nm to about 2500 mM NaCl. In one embodiment, the process results in three (3) partitions. Molecules are contacted with a solution at a first salt concentration and comprising a molecule comprising an agent that recognizes a modified nucleobase, which molecule can be attached to a capture moiety, such as streptavidin. At the first salt concentration a population of molecules will bind to the agent and a population will remain unbound. The unbound population can be separated as a “hypom ethylated” population. For example, a first partition enriched in hypomethylated form of DNA is that which remains unbound at a low salt concentration, e.g., 100 mM or 160 mM. A second partition enriched in intermediate methylated DNA is eluted using an intermediate salt concentration, e g., between 100 mM and 2000 mM concentration. This is also separated from the sample. A third partition enriched in hypermethylated form of DNA is eluted using a high salt concentration, e.g., at least about 2000 mM.
[0362] In some embodiments, a monoclonal antibody raised against 5-methylcytidine (5mC) is used to purify methylated DNA. DNA is denatured, e.g., at 95°C in order to yield single-stranded DNA fragments. Protein G coupled to standard or magnetic beads as well as washes following incubation with the anti-5mC antibody are used to immunoprecipitate DNA bound to the antibody. Such DNA may then be eluted. Partitions may comprise unprecipitated DNA and one or more partitions eluted from the beads.
[0363] In some embodiments, the partitions of DNA are desalted and concentrated in preparation for enzymatic steps of library preparation.
[0364] Sequences that comprise aberrantly high copy numbers may tend to be hypermethylated. Accordingly, in some embodiments, the DNA contacted with capture probes specific for members of an epigenetic target region set comprising a plurality of target regions that are both type-specific differentially methylated regions and copy number variants comprises at least a portion of a hypermethylated partition. The DNA from or comprising at least a portion of the hypermethylated partition may or may not be combined with DNA from or comprising at least a portion of one or more other partitions, such as an intermediate partition or a hypomethylated partition.
[0365] In some cases, different procedures are applied to different partitions to determine different characteristics of the initial sample. In some embodiments, the DNA of at least one partition is subjected to an end repair and sequencing procedure described herein. In some embodiments at least one partition is not subjected to the end repair and sequencing procedure according to the methods of the disclosure described herein. In cases where the sequencing procedure comprises a conversion procedure, corresponding sequences from the converted and non-converted partitions can be compared to identify single nucleotides that have undergone conversion and therefore identify corresponding modified nucleosides in the initial sample. [0366] Disclosed methods herein can comprise analyzing DNA in a sample. In some embodiments described herein, the disclosed methods comprise partitioning DNA. In such methods, different forms of DNA (e.g., hypermethylated and hypomethylated DNA) can be physically partitioned based on one or more characteristics of the DNA. This approach can be used to determine, for example, whether certain sequences are hypermethylated or hypomethylated. In some embodiments, a first subsample or aliquot of a sample is subjected to steps for making capture probes as described elsewhere herein and a second subsample or aliquot of a sample is subjected to partitioning. In some embodiments, a sample or subsample or aliquot thereof is subjected to partitioning and differential tagging, followed by a capture step using capture probes for rearranged sequences and optionally additional capture probes, e.g., for sequence-variable and/or epigenetic target regions.
[0367] Methylation profiling can involve determining methylation patterns across different regions of the genome. For example, after partitioning molecules based on extent of methylation (e.g., relative number of methylated nucleobases per molecule) and sequencing, the sequences of molecules in the different partitions can be mapped to a reference genome. This can show regions of the genome that, compared with other regions, are more highly methylated or are less highly methylated. In this way, genomic regions, in contrast to individual molecules, may differ in their extent of methylation.
H. Amplification
[0368] In some embodiments, DNA is amplified. In some embodiments, the DNA can be subjected to a plurality of distinct amplification reactions. For example, DNA in a converted sample, as described herein, can be selectively amplified.
[0369] In some embodiments, the adapters are added to the DNA to yield DNA flanked by adapters. DNA flanked by adapters, as described herein, can be selectively amplified and, optionally, be subjected to methylation-preserving amplification. In some embodiments, the adapters are added to the DNA before methylation-preserving amplification, before contacting the DNA in the sample with a deaminase, and/or before selective amplification of the DNA in the converted sample. In some embodiments, the adapters are added to the DNA after methylation-preserving amplification, after contacting the DNA in the sample with a deaminase, and/or after selective amplification of the DNA in the converted sample.
[0370] In some embodiments, the selective amplification of the DNA in the converted sample comprises amplifying using a uracil-intolerant DNA polymerase.
[0371] In some embodiments, the selective amplification of the DNA in the converted sample comprises contacting the DNA with a uracil-DNA glycosylase (UDG) and amplifying the DNA using an AP site-intolerant DNA polymerase, a uracil-intolerant DNA polymerase, or a DNA polymerase that is an AP site-intolerant DNA polymerase and a uracil-intolerant DNA polymerase. In some embodiments, the contacting the DNA with a UDG converts uracils in the DNA to apyrimidinic sites (AP sites).
[0372] In some embodiments, the UDG is an E. coli UDG.
[0373] In some embodiments, the selective amplification of the DNA in the converted sample comprises contacting the DNA with a UDG; cutting DNA comprising AP sites using an AP lyase; and amplifying DNA that was not cut by the AP lyase using a DNA polymerase. In some embodiments, contacting the DNA with a UDG converts uracils in the DNA to AP sites. In some embodiments, the DNA polymerase is an AP-site intolerant DNA polymerase and/or a uracil- intolerant DNA polymerase.
[0374] In some embodiments, the steps of contacting the DNA with the UDG and cutting DNA comprising the AP sites using the AP lyase are in the same reaction mixture.
[0375] In some embodiments, the DNA in the converted sample comprises adapters. In some embodiments, at least one adapter is at each end of the DNA in the converted sample. In some embodiments, the amplifying DNA that was not cut by the AP lyase using a DNA polymerase comprises amplification using primers (e.g., amplification primers) in which at least one primer binds to at least one site in each adapter. In some embodiments, the amplifying DNA that was not cut by the AP lyase using a DNA polymerase comprises amplification using primers (e.g., amplification primers) that bind to sites in the adapters. In some embodiments, the cutting of the DNA comprising adapters and an AP site using an AP lyase inhibits or reduces amplification relative to amplification of DNA comprising adapters and an AP site that has not been cut using an AP lyase or relative to amplification of the DNA comprising adapters and that does not contain AP sites. In some embodiments, the distance between the adapters after cutting the DNA comprising the AP sites using an AP lyase inhibits or reduces amplification relative to amplification of the DNA containing adapters and comprising the AP site that has not been cut using an AP lyase or relative to amplification of DNA containing adapters and that does not contain AP sites.
[0376] In some embodiments, the AP lyase is endonuclease VIII, formamidopyrimidine (fpg) DNA Glycosylase, thermostable oxoguanine glycosylase (OGG), or any combination thereof. [0377] In some embodiments, the selective amplification of the DNA in the converted sample comprises contacting the DNA with a uracil-specific excision reagent enzyme; cutting the DNA; and amplifying DNA that was not cut by the uracil-specific excision reagent enzyme using a DNA polymerase. In some embodiments, the contacting the DNA with a uracil-specific excision reagent enzyme converts uracils in the DNA to AP sites. In some embodiments, the uracilspecific excision reagent enzyme is USER® (New England Biolabs, Massachusetts, United States). In some embodiments, the DNA polymerase is an AP-site intolerant DNA polymerase or a uracil-intolerant DNA polymerase. In some embodiments, the DNA in the converted sample comprises adapters. In some embodiments, the amplifying DNA that was not cut by the uracilspecific excision reagent enzyme using a DNA polymerase comprises amplification using primers (e.g., amplification primers) in which at least one primer binds at least one site in each adapter. In some embodiments, the amplifying DNA that was not cut by the uracil-specific excision reagent enzyme using a DNA polymerase comprises amplification using primers (e.g., amplification primers) that bind sites in the adapters. In some embodiments, the cutting of the DNA comprising adapters using a uracil-specific excision reagent enzyme inhibits or reduces amplification relative to amplification of the DNA comprising adapters that has not been cut using a uracil-specific excision reagent enzyme. In some embodiments, the distance between the adapters after cutting the DNA using a uracil-specific excision reagent enzyme inhibits or reduces amplification relative to amplification of the DNA containing adapters that has not been cut using a uracil-specific excision reagent enzyme.
[0378] In some embodiments, the selective amplification of the DNA in the converted sample comprises cutting DNA comprising UpGs using a mismatch endonuclease (MME) and amplifying DNA that was not cut by the MME using a DNA polymerase. In some embodiments, the DNA in the converted sample is converted using a dsDNA deaminase. In some embodiments, the DNA in the converted sample comprises adapters. In some embodiments, the amplifying DNA that was not cut by the MME using a DNA polymerase comprises amplification using primers (e.g., amplification primers) in which at least one primer binds at least one site in each adapter. In some embodiments, the amplifying DNA that was not cut by the MME using a DNA polymerase comprises amplification using primers (e.g., amplification primers) that bind sites in the adapters. In some embodiments, the cutting of the DNA comprising adapters using an MME inhibits or reduces amplification relative to amplification of the DNA comprising adapters that has not been cut using an MME. In some embodiments, the distance between the adapters after cutting the DNA using an MME inhibits or reduces amplification relative to amplification of the DNA that has not been cut using a MME.
[0379] In some embodiments, the MME is endonuclease I or Authenticase®. [0380] In some embodiments, the selective amplification of the DNA in the converted sample occurs after enriching the DNA for a plurality of target regions. In some embodiments, the selective amplification of the DNA in the converted sample occurs prior to enriching the DNA for a plurality of target regions. In some embodiments, the selective amplification of the DNA in the converted sample occurs after ligating adapters to the DNA. In some embodiments, the selective amplification of the DNA in the converted sample occurs prior to ligating adapters to the DNA. In some embodiments, the selective amplification of the DNA in the converted sample occurs prior to a step of sequencing the DNA.
[0381] In some embodiments, the uracil-intolerant DNA polymerase used in the amplification reaction may be Q5® High-Fidelity DNA Polymerase, Phusion® High-Fidelity DNA Polymerase, Vent® DNA Polymerase, Vent® (exo-) DNA Polymerase, Deep Vent® DNA Polymerase, Deep Vent® (exo-) DNA Polymerase, or any combination thereof. In some embodiments, the uracil-intolerant DNA polymerase used in the amplification reaction may be an Archaeal uracil -intolerant DNA polymerase, such as a uracil -intolerant DNA polymerase from Pyrococcus furiosus or Methanosarcina acetivorans (see, e.g., Wardle J, Burgers PM, Cann IK, Darley K, Heslop P, Johansson E, Lin LJ, McGlynn P, Sanvoisin J, Stith CM, Connolly BA. Uracil recognition by replicative DNA polymerases is limited to the archaea, not occurring with bacteria and eukarya. Nucleic Acids Res. 2008 Feb;36(3):705-l L). In some embodiments, the Archaeal uracil-intolerant DNA polymerase is a Family B DNA polymerase, such as Pfu-Pol or Mac-Pol.
[0382] In some embodiments, the AP site-intolerant DNA polymerase may be Q5® High- Fidelity DNA Polymerase, Q5U® Hot Start High-Fidelity DNA Polymerase, Phusion® High- Fidelity DNA Polymerase, One/ q" DNA Polymerase, Taq DNA Polymerase, LongAmp® Taq DNA Polymerase, Hemo Klen /i/ , Epimark® Hot Start Taq DNA Polymerase, Bst DNA Polymerase, Full Length, Bst DNA Polymerase, Large Fragment, Bst 2.0 DNA Polymerase, Bst 3.0 DNA Polymerase, Bsu DNA Polymerase, Large Fragment, phi29 DNA Polymerase, phi29-XT DNA Polymerase, Sulfolobus DNA Polymerase IV, Therminator™ DNA Polymerase, T7 DNA Polymerase, DNA Polymerase I (E. coli), DNA Polymerase I, Large (KI enow) Fragment (“KI enow fragment”), KI enow Fragment (3 '— 5' exo-), T4 DNA Polymerase, Vent® DNA Polymerase, Vent® (exo-) DNA Polymerase, Deep Vent® DNA Polymerase, Deep Vent® (exo-) DNA Polymerase, or any combination thereof. [0383] In some embodiments, the DNA polymerase may be Q5® High-Fidelity DNA Polymerase, Q5U® Hot Start High-Fidelity DNA Polymerase, Phusion® High-Fidelity DNA Polymerase, One aq® DNA Polymerase, Taq DNA Polymerase, LongAmp® Taq DNA Polymerase, Hemo Klen 7i«/, Epimark® Hot Start Taq DNA Polymerase, Bst DNA Polymerase, Full Length, Bst DNA Polymerase, Large Fragment, Bst 2.0 DNA Polymerase, Bst 3.0 DNA Polymerase, Bsu DNA Polymerase, Large Fragment, phi29 DNA Polymerase, phi29-XT DNA Polymerase, Sulfolobus DNA Polymerase IV, Therminator™ DNA Polymerase, T7 DNA Polymerase, DNA Polymerase I (E. coli), DNA Polymerase I, Large (Klenow) Fragment (“Klenow fragment”), Klenow Fragment (3 ' — >5' exo-), T4 DNA Polymerase, Vent® DNA Polymerase, Vent® (exo-) DNA Polymerase, Deep Vent® DNA Polymerase, Deep Vent® (exo-) DNA Polymerase, or any combination thereof.
[0384] In some embodiments, DNA can be amplified by methylation-preserving amplification. In some embodiments, the methylation-preserving amplification can occur before the selective amplification of the DNA in a converted sample. In some embodiments, the methylationpreserving amplification can occur after the selective amplification of the DNA in a converted sample.
[0385] Amplification, including methylation-preserving amplification, is typically primed by primers binding to primer binding sites in adapters flanking a DNA molecule to be amplified. Amplification methods can involve cycles of denaturation, annealing and extension, resulting from thermocycling or can be isothermal as in transcription-mediated amplification. For example, DNA flanked by adapters added to the DNA as described herein can be amplified by PCR or other amplification methods. Amplification methods of use herein, including methylation-preserving amplification, can include any suitable methods, such as known to those of ordinary skill in the art. In some embodiments, amplification is primed by primers binding to primer binding sites in adapters flanking a DNA molecule to be amplified. Amplification methods can involve cycles of denaturation, annealing and extension, resulting from thermocycling, such as polymerase chain reaction (PCR), or can be isothermal, such as in linear amplification methods, transcription-mediated amplification, recombinase polymerase amplification (RPA), helices dependent amplification (HDA), loop-mediated isothermal amplification (LAMP) (Notomi et al., Nuc. Acids Res., 28, e63, 2000), rolling-circle amplification (RCA) (Blanco et al., J. Biol. Chem., 264, 8935-8940, 1989), or hyperbranched rolling circle amplification (Lizard et al., Nat. Genetics, 19, 225-232, 1998). Other amplification methods include the ligase chain reaction, strand displacement amplification, nucleic acid sequence-based amplification, and self-sustained sequence based replication. In some embodiments, the methylation-preserving amplification comprises linear amplification with thermocycling.
[0386] In some embodiments, methylation-preserving amplification comprises amplification performed in the presence of a methyltransferase. Methylating agents of use in methylationpreserving amplification methods described herein are known to those of ordinary skill in the art, and can include, for example, any suitable methyltransferase. In some embodiments, the methylating agent is DNMT1. DNMT1 is the most abundant DNA methyltransferase in mammalian cells and predominantly methylates hemimethylated CpG di-nucleotides in the mammalian genome. For example, DNA molecules replicated using PCR amplification with DNMT1 incubation will maintain their methylation status post-amplification, for use in further analyses, such as those described herein (such as an epigenetic base conversion step and/or an enrichment step).
[0387] Additional methylating agents useful herein include the mammalian methyltransferases, DNMT3a and DNMT3b, the plant methyltransferases, MET1, and CMT3. In some embodiments, DNMT1 or another suitable methyltransferase is used with a methyl donor and may be used with or without cofactors known to those of ordinary skill in the art. DNMT1 works in vitro at 95% efficiency without a cofactor; however, DNMT1 may be used with a cofactor such as NP95(Uhrfl), such as described in Bashtrykov PI, et al. “The UHRF1 protein stimulates the activity and specificity of the maintenance DNA methyltransferase DNMT1 by an allosteric mechanism.” J Biol Chem. 2014. In some embodiments, DNMT1 is used at a concentration of about 50-10000 U/mL, such as about 50-2000, about 50-5000, about 2500-7500, or about 5000- 10000 U/mL. In some embodiments, DNMT1 is used at a concentration of about 100-500, about 500-1000, about 100-1000, about 1000-1500, about 500-1500, about 600-1400, about 700-1300, about 800-1200, about 900-1100, or about 950-1050 U/mL. In some embodiments, DNMT1 is used at a concentration of about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, or about 2000 U/mL. In some embodiments, DNMT1 is used at a concentration of about 1,000 U/ml.
[0388] In some embodiments, enriching methylated DNA in a sample comprises amplification, such as embodiments comprising quantitative PCR (qPCR) or digital PCR. Some such embodiments comprising targeted detection of DNA sequences using qPCR or digital PCR do not comprise standard DNA library preparation steps, such as adapter ligation or tagging.
[0389] In some embodiments, the present methods perform dsDNA ligations with T-tailed and C-tailed adapters. The addition of C-tailed adapters can increase ligation efficiency because the A-tailing reaction can also add G-tails to a small portion of the DNA molecules, when the A tailing is performed in the presence of dGTP, such as when the A-tailing is performed in the same reaction as the end repair. The use of T-tailed and C-tailed adapters can result in amplification of at least 50, 60, 70 or 80% of double stranded nucleic acids. The present methods can increase the amount or number of amplified molecules relative to control methods performed with T-tailed adapters alone by at least 10, 15, or 20%.
[0390] In some embodiments, an amplification of the DNA in a sample, such as a converted sample, comprises amplifying rolling-circle amplification (RCA). In some embodiments, RCA comprises circularizing a DNA template (e.g., DNA in the converted sample). In some embodiments, RCA comprises copying the circularized DNA template using a rolling circle polymerase to generate a plurality of circularized DNA templates. In some embodiments, the rolling circle polymerase is a phi29 DNA polymerase. Exemplary methods of RCA are provided, e.g., in Lou et al., Proc. Natl. Acad. Sci. 110 (49) 19872-19877 (2013). In some embodiments, the RCA occurs prior to a step of sequencing the DNA.
[0391] In some embodiments, adapted DNA is amplified before sequencing. This may be an additional amplification step subsequent to an earlier amplification step, such as selective amplification as described elsewhere herein. In some embodiments, amplification of adapted DNA comprises RCA, e.g., as described above. In some embodiments, RCA comprises copying the circularized DNA template using a rolling circle polymerase to generate a plurality of circularized DNA templates. In some embodiments, the rolling circle polymerase is a phi29 DNA polymerase. Amplification may in some cases be before one or more capture steps. In some embodiments, the ligation step occurs after the conversion step. In some embodiments, the ligation occurs before or simultaneously with amplification.
[0392] In some embodiments, sequencing DNA that was amplified using RCA provides sequence reads comprising multiple copies of the sequence of an original sample molecule or converted molecule and the copies are used to determine a consensus sequence of the original sample molecule or converted molecule. I. Enriching, Capturing, and Using Capture Probes
[0393] DNA molecules in a sample can be subjected to a capture step, in which molecules having target sequences are captured for subsequent analysis. In some embodiments, methods disclosed herein comprise a step of capturing one or more sets of target regions of DNA, such as cfDNA. In some embodiments, the capture step (also referred to herein as an “enriching” or “enrichment” step) is performed prior to a step of subjecting the end-repaired DNA molecules to sequencing, prior to a step of selectively amplifying DNA in a converted sample, prior to a step of subjecting a DNA sample to sequencing, and/or prior to a step of subjecting a DNA sample comprising a plurality of DNA molecules to sequencing. Capture may be performed using any suitable approach known in the art. Target capture can involve use of a bait set comprising oligonucleotide baits (a type of probe useful herein) labeled with a capture moiety, such as biotin or the other examples noted below. The probes can have sequences selected to tile across a panel of regions, such as genes. Such bait sets are combined with a sample under conditions that allow hybridization of the target molecules with the baits. Then, captured molecules are isolated using the capture moiety. For example, a biotin capture moiety by bead-based streptavidin. Such methods are further described in, for example, U.S. patent 9,850,523, issuing December 26, 2017, which is incorporated herein by reference.
[0394] Capture moieties include, without limitation, biotin, avidin, streptavidin, a nucleic acid comprising a particular nucleotide sequence, a hapten recognized by an antibody, and magnetically attractable particles. The extraction moiety can be a member of a binding pair, such as biotin/ streptavidin or hapten/antibody. In some embodiments, a capture moiety that is attached to an analyte is captured by its binding pair which is attached to an isolatable moiety, such as a magnetically attractable particle or a large particle that can be sedimented through centrifugation. The capture moiety can be any type of molecule that allows affinity separation of nucleic acids bearing the capture moiety from nucleic acids lacking the capture moiety. Exemplary capture moieties are biotin which allows affinity separation by binding to streptavidin linked or linkable to a solid phase or an oligonucleotide, which allows affinity separation through binding to a complementary oligonucleotide linked or linkable to a solid phase.
[0395] A panel of regions targeted for enrichment can be selected such that they do not contain regions known to include the base modification used in the end repair reaction. When the end repair is performed with dNTPs comprising 5mC or 5hmC, a panel of regions targeted for enrichment may be selected such that they do not contain CpH dinucleotides which are known to be naturally methylated in the subject (e.g. humans). Such CpH dinucleotides can be identified through the use of publicly available resources (e.g. MethBank3.0: a database ofDNA methylomes across a variety of species Nucleic Acids Res 2018). Such an approach has the advantage that any detected methylated CpH dinucleotides can unambiguously be attributed to regions synthesized in the end repair.
[0396] In some embodiments, capturing comprises contacting the DNA to be captured with a set of target-specific probes. The set of target-specific probes may have any of the features described herein for sets of target-specific probes, including but not limited to in the embodiments set forth above and the sections relating to probes below. Capturing may be performed on one or more subsamples prepared during methods disclosed herein. In some embodiments, DNA is captured from at least the first subsample or the second subsample, e.g., at least the first subsample and the second subsample. In some embodiments, the subsamples are differentially tagged (e.g., as described herein) and then pooled before undergoing capture.
[0397] The capturing step may be performed using conditions suitable for specific nucleic acid hybridization, which generally depend to some extent on features of the probes such as length, base composition, etc. Those skilled in the art will be familiar with appropriate conditions given general knowledge in the art regarding nucleic acid hybridization. In some embodiments, complexes of target-specific probes and DNA are formed.
[0398] In some embodiments, a method described herein comprises capturing cfDNA obtained from a subject for a plurality of sets of target regions. The target regions comprise epigenetic target regions, which may show differences in methylation levels and/or fragmentation patterns depending on whether they originated from a tumor or from healthy cells. The target regions also comprise sequence-variable target regions, which may show differences in sequence depending on whether they originated from a tumor or from healthy cells. The capturing step produces a captured set of cfDNA molecules, and the cfDNA molecules corresponding to the sequencevariable target region set are captured at a greater capture yield in the captured set of cfDNA molecules than cfDNA molecules corresponding to the epigenetic target region set. For additional discussion of capturing steps, capture yields, and related aspects, see W02020/160414, which is incorporated herein by reference for all purposes.
[0399] In some embodiments, a method described herein comprises contacting cfDNA obtained from a subject with a set of target-specific probes, wherein the set of target-specific probes is configured to capture cfDNA corresponding to the sequence-variable target region set at a greater capture yield than cfDNA corresponding to the epigenetic target region set.
[0400] It can be beneficial to capture cfDNA corresponding to the sequence-variable target region set at a greater capture yield than cfDNA corresponding to the epigenetic target region set because a greater depth of sequencing may be necessary to analyze the sequence-variable target regions with sufficient confidence or accuracy than may be necessary to analyze the epigenetic target regions. The volume of data needed to determine fragmentation patterns (e.g., to test fsor perturbation of transcription start sites or CTCF binding sites) or fragment abundance (e.g., in hypermethylated and hypomethylated partitions) is generally less than the volume of data needed to determine the presence or absence of cancer-related sequence mutations. Capturing the target region sets at different yields can facilitate sequencing the target regions to different depths of sequencing in the same sequencing run (e.g., using a pooled mixture and/or in the same sequencing cell).
[0401] In various embodiments, the methods further comprise sequencing the captured cfDNA, e.g., to different degrees of sequencing depth for the epigenetic and sequence-variable target region sets, consistent with the discussion herein.
[0402] In some embodiments, complexes of target-specific probes and DNA are separated from DNA not bound to target-specific probes. For example, where target-specific probes are bound covalently or noncovalently to a solid support, a washing or aspiration step can be used to separate unbound material. Alternatively, where the complexes have chromatographic properties distinct from unbound material (e.g., where the probes comprise a ligand that binds a chromatographic resin), chromatography can be used.
[0403] As discussed in detail elsewhere herein, the set of target-specific probes may comprise a plurality of sets such as probes for a sequence-variable target region set and probes for an epigenetic target region set. In some such embodiments, the capturing step is performed with the probes for the sequence-variable target region set and the probes for the epigenetic target region set in the same vessel at the same time, e.g., the probes for the sequence-variable and epigenetic target region sets are in the same composition. This approach provides a relatively streamlined workflow. In some embodiments, the concentration of the probes for the sequence-variable target region set is greater than the concentration of the probes for the epigenetic target region set. [0404] Alternatively, the capturing step is performed with the sequence-variable target region probe set in a first vessel and with the epigenetic target region probe set in a second vessel, or the contacting step is performed with the sequence-variable target region probe set at a first time and a first vessel and the epigenetic target region probe set at a second time before or after the first time. This approach allows for preparation of separate first and second compositions comprising captured DNA corresponding to the sequence-variable target region set and captured DNA corresponding to the epigenetic target region set. The compositions can be processed separately as desired (e.g., to fractionate based on methylation as described elsewhere herein) and recombined in appropriate proportions to provide material for further processing and analysis such as sequencing.
[0405] In some embodiments, a captured set of DNA (e.g., cfDNA) is provided. With respect to the disclosed methods, the captured set of DNA may be provided, e g., by performing a capturing step prior to a sequencing step as described herein. The captured set may comprise DNA corresponding to a sequence-variable target region set, an epigenetic target region set, or a combination thereof. In some embodiments, a capture step is performed prior to a conversion step or after a conversion step.
[0406] In some embodiments, a first target region set is captured (e.g., from a sample or a first subsample), comprising at least epigenetic target regions. The epigenetic target regions captured from the first subsample may comprise hypermethylation variable target regions. In some embodiments, the hypermethylation variable target regions are CpG-containing regions that are unmethylated or have low methylation in cfDNA from healthy subjects (e.g., below-average methylation relative to bulk cfDNA). In some embodiments, the hypermethylation variable target regions are regions that show lower methylation in healthy cfDNA than in at least one other tissue type. Without wishing to be bound by any particular theory, cancer cells may shed more DNA into the bloodstream than healthy cells of the same tissue type. As such, the distribution of tissue of origin of cfDNA may change upon carcinogenesis. Thus, an increase in the level of hypermethylation variable target regions in the first subsample can be an indicator of the presence (or recurrence, depending on the history of the subject) of cancer.
[0407] In some embodiments, a second target region set is captured from the second subsample, comprising at least epigenetic target regions. The epigenetic target regions may comprise hypomethylation variable target regions. In some embodiments, the hypomethylation variable target regions are CpG-containing regions that are methylated or have high methylation in cfDNA from healthy subjects (e.g., above-average methylation relative to bulk cfDNA). In some embodiments, the hypomethylation variable target regions are regions that show higher methylation in healthy cfDNA than in at least one other tissue type. Without wishing to be bound by any particular theory, cancer cells may shed more DNA into the bloodstream than healthy cells of the same tissue type. As such, the distribution of tissue of origin of cfDNA may change upon carcinogenesis. Thus, an increase in the level of hypomethylation variable target regions in the second subsample can be an indicator of the presence (or recurrence, depending on the history of the subject) of cancer.
[0408] In some embodiments the quantity of captured sequence-variable target region DNA is greater than the quantity of the captured epigenetic target region DNA, when normalized for the difference in the size of the targeted regions (footprint size).
[0409] Alternatively, first and second captured sets may be provided, comprising, respectively, DNA corresponding to a sequence-variable target region set and DNA corresponding to an epigenetic target region set. The first and second captured sets may be combined to provide a combined captured set.
[0410] In some embodiments, a probe (e.g., a capture probe) is specific for members of an epigenetic target region set that includes only methylated DNA molecules. In some embodiments, the methylated DNA molecules comprise methylated cytosines. In some embodiments, the methylated cytosines are in CpG dinucleotides. In some embodiments, a probe (e.g., a capture probe) is specific for members of an epigenetic target region set that includes only unmethylated DNA molecules. In some embodiments, the unmethylated DNA molecules comprise uracils as a result of the conversion of unmethylated cytosines. In some embodiments, the unmethylated molecules comprise thymines as a result of the conversion of methylated cytosines. In some embodiments, the uracils are in UpG dinucleotides. In some embodiments, the thymines are in TpG dinucleotides. In some embodiments, a probe (e.g., a capture probe) captures both unmethylated and methylated DNA molecules.
[0411] In some embodiments in which a captured set comprising DNA corresponding to the sequence-variable target region set and the epigenetic target region set includes a combined captured set as discussed above, the DNA corresponding to the sequence-variable target region set may be present at a greater concentration than the DNA corresponding to the epigenetic target region set, e g., a 1.1 to 1.2-fold greater concentration, a 1.2- to 1.4-fold greater concentration, a 1.4- to 1.6-fold greater concentration, a 1.6- to 1.8-fold greater concentration, a 1.8- to 2.0-fold greater concentration, a 2.0- to 2.2-fold greater concentration, a 2.2- to 2.4-fold greater concentration a 2.4- to 2.6-fold greater concentration, a 2.6- to 2.8-fold greater concentration, a 2.8- to 3.0-fold greater concentration, a 3.0- to 3.5-fold greater concentration, a 3.5- to 4.0, a 4.0- to 4.5-fold greater concentration, a 4.5- to 5.0-fold greater concentration, a 5.0- to 5.5-fold greater concentration, a 5.5- to 6.0-fold greater concentration, a 6.0- to 6.5-fold greater concentration, a 6.5- to 7.0-fold greater, a 7.0- to 7.5-fold greater concentration, a 7.5- to 8.0-fold greater concentration, an 8.0- to 8.5-fold greater concentration, an 8.5- to 9.0-fold greater concentration, a 9.0- to 9.5-fold greater concentration, 9.5- to 10.0-fold greater concentration, a 10- to 11 -fold greater concentration, an 11- to 12-fold greater concentration a 12- to 13-fold greater concentration, a 13- to 14-fold greater concentration, a 14- to 15-fold greater concentration, a 15- to 16-fold greater concentration, a 16- to 17-fold greater concentration, a 17- to 18-fold greater concentration, an 18- to 19-fold greater concentration, a 19- to 20-fold greater concentration, a 20- to 30-fold greater concentration, a 30- to 40-fold greater concentration, a 40- to 50-fold greater concentration, a 50- to 60-fold greater concentration, a 60- to 70-fold greater concentration, a 70- to 80-fold greater concentration, a 80- to 90-fold greater concentration, or a 90- to 100-fold greater concentration. The degree of difference in concentrations accounts for normalization for the footprint sizes of the target regions, as discussed in the definition section.
[0412] In some embodiments, the DNA that is captured comprises intronic regions. In some embodiments, the intronic regions comprise one or more introns likely to differentiate DNA from neoplastic (e.g., tumor or cancer) cells and from healthy cells, e.g., non-neoplastic circulating cells. For example, an intron comprising a rearrangement known to be present in some neoplastic cells and absent from healthy cells can be used to differentiate DNA from neoplastic (e.g., tumor or cancer) cells and from healthy cells. In some embodiments, the rearrangement is a translocation.
[0413] In some embodiments, captured intronic regions have a footprint of at least 30 bp, e.g., at least 100 bp, at least 200 bp, at least 500 bp, at least 1 kb, at least 2 kb, at least 5 kb, at least 10 kb, at least 20 kb, at least 50 kb, at least 200 kb, at least 300 kb, or at least 400 kb. In some embodiments, the intronic target region set has a footprint in the range of 30 bp- 1000 kb, e.g., 30 bp-100 bp, 100 bp-200 bp, 200 bp-500 bp, 500 bp-lkb, 1 kb-2 kb, 2 kb-5 kb, 5 kb-10 kb, 10 kb- 20 kb, 20 kb-50 kb, 50 kb-100 kb, 100-200 kb, 200-300 kb, 300-400 kb, 400-500 kb, 500-600 kb, 600-700 kb, 700-800 kb, 800-900 kb, and 900-1,000 kb.
[0414] Exemplary rearrangements, such as intronic translocations that can be detected using the methods described herein include but are not limited to translocations wherein at least one of the two genes involved in the translocation is a receptor tyrosine kinase. Exemplary translocation products are the BCR-ABL fusion, and fusions comprising any of ALK, FGFR2, FGFR3, NTRK1, RET, or ROSE
[0415] In some embodiments, the DNA that is captured comprises target regions having a typespecific epigenetic variation. In some embodiments, an epigenetic target region set consists of target regions having a type-specific epigenetic variation. In some embodiments, the typespecific epigenetic variations, e.g., differential methylation or a type-specific fragmentation pattern, are likely to differentiate DNA from one or more related cell or tissue types cells from DNA from other cell or tissue types present in a sample or in a subject.
[0416] In some embodiments, nucleic acids captured or enriched using a method described herein comprise captured DNA, such as one or more captured sets of DNA. In some embodiments, the captured DNA comprise target regions that are differentially methylated in different immune cell types. In some embodiments, the immune cell types comprise rare or closely related immune cell types, such as activated and naive lymphocytes or myeloid cells at different stages of differentiation.
[0417] In some embodiments, a captured epigenetic target region set captured from a sample or a subsample comprises genomic regions that show no or negligible methylation signal when analyzing cell-free DNA (cfDNA) from healthy individuals (e g. in blood) but exhibit detectable methylation when analyzing cfDNA from individuals with cancer. Such regions are characterized by low background methylation levels in healthy populations, thereby providing an enhanced contrast that facilitates sensitive detection of tumor-derived DNA. In some embodiments, a captured epigenetic target region set captured from a sample or a subsample comprises genomic regions that show no or negligible methylation signal for a particular cell or tissue type (e.g., lung tissue) when analyzing cell-free DNA (cfDNA) from healthy individuals (e.g. in blood) but exhibit detectable methylation when analyzing cfDNA from individuals with disease associated with that particular cell or tissue type (e.g., if the tissue type is lung, then the disease can be lung cancer or pulmonary disorder).
[0418] In some embodiments, a captured epigenetic target region set captured from a sample or first subsample comprises hypermethylation variable target regions. In some embodiments, the hypermethylation variable target regions are differentially or exclusively hypermethylated in one or more related cell or tissue types. In some embodiments, the hypermethylation variable target regions are differentially or exclusively hypermethylated in one cell type or in one immune cell type, or in one immune cell type within a cluster. In some embodiments, the hypermethylation variable target regions are hypermethylated to an extent that is distinguishably higher or exclusively present in one cell type or one immune cell type or one immune cell type within a cluster. Such hypermethylation variable target regions may be hypermethylated in other cell or tissue types but not to the extent observed in the one or more related cell or tissue types. In some embodiments, the hypermethylation variable target regions show lower methylation in healthy cfDNA than in at least one other tissue type. In some embodiments, the hypermethylation variable target regions show even higher methylation in cfDNA from a diseased cell of the one or more related cell or tissue types. In some embodiments, target regions comprise hypermethylated regions with aberrantly high copy number. In some such embodiments, the target regions are hypermethylated in healthy and diseased colon tissue and have aberrantly high copy number in pre-cancerous or cancerous colon tissue. Examples of such target regions are shown in Table 2 below. A gene is considered to comprise a DMR when the DMR is located within an untranslated region (UTR), intron, or exon of the gene, or within 5000 nucleotides of either the 5’ end of the sense strand of the 5’ UTR or the 3’ end of the sense strand of the 3’ UTR.
[0419] Table 2: Hypermethylated target regions with aberrantly high copy number in colon cancer or pre-cancer
[0420] Table 3. Exemplary Hypermethylation Target Regions based on Lung Cancer studies [0421] In some embodiments, a captured epigenetic target region set captured from a sample or subsample comprises hypomethylation variable target regions. In some embodiments, the hypomethylation variable target regions are exclusively hypomethylated in one or more related cell or tissue types. In some embodiments, the hypomethylation variable target regions are exclusively hypomethylated in one cell type or in one immune cell type or in one immune cell type within a cluster. In some embodiments, the hypomethylation variable target regions are hypomethylated to an extent that is exclusively present in one cell type or one immune cell type or in one immune cell type within a cluster. Such hypomethylation variable target regions may be hypomethylated in other cell or tissue types but not to the extent observed in the one or more cell or tissue types. In some embodiments, the hypomethylation variable target regions show higher methylation in healthy cfDNA than in at least one other tissue type.
[0422] Without wishing to be bound by any particular theory, in an individual with cancer, proliferating or activated immune cells and/or dying cancer cells may shed more DNA into the bloodstream than immune cells in a healthy individual and/or healthy cells of the same tissue type, respectively. As such, the distribution of cell type and/or tissue of origin of cfDNA may change upon carcinogenesis. Thus, the presence and/or levels of cfDNA originating from certain cell or tissue types can be an indicator of disease. Variations in hypermethylation and/or hypomethylation can be an indicator of disease. For example, an increase in the level of hypermethylation variable target regions and/or hypomethylation variable target regions in a subsample following a partitioning step can be an indicator of the presence (or recurrence, depending on the history of the subject) of cancer.
[0423] Exemplary hypermethylation variable target regions and hypomethylation variable target regions useful for distinguishing between various cell types, including but not limited to immune cell types, have been identified by analyzing DNA obtained from various cell types via whole genome bisulfite sequencing, as described, e.g., in Scott, C. A , Duryea, J.D., MacKay, H. et al., “Identification of cell type-specific methylation signals in bulk whole genome bisulfite sequencing data,” Genome Biol 21, 156 (2020) (doi.org/10.1186/sl3059-020-02065-5). Wholegenome bisulfite sequencing data is available from the Blueprint consortium, available on the internet at dcc.blueprint-epigenome.eu.
[0424] In some embodiments, first and second captured target region sets comprise, respectively, DNA corresponding to a sequence-variable target region set and DNA corresponding to an epigenetic target region set, for example, as described in WO 2020/160414. The first and second captured sets may be combined to provide a combined captured set. The sequence-variable target region set and epigenetic target region set may have any of the features described for such sets in WO 2020/160414, which is incorporated by reference herein in its entirety. In some embodiments, the epigenetic target region set comprises a hypermethylation variable target region set. In some embodiments, the epigenetic target region set comprises a hypomethylation variable target region set. In some embodiments, the epigenetic target region set comprises CTCF binding regions. In some embodiments, the epigenetic target region set comprises fragmentation variable target regions. In some embodiments, the epigenetic target region set comprises transcriptional start sites. In some embodiments, the epigenetic target region set comprises regions that may show focal amplifications in cancer, e.g., one or more of AR, BRAF, CCND1, CCND2, CCNE1, CDK4, CDK6, EGFR, ERBB2, FGFR1, FGFR2, KIT, KRAS, MET, MYC, PDGFRA, PIK3CA, and RAFI. For example, in some embodiments, the epigenetic target region set comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 of the foregoing targets.
[0425] In some embodiments, the sequence-variable target region set comprises a plurality of regions known to undergo somatic mutations in cancer. In some aspects, the sequence-variable target region set targets a plurality of different genes or genomic regions (“panel”) selected such that a determined proportion of subjects having a cancer exhibits a genetic variant or tumor marker in one or more different genes or genomic regions in the panel. The panel may be selected to limit a region for sequencing to a fixed number of base pairs. The panel may be selected to sequence a desired amount of DNA, e.g., by adjusting the affinity and/or amount of the probes as described elsewhere herein. The panel may be further selected to achieve a desired sequence read depth. The panel may be selected to achieve a desired sequence read depth or sequence read coverage for an amount of sequenced base pairs. The panel may be selected to achieve a theoretical sensitivity, a theoretical specificity, and/or a theoretical accuracy for detecting one or more genetic variants in a sample.
[0426] Probes for detecting the panel of regions can include those for detecting genomic regions of interest (hotspot regions). Information about chromatin structure can be taken into account in designing probes, and/or probes can be designed to maximize the likelihood that particular sites (e.g., KRAS codons 12 and 13) can be captured, and may be designed to optimize capture based on analysis of cfDNA coverage and fragment size variation impacted by nucleosome binding patterns and GC sequence composition. Regions used herein can also include non-hotspot regions optimized based on nucleosome positions and GC models.
[0427] Probes for detecting the panel of regions can include those for detecting genomic regions of interest (hotspot regions). Information about chromatin structure can be taken into account in designing probes, and/or probes can be designed to maximize the likelihood that particular sites (e.g., KRAS codons 12 and 13) can be captured, and may be designed to optimize capture based on analysis of cfDNA coverage and fragment size variation impacted by nucleosome binding patterns and GC sequence composition. Regions used herein can also include non-hotspot regions optimized based on nucleosome positions and GC models.
[0428] Examples of listings of genomic locations of interest may be found in Table 3 and Table 4 of WO 2020/160414. In some embodiments, a sequence-variable target region set used in the methods of the present disclosure comprises at least a portion of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, or 70 of the genes of Table 3 of WO 2020/160414. In some embodiments, a sequence-variable target region set used in the methods of the present disclosure comprises at least a portion of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, or 73 of the genes of Table 4 of WO 2020/160414. Additionally or alternatively, suitable target region sets are available from the literature. For example, Gale et al., PLoS One 13: e0194630 (2018), which is incorporated herein by reference, describes a panel of 35 cancer-related gene targets that can be used as part or all of a sequence-variable target region set. These 35 targets are AKT1, ALK, BRAF, CCND1, CDK2A, CTNNB1, EGFR, ERBB2, ESRI, FGFR1, FGFR2, FGFR3, FOXL2, GAT A3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MED 12, MET, MYC, NFE2L2, NRAS, PDGFRA, PIK3CA, PPP2R1A, PTEN, RET, STK11, TP53, and U2AF1.
[0429] In some embodiments, the sequence-variable target region set comprises target regions from at least 10, 20, 30, or 35 cancer-related genes, such as the cancer-related genes listed above and in WO 2020/160414.
[0430] In some embodiments, a collection of capture probes is used in methods described herein, e.g., comprising capture probes prepared by any method disclosed herein for doing so. In some embodiments, the collection of capture probes further comprises target-binding probes specific for a sequence-variable target region set and/or target-binding probes specific for an epigenetic target region set. In some embodiments, the capture yield of the target-binding probes specific for the sequence-variable target region set is higher (e.g., at least 2-fold higher) than the capture yield of the target-binding probes specific for the epigenetic target region set. In some embodiments, the collection of capture probes is configured to have a capture yield specific for the sequence-variable target region set higher (e.g., at least 2-fold higher) than its capture yield specific for the epigenetic target region set.
[0431] In some embodiments, the capture yield of the target-binding probes specific for the sequence-variable target region set is at least 1.25-, 1.5-, 1.75-, 2-, 2.25-, 2.5-, 2.75-, 3-, 3.5-, 4-,
4.5-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, 14-, or 15-fold higher than the capture yield of the target -binding probes specific for the epigenetic target region set. In some embodiments, the capture yield of the target-binding probes specific for the sequence-variable target region set is 1.25- to 1.5-, 1.5- to 1.75-, 1.75- to 2-, 2- to 2.25-, 2.25- to 2.5-, 2.5- to 2.75-, 2.75- to 3-, 3- to
3.5-, 3.5- to 4-, 4- to 4.5-, 4.5- to 5-, 5- to 5.5-, 5.5- to 6-, 6- to 7-, 7- to 8-, 8- to 9-, 9- to 10-, 10- to 11-, 11- to 12-, 13- to 14-, or 14- to 15-fold higher than the capture yield of the target-binding probes specific for the epigenetic target region set.
[0432] In some embodiments, the collection of capture probes is configured to have a capture yield specific for the sequence-variable target region set at least 1.25-, 1.5-, 1.75-, 2-, 2.25-, 2.5-, 2.75-, 3-, 3.5-, 4-, 4.5-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, 14-, or 15-fold higher than its capture yield for the epigenetic target region set. In some embodiments, the collection of capture probes is configured to have a capture yield specific for the sequence-variable target region set is 1.25- to 1.5-, 1.5- to 1.75-, 1.75- to 2-, 2- to 2.25-, 2.25- to 2.5-, 2.5- to 2.75-, 2.75- to 3-, 3- to 3.5-,
3.5- to 4-, 4- to 4.5-, 4.5- to 5-, 5- to 5.5-, 5.5- to 6-, 6- to 7-, 7- to 8-, 8- to 9-, 9- to 10-, 10- to 11-, 11- to 12-, 13- to 14-, or 14- to 15-fold higher than its capture yield specific for the epigenetic target region set.
[0433] The collection of probes can be configured to provide higher capture yields for the sequence-variable target region set in various ways, including concentration, different lengths and/or chemistries (e.g., that affect affinity), and combinations thereof. Affinity can be modulated by adjusting probe length and/or including nucleotide modifications as discussed below.
[0434] In some embodiments, the capture probes specific for the sequence-variable target region set are present at a higher concentration than the capture probes specific for the epigenetic target region set. In some embodiments, concentration of the target-binding probes specific for the sequence-variable target region set is at least 1.25-, 1.5-, 1.75-, 2-, 2.25-, 2.5-, 2.75-, 3-, 3.5-, 4-, 4.5-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, 14-, or 15-fold higher than the concentration of the target-binding probes specific for the epigenetic target region set. In some embodiments, the concentration of the target-binding probes specific for the sequence-variable target region set is 1.25- to 1.5-, 1.5- to 1.75-, 1.75- to 2-, 2- to 2.25-, 2.25- to 2.5-, 2.5- to 2.75-, 2.75- to 3-, 3- to
3.5-, 3.5- to 4-, 4- to 4.5-, 4.5- to 5-, 5- to 5.5-, 5.5- to 6-, 6- to 7-, 7- to 8-, 8- to 9-, 9- to 10-, 10- to 11-, 11- to 12-, 13- to 14-, or 14- to 15-fold higher than the concentration of the target-binding probes specific for the epigenetic target region set. In such embodiments, concentration may refer to the average mass per volume concentration of individual probes in each set.
[0435] In some embodiments, the capture probes specific for the sequence-variable target region set have a higher affinity for their targets than the capture probes specific for the epigenetic target region set. Affinity can be modulated in any way known to those skilled in the art, including by using different probe chemistries. For example, certain nucleotide modifications, such as cytosine 5-methylation (in certain sequence contexts), modifications that provide a heteroatom at the 2’ sugar position, and LNA nucleotides, can increase stability of doublestranded nucleic acids, indicating that oligonucleotides with such modifications have relatively higher affinity for their complementary sequences. See, e.g., Severin et al., Nucleic Acids Res. 39: 8740-8751 (2011); Freier et al., Nucleic Acids Res. 25: 4429-4443 (1997); US Patent No. 9,738,894. Also, longer sequence lengths will generally provide increased affinity. Other nucleotide modifications, such as the substitution of the nucleobase hypoxanthine for guanine, reduce affinity by reducing the amount of hydrogen bonding between the oligonucleotide and its complementary sequence. In some embodiments, the capture probes specific for the sequencevariable target region set have modifications that increase their affinity for their targets. In some embodiments, alternatively or additionally, the capture probes specific for the epigenetic target region set have modifications that decrease their affinity for their targets. In some embodiments, the capture probes specific for the sequence-variable target region set have longer average lengths and/or higher average melting temperatures than the capture probes specific for the epigenetic target region set. These embodiments may be combined with each other and/or with differences in concentration as discussed above to achieve a desired fold difference in capture yield, such as any fold difference or range thereof described above.
[0436] In some embodiments, the capture probes comprise a capture moiety. The capture moiety may be any of the capture moieties described herein, e.g., biotin. In some embodiments, the capture probes are linked to a solid support, e.g., covalently or non-covalently such as through the interaction of a binding pair of capture moieties. In some embodiments, the solid support is a bead, such as a magnetic bead.
[0437] In some embodiments, the capture probes specific for the sequence-variable target region set and/or the capture probes specific for the epigenetic target region set are a capture probe set as discussed above, e.g., probes comprising capture moieties and sequences selected to tile across a panel of regions, such as genes.
[0438] In some embodiments, the capture probes are provided in a single composition. The single composition may be a solution (liquid or frozen). Alternatively, it may be a lyophilizate. [0439] Alternatively, the capture probes may be provided as a plurality of compositions, e.g., comprising a first composition comprising probes specific for the epigenetic target region set and a second composition comprising probes specific for the sequence-variable target region set.
These probes may be mixed in appropriate proportions to provide a combined probe composition with any of the foregoing fold differences in concentration and/or capture yield. Alternatively, they may be used in separate capture procedures (e.g., with aliquots of a sample or sequentially with the same sample) to provide first and second compositions comprising captured epigenetic target regions and sequence-variable target regions, respectively.
1. Probes specific for epigenetic target regions
[0440] The probes for the epigenetic target region set may comprise probes specific for one or more types of target regions likely to differentiate DNA from neoplastic (e.g., tumor or cancer) cells from healthy cells, e.g., non-neoplastic circulating cells. Exemplary types of such regions are discussed in detail herein, e.g., in the sections above concerning captured sets. The probes for the epigenetic target region set may also comprise probes for one or more control regions, e.g., as described herein.
[0441] In some embodiments, the probes for the epigenetic target region set have a footprint of at least 100 kbp, e.g., at least 200 kbp, at least 300 kbp, or at least 400 kbp. In some embodiments, the epigenetic target region set has a footprint in the range of 100-20 Mbp, e.g., 100-200 kbp, 200-300 kbp, 300-400 kbp, 400-500 kbp, 500-600 kbp, 600-700 kbp, 700-800 kbp, 800-900 kbp, 900-1,000 kbp, 1-1.5 Mbp, 1.5-2 Mbp, 2-3 Mbp, 3-4 Mbp, 4-5 Mbp, 5-6 Mbp, 6-7 Mbp, 7-8 Mbp, 8-9 Mbp, 9-10 Mbp, or 10-20 Mbp. In some embodiments, the epigenetic target region set has a footprint of at least 20 Mbp. a. Hypermethylation variable target regions
[0442] In some embodiments, the probes for the epigenetic target region set comprise probes specific for one or more hypermethylation variable target regions. Hypermethylation variable target regions may also be referred to herein as hypermethylated DMRs (differentially methylated regions). The hypermethylation variable target regions may be any of those set forth above. For example, in some embodiments, the probes specific for hypermethylation variable target regions comprise probes specific for a plurality of loci listed in Table 2, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the loci listed in Table 2. In some embodiments, the probes specific for hypermethylation variable target regions comprise probes specific for a plurality of loci listed in Table 3, e g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the loci listed in Table 3. In some embodiments, the probes specific for hypermethylation variable target regions comprise probes specific for a plurality of loci listed in Table 2 or Table 3, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the loci listed in Table 2 or Table 3. In some embodiments, for each locus included as a target region, there may be one or more probes with a hybridization site that binds between the transcription start site and the stop codon (the last stop codon for genes that are alternatively spliced) of the gene. In some embodiments, the one or more probes bind within 300 bp of the listed position, e.g., within 200 or 100 bp. In some embodiments, a probe has a hybridization site overlapping the position listed above. In some embodiments, the probes specific for the hypermethylation target regions include probes specific for one, two, three, four, or five subsets of hypermethylation target regions that collectively show hypermethylation in one, two, three, four, or five of breast, colon, kidney, liver, and lung cancers. b. Hypomethylation variable target regions
[0443] In some embodiments, the probes for the epigenetic target region set comprise probes specific for one or more hypomethylation variable target regions. Hypomethylation variable target regions may also be referred to herein as hypomethylated DMRs (differentially methylated regions). The hypomethylation variable target regions may be any of those set forth above. For example, the probes specific for one or more hypomethylation variable target regions may include probes for regions such as repeated elements, e.g., LINE1 elements, Alu elements, centromeric tandem repeats, peri centromeric tandem repeats, and satellite DNA, and intergenic regions that are ordinarily methylated in healthy cells may show reduced methylation in tumor cells.
[0444] In some embodiments, probes specific for hypomethylation variable target regions include probes specific for repeated elements and/or intergenic regions. In some embodiments, probes specific for repeated elements include probes specific for one, two, three, four, or five of LINE1 elements, Alu elements, centromeric tandem repeats, pericentromeric tandem repeats, and/or satellite DNA.
[0445] Exemplary probes specific for genomic regions that show cancer-associated hypomethylation include probes specific for nucleotides 8403565-8953708 and/or 151104701- 151106035 of human chromosome 1. In some embodiments, the probes specific for hypomethylation variable target regions include probes specific for regions overlapping or comprising nucleotides 8403565-8953708 and/or 151104701-151106035 of human chromosome 1. c. CTCF binding regions
[0446] In some embodiments, the probes for the epigenetic target region set include probes specific for CTCF binding regions. In some embodiments, the probes specific for CTCF binding regions comprise probes specific for at least 10, 20, 50, 100, 200, or 500 CTCF binding regions, or 10-20, 20-50, 50-100, 100-200, 200-500, or 500-1000 CTCF binding regions, e g., such as CTCF binding regions described above or in one or more of CTCFBSDB or the Cuddapah et al., Martin et al., or Rhee et al. articles cited above. In some embodiments, the probes for the epigenetic target region set comprise at least 100 bp, at least 200 bp at least 300 bp, at least 400 bp, at least 500 bp, at least 750 bp, or at least 1000 bp upstream and downstream regions of the CTCF binding sites. d. Transcription start sites
[0447] In some embodiments, the probes for the epigenetic target region set include probes specific for transcriptional start sites. In some embodiments, the probes specific for transcriptional start sites comprise probes specific for at least 10, 20, 50, 100, 200, or 500 transcriptional start sites, or 10-20, 20-50, 50-100, 100-200, 200-500, or 500-1000 transcriptional start sites, e.g., such as transcriptional start sites listed in DBTSS. In some embodiments, the probes for the epigenetic target region set comprise probes for sequences at least 100 bp, at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 750 bp, or at least 1000 bp upstream and downstream of the transcriptional start sites. e. Focal amplifications
[0448] As noted above, although focal amplifications are somatic mutations, they can be detected by sequencing based on read frequency in a manner analogous to approaches for detecting certain epigenetic changes such as changes in methylation. As such, regions that may show focal amplifications in cancer can be included in the epigenetic target region set, as discussed above. In some embodiments, the probes specific for the epigenetic target region set include probes specific for focal amplifications. In some embodiments, the probes specific for focal amplifications include probes specific for one or more of AR, BRAF, CCND1, CCND2, CCNE1, CDK4, CDK6, EGFR, ERBB2, FGFR1, FGFR2, KIT, KRAS, MET, MYC, PDGFRA, PIK3CA, and RAFI. For example, in some embodiments, the probes specific for focal amplifications include probes specific for one or more of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 of the foregoing targets. f. Control regions
[0449] It can be useful to include control regions to facilitate data validation. In some embodiments, the probes specific for the epigenetic target region set include probes specific for control methylated regions that are expected to be methylated in essentially all samples. In some embodiments, the probes specific for the epigenetic target region set include probes specific for control hypomethylated regions that are expected to be hypomethylated in essentially all samples.
2. Probes specific for sequence-variable target regions
[0450] The probes for the sequence-variable target region set may comprise probes specific for a plurality of regions known to undergo somatic mutations in cancer. The probes may be specific for any sequence-variable target region set described herein. Exemplary sequence-variable target region sets are discussed in detail herein, e.g., in the sections above concerning captured sets.
[0451] In some embodiments, the sequence-variable target region probe set has a footprint of at least 0.5 kb, e g., at least 1 kb, at least 2 kb, at least 5 kb, at least 10 kb, at least 20 kb, at least 30 kb, or at least 40 kb. In some embodiments, the epigenetic target region probe set has a footprint in the range of 0.5-100 kb, e.g., 0.5-2 kb, 2-10 kb, 10-20 kb, 20-30 kb, 30-40 kb, 40-50 kb, 50-60 kb, 60-70 kb, 70-80 kb, 80-90 kb, and 90-100 kb. In some embodiments, the sequence-variable target region probe set has a footprint of at least 50 kbp, e.g., at least 100 kbp, at least 200 kbp, at least 300 kbp, or at least 400 kbp. In some embodiments, the sequence-variable target region probe set has a footprint in the range of 100-2000 kbp, e.g., 100-200 kbp, 200-300 kbp, 300-400 kbp, 400-500 kbp, 500-600 kbp, 600-700 kbp, 700-800 kbp, 800-900 kbp, 900-1,000 kbp, 1-1.5 Mbp or 1.5-2 Mbp. In some embodiments, the sequence-variable target region set has a footprint of at least 2 Mbp.
[0452] In some embodiments, probes specific for the sequence-variable target region set comprise probes specific for at least a portion of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, or at 70 of the genes of Table 4. In some embodiments, probes specific for the sequencevariable target region set comprise probes specific for the at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, or 70 of the SNVs of Table 4. In some embodiments, probes specific for the sequence-variable target region set comprise probes specific for at least 1, at least 2, at least 3, at least 4, at least 5, or 6 of the fusions of Table 4. In some embodiments, probes specific for the sequence-variable target region set comprise probes specific for at least a portion of at least 1, at least 2, or 3 of the indels of Table 4. In some embodiments, probes specific for the sequencevariable target region set comprise probes specific for at least a portion of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, or 73 of the genes of Table 5. In some embodiments, probes specific for the sequence-variable target region set comprise probes specific for at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, or 73 of the SNVs of Table 5. In some embodiments, probes specific for the sequence-variable target region set comprise probes specific for at least 1 , at least 2, at least 3, at least 4, at least 5, or 6 of the fusions of Table 5. In some embodiments, probes specific for the sequence-variable target region set comprise probes specific for at least a portion of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, or 18 of the indels of Table 5. In some embodiments, probes specific for the sequence-variable target region set comprise probes specific for at least a portion of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 of the genes of Table 6.
[0453] Table 4
[0454] Table 5
[0455] Table 6
[0456] In some embodiments, the probes specific for the sequence-variable target region set comprise probes specific for target regions from at least 10, 20, 30, or 35 cancer-related genes, such as AKT1, ALK, BRAF, CCND1, CDK2A, CTNNB1, EGFR, ERBB2, ESRI, FGFR1, FGFR2, FGFR3, FOXL2, GATA3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MED12, MET, MYC, NFE2L2, NRAS, PDGFRA, PIK3CA, PPP2R1 A, PTEN, RET, STK11, TP53, and U2AFl. J. Sequencing
[0457] In general, sample nucleic acids flanked by adapters with or without prior amplification can be subject to sequencing. Sequencing methods include, for example, Sanger sequencing, high-throughput sequencing, pyrosequencing, sequencing-by-synthesis, long-read sequencing (also known as single-molecule sequencing or third generation sequencing), nanopore sequencing (a type of long-read sequencing), 5-letter sequencing or 6-letter sequencing, semiconductor sequencing, sequencing-by-ligation, sequencing-by-hybridization, Digital Gene Expression (Helicos), Next generation sequencing (NGS), Single Molecule Sequencing by Synthesis (SMSS) (Helicos), massively-parallel sequencing, Clonal Single Molecule Array (Solexa), shotgun sequencing, Ion Torrent, Oxford Nanopore, Roche Genia, Maxim-Gilbert sequencing, primer walking, and sequencing using PacBio, SOLiD, Ion Torrent, or Nanopore platforms. Sequencing reactions can be performed in a variety of sample processing units, which may include multiple lanes, multiple channels, multiple wells, or other means of processing multiple sample sets substantially simultaneously. Sample processing unit can also include multiple sample chambers to enable processing of multiple runs simultaneously.
[0458] In some embodiments, sequencing comprises detecting and/or distinguishing unmodified and modified nucleobases. For example, long-read sequencing (also referred to herein as third generation sequencing) methods include those that can generate longer sequencing reads, such as reads in excess of 10 kilobases, as compared to short-read sequencing methods, which generally produce reads of up to about 600 bases in length. Compared to short reads, long reads can improve de novo assembly, transcript isoform identification, and detection and/or mapping of structural variants. Furthermore, long-read sequencing of native DNA or RNA molecules reduces amplification bias and preserves base modifications, such as methylation status. Long- read sequencing technologies useful herein can include any suitable long-read sequencing methods, including, but not limited to, Pacific Biosciences (PacBio) single-molecule real-time (SMRT) sequencing, Oxford Nanopore Technologies (ONT) nanopore sequencing, and synthetic long-read sequencing approaches, such as linked reads, proximity ligation strategies, and optical mapping. Synthetic long-read approaches comprise assembly of short reads from the same DNA molecule to generate synthetic long reads, and may be used in conjunction with “true” long-read sequencing technologies, such as SMRT and nanopore sequencing methods. [0459] Single-molecule real-time (SMRT) sequencing can facilitate direct detection of, e.g., 5- methylcytosine and 5-hydroxymethylcytosine as well as unmodified cytosine (Weirather JL, et al., “Comprehensive comparison of Pacific Biosciences and Oxford Nanopore Technologies and their applications to transcriptome analysis,” FlOOOResearch, 6:100, 2017). Whereas nextgeneration sequencing methods detect augmented signals from a clonal population of amplified DNA fragments, SMRT sequencing captures a single DNA molecule, maintaining base modification during sequencing. The error rate of raw PacBio SMRT sequencing-generated data is about 13-15%, as the signal -to-noise ratio from single DNA molecules not high. To increase accuracy, this platform uses a circular DNA template by ligating hairpin adaptors to both ends of target double-stranded DNA. As the polymerase repeatedly traverses and replicates the circular molecule, the DNA template is sequenced multiple times to generate a continuous long read (CLR). The CLR can be split into multiple reads (“subreads”) by removing adapter sequences, and multiple subreads generate circular consensus sequence (“CCS”) reads with higher accuracy. The average length of a CLR is >10 kb and up to 60 kb, with length depending on the polymerase lifetime. Thus, the length and accuracy of CCS reads depends on the fragment sizes. PacBio sequencing has been utilized for genome (e.g., de novo assembly, detection of structural variants and haplotyping) and transcriptome (e.g., gene isoform reconstruction and novel gene/isoform discovery) studies.
[0460] SMRT sequencing relies on sequencing-by-synthesis, where the sequence of a circular DNA template is determined from the succession of fluorescence pulses, each resulting from the addition of one labelled nucleotide by a polymerase fixed to the bottom of a well. Base modifications do not affect the base-called sequence, but they affect the kinetics of the polymerase. By considering the inter-pulse duration (IPD), base modifications can be inferred from the comparison of a modified template to an in silico model or an unmodified template. Such methods can therefore use the pulse width of a signal from sequencing bases, the interpulse duration (IPD) of bases, and the identity of the bases in order to detect a modification in a base or in a neighboring base. (See e.g., Weirather etal., FlOOOResearch, 6: 100, 2017.) SMRT sequencing can thus be used to detect base modifications such as 5-caC, 4mC, 5mC, 5hmC, 6mA, and 8oxoG (Gouil & Keniry Essays in Biochemistry (2019) 63 639-648). Accordingly, in some embodiments, the sequencing comprises SMRT sequencing. In such embodiments, the end repair may be performed using dNTPs, which comprise 5-caC, 4mC, 5mC, 5hmC, 6mA, and/or 8oxoG. [0461] Some sequencing reactions involve use of an enzyme to control passage of a nucleic acid through a nanopore, and in such cases reaction data can include both kinetics and other behavior of the enzyme and fluctuations in current through the nanopore. For example, ratchet proteins, helicases, or motor proteins can be used to push or pull a nucleic acid molecule through a hole in a biological or synthetic membrane. The kinetics of these proteins can vary depending on the sequence context of a nucleic acid on which they are acting. For example, they may slow down or pause at a modified base, and this behavior, captured as a part of the reaction data, is indicative of the presence of the modified base even where the modified base is not within the sensing portion of the nanopore.
[0462] One example of a nanopore-based single molecule sequencing system is that commercialized by Oxford Nanopore Technologies (ONT). (Weirather JL, et al., FlOOOResearch, 6: 100, 2017). ONT directly sequences a native single-stranded DNA (ssDNA) molecule by measuring characteristic current changes as the bases are threaded through the nanopore by a molecular motor protein. ONT uses a hairpin library structure similar to the PacBio circular DNA template: the DNA template and its complement are bound by a hairpin adaptor. Therefore, the DNA template passes through the nanopore, followed by a hairpin and finally the complement. The raw read can be split into two “ID” reads (“template” and “complement”) by removing the adaptor. The consensus sequence of two “ID” reads is a “2D” read with a higher accuracy.
[0463] Nanopore sequencing can be used to detect base modifications including 5-caC, 5mC, 5hmC, 6mA, BrdU, FldU, IdU, and EdU (see e.g., Gouil & Keniry Essays in Biochemistry (2019) 63 639-648; Kutyavin, Biochemistry (2008), 47, 51, 13666-1367; Muller et al., Nature Methods (2019), volume 16, pages 429-436; Hennion et al., Genome Biology (2020), volume 21, Article number: 125). Accordingly, in some embodiments, the sequencing comprises nanopore sequencing. In such embodiments, the end repair may be performed using dNTPs, which comprise 5-caC, 4mC, 5mC, 5hmC, 6mA, BrdU, FldU, IdU, and/or EdU.
[0464] 5 -letter and 6-letter sequencing methods include whole genome sequencing methods capable of sequencing A, C, T, and G in addition to 5mC and 5hmC to provide a 5-letter (A, C, T, G, and either 5mC or 5hmC) or 6-letter (A, C, T, G, 5mC, and 5hmC) digital readout in a single workflow. The processing of the DNA sample is entirely enzymatic and avoids the DNA degradation and genome coverage biases of bisulfite treatment. In an exemplary 5-letter sequencing method developed by Cambridge Epigenetix, the sample DNA is first fragmented via sonication and then ligated to short, synthetic DNA hairpin adaptors at both ends (Ftillgrabe, et al. 2022, bioRxiv doi: https://doi.org/10.! 101/2022.07.08.499285). The construct is then split to separate the sense and antisense sample strands. For each original sample strand a complementary copy strand is synthesized by DNA polymerase extension of the 3 ’-end to generate a hairpin construct with the original sample DNA strand connected to its complementary strand, lacking epigenetic modifications, via a synthetic loop. Sequencing adapters are then ligated to the end. Modified cytosines are enzymatically protected. The unprotected Cs are then deaminated to uracil, which is subsequently read as thymine. In any such embodiments, amplification methods may comprise uracil- and/or dihydrouracil-tolerant amplification methods, such as PCR using a uracil- and/or dihydrouracil-tolerant DNA polymerase (i.e., a DNA polymerase that can read and amplify templates comprising uracil and/or dihydrouracil bases). The deaminated constructs are no longer fully complementary and have substantially reduced duplex stability, thus the hairpins can be readily opened and amplified by PCR. The constructs can be sequenced in paired-end format whereby read 1 (Pl primed) is the original stand and read 2 (P2 primed) is the copy stand. The read data is pairwise aligned so read 1 is aligned to its complementary read 2. Cognate residues from both reads are computationally resolved to produce a single genetic or epigenetic letter. Pairings of cognate bases that differ from the permissible five are the result of incomplete fidelity at some stage(s) comprising sample preparation, amplification, or erroneous base calling during sequencing. As these errors occur independently to cognate bases on each strand, substitutions result in a non- permissible pair. Non-permissible pairs are masked (marked as N) within the resolved read and the read itself is retained, leading to minimal information loss and high accuracy at read-level. The resolved read is aligned to the reference genome. Genetic variants and methylation counts are produced by read-counting at base-level.
[0465] 5hmC has been shown to have value as a marker of biological states and disease which includes early cancer detection from cell-free DNA. In adapting 5-letter to 6-letter sequencing, 5mC is disambiguated from 5hmC without compromising genetic base calling within the same sample fragment. The first three steps of the workflow are identical to 5-letter sequencing described above, to generate the adapter ligated sample fragment with the synthetic copy strand. Methylation at 5mC is enzymatically copied across the CpG unit to the C on the copy strand, whilst 5hmC is enzymatically protected from such a copy. Thus, unmodified C, 5mC and 5hmC in each of the original CpG units are distinguished by unique 2-base combinations. The unmodified cytosines are then deaminated to uracil, which is subsequently read as thymine. The DNA is subjected to PCR amplification and sequencing as described earlier. The reads are pairwise aligned and resolved using a 2-base code. Each of unmodified C, 5mC, and 5hmC can be resolved as the three CpG units are distinct sequencing environments of the 2-base code. [0466] In some embodiments, sequence coverage of the genome may be, for example, less than 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or 100%. In some embodiments, the sequence reactions may provide for sequence coverage of, for example, at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, or 80% of the genome. Sequence coverage can be performed on, for example, at least 5, 10, 20, 70, 100, 200 or 500 different genes, or up to, for example, 5000, 2500, 1000, 500 or 100 different genes.
[0467] Simultaneous sequencing reactions may be performed using multiplex sequencing. In some embodiments, cell-free nucleic acids may be sequenced with at least, for example, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 50000, or 100,000 sequencing reactions. In other embodiments, cell-free nucleic acids may be sequenced with less than, for example, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 50000, or 100,000 sequencing reactions. Sequencing reactions may be performed sequentially or simultaneously. Subsequent data analysis may be performed on all or part of the sequencing reactions. In some cases, data analysis may be performed on at least, for example, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 50000, or 100,000 sequencing reactions. In other cases, data analysis may be performed on less than, for example, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 50000, or 100,000 sequencing reactions. An exemplary read depth is 1000- 50000 or 1000-10000 or 1000-20000 reads per locus (base).
[0468] In general, sequencing of epigenetic target regions, e.g. to analyze a modified nucleoside profile of DNA, requires a lesser depth of sequencing than sequencing of a sequence-variable target region, e.g. for analysis of mutations. Hence, lesser sequencing depths, as described herein, may in some cases be adequate for the methods described herein.
[0469] In some embodiments, sequencing DNA that was amplified using RCA provides sequence reads comprising multiple copies of the sequence of an original sample molecule or converted molecule and the copies are used to determine a consensus sequence of the original sample molecule or converted molecule. 1. Differential depth of sequencing
[0470] In some embodiments, nucleic acids corresponding to the sequence-variable target region set are sequenced to a greater depth of sequencing than nucleic acids corresponding to the epigenetic target region set. In some embodiments, nucleic acids corresponding to the hydroxymethylation-variable target region set are sequenced to a greater depth of sequencing than nucleic acids corresponding to at least one other target region set. For example, the depth of sequencing for nucleic acids corresponding to the sequence-variable and/or hydroxymethylationvariable target region sets may be at least 1.25-, 1.5-, 1.75-, 2-, 2.25-, 2.5-, 2.75-, 3-, 3.5-, 4-,
4.5-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, 14-, or 15 -fold greater, or 1.25- to 1.5-, 1.5- to 1.75-, 1.75- to 2-, 2- to 2.25-, 2.25- to 2.5-, 2.5- to 2.75-, 2.75- to 3-, 3- to 3.5-, 3.5- to 4-, 4- to 4.5-,
4.5- to 5-, 5- to 5.5-, 5.5- to 6-, 6- to 7-, 7- to 8-, 8- to 9-, 9- to 10-, 10- to 11-, 11- to 12-, 13- to 14-, 14- to 15-fold, or 15- to 100-fold greater, than the depth of sequencing for nucleic acids corresponding to the epigenetic target region set or to at least one other target region set. In some embodiments, said depth of sequencing is at least 2-fold greater. In some embodiments, said depth of sequencing is at least 5-fold greater. In some embodiments, said depth of sequencing is at least 10-fold greater. In some embodiments, said depth of sequencing is 4- to 10-fold greater. In some embodiments, said depth of sequencing is 4- to 100-fold greater. Each of these embodiments refer to the extent to which nucleic acids corresponding to the sequence-variable target region set are sequenced to a greater depth of sequencing than nucleic acids corresponding to the epigenetic target region set.
[0471] In some embodiments, the captured cfDNA corresponding to the sequence-variable target region set and the captured cfDNA corresponding to the epigenetic target region set are sequenced concurrently, e.g., in the same sequencing cell (such as the flow cell of an Illumina sequencer) and/or in the same composition, which may be a pooled composition resulting from recombining separately captured sets or a composition obtained by capturing the cfDNA corresponding to the sequence-variable target region set and the captured cfDNA corresponding to the epigenetic target region set in the same vessel.
[0472] In some embodiments, the captured cfDNA corresponding to the hydroxymethylation variable target region set and the captured cfDNA corresponding to the at least one other target region set are sequenced concurrently, e.g., in the same sequencing cell (such as the flow cell of an Illumina sequencer) and/or in the same composition, which may be a pooled composition resulting from recombining separately captured sets or a composition obtained by capturing the cfDNA corresponding to the hydroxymethylation variable target region set and the captured cfDNA corresponding to the at least one other target region set in the same vessel.
K. Contacting DNA with a methylation-sensitive or methylation-dependent nuclease
[0473] In some embodiments, DNA or a subsample thereof (e.g., a first, second, or third subsample prepared by partitioning a sample as described herein, such as on the basis of a level of a cytosine modification, such as methylation, e.g., 5 -methylation) is contacted with a methylation-dependent nuclease or methylation-sensitive nuclease. The contacting can be performed using a sample that has been divided into a plurality of subsamples as disclosed herein, and/or using a sample that has been partitioned into a plurality of subsamples as disclosed herein. Unless otherwise indicated, where partitioning is performed on the basis of a cytosine modification, the first subsample is the subsample with a higher level of the modification; the second subsample is the subsample with a lower level of the modification; and, when present, the third subsample has a level of the modification intermediate between the first and second subsamples.
[0474] In some embodiments, methods herein comprise contacting DNA with a methylationsensitive nuclease, thereby degrading DNA comprising unmethylated sequences or sequences having low levels of methylation. In some such embodiments, the methylation-sensitive nuclease is a methylation-sensitive restriction enzyme (MSRE), thereby degrading DNA comprising an unmethylated recognition site of the MSRE. Methylation-sensitive nucleases can thus be used in methods herein comprising one or more steps that deplete unmodified or unmethylated sequences, such as those that are prevalent in cfDNA from a subject.
[0475] In some embodiments, methods herein comprise contacting DNA with a methylationdependent nuclease, thereby degrading DNA comprising methylated sequences or sequences having high levels of methylation. In some such embodiments, the methylation-dependent nuclease is a methylation-dependent restriction enzyme (MORE), thereby degrading DNA comprising an methylated recognition site of the MSRE. Methylation-dependent nucleases can thus be used in methods herein comprising one or more steps that deplete modified or methylated sequences, such as those that are prevalent in cfDNA from a subject.
[0476] As discussed above, partitioning procedures may result in imperfect sorting of DNA molecules among the subsamples. The choice of a methylation-dependent nuclease or methylation-sensitive nuclease can be made so as to degrade nonspecifically partitioned DNA. For example, the second subsample can be contacted with a methylation-dependent nuclease, such as a methylation-dependent restriction enzyme. This can degrade nonspecifically partitioned DNA in the second subsample (e.g., methylated DNA) to produce a treated second subsample. Alternatively or in addition, the first subsample can be contacted with a methylationsensitive endonuclease, such as a methylation-sensitive restriction enzyme, thereby degrading nonspecifically partitioned DNA in the first subsample to produce a treated first subsample. Degradation of nonspecifically partitioned DNA in either or both of the first or second subsamples is proposed as an improvement to the performance of methods that rely on accurate partitioning of DNA on the basis of a cytosine modification, e.g., to detect the presence of aberrantly modified DNA in a sample, to determine the tissue of origin of DNA, and/or to determine whether a subject has cancer. For example, such degradation may provide improved sensitivity and/or simplify downstream analyses. In general, where nonspecifically partitioned DNA would be hypermethylated, such as in a hypomethylated partition, a methylation-dependent nuclease, such as a methylation-dependent restriction enzyme, should be used. Conversely, where nonspecifically partitioned DNA would be hypomethylated, such as in a hypermethylated partition, a methylation-sensitive nuclease, such as a methylation-sensitive restriction enzyme, should be used. Methylation-dependent nucleases, such as methylation-dependent restriction enzymes, preferentially cut methylated DNA relative to unmethylated DNA, while methylationsensitive nucleases, such as methylation-sensitive restriction enzymes, preferentially cut unmethylated DNA relative to methylated DNA.
[0477] In contacting a subsample with a nuclease, one or more nucleases can be used. In some embodiments, a subsample is contacted with a plurality of nucleases. The subsample may be contacted with the nucleases sequentially or simultaneously. Simultaneous use of nucleases may be advantageous when the nucleases are active under similar conditions (e.g., buffer composition) to avoid unnecessary sample manipulation. Contacting the second subsample with more than one methylation-dependent restriction enzyme can more completely degrade nonspecifically partitioned hypermethylated DNA. Similarly, contacting the first subsample with more than one methylation-sensitive restriction enzyme can more completely degrade nonspecifically partitioned hypomethylated and/or unmethylated DNA.
[0478] In some embodiments, a methylation-dependent nuclease comprises one or more of MspJI, LpnPI, FspEI, or McrBC. In some embodiments, at least two methylation-dependent nucleases are used. In some embodiments, at least three methylation-dependent nucleases are used. In some embodiments, the methylation-dependent nuclease comprises FspEI. In some embodiments, the methylation-dependent nuclease comprises FspEI and MspJI, e.g., used sequentially.
[0479] In some embodiments, a methylation-sensitive nuclease comprises one or more of Aatll, AccII, Acil, Aorl3HI, Aorl5HI, BspT104I, BssHII, BstUI, CfrlOI, Clal, Cpol, Eco52I, Haell, HapII, Hhal, Hin6I, Hpall, HpyCH4IV, Mlul, MspI, Nael, Notl, Nrul, Nsbl, PmaCI, Psp 14061, Pvul, SacII, Sall, Smal, and SnaBI. In some embodiments, at least two methylation-sensitive nucleases are used. In some embodiments, at least three methylation-sensitive nucleases are used. In some embodiments, the methylation-sensitive nucleases comprise BstUI and Hpall. In some embodiments, the two methylation-sensitive nucleases comprise Hhal and AccII. In some embodiments, the methylation-sensitive nucleases comprise BstUI, Hpall and Hin6I.
[0480] In some embodiments, FspEI is used for digesting the nucleic acid molecules in at least one subsample (e.g., a hypomethylated partition). In some embodiments, BstUI, Hpall and Hin6I are used for digesting the nucleic acid molecules in at least one subsample (e.g., a hypermethylated partition) and FspEI is used for digesting the nucleic acid molecules in at least one other subsample (e.g., a hypomethylated partition). In embodiments involving an intermediately methylated partition, the nucleic acid molecules therein may be digested with a methylation-sensitive nuclease or a methylation-dependent nuclease. In some embodiments, the nucleic acid molecules in an intermediately methylated partition are digested with the same nuclease(s) as the hypermethylated partition. For example, the intermediately methylated partition may be pooled with the hypermethylated partition and then the pooled partitions may be subjected to digestion. In some embodiments, the nucleic acid molecules in an intermediately methylated partition are digested with the same nuclease(s) as the hypomethylated partition. For example, the intermediately methylated partition may be pooled with the hypomethylated partition and then the pooled partitions may be subjected to digestion.
[0481] In some embodiments, a subsample is contacted with a nuclease as described above after a step of tagging or attaching adapters to both ends of the DNA. The tags or adapters can be resistant to cleavage by the nuclease using any of the approaches described above. In this approach, cleavage can prevent the nonspecifically partitioned molecule from being carried through the analysis because the cleavage products lack tags or adapters at both ends.
[0482] Alternatively, a step of tagging or attaching adapters can be performed after cleavage with a nuclease as described above. Cleaved molecules can be then identified in sequence reads based on having an end (point of attachment to tag or adapter) corresponding to a nuclease recognition site. Processing the molecules in this way can also allow the acquisition of information from the cleaved molecule, e.g., observation of somatic mutations. When tagging or attaching adapters after contacting the subsample with a nuclease, and low molecular weight DNA such as cfDNA is being analyzed, it may be desirable to remove high molecular weight DNA (such as contaminating genomic DNA) from the sample before the contacting step. It may also be desirable to use nucleases that can be heat-inactivated at a relatively low temperature (e.g., 65°C or less, or 60°C or less) to avoid denaturing DNA, in that denaturation may interfere with subsequent ligation steps.
[0483] Where a sample is partitioned into three subsamples, including a third subsample containing intermediately methylated molecules, the third subsample is in some embodiments contacted with a methylation- sensitive nuclease. Such a step may have any of the features described elsewhere herein with respect to contacting steps, and may be performed before or after a step of tagging or attaching adapters as discussed above. In some embodiments, the first and third subsamples are combined before being contacted with a methylation-sensitive nuclease. Such a step may have any of the features described elsewhere herein with respect to contacting steps, and may be performed before or after a step of tagging or attaching adapters as discussed above. In some embodiments, the first and third subsamples are differentially tagged before being combined.
[0484] Alternatively, where a sample is partitioned into three subsamples, including a third subsample containing intermediately methylated molecules, the third subsample is in some embodiments contacted with a methylation-dependent nuclease. Such a step may have any of the features described elsewhere herein with respect to contacting steps, and may be performed before or after a step of tagging or attaching adapters as discussed above. In some embodiments, the second and third subsamples are combined before being contacted with a methylationdependent nuclease. Such a step may have any of the features described elsewhere herein with respect to contacting steps, and may be performed before or after a step of tagging or attaching adapters as discussed above. In some embodiments, the second and third subsamples are differentially tagged before being combined.
[0485] In some embodiments, the DNA is purified after being contacted with the nuclease, e.g., using SPRI beads. Such purification may occur after heat inactivation of the nuclease. Alternatively, purification can be omitted; thus, for example, a subsequent step such as amplification can be performed on the subsample containing heat-inactivated nuclease. In another embodiment, the contacting step can occur in the presence of a purification reagent such as SPRI beads, e.g., to minimize losses associated with tube transfers. After cleavage and heat inactivation, the SPRI beads can be re-used for cleanup by adding molecular crowding reagents (e.g., PEG) and salt.
L. Analysis
[0486] The present disclosure provides methods of enriching methylated DNA in a sample. In the disclosed methods, DNA in the sample is contacted with a deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs. DNA in the converted sample that comprises methylated CpGs or conversion products of methylated CpGs is then selectively amplified. In some embodiments, the methods disclosed herein further comprise sequencing the selectively amplified DNA, and analyzing at least some of the sequence data to detect the presence or absence of base modifications and/or mutations present in the DNA sample. In some embodiments of the disclosed methods, analyzing the sequence data further comprises filtering out one or more repaired regions of end-repaired DNA such that the one or more repaired regions are not used to determine the methylation status of cytosines in the DNA sample. In some embodiments, analyzing the sequence data further comprises classifying all base calls within the one or more repaired regions as not having double stranded support. In some embodiments, the method further comprises quantifying DNA damage in the DNA sample through the identification of the one or more regions of the end-repaired DNA that were synthesized during the end repair.
[0487] Genetic data can be used for characterizing a specific form of cancer. Cancers are often heterogeneous in both composition and staging. Genetic profile data may allow characterization of specific sub-types of cancer that may be useful in the diagnosis or treatment of that specific sub-type. This information may also provide a subject or practitioner clues regarding the prognosis of a specific type of cancer and allow either a subject or practitioner to adapt treatment options in accord with the progress of the disease. Some cancers progress, becoming more aggressive and genetically unstable. Other cancers may remain benign, inactive or dormant. The system and methods of this disclosure may be useful in determining disease progression.
[0488] The present methods are useful in determining the efficacy of a particular treatment option. The present methods can also be used for detecting epigenetic variations in conditions other than cancer. Further, the methods of the disclosure may be used to characterize the heterogeneity of an abnormal condition in a subject, the method comprising generating a genetic profile of extracellular polynucleotides in the subject, wherein the genetic profile comprises a plurality of data resulting from epigenetic information (such as methylation profiling), and optionally copy number variation and rare mutation analyses. In some cases, including but not limited to cancer, a disease may be heterogeneous. Disease cells may not be identical. In the example of cancer, some tumors are known to comprise different types of tumor cells, some cells in different stages of the cancer. In other examples, heterogeneity may comprise multiple foci of disease. Again, in the example of cancer, there may be multiple tumor foci, perhaps where one or more foci are the result of metastases that have spread from a primary site.
[0489] The present methods can thus be used to generate_or profile, fingerprint or set of data that is a summation of epigenetic, and optionally genetic, information derived from different cells in a heterogeneous disease. This set of data may comprise epigenetic information, copy number variation, and/or rare mutation analyses alone or in combination.
[0490] The present disclosure provides methods of analyzing DNA. In some embodiments, the disclosed methods comprise analyzing DNA (such as DNA from a subject) to identify at least one cell type, cell cluster type, tissue type, and/or cancer type from which one or more typespecific epigenetic target regions and/or type-specific sequence-variable target regions originated. In some embodiments, methods comprise determining the level of one or more typespecific epigenetic target regions and/or type-specific sequence-variable target regions that originated from the at least one cell type, cell cluster type, tissue type, and/or cancer type.
[0491] In some embodiments, detecting the presence, levels, or absence of DNA sequences and/or modifications facilitates disease diagnosis or identification of appropriate treatments. In some embodiments, the presence of or a change in the levels of one or more sequences and/or modifications is indicative of the presence or absence of a disease or disorder in a subject, such as cancer or precancer, or other disorder that causes changes in nucleic acids relative to a healthy subject.
[0492] Information and data generated by the methods disclosed herein can also be used for characterizing a specific form of cancer. The methods disclosed herein may allow characterization of specific sub-types of cancer that may be important in the diagnosis or treatment of that specific sub-type. This information may also provide a subject or practitioner clues regarding the prognosis of a specific type of cancer and allow either a subject or practitioner to adapt treatment options in accord with the progress of the disease. Some cancers can progress to become more aggressive and genetically unstable. Other cancers may remain benign, inactive or dormant. The system and methods of this disclosure may be useful in determining disease progression.
[0493] Further, the methods of the disclosure may be used to characterize the heterogeneity of a condition in a subject. Such methods can include, e.g., generating an aggregate profile of extracellular nucleic acids derived from the subject, wherein the aggregate profile comprises a plurality of data resulting from various nucleic acid analyses. In some embodiments, the aggregate profile comprises epigenetic and mutation analyses. In some embodiments, an aggregate profile comprises a summation of information derived from different cells in a heterogeneous disease. This summation may comprise structural variation identities and levels, copy number variation, epigenetic variation, or other mutation analyses.
[0494] An exemplary method for analyzing DNA comprises the following steps (e.g., in the order listed below), which is illustrated in FIG. 1A:
1. Preparing or obtaining an extracted DNA sample (e g., extracting DNA, such as cfDNA, from a human, such as a blood sample).
2. Converting DNA in the sample using a methyl -insensitive, CpG specific deaminase or a methyl-sensitive, CpG specific deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs. Conversion of DNA in the sample using a methyl-insensitive, CpG specific deaminase provides a converted sample in which at least a portion of the methylated CpGs in the DNA are converted to TpGs, and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs. Conversion of DNA in the sample using a methyl-sensitive, CpG specific deaminase provides a converted sample in which the methylated CpGs in the DNA remain as CpGs and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs.
3. Selectively amplifying the DNA in the converted sample that comprises methylated CpGs or conversion products of methylated CpGs using a uracil-intolerant DNA polymerase.
4. Optionally sequencing at least a portion of the amplified DNA, and further optionally quantifying a level of methylation at one or more differentially methylated regions of the DNA. [0495] Another exemplary method for analyzing DNA comprises the following steps (e.g., in the order listed below), which is illustrated in FIG. IB:
1. Preparing or obtaining an extracted DNA sample (e.g., extracting DNA, such as cfDNA, from a human, such as a blood sample). 2. Converting DNA in the sample using a methyl-insensitive, CpG specific deaminase or a methyl-sensitive, CpG specific deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs. Conversion of DNA in the sample using a methyl -insensitive, CpG specific deaminase provides a converted sample in which at least a portion of the methylated CpGs in the DNA are converted to TpGs, and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs. Conversion of DNA in the sample using a methyl-sensitive, CpG specific deaminase provides a converted sample in which the methylated CpGs in the DNA remain as CpGs and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs.
3. Converting uracils in the DNA in the converted sample to apyrimidinic sites (AP sites) using a uracil-DNA glycosylase (UDG).
4. Selectively amplifying the DNA in the converted sample that comprises methylated CpGs or conversion products of methylated CpGs using an AP site-intolerant DNA polymerase.
5. Optionally sequencing at least a portion of the amplified DNA, and further optionally quantifying a level of methylation at one or more differentially methylated regions of the DNA. [0496] Another exemplary method for analyzing DNA comprises the following steps (e.g., in the order listed below), which is illustrated in FIG. 1C:
1. Preparing or obtaining an extracted DNA sample (e.g., extracting DNA, such as cfDNA, from a human, such as a blood sample).
2. Converting DNA in the sample using a methyl-insensitive, CpG specific deaminase or a methyl-sensitive, CpG specific deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs. Conversion of DNA in the sample using a methyl -insensitive, CpG specific deaminase provides a converted sample in which at least a portion of the methylated CpGs in the DNA are converted to TpGs, and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs. Conversion of DNA in the sample using a methyl -sensitive, CpG specific deaminase provides a converted sample in which the methylated CpGs in the DNA remain as CpGs and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs.
3. Converting uracils in the DNA in the converted sample to AP sites using a uracil-DNA glycosylase (UDG).
4. Cutting DNA comprising the AP sites using an AP lyase (e.g., Endonuclease VIII).
5. Selectively amplifying the DNA that was not cut by the AP lyase using a DNA polymerase. 6. Optionally sequencing at least a portion of the amplified DNA, and further optionally quantifying a level of methylation at one or more differentially methylated regions of the DNA. [0497] Another exemplary method for analyzing DNA comprises the following steps (e.g., in the order listed below), which is illustrated in FIG. ID:
1. Preparing or obtaining an extracted DNA sample (e.g., extracting DNA, such as cfDNA, from a human, such as a blood sample).
2. Converting DNA in the sample using a methyl-sensitive, CpG specific dsDNA deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs. Conversion of DNA in the sample using a methyl-sensitive, CpG specific deaminase provides a converted sample in which the methylated CpGs in the DNA remain as methylated cytosines and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs.
3. Cutting the DNA comprising UpGs using a mismatch endonuclease (MME);
4. Selectively amplifying the DNA that was not cut by the MME using a DNA polymerase.
5. Optionally sequencing at least a portion of the amplified DNA, and further optionally quantifying a level of methylation at one or more differentially methylated regions of the DNA. [0498] Another exemplary method for analyzing DNA comprises the following steps (e.g., in the order listed below), which is illustrated in FIG. 2:
1. Preparing or obtaining an extracted DNA sample (e.g., extracting DNA, such as cfDNA, from a human, such as a blood sample).
2. Subjecting the DNA in the sample to end repair (and subsequent A-tailing) to generate end- repaired DNA molecules, wherein the end repair is performed with dNTPs, wherein at least one type of dNTP is a deaminase-resistant modified cytosine, and the deaminase-resistant modified cytosine (e.g., 5-caC) is incorporated into repaired regions of the end-repaired DNA molecules at one or more locations.
3. Ligating next-generation sequencing (NGS) adapters to the DNA molecule after the endrepair and A-tailing reactions. The NGS adapters are Y-shaped adapters containing deaminase- resistance modified cytosines.
4. Converting the DNA molecules with ligated NGS adapters using a methyl -insensitive, CpG specific dsDNA deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs. Conversion of DNA in the sample using a methylinsensitive, CpG specific deaminase provides a converted sample in which at least a portion of the methylated CpGs in the DNA are converted to TpGs, and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs.
5. Selectively amplifying the DNA in the converted sample that comprises methylated CpGs using a uracil-intolerant DNA polymerase. During this step, the amplified DNA can be subjected to library preparation, including attaching adapters (which may comprise barcodes) to the selectively amplified DNA molecules.
6. Sequencing at least a portion of the selectively amplified DNA molecules, and optionally quantifying a level of methylation at one or more differentially methylated regions of the DNA.
M. Applications
[0499] The methods disclosed herein allow for enrichment and optionally detection of methylated cytosines in DNA of a sample. This information has utility in a wide range of contexts, including determining the methylation status of DNA in the DNA sample and optionally in the detection of mutations in the DNA.
[0500] The methods presented herein may be used as part of any method that benefits from obtaining an accurate modified nucleoside profile of DNA in any DNA sample and/or accurate mutation calling of DNA in any DNA sample. This is because the methods disclosed herein allow for enrichment of methylated DNA from a sample, which can improve the efficiency of methylation analysis by reducing or avoiding subsequent amplification and sequencing of CpG sites containing unmethylated cytosines. One useful exemplary application of the methods of the disclosure is using the resulting sequencing data in diagnosing and prognosing cancer or other genetic diseases or conditions.
[0501] Hence, in some embodiments, methods described herein comprise identifying or predicting the presence or absence of DNA produced by a tumor (or neoplastic cells, or cancer cells), determining the probability that a test subject has a tumor or cancer, and/or characterizing a tumor, neoplastic cells or cancer as described herein.
1. Cancer and Other Diseases; Cell type quantification
[0502] The present methods can be used to diagnose presence of a condition, e.g., cancer or precancer, in a subject, to characterize a condition (such as to determine a cancer stage or heterogeneity of a cancer), to monitor a subject’s response to receiving a treatment for a condition (such as a response to a chemotherapeutic or immunotherapeutic), assess prognosis of a subject (such as to predict a survival outcome in a subject having a cancer), to determine a subject’s risk of developing a condition, to predict a subsequent course of a condition in a subject, to determine metastasis or recurrence of a cancer in a subject (or a risk of cancer metastasis or recurrence), and/or to monitor a subject’s health as part of a preventative health monitoring program (such as to determine whether and/or when a subject is in need of further diagnostic screening). The present disclosure can also be useful in determining the efficacy of a particular treatment option. Successful treatment options may increase the amount of rare mutations detected in subject's blood if the treatment is successful as more cancers may die and shed DNA. In other examples, this may not occur. In another example, certain treatment options may be correlated with genetic profiles of cancers over time. This correlation may be useful in selecting a therapy. In some embodiments, target regions are analyzed to determine whether they show methylation characteristics of tumor cells or cells that do not ordinarily contribute significantly to cfDNA and/or target regions are analyzed to determine whether they show methylation characteristic of tumor cells or cells that do not ordinarily contribute significantly to cfDNA. In some embodiments, successful treatment options may result in changes in levels of different immune cell types (including rare immune cell types), and/or increases in the amount of target proteins, copy number variation, rare mutations, and/or cancer-related epigenetic signatures (such as hypermethylated regions or hypom ethylated regions) detected in, e.g., a sample from a subject, such as detected in a subject's blood (such as in DNA isolated from a buffy coat sample or any other sample comprising cells, such as in a blood sample (e.g., a whole blood sample, a leukapheresis sample, or a PBMC sample) from the subject) if the treatment is successful as more cancer cells may die and shed DNA, or, e.g., if a successful treatment results in an increase or decrease in the quantity of a specific protein in the blood and an unsuccessful treatment results in no change.
[0503] Additionally, if a cancer is observed to be in remission after treatment, the present methods can be used to monitor the likelihood of residual disease or the likelihood of recurrence of disease.
[0504] In some embodiments, the present methods are used for screening for a cancer, such as a metastasis, or in a method for screening cancer, such as in a method of detecting the presence or absence of a metastasis. For example, the sample can be a sample from a subject who has or has not been previously diagnosed with cancer. In some embodiments, one or more, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more samples are collected from a subject as described herein, such as before and/or after the subject is diagnosed with a cancer. In some embodiments, the subject may or may not have cancer. In some embodiments, the subject may or may not have an early-stage cancer. In some embodiments, the subject has one or more risk factors for cancer, such as tobacco use (e.g., smoking), being overweight or obese, having a high body mass index (BMI), being of advanced age, poor nutrition, high alcohol consumption, or a family history of cancer. [0505] In some embodiments, the subject has used tobacco, e.g., for at least 1, 5, 10, or 15 years. In some embodiments, the subject has a high BMI, e.g., a BMI of 25 or greater, 26 or greater, 27 or greater, 28 or greater, 29 or greater, or 30 or greater. In some embodiments, the subject is at least 40, 45, 50, 55, 60, 65, 70, 75, or 80 years old. In some embodiments, the subject has poor nutrition, e.g., high consumption of one or more of red meat and/or processed meat, trans fat, saturated fat, and refined sugars, and/or low consumption of fruits and vegetables, complex carbohydrates, and/or unsaturated fats. High and low consumption can be defined, e.g., as exceeding or falling below, respectively, recommendations in Dietary Guidelines for Americans 2020-2025, available at dietaryguidelines.gov/sites/default/files/2021-
03/Di etary_Guidelines_for_Americans-2020-2025.pdf . In some embodiments, the subject has high alcohol consumption, e.g., at least three, four, or five drinks per day on average (where a drink is about one ounce or 30 mL of 80-proof hard liquor or the equivalent). In some embodiments, the subject has a family history of cancer, e.g., at least one, two, or three blood relatives were previously diagnosed with cancer. In some embodiments, the relatives are at least third-degree relatives (e.g., great-grandparent, great aunt or uncle, first cousin), at least second- degree relatives (e.g., grandparent, aunt or uncle, or half-sibling), or first-degree relatives (e.g., parent or full sibling). Furthermore, in some embodiments, the one or more methods described in the present disclosure may be used to assist in the treatment of a type of cancer.
[0506] In some embodiments, the methods and systems disclosed herein may be used to identify customized or targeted therapies to treat a given disease or condition in patients based on the classification of a nucleic acid variant as being of somatic or germline origin. Typically, the disease under consideration is a type of cancer. Non-limiting examples of such cancers include biliary tract cancer, bladder cancer, transitional cell carcinoma, urothelial carcinoma, brain cancer, gliomas, astrocytomas, breast cancer, metaplastic carcinoma, cervical cancer, cervical squamous cell carcinoma, rectal cancer, colorectal carcinoma, colon cancer, hereditary nonpolyposis colorectal cancer, colorectal adenocarcinomas, gastrointestinal stromal tumors (GISTs), endometrial carcinoma, endometrial stromal sarcomas, esophageal cancer, esophageal squamous cell carcinoma, esophageal adenocarcinoma, ocular melanoma, uveal melanoma, gallbladder carcinomas, gallbladder adenocarcinoma, renal cell carcinoma, clear cell renal cell carcinoma, transitional cell carcinoma, urothelial carcinomas, Wilms tumor, leukemia, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), liver cancer, liver carcinoma, hepatoma, hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, Lung cancer, non-small cell lung cancer (NSCLC), mesothelioma, B-cell lymphomas, non-Hodgkin lymphoma, diffuse large B-cell lymphoma, Mantle cell lymphoma, T cell lymphomas, non- Hodgkin lymphoma, precursor T-lymphoblastic lymphoma/leukemia, peripheral T cell lymphomas, multiple myeloma, nasopharyngeal carcinoma (NPC), neuroblastoma, oropharyngeal cancer, oral cavity squamous cell carcinomas, osteosarcoma, ovarian carcinoma, pancreatic cancer, pancreatic ductal adenocarcinoma, pseudopapillary neoplasms, acinar cell carcinomas, Prostate cancer, prostate adenocarcinoma, skin cancer, melanoma, malignant melanoma, cutaneous melanoma, small intestine carcinomas, stomach cancer, gastric carcinoma, gastrointestinal stromal tumor (GIST), uterine cancer, or uterine sarcoma.
[0507] In some embodiments, the cancer is a type of cancer that is not a hematological cancer, e.g., a solid tumor cancer such as a carcinoma, adenocarcinoma, or sarcoma. Type and/or stage of cancer can be detected from genetic variations including mutations, rare mutations, indels, rearrangements, copy number variations, transversions, translocations, recombinations, inversion, deletions, aneuploidy, partial aneuploidy, polyploidy, chromosomal instability, chromosomal structure alterations, gene fusions, chromosome fusions, gene truncations, gene amplification, gene duplications, chromosomal lesions, DNA lesions, abnormal changes in nucleic acid chemical modifications, abnormal changes in epigenetic patterns, such as 5mC and 5mC profiles. Hence, the present methods can in some cases be used in combination with methods used to detect other gen etic/epi genetic variations, e g. in a method of detecting or characterizing a cancer or other methods described herein.
[0508] In some embodiments, a method described herein comprises identifying the presence of target regions and/or DNA produced by a tumor (or neoplastic cells, or cancer cells) or by precancer cells. In some embodiments, a method described herein comprises determining the level of target regions and/or identifying the presence of DNA produced by a tumor (or neoplastic cells, or cancer cells) or by precancer cells. In some embodiments, determining the level of target regions comprises determining either an increased level or decreased level of target regions, wherein the increased or decreased level of target regions is determined by comparing the level of target regions with a threshold level/value.
[0509] Genetic and/or epigenetic data can also be used for characterizing a specific form of cancer. Cancers are often heterogeneous in both composition and staging. Genetic and/or epigenetic profile data may allow characterization of specific sub-types of cancer that may be important in the diagnosis or treatment of that specific sub-type. This information may also provide a subject or practitioner clues regarding the prognosis of a specific type of cancer and allow either a subject or practitioner to adapt treatment options in accord with the progress of the disease. Some cancers can progress to become more aggressive and genetically unstable. Other cancers may remain benign, inactive or dormant. The system and methods of this disclosure may be useful in determining disease progression.
[0510] Further, the methods of the disclosure may be used to characterize the heterogeneity of an abnormal condition in a subject. Such methods can include, e.g., generating a genetic and/or epigenetic profile of cfDNA derived from the subject, wherein the genetic and/or epigenetic profile comprises a plurality of data resulting from copy number variation and rare mutation analyses. In some embodiments, an abnormal condition is cancer, e.g. as described herein. In some embodiments, the abnormal condition may be one resulting in a heterogeneous genomic population. In the example of cancer, some tumors are known to comprise tumor cells in different stages of the cancer. In other examples, heterogeneity may comprise multiple foci of disease such as where one or more foci (such as one or more tumor foci) are the result of metastases that have spread from a primary site of a cancer. The tissue(s) of origin can be useful for identifying organs affected by the cancer, including the primary cancer and/or metastatic tumors.
[0511] The present methods can also be used to quantify levels of different cell types, such as immune cell types, including rare immune cell types, such as activated lymphocytes and myeloid cells at particular stages of differentiation. Such quantification can be based on the numbers of molecules corresponding to a given cell type in a sample. Sequence information obtained in the present methods may comprise sequence reads of the nucleic acids generated by a nucleic acid sequencer. In some embodiments, the nucleic acid sequencer performs pyrosequencing, singlemolecule sequencing, nanopore sequencing, semiconductor sequencing, sequencing-by- synthesis, 5-letter sequencing, 6-letter sequencing, sequencing-by -ligation or sequencing-by- hybridization on the nucleic acids to generate sequencing reads. In some embodiments, the method further comprises grouping the sequence reads into families of sequence reads, each family comprising sequence reads generated from a nucleic acid in the sample. In some embodiments, the methods comprise determining the likelihood that the subject from which the sample was obtained has cancer or precancer, or has a metastasis, that is related to changes in proportions of types of immune cells.
[0512] The present methods can be used to generate or profile, fingerprint or set of data that is a summation of genetic and/or epigenetic information derived from different cells in a heterogeneous disease. This set of data may comprise copy number variation, epigenetic variation, and mutation analyses alone or in combination.
[0513] The present methods can be used to diagnose, prognose, monitor or observe cancers, or other diseases. In some embodiments, the methods herein do not involve the diagnosing, prognosing or monitoring a fetus and as such are not directed to non-invasive prenatal testing. In other embodiments, these methodologies may be employed in a pregnant subject to diagnose, prognose, monitor or observe cancers or other diseases in an unborn subject whose DNA and other polynucleotides may co-circulate with maternal molecules.
[0514] Non-limiting examples of other genetic-based diseases, disorders, or conditions that are optionally evaluated using the methods and systems disclosed herein include achondroplasia, alpha- 1 antitrypsin deficiency, antiphospholipid syndrome, autism, autosomal dominant polycystic kidney disease, Charcot-Mari e-Tooth (CMT), cri du chat, Crohn's disease, cystic fibrosis, Dercum disease, down syndrome, Duane syndrome, Duchenne muscular dystrophy, Factor V Leiden thrombophilia, familial hypercholesterolemia, familial mediterranean fever, fragile X syndrome, Gaucher disease, hemochromatosis, hemophilia, holoprosencephaly, Huntington's disease, Klinefelter syndrome, Marfan syndrome, myotonic dystrophy, neurofibromatosis, Noonan syndrome, osteogenesis imperfecta, Parkinson's disease, phenylketonuria, Poland anomaly, porphyria, progeria, retinitis pigmentosa, severe combined immunodeficiency (SCID), sickle cell disease, spinal muscular atrophy, Tay-Sachs, thalassemia, trimethylaminuria, Turner syndrome, velocardiofacial syndrome, WAGR syndrome, Wilson disease, or the like.
[0515] In some embodiments, the methods can provide a measure of the extent of DNA damage through the quantification of the methylated cytosines of CpG sites, the methods disclosed herein can also be used to quantify the level of DNA damage present in the original DNA sample. [0516] In some embodiments, the method further comprises calculating a synthesis index which is a quantitative measure of the regions synthesized in the end repair. The synthesis index may be on a molecule level and/or a sample level. The synthesis index may be the proportion of sequencing data which corresponds to synthesized regions. In some embodiments, the method further comprises comparing the synthesis index to one or more reference values to classify the DNA sample. The classification may be whether the DNA sample derives from a subject with or without cancer. The reference values may be derived from one or more control DNA samples which are known to have a specific properties, such as being derived from a subject known to have cancer, e.g. a specific type of cancer. The reference values may be obtained by performing the method used to obtain the synthesis index on control samples (i.e. using the same end repair, deamination, amplification, ligation and/or sequencing methods).
[0517] In some embodiments, a method described herein comprises detecting a presence or absence of DNA originating or derived from a tumor cell at a preselected timepoint following a previous cancer treatment of a subject previously diagnosed with cancer using a set of sequence information obtained as described herein. The method may further comprise determining a cancer recurrence score that is indicative of the presence or absence of the DNA originating or derived from the tumor cell for the subject.
[0518] Where a cancer recurrence score is determined, it may further be used to determine a cancer recurrence status. The cancer recurrence status may be at risk for cancer recurrence, e.g., when the cancer recurrence score is above a predetermined threshold. The cancer recurrence status may be at low or lower risk for cancer recurrence, e.g., when the cancer recurrence score is above a predetermined threshold. In particular embodiments, a cancer recurrence score equal to the predetermined threshold may result in a cancer recurrence status of either at risk for cancer recurrence or at low or lower risk for cancer recurrence.
[0519] In some embodiments, a cancer recurrence score is compared with a predetermined cancer recurrence threshold, and the subject is classified as a candidate for a subsequent cancer treatment when the cancer recurrence score is above the cancer recurrence threshold or not a candidate for therapy when the cancer recurrence score is below the cancer recurrence threshold. In particular embodiments, a cancer recurrence score equal to the cancer recurrence threshold may result in classification as either a candidate for a subsequent cancer treatment or not a candidate for therapy. [0520] The present methods can also be used to quantify levels of different cell types, such as immune cell types, including rare immune cell types, such as activated lymphocytes and myeloid cells at particular stages of differentiation. Such quantification can be based on the numbers of molecules corresponding to a given cell type in a sample. Sequence information obtained in the present methods may comprise sequence reads of the nucleic acids generated by a nucleic acid sequencer. In some embodiments, the nucleic acid sequencer performs pyrosequencing, singlemolecule sequencing, nanopore sequencing, semiconductor sequencing, sequencing-by- synthesis, 5-letter sequencing, 6-letter sequencing, sequencing-by-ligation or sequencing-by- hybridization on the nucleic acids to generate sequencing reads. In some embodiments, the method further comprises grouping the sequence reads into families of sequence reads, each family comprising sequence reads generated from a nucleic acid in the sample. In some embodiments, the methods comprise determining the likelihood that the subject from which the sample was obtained has cancer, precancer, an infection, transplant rejection, or other diseases or disorder that is related to changes in proportions of types of immune cells. Comparisons of immune cell identities and/or immune cell quantities/proportions between two or more samples collected from a subject at two different time points can allow for monitoring of one or more aspects of a condition in the subject over time, such as a response of the subject to a treatment, the severity of the condition (such as a cancer stage) in the subject, a recurrence of the condition (such as a cancer), and/or the subject’s risk of developing the condition (such as a cancer).
[0521] The methods discussed above may further comprise any compatible feature or features set forth elsewhere herein, including in the section regarding methods of determining a risk of cancer recurrence in a subject and/or classifying a subject as being a candidate for a subsequent cancer treatment.
2. Methods of determining a risk of cancer recurrence in a test subject and/or classifying a subject as being a candidate for a subsequent cancer treatment
[0522] In some embodiments, a method provided herein is or comprises a method of determining a risk of cancer recurrence in a subject. In some embodiments, a method provided herein is or comprises a method of detecting the presence of absence of a metastasis in a subject. In some embodiments, a method provided herein is or comprises a method of classifying a subject as being a candidate for a subsequent cancer treatment. [0523] Any of such methods may comprise collecting a sample (such as DNA, such as DNA originating or derived from a tumor cell) from the subject diagnosed with the cancer at one or more preselected timepoints following one or more previous cancer treatments to the subject. The subject may be any of the subjects described herein. The sample may comprise chromatin, cfDNA, or other cell materials. The sample, such as the DNA sample, may be a tissue sample. The DNA may be DNA, such as cfDNA, from a blood sample (e.g., a whole blood sample, a buffy coat sample, a leukapheresis sample, or a PBMC sample). The DNA may comprise DNA obtained from a tissue sample.
[0524] Any of such methods may comprise capturing a plurality of sets of target regions from DNA from the subject, wherein the plurality of target region sets comprises a sequence-variable target region set and an epigenetic target region set, whereby a captured set of DNA molecules is produced. The capturing step may be performed according to any of the embodiments described elsewhere herein.
[0525] In any of such methods, the previous cancer treatment may comprise surgery, administration of a therapeutic composition, and/or chemotherapy.
[0526] Any of such methods may comprise sequencing the captured DNA molecules, whereby a set of sequence information is produced. The captured DNA molecules of the sequence-variable target region set may be sequenced to a greater depth of sequencing than the captured DNA molecules of the epigenetic target region set.
[0527] Any of such methods may comprise detecting a presence or absence of DNA originating or derived from a tumor cell at a preselected timepoint using the set of sequence information.
The detection of the presence or absence of DNA, such as cfDNA, originating or derived from a tumor cell may be performed according to any of the embodiments thereof described elsewhere herein.
[0528] Methods of determining a risk of cancer recurrence in a subject may comprise determining a cancer recurrence score that is indicative of the presence or absence, or amount, of the DNA, such as genomic regions of interest and target regions, originating or derived from the tumor cell for the subject. The cancer recurrence score may further be used to determine a cancer recurrence status. The cancer recurrence status may be at risk for cancer recurrence, e.g., when the cancer recurrence score is above a predetermined threshold. The cancer recurrence status may be at low or lower risk for cancer recurrence, e.g., when the cancer recurrence score is above a predetermined threshold. In particular embodiments, a cancer recurrence score equal to the predetermined threshold may result in a cancer recurrence status of either at risk for cancer recurrence or at low or lower risk for cancer recurrence.
[0529] Methods of detecting the presence or absence of metastasis in a subject may comprise comparing the presence or level of a tissue-specific cell material to the presence or level of the tissue-specific cell material obtained from the subject at a different time, a reference level of the tissue-specific cell material, or to a comparator cell material. Methods herein may comprise additional steps to determine whether a metastasis is present.
[0530] Methods of classifying a subject as being a candidate for a subsequent cancer treatment may comprise comparing the cancer recurrence score of the subject with a predetermined cancer recurrence threshold, thereby classifying the subject as a candidate for the subsequent cancer treatment when the cancer recurrence score is above the cancer recurrence threshold or not a candidate for therapy when the cancer recurrence score is below the cancer recurrence threshold. In particular embodiments, a cancer recurrence score equal to the cancer recurrence threshold may result in classification as either a candidate for a subsequent cancer treatment or not a candidate for therapy. In some embodiments, the subsequent cancer treatment comprises chemotherapy or administration of a therapeutic composition.
[0531] Any of such methods may comprise determining a disease-free survival (DFS) period for the subject based on the cancer recurrence score; for example, the DFS period may be 1 year, 2 years, 3, years, 4 years, 5 years, or 10 years.
[0532] In some embodiments, sequence-variable target region sequences are obtained, and determining the cancer recurrence score may comprise determining at least a first subscore indicative of the amount of the levels of particular immune cell types, SNVs, insertions/deletions, CNVs and/or fusions present in sequence-variable target region sequences. [0533] In some embodiments, a number of mutations in the sequence-variable target regions chosen from 1, 2, 3, 4, or 5 is sufficient for the first subscore to result in a cancer recurrence score classified as positive for cancer recurrence. In some embodiments, the number of mutations is chosen from 1, 2, or 3.
[0534] In some embodiments, epigenetic target region sequences are obtained, and determining the cancer recurrence score comprises determining a second subscore indicative of the amount of molecules (obtained from the epigenetic target region sequences) that represent an epigenetic state different from DNA found in a corresponding sample from a healthy subject (e.g., DNA, such as cfDNA, found in a blood sample (e.g., a whole blood sample, a buffy coat sample, a leukapheresis sample, or a PBMC sample) from a healthy subject, or DNA found in a tissue sample from a healthy subject where the tissue sample is of the same type of tissue as was obtained from the subject). These abnormal molecules (i.e., molecules with an epigenetic state different from DNA found in a corresponding sample from a healthy subject) may be consistent with epigenetic changes associated with cancer (such as with a metastasis), e.g., methylation of hypermethylation variable target regions and/or perturbed fragmentation of fragmentation variable target regions, where “perturbed” means different from DNA found in a corresponding sample from a healthy subject.
[0535] In some embodiments, a proportion of molecules corresponding to the hypermethylation variable target region set and/or fragmentation variable target region set that indicate hypermethylation in the hypermethylation variable target region set and/or abnormal fragmentation in the fragmentation variable target region set greater than or equal to a value in the range of 0.001%-10% is sufficient for the subscore to be classified as positive for cancer recurrence. The range may be 0.001%-l%, 0.005%-!%, 0.01%-5%, 0.01%-2%, or 0.01%-!%. [0536] In some embodiments, any of such methods may comprise determining a fraction of tumor DNA from the fraction of molecules in the set of sequence information that indicate one or more features indicative of origination from a tumor cell. This may be done for molecules corresponding to some or all of the target regions, e.g., including one or more of hypermethylation variable target regions, hypomethylation variable target regions, and fragmentation variable target regions (hypermethylation of a hypermethylation variable target region and/or abnormal fragmentation of a fragmentation variable target region may be considered indicative of origination from a tumor cell). This may be done for molecules corresponding to sequence variable target regions, e.g., molecules comprising alterations consistent with cancer, such as SNVs, indels, CNVs, and/or fusions. The fraction of tumor DNA may be determined based on a combination of molecules corresponding to epigenetic target regions and molecules corresponding to sequence variable target regions.
[0537] Determination of a cancer recurrence score may be based at least in part on the fraction of tumor DNA, wherein a fraction of tumor DNA greater than a threshold in the range of 10’11 to 1 or 10’10 to 1 is sufficient for the cancer recurrence score to be classified as positive for cancer recurrence. In some embodiments, a fraction of tumor DNA greater than or equal to a threshold in the range of 10 10 to 10 9, 10 9 to 10 8, 10 8 to 10 7, 10 7 to I O 6, 10 6 to 10 5, I 0 5 to I O 4, 10^ to I O 3, I O 3 to I O 2, or 10 2 to I 0 1 is sufficient for the cancer recurrence score to be classified as positive for cancer recurrence. In some embodiments, the fraction of tumor DNA greater than a threshold of at least 10'7 is sufficient for the cancer recurrence score to be classified as positive for cancer recurrence. A determination that a fraction of tumor DNA is greater than a threshold, such as a threshold corresponding to any of the foregoing embodiments, may be made based on a cumulative probability. For example, the sample was considered positive if the cumulative probability that the tumor fraction was greater than a threshold in any of the foregoing ranges exceeds a probability threshold of at least 0.5, 0.75, 0.9, 0.95, 0.98, 0.99, 0.995, or 0.999. In some embodiments, the probability threshold is at least 0.95, such as 0.99.
[0538] In some embodiments, the set of sequence information comprises sequence-variable target region sequences and epigenetic target region sequences, and determining the cancer recurrence score comprises determining a subscore indicative of the amount of SNVs, insertions/deletions, CNVs and/or fusions present in sequence-variable target region sequences and a subscore indicative of the amount of abnormal molecules in epigenetic target region sequences, and combining the subscores to provide the cancer recurrence score. Where the subscores are combined, they may be combined by applying a threshold to each subscore independently (e.g., greater than a predetermined number of mutations (e.g., > 1) in sequencevariable target regions, and greater than a predetermined fraction of abnormal molecules (i.e., molecules with an epigenetic state different from the DNA found in a corresponding sample from a healthy subject; e.g., tumor) in epigenetic target regions), or training a machine learning classifier to determine status based on a plurality of positive and negative training samples.
In some embodiments, the set of sequence information comprises sequence-variable target region sequences and epigenetic target region sequences, and determining the cancer recurrence score comprises determining a first subscore indicative of the levels of particular immune cell types, a second subscore indicative of the amount of SNVs, insertions/deletions, CNVs and/or fusions present in sequence-variable target region sequences and a third subscore indicative of the amount of abnormal molecules in epigenetic target region sequences, and combining the first, second, and third subscores to provide the cancer recurrence score. Where the subscores are combined, they may be combined by applying a threshold to each subscore independently in sequence-variable target regions, respectively, and greater than a predetermined fraction of abnormal molecules (i.e., molecules with an epigenetic state different from the DNA found in a corresponding sample from a healthy subject; e.g., tumor) in epigenetic target regions), or training a machine learning classifier to determine status based on a plurality of positive and negative training samples.
[0539] In some embodiments, a value for the combined score in the range of -4 to 2 or -3 to 1 is sufficient for the cancer recurrence score to be classified as positive for cancer recurrence.
[0540] In any embodiment where a cancer recurrence score is classified as positive for cancer recurrence, the cancer recurrence status of the subject may be at risk for cancer recurrence and/or the subject may be classified as a candidate for a subsequent cancer treatment.
[0541] In some embodiments, the cancer is any one of the types of cancer described elsewhere herein, e.g., colorectal cancer.
3. Methods of monitoring a cancer in a subject over time; sample collection at two or more time points
[0542] In some embodiments, the present methods can be used to monitor one or more aspects of a condition in a subject over time, such as a subject’s response to receiving a treatment for a condition (such as a response to a chemotherapeutic or immunotherapeutic), the severity of the condition (such as a cancer stage) in the subject, a recurrence of the condition (such as a cancer), and/or the subject’s risk of developing the condition (such as a cancer) and/or to monitor a subject’s health as part of a preventative health monitoring program (such as to determine whether and/or when a subject is in need of further diagnostic screening). In some embodiments, monitoring comprises analysis of at least two samples collected from a subject at at least two different time points as described herein.
[0543] The methods according to the present disclosure can be useful in predicting a subject’s response to a particular treatment option, such as over a period of time. As described elsewhere herein, successful treatment options may increase the amount of cancer associated DNA sequences detected in a subject's blood, such as if the treatment is successful as more cancers may die and shed DNA. In such examples, certain treatment options may be correlated with genetic profiles of cancers over time. This correlation may be useful in selecting a therapy. In some embodiments, successful treatment options may result in an increase or decrease in the levels of different immune cell types (including rare immune cell types), and/or an increase or decrease in the levels of a specific protein or proteins and/or a specific DNA sequence (e.g., of a CDR3), such as in the blood, and an unsuccessful treatment may result in no change. In other examples, this may not occur. [0544] As disclosed herein, in some embodiments, quantities of each of a plurality of cell types, such as immune cell types, are determined based on sequencing and analysis (such as determination of epigenetic and/or genomic signatures) of DNA isolated from at least one sample comprising cells (such as a tissue sample or a blood sample, e.g., a whole blood sample, a huffy coat sample, a leukapheresis sample, or a PBMC sample) from a subject. In some embodiments, differences in levels and/or presence of particular genetic and/or epigenetic signatures in DNA isolated from blood samples from a subject can be used to quantify cell types, such as immune cell types, within the sample. Thus, a comparison of the disclosed genetic and/or epigenetic signatures in DNA isolated from blood samples collected from a subject at two or more time points can be used to monitor changes in cell type quantities in the subject under different conditions (such as prior to and after a treatment), or over time (e.g., as part of a preventative health monitoring program).
[0545] The disclosed methods can include evaluating (such as quantifying) and/or interpreting cell types (such as immune cell types) present in one or more samples (such as a tissue sample or a blood sample, e.g., a whole blood sample, a buffy coat sample, a leukapheresis sample, or a PBMC sample) collected from a subject at one or more timepoints in comparison to a selected baseline value or reference standard (or a selected set of baseline values or reference standards). A baseline value or reference standard may be a quantity of cell types measured in one or more samples (such as an average quantity or range of quantities of cell types present in at least two samples) collected from the subject at one or more time points, such as prior to receiving a treatment, prior to diagnosis of a condition (such as a cancer), or as part of a preventative health monitoring program. A baseline value or reference standard may be a quantity of cell types measured in one or more samples (such as an average quantity or range of quantities of cell types present in at least two samples) collected at one or more timepoints from one or more subjects that do not have the condition (such as a healthy subject that does not have a cancer), one or more subjects that responded favorably to the treatment, or one or more subjects that have not received the treatment. In certain embodiments, the baseline value or reference standard utilized is a standard or profile derived from a single reference subject. In other embodiments, the baseline value or reference standard utilized is a standard or profile derived from averaged data from multiple reference subjects. The reference standard, in various embodiments, can be a single value, a mean, an average, a numerical mean or range of numerical means, a numerical pattern, or a graphical pattern created from the cell type quantity data derived from a single reference subject or from multiple reference subjects. Selection of the particular baseline values or reference standards, or selection of the one or more reference subjects, depends upon the use to which the methods described herein are to be put by, for example, a research scientist or a clinician (such as a physician).
[0546] In some embodiments, one or more samples (such as a tissue sample or a blood sample, e g., a whole blood sample, a buffy coat sample, a leukapheresis sample, or a PBMC sample) may be collected from a subject at two or more timepoints, to assess changes in cell types (such as changes in quantities of cell types) between the two or more timepoints. In some embodiments, a sample collected at a first time point is a tissue sample or a blood sample, and a sample collected at a subsequent time point (such as a second time point) is a blood sample. In some embodiments, a sample collected at a first time point is a tissue sample and a sample collected at a subsequent time point (such as a second time point) is a blood sample. By monitoring cell types and identifying differences between cell types in samples collected from a subject at two or more timepoints, the present methods can be used, for example, to determine the presence or absence of a condition (such as a cancer), a response of the subject to a treatment, one or more characteristic of a condition (such as a cancer stage) in the subject, recurrence of a condition (such as a cancer), and/or a subject’s risk of developing a condition (such as a cancer). Thus, in some embodiments, methods are provided wherein quantities of cell types present in at least one sample (such as at least one tissue sample and/or at least one blood sample, e.g., a whole blood sample, buffy coat sample, leukapheresis sample, or PBMC sample) collected from a subject at one or more timepoints (such as prior to receiving a treatment) are compared to quantities of cell types present in at least one sample collected from the subject at one or more different time points (such as after receiving the treatment). The disclosed methods can allow for patient-specific monitoring, such that, for example, differences in cell type quantities between samples collected from the subject at different timepoints may indicate changes (such as presence or absence of a condition, response to a treatment, a prognosis, or the like) that are significant with respect to the subject but may yet fall within a normal range of a general healthy population.
[0547] As disclosed herein, methods are provided for monitoring one or more aspects of a condition in a subject over time, such as but not limited to, a subject’s response to receiving a treatment for a condition (such as a response to a chemotherapeutic or immunotherapeutic). In certain embodiments, one or more samples is collected from the subject at at least 1-10, at least 1-5, at least 2-5, or at least 1, at least 2, least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, or at least 20 time points prior to the subject receiving the treatment. In certain embodiments, one or more samples is collected from the subject at at least
1-10, at least 1-5, at least 2-5, or at least 1, at least 2, least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, or at least 20 time points after the subject has received the treatment. Sample collection from a subject can be ongoing during and/or after treatment to monitor the subject’s response to the treatment.
[0548] In some embodiments, samples are not collected from a subject prior to diagnosis of a condition (such as a cancer) or prior to receiving a treatment. In such embodiments, wherein the response of a subject to a treatment, or the course or stage of a condition (such as a cancer) in the subject is being monitored over time, cell types are compared between samples taken at at least
2-10, at least 2-5, at least 3-6, or at least 2, such as at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, or at least 20 time points collected after the subject has been diagnosed and/or after the subject has received the treatment. Sample collection from a subject can be ongoing during and/or after treatment to monitor the subject’s response to the treatment.
[0549] In some embodiments of the disclosed methods, one or more samples (such as one or more tissue, whole blood, buffy coat, leukapheresis, or PBMC samples) is collected from a subject at least once per year, such as about 1-12 times or about 2-6 times, such as about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 times per year. In other embodiments, one or more samples is collected from the subject less than once per year, such as about once every 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 months. In some embodiments, one or more samples is collected from the subject about once every 1-5 years or about once every 1-2 years, such as about every 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5 years.
[0550] In other embodiments of the disclosed methods, one or more samples (such as one or more tissue samples or blood samples, e g., or one or more buffy coat samples, whole blood samples, leukapheresis samples, or PBMC samples) are collected from a subject at least once per week, such as on 1-4 days, 1-2 days, or on 1, 2, 3, 4, 5, 6, or 7 days per week. In certain embodiments, one or more samples is collected from the subject at least once per month, such as 1-15 times, 1-10 times, 2-5 times, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 times per month. In other embodiments, one or more samples is collected from the subject every month, every 2 months, every 3 months, every 4 months, every 5 months, every 6 months, every 7 months, every 8 months, every 9 months, every 10 months, every 11 months, or every 12 months. In some embodiments, one or more samples is collected from the subject at least once per day, such as 1, 2, 3, 4, 5, or 6 times per day. Selection of the one or more sample collection timepoints (e.g., the frequency of sample collection), or of the number of samples to be collected at each timepoint, depends upon the use to which the methods described herein are to be put by, for example, a research scientist or a clinician (such as a physician).
4. Therapies and Related Administration
[0551] In certain embodiments, the methods disclosed herein relate to identifying and administering customized therapies, such as customized therapies to patients. In some embodiments, determination of the levels of particular immune cell types, including rare immune cell types, facilitates selection of appropriate treatment. In some embodiments, the patient or subject has a given disease, disorder or condition, e.g., any of the cancers or other conditions described elsewhere herein. Essentially any cancer therapy (e g., surgical therapy, radiation therapy, chemotherapy, immunotherapy, and/or the like) may be included as part of these methods. In certain embodiments, the therapy administered to a subject comprises at least one chemotherapy drug. In some embodiments, the chemotherapy drug may comprise alkylating agents (for example, but not limited to, Chlorambucil, Cyclophosphamide, Cisplatin and Carboplatin), nitrosoureas (for example, but not limited to, Carmustine and Lomustine), antimetabolites (for example, but not limited to, Fluorauracil, Methotrexate and Fludarabine), plant alkaloids and natural products (for example, but not limited to, Vincristine, Paclitaxel and Topotecan), anti- tumor antibiotics (for example, but not limited to, Bleomycin, Doxorubicin and Mitoxantrone), hormonal agents (for example, but not limited to, Prednisone, Dexamethasone, Tamoxifen and Leuprolide) and biological response modifiers (for example, but not limited to, Herceptin and Avastin, Erbitux and Rituxan). In some embodiments, the chemotherapy administered to a subject may comprise FOLFOX or FOLFIRI. In certain embodiments, a therapy may be administered to a subject that comprises at least one PARP inhibitor. In some embodiments, the therapies are PARP inhibitors, such as Olaparib (LYNPARZA®), Rucaparib (RUBRACA®), Niraparib (ZEJULA®), and Talazoparib (TALZENNA®). These may be used for treating mutations in BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L alterations, and/or for genes associated Homologous Recombination Repair (HRR). Typically, therapies include at least one immunotherapy (or an immunotherapeutic agent). Immunotherapy refers generally to methods of enhancing an immune response against a given cancer type. In certain embodiments, immunotherapy refers to methods of enhancing a T cell response against a tumor or cancer. [0552] Therapies can function by helping the immune system destroy cancer cells. For example, certain targeted therapies may mark cancer cells for the immune system to destroy them. Other targeted therapies may support the immune system to work more effectively against cancer. Yet other therapies may stop cancer cells from growing, for example, by interfering with cancer cell surface markers preventing them from dividing. Additionally, therapies can inhibit signals that promote angiogenesis. Such angiogenesis inhibitors prevent blood supply into the tumor thereby, preventing tumor growth. Other targeted therapies can deliver toxic substances to the tumor. Examples include monoclonal antibodies combined with toxins, chemotherapy, or radiation. Some targeted therapies induce apoptosis or deplete cancer of hormones.
[0553] In some embodiments, therapy is customized based on the status of a nucleic acid variant as being of somatic or germline origin. In some embodiments, essentially any cancer therapy (e.g., surgical therapy, radiation therapy, chemotherapy, immunotherapy, and/or the like) may be included as part of these methods. Customized therapies can include at least one immunotherapy (or an immunotherapeutic agent). Immunotherapy refers generally to methods of enhancing an immune response against a given cancer type. In certain embodiments, immunotherapy refers to methods of enhancing a T cell response against a tumor or cancer.
[0554] In some embodiments, the immunotherapy or immunotherapeutic agent targets an immune checkpoint molecule. Certain tumors are able to evade the immune system by co-opting an immune checkpoint pathway. Thus, targeting immune checkpoints has emerged as an effective approach for countering a tumor’s ability to evade the immune system and activating anti-tumor immunity against certain cancers. Pardoll, Nature Reviews Cancer, 2012, 12:252-264. [0555] In some embodiments the treatment comprises immunotherapies and/or immune checkpoint inhibitors (ICTS). Immunotherapies are treatments with one or more agents that act to stimulate the immune system so as to kill or at least to inhibit growth of cancer cells, and preferably to reduce further growth of the cancer, reduce the size of the cancer and/or eliminate the cancer. Some such agents bind to a target present on cancer cells; some bind to a target present on immune cells and not on cancer cells; some bind to a target present on both cancer cells and immune cells. Such agents include, but are not limited to, checkpoint inhibitors and/or antibodies. Checkpoint inhibitors are inhibitors of pathways of the immune system that maintain self-tolerance and modulate the duration and amplitude of physiological immune responses in peripheral tissues to minimize collateral tissue damage (see, e.g., Pardoll, Nature Reviews Cancer 12, 252-264 (2012)). Exemplary agents include antibodies against any of PD-1, PD-2, PD-L1, PD-L2, CTLA-4, 0X40, B7.1, B7He, LAG3, CD137, KIR, CCR5, CD27, CD40, or CD47. Other exemplary agents include proinflammatory cytokines, such as IL-ip, IL-6, and TNF-a. Other exemplary agents are T-cells activated against a tumor, such as T-cells activated by expressing a chimeric antigen targeting a tumor antigen recognized by the T-cell. In some embodiments, anti-PD-1 or anti-PD-Ll therapies comprise pembrolizumab (KEYTRUDA®), nivolumab (OPDIVO®), and cemiplimab (LIBTAYO®), atezolizumab (TECENTRIQ®), durvalumab (INFINZI®), and avelumab (BAVENCIO®). These therapies may be used to treat patients identified as having high microsatehite instability (MSI) status or high tumor mutational burden (TMB).
[0556] In certain embodiments, the immune checkpoint molecule is an inhibitory molecule that reduces a signal involved in the T cell response to antigen. For example, CTLA4 is expressed on T cells and plays a role in downregulating T cell activation by binding to CD80 (aka B7.1) or CD86 (aka B7.2) on antigen presenting cells. PD-1 is another inhibitory checkpoint molecule that is expressed on T cells. PD-1 limits the activity of T cells in peripheral tissues during an inflammatory response. In addition, the ligand for PD-1 (PD-L1 or PD-L2) is commonly upregulated on the surface of many different tumors, resulting in the downregulation of antitumor immune responses in the tumor microenvironment. In certain embodiments, the inhibitory immune checkpoint molecule is CTLA4 or PD-1. In other embodiments, the inhibitory immune checkpoint molecule is a ligand for PD-1, such as PD-L1 or PD-L2. In other embodiments, the inhibitory immune checkpoint molecule is a ligand for CTLA4, such as CD80 or CD86. In other embodiments, the inhibitory immune checkpoint molecule is lymphocyte activation gene 3 (LAG3), killer cell immunoglobulin like receptor (KIR), T cell membrane protein 3 (TTM3), gal ectin 9 (GAL9), or adenosine A2a receptor (A2aR).
[0557] Antagonists that target these immune checkpoint molecules can be used to enhance antigen-specific T cell responses against certain cancers. Accordingly, in certain embodiments, the immunotherapy or immunotherapeutic agent is an antagonist of an inhibitory immune checkpoint molecule. In certain embodiments, the inhibitory immune checkpoint molecule is PD-1. In certain embodiments, the inhibitory immune checkpoint molecule is PD-L1. In certain embodiments, the antagonist of the inhibitory immune checkpoint molecule is an antibody (e.g., a monoclonal antibody). In certain embodiments, the antibody or monoclonal antibody is an anti- CTLA4, anti-PD-1, anti-PD-Ll, or anti-PD-L2 antibody. In certain embodiments, the antibody is a monoclonal anti-PD-1 antibody. In some embodiments, the antibody is a monoclonal anti-PD- Ll antibody. In certain embodiments, the monoclonal antibody is a combination of an anti- CTLA4 antibody and an anti-PD-1 antibody, an anti-CTLA4 antibody and an anti-PD-Ll antibody, or an anti-PD-Ll antibody and an anti-PD-1 antibody. In certain embodiments, the anti-PD-1 antibody is one or more of pembrolizumab (Keytruda®) or nivolumab (Opdivo®). In certain embodiments, the anti-CTLA4 antibody is ipilimumab (Yervoy®). In certain embodiments, the anti-PD-Ll antibody is one or more of atezolizumab (Tecentriq®), avelumab (Bavencio®), or durvalumab (Imfinzi®).
[0558] In certain embodiments, the immunotherapy or immunotherapeutic agent is an antagonist (e.g., antibody) against CD80, CD86, LAG3, KIR, TIM3, GAL9, or A2aR. In other embodiments, the antagonist is a soluble version of the inhibitory immune checkpoint molecule, such as a soluble fusion protein comprising the extracellular domain of the inhibitory immune checkpoint molecule and an Fc domain of an antibody. In certain embodiments, the soluble fusion protein comprises the extracellular domain of CTLA4, PD-1, PD-L1, or PD-L2. In some embodiments, the soluble fusion protein comprises the extracellular domain of CD80, CD86, LAG3, KIR, TIM3, GAL9, or A2aR. In one embodiment, the soluble fusion protein comprises the extracellular domain of PD-L2 or LAG3.
[0559] In some embodiments, the therapies target mutated forms of the EGFR protein. Such therapies can include osimertinib (TAGRISSO®), erlotinib (TARCEVA®), and gefmitib (IRESSA®).
[0560] Therapies can include one or more of treatments for target therapies, including abemaciclib (VERZENIO®), abiraterone acetate (ZYTIGA®), acalabrutinib (CALQUENCE®), adagrasib (KRAZATI®), ado-trastuzumab emtansine (KADCYLA®), afatinib dimaleate (GILOTRIF®), alectinib (ALCENSA®), alemtuzumab (CAMPATH®), alitretinoin (PANRETIN®), alpelisib (PIQRAY®), amivantamab- vmjw (RYBREVANT®), anastrozole (ARIMIDEX®), apalutamide (ERLEADA®), asciminib hydrochloride (SCEMBLIX®), atezolizumab (TECENTRIQ®), avapritinib (AYVAKIT®), avelumab (BAVENCIO®), axicabtagene ciloleucel (YESCARTA®), axitinib (INLYTA®), belinostat (BELEODAQ®), belzutifan (WELIREG®), bevacizumab (AVASTIN®), bexarotene (TARGRETIN®), binimetinib (MEKTOVI®), blinatumomab (BLINCYTO®), bortezomib (VELCADE®), bosutinib (BOSULIF®), brentuximab vedotin (ADCETRIS®), brexucabtagene autoleucel (TEC ARTUS®), brigatinib (ALUNBRIG®), cabazitaxel (JEVTANA), cabozantinib-s-malate (CABOMETYX®), cabozantinib-s-malate (COMETRIQ®), capmatinib hydrochloride (TABRECTA®), carfilzomib (KYPROLIS®), cemiplimab-rwlc (LIBTAYO®), ceritinib (ZYKADIA®), cetuximab (ERBITUX®), ciltacabtagene autoleucel (CARVYKTI®), cobimetinib fumarate (COTELLIC®), copanlisib hydrochloride (ALIQUOPA®), crizotinib (XALKORI®), dabrafenib (TAFMLAR®), dabrafenib mesylate (TAFMLAR®), dacomitinib (VIZIMPRO®), daratumumab (DARZALEX®), daratumumab and hyaluronidase-fihj (DARZALEX FASPRO®), darolutamide (NUBEQA®), dasatinib (SPRYCEL®), denileukin diftitox (ONTAK®), denosumab (XGEVA®), dinutuximab (UNITUXIN®), dostarlimab-gxly (JEMPERLI®), durvalumab (IMFINZI®), duvelisib (COPIKTRA®), elacestrant dihydrochloride (ORSERDU®), elotuzumab (EMPLICITI®), enasidenib mesylate (IDHIFA®), encorafenib (BRAFTOVI®), enfortumab vedotin-ejfv (PADCEV®), entrectinib (ROZLYTREK®), enzalutamide (XTANDI®), erdafitinib (BAL VERSA®), erlotinib hydrochloride (TARCEVA®), everolimus (AFINITOR®), exemestane (AROMASIN®), famtrastuzumab deruxtecan-nxki (ENHERTU®), fedratinib hydrochloride (INREBIC®), fulvestrant (FASLODEX®), futibatinib (LYTGOBI®), gefitinib (IRESSA®), gemtuzumab ozogamicin (MYLOTARG®), gilteritinib fumarate (XOSPATA®), glasdegib maleate (DAURISMO®), ibritumomab tiuxetan (ZEVALIN®), ibrutinib (IMBRUVICA®), idecabtagene vicleucel (ABECMA®), idelalisib (ZYDELIG®), imatinib mesylate (GLEEVEC®), infigratinib phosphate (TRUSELTIQ®), inotuzumab ozogamicin (BESPONSA®), iobenguane 1 131 (AZEDRA®), ipilimumab (YERVOY®), isatuximab-irfc (SARCLISA®), ivosidenib (TIBSOVO®), ixazomib citrate (NINLARO®), lanreotide acetate (SOMATULINE DEPOT®), lapatinib ditosylate (TYKERB®), larotrectinib sulfate (VITRAKVI®), lenvatinib mesylate (LENVIMA®), letrozole (FEMARA®), lisocabtagene maraleucel (BREYANZI®), loncastuximab tesirine-lpyl (ZYNLONTA®), lorlatinib (LORBRENA®), lutetium Lu 177 vipivotide tetraxetan (PLUVICTO®), lutetium Lu 177-dotatate (LUTATHRA®), margetuximab- cmkb (MARGENZA®), midostaurin (R YD APT®), mirvetuximab soravtansine-gynx (ELAHERE®), mobocertinib succinate (EXKIVITY®), mogamulizumab-kpkc (POTELIGEO®), mosunetuzumab-axgb (LUNSUMIO®), moxetumomab pasudotox-tdfk (LUMOXITI®), naxitamab-gqgk (DANYELZA®), necitumumab (PORTRAZZA®), neratinib maleate (NERLYNX®), nilotinib (TASIGNA®), niraparib tosylate monohydrate (ZEJULA®), nivolumab (OPDIVO®), nivolumab and relatlimab-rmbw (OPDUALAG®), obinutuzumab (GAZYVA®), ofatumumab (ARZERRA®), olaparib (LYNPARZA®), olutasidenib (REZLHIDIA®), osimertinib mesylate (TAGRISSO®), pacritinib citrate (VONJO®), palbociclib (IBRANCE®), panitumumab (VECTIBIX®), pazopanib hydrochloride (VOTRIENT®), pembrolizumab (KEYTRUDA®), pemigatinib (PEMAZYRE®), pertuzumab (PERJETA®), pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO®), pexidartinib hydrochloride (TURALIO®), pirtobrutinib (JAYPIRCA®), polatuzumab vedotin-piiq (POLIVY®), ponatinib hydrochloride (ICLUSIG®), pralatrexate (FOLOTYN®), pralsetinib (GAVRETO®), radium 223 dichloride (XOFIGO®), ramucirumab (CYRAMZA®), regorafenib (STIVARGA®), retifanlimab-dlwr (ZYNYZ®), ribociclib (KISQALI®), ripretinib (QINLOCK®), rituximab (RITUXAN®), rituximab and hyaluronidase human (RITUXAN HYCELA®), romidepsin (ISTODAX®), rucaparib camsylate (RUBRACA®), ruxolitinib phosphate (JAKAFI®), sacituzumab govitecan-hziy (TRODELVY®), selinexor (XPOVIO®), selpercatinib (RETEVMO®), selumetinib sulfate (KOSELUGO®), siltuximab (SYLVANT®), sirolimus protein-bound particles (FYARRO®), sonidegib (ODOMZO®), sorafenib tosylate (NEXAVAR®), sotorasib (LUMAKRAS®), sunitinib malate (SUTENT®), tafasitamab-cxix (MONJUVI®), tagraxofusp-erzs (ELZONRIS®), talazoparib tosylate (TALZENNA®), tamoxifen citrate (SOLTAMOX®), tazemetostat hydrobromide (TAZVERIK®), tebentafusp- tebn (KIMMTRAK®), teclistamab-cqyv (TECVAYLI®), temsirolimus (TORISEL®), tepotinib hydrochloride (TEPMETKO®), tisagenlecleucel (KYMRIAH®), tisotumab vedotin-tftv (TIVDAK®), tivozanib hydrochloride (FOTIVDA®), toremifene (FARESTON®), trametinib (MEKINIST®), trametinib dimethyl sulfoxide (MEKINIST®), trastuzumab (HERCEPTIN®), tremelimumab-actl (IMJUDO®), tretinoin (VESANOID®), tucatinib (TUKYSA®), vandetanib (CAPRELSA®), vemurafenib (ZELBORAF®), venetoclax (VENCLEXTA®), vismodegib (ERIVEDGE®), vorinostat (ZOLINZA®), zanubrutinib (BRUKINSA®), and/or ziv-aflibercept (ZALTRAP®).
[0561] Table 7 provides an exemplary list of drugs used to treat cancers with mutations observed in target genes associated with certain cancer types. In certain embodiments, the subject has a cancer of a type listed in Table 7 including a mutation in one or more target genes listed in Table 7 for that cancer type, and the therapy administered to the subject comprises the drug listed in Table 7 for that cancer type and mutation.
[0562] Table 7. Exemplary drugs
[0563] In some embodiments, the methods described herein can be used to treat patients by (i) detecting one or more mutations in the one or more target genes listed in Table 7; and (ii) administering the corresponding one or more drugs listed in Table 7. In some embodiments, these therapies may be used alone or in combination with other therapies to treat a disease.
[0564] In certain embodiments, the immune checkpoint molecule is a co-stimulatory molecule that amplifies a signal involved in a T cell response to an antigen. For example, CD28 is a costimulatory receptor expressed on T cells. When a T cell binds to antigen through its T cell receptor, CD28 binds to CD80 (aka B7.1) or CD86 (aka B7.2) on antigen-presenting cells to amplify T cell receptor signaling and promote T cell activation. Because CD28 binds to the same ligands (CD80 and CD86) as CTLA4, CTLA4 is able to counteract or regulate the co-stimulatory signaling mediated by CD28. In certain embodiments, the immune checkpoint molecule is a co- stimulatory molecule selected from CD28, inducible T cell co-stimulator (ICOS), CD137, 0X40, or CD27. In other embodiments, the immune checkpoint molecule is a ligand of a co-stimulatory molecule, including, for example, CD80, CD86, B7RP1, B7-H3, B7-H4, CD137L, OX40L, or CD70.
[0565] Agonists that target these co-stimulatory checkpoint molecules can be used to enhance antigen-specific T cell responses against certain cancers. Accordingly, in certain embodiments, the immunotherapy or immunotherapeutic agent is an agonist of a co-stimulatory checkpoint molecule. In certain embodiments, the agonist of the co-stimulatory checkpoint molecule is an agonist antibody and preferably is a monoclonal antibody. In certain embodiments, the agonist antibody or monoclonal antibody is an anti-CD28 antibody. In other embodiments, the agonist antibody or monoclonal antibody is an anti-ICOS, anti-CD137, anti -0X40, or anti-CD27 antibody. In other embodiments, the agonist antibody or monoclonal antibody is an anti-CD80, anti-CD86, anti-B7RPl, anti-B7-H3, anti-B7-H4, anti-CD137L, anti-OX40L, or anti-CD70 antibody.
[0566] These methods provided herein provide a deeper understanding of the changes in DNA and proteins that cause cancer, allowing the identification of biomarkers and design of treatments that target these proteins. In some embodiments, the biomarker may include an epigenetic signature, such as a methylation state, methylation score and/or DNA fragmentation pattem/score. In some embodiments, the epigenetic signature can be determined for one or more regions that include, but not limited to, transcription start sites, promoter regions, CTCF binding regions and regulatory protein binding regions. In some embodiments, the epigenetic signature is determined for one or more regions that include, but not limited to, transcription start sites, promoter regions, intergenic regions and/or intronic regions that are associated with at least one or more genes listed in Table 7. Such treatments may include small-molecule drugs or monoclonal antibodies. The methods may also improve biomarker testing in individuals suffering from disease and help determine if the individual is a candidate for a certain drug or combination of drugs based on the presence or absence of the biomarker. Additionally, the methods can improve identification of mutations that contribute to the development of resistance to targeted therapy. Consequently, the analysis techniques may reduce unnecessary or untimely therapeutic interventions, patient suffering, and patient mortality.
[0567] In certain embodiments, the status of a nucleic acid variant from a sample from a subject as being of somatic or germline origin may be compared with a database of comparator results from a reference population to identify customized or targeted therapies for that subject. Typically, the reference population includes patients with the same cancer or disease type as the subject and/or patients who are receiving, or who have received, the same therapy as the subject. A customized or targeted therapy (or therapies) may be identified when the nucleic variant and the comparator results satisfy certain classification criteria (e.g., are a substantial or an approximate match).
[0568] In certain embodiments, the customized therapies described herein are typically administered parenterally (e.g., intravenously or subcutaneously). Pharmaceutical compositions containing an immunotherapeutic agent are typically administered intravenously. Certain therapeutic agents are administered orally. However, customized therapies (e.g., immunotherapeutic agents, etc.) may also be administered by any method known in the art, for example, buccal, sublingual, rectal, vaginal, intraurethral, topical, intraocular, intranasal, and/or intraauricular, which administration may include tablets, capsules, granules, aqueous suspensions, gels, sprays, suppositories, salves, ointments, or the like.
[0569] In some embodiments, therapy is customized based on the status of a nucleic acid variant as being of somatic or germline origin. In some embodiments, determination of the levels of particular cell types, e.g., immune cell types, including rare immune cell types, facilitates selection of appropriate treatment.
[0570] The present methods can be used to diagnose the presence of a condition, e.g., cancer or precancer, in a subject, to characterize a condition (such as to determine a cancer stage or heterogeneity of a cancer), to monitor a subject’s response to receiving a treatment for a condition (such as a response to a chemotherapeutic or immunotherapeutic), assess prognosis of a subject (such as to predict a survival outcome in a subject having a cancer), to determine a subject’s risk of developing a condition, to predict a subsequent course of a condition in a subject, to determine metastasis or recurrence of a cancer in a subject (or a risk of cancer metastasis or recurrence), and/or to monitor a subject’s health as part of a preventative health monitoring program (such as to determine whether and/or when a subject is in need of further diagnostic screening). The methods according to the present disclosure can also be useful in predicting a subject’s response to a particular treatment option. Successful treatment options may increase the amount of copy number variation, rare mutations, and/or cancer-related epigenetic signatures (such as hypermethylated regions or hypomethylated regions) detected in a subject's blood (such as in DNA isolated from a buffy coat sample or any other sample comprising cells, such as a blood sample (e.g., a whole blood sample, a buffy coat sample, a leukapheresis sample, or a PBMC sample) from the subject) if the treatment is successful as more cancer cells may die and shed DNA, or if a successful treatment results in an increase or decrease in the quantity of a specific immune cell type in the blood and an unsuccessful treatment results in no change. In other examples, this may not occur. In another example, certain treatment options may be correlated with genetic profiles of cancers over time. This correlation may be useful in selecting a therapy for a subject. In some embodiments, determination of the metastasis site facilitates selection of appropriate treatment.
[0571] Thus, in some embodiments, quantities of each of one or more of a particular genetic and/or epigenetic signature (e.g., quantities of fusions, indels, SNPs, CNVs, and/or rare mutations, and/or cancer-related epigenetic signatures (such as specific (e.g., DMRs) or global hypermethylated or hypomethylated regions, and/or fragmentation variable regions)) in DNA from a subject's blood (such as in DNA (e.g., cfDNA) isolated from a blood sample (e.g., a whole blood sample) from the subject)) are determined based on sequencing and analysis. In some embodiments, quantities of each of a plurality of cell types, such as immune cell types, are determined based on sequencing and analysis (such as determination of epigenetic and/or genomic signatures) of DNA isolated from at least one sample comprising cells (such as blood sample (e.g., a whole blood sample, a buffy coat sample, a leukapheresis sample, or a PBMC sample) from a subject. The plurality of immune cell types can include, but is not limited to, macrophages (including Ml macrophages and M2 macrophages), activated B cells (including regulatory B cells, memory B cells and plasma cells); T cell subsets, such as central memory T cells, naive-like T cells, and activated T cells (including cytotoxic T cells, regulatory T cells (Tregs), CD4 effector memory T cells, CD4 central memory T cells, CD8 effector memory T cells, and CD8 central memory T cells); immature myeloid cells (including myeloid-derived suppressor cells (MDSCs), low-density neutrophils, immature neutrophils, and immature granulocytes); and natural killer (NK) cells. As disclosed herein, differences in levels and/or presence of particular genetic and/or epigenetic signatures in DNA isolated from blood samples from a subject can be used to quantify cell types, such as immune cell types, within the sample. Thus, a comparison of one or more genetic and/or epigenetic signatures in DNA isolated from blood samples collected from a subject at two or more time points can be used to monitor changes in the one or more signatures and/or the one or more cell type quantities in the subject under different conditions (such as prior to and after a treatment), or over time (e.g., as part of a preventative health monitoring program). [0572] In some embodiments, therapy is customized based on the status of a detected nucleic acid variant as being of somatic or germline origin. In some embodiments, essentially any cancer therapy (e.g., surgical therapy, radiation therapy, chemotherapy, and/or the like) may be included as part of these methods. Typically, customized therapies include at least one immunotherapy (or an immunotherapeutic agent). Immunotherapy refers generally to methods of enhancing an immune response against a given cancer type. In certain embodiments, immunotherapy refers to methods of enhancing a T cell response against a tumor or cancer.
[0573] In certain embodiments, the status of a nucleic acid variant from a sample from a subject as being of somatic or germline origin may be compared with a database of comparator results from a reference population to identify customized or targeted therapies for that subject. Typically, the reference population includes patients with the same cancer or disease type as the subject and/or patients who are receiving, or who have received, the same therapy as the subject. A customized or targeted therapy (or therapies) may be identified when the nucleic variant and the comparator results satisfy certain classification criteria (e.g., are a substantial or an approximate match).
[0574] The disclosed methods can include evaluating (such as quantifying) and/or interpreting at least one cell material released from a potential metastasis site (such as at least one cell material in a sample from a subject) and/or cell types that contribute to DNA, such as cfDNA, in one or more samples collected from a subject at one or more timepoints in comparison to a selected baseline value or reference standard (or a selected set of baseline values or reference standards). A baseline value or reference standard may be a presence or level of at least one cell material and/or a quantity of cell types measured in one or more samples (such as an average quantity or range of quantities of cell types present in at least two samples) collected from the subject at one or more time points, such as prior to receiving a treatment, prior to diagnosis of a condition (such as a cancer), or as part of a preventative health monitoring program. A baseline value or reference standard may be a presence or level of at least one cell material and/or a quantity of cell types measured with respect to one or more samples (such as an average quantity or range of quantities of cell types present in at least two samples) collected at one or more timepoints from one or more subjects that do not have the condition (such as a healthy subject that does not have a cancer), one or more subjects that responded favorably to the treatment, or one or more subjects that have not received the treatment. In certain embodiments, the baseline value or reference standard utilized is a standard or profde derived from a single reference subject. In other embodiments, the baseline value or reference standard utilized is a standard or profile derived from averaged data from multiple reference subjects. The reference standard, in various embodiments, can be a single value, a mean, an average, a numerical mean or range of numerical means, a numerical pattern, or a graphical pattern created from the cell type quantity data derived from a single reference subject or from multiple reference subjects. Selection of the particular baseline values or reference standards, or selection of the one or more reference subjects, depends upon the use to which the methods described herein are to be put by, for example, a research scientist or a clinician (such as a physician).
[0575] The disclosed methods can include evaluating (such as quantifying) and/or interpreting one or more genetic and/or epigenetic signatures, and/or one or more cell types (such as one or more immune cell types), present in one or more samples (e.g., in DNA, such as cfDNA, from a blood sample(e.g., a whole blood sample, a buffy coat sample, a leukapheresis sample, or a PBMC sample)) collected from a subject at one or more timepoints in comparison to a selected baseline value or reference standard (or a selected set of baseline values or reference standards). A baseline value or reference standard may be a quantity of copy number variation, rare mutations, cancer-related epigenetic signatures (such as hypermethylated regions or hypomethylated regions), and/or cell types measured in one or more samples (such as an average quantity or range of quantities of such signatures present in at least two samples) collected from the subject at one or more time points, such as prior to receiving a treatment, prior to diagnosis of a condition (such as a cancer), or as part of a preventative health monitoring program. A baseline value or reference standard may be a quantity of, e.g., copy number variation, rare mutations, cancer-related epigenetic signatures (such as hypermethylated regions or hypomethylated regions), and/or cell types measured in one or more samples (such as an average quantity or range of quantities of such signatures and/or cell types present in at least two samples) collected at one or more timepoints from one or more subjects that do not have the condition (such as a healthy subject that does not have a cancer), one or more subjects that responded favorably to the treatment, or one or more subjects that have not received the treatment.
[0576] In certain embodiments, the baseline value or reference standard utilized is a standard or profile derived from a single reference subject. In other embodiments, the baseline value or reference standard utilized is a standard or profile derived from averaged data from multiple reference subjects. The reference standard, in various embodiments, can be a single value, a mean, an average, a numerical mean or range of numerical means, a numerical pattern, or a graphical pattern created from the genetic and/or epigenetic signature quantity data derived from a single reference subject or from multiple reference subjects. Selection of the particular baseline values or reference standards, or selection of the one or more reference subjects, depends upon the use to which the methods described herein are to be put by, for example, a research scientist or a clinician (such as a physician).
[0577] In some embodiments, one or more samples comprising cells (such as a huffy coat sample or any other sample comprising cells, such as a blood sample (e.g., a whole blood sample, a leukapheresis sample, or a PBMC sample) may be collected from a subject at two or more timepoints, to assess changes in cell types (such as changes in quantities of cell types) between the two timepoints. By monitoring cell types and identifying differences between cell types in samples collected from a subject at two or more timepoints, the present methods can be used, for example, to determine the presence or absence of a condition (such as a cancer), a response of the subject to a treatment, one or more characteristic of a condition (such as a cancer stage) in the subject, recurrence of a condition (such as a cancer), and/or a subject’s risk of developing a condition (such as a cancer). Thus, in some embodiments, methods are provided wherein quantities of cell types present in at least one sample (such as at least one whole blood sample, buffy coat sample, leukapheresis sample, or PBMC sample) collected from a subject at one or more timepoints (such as prior to receiving a treatment) are compared to quantities of cell types present in at least one sample collected from the subject at one or more different time points (such as after receiving the treatment). The disclosed methods can allow for patientspecific monitoring, such that, for example, differences in cell type quantities between samples collected from the subject at different timepoints may indicate changes (such as presence or absence of a condition, response to a treatment, a prognosis, or the like) that are significant with respect to the subject but may yet fall within a normal range of a general healthy population.
[0578] In some embodiments, methods are provided for monitoring a response (such as a change in disease state, such as a presence or absence of a metastasis in a subject, such as measured by assessing a presence or level of at least one cell material released from a potential metastasis site in a sample from the subject) of a subject to a treatment (such as a chemotherapy or an immunotherapy). In certain embodiments, one or more samples is collected from the subject at at least 1-10, at least 1-5, at least 2-5, or at least 1, at least 2, least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, or at least 20 time points prior to the subject receiving the treatment. In certain embodiments, one or more samples is collected from the subject at at least 1-10, at least 1-5, at least 2-5, or at least 1, at least 2, least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, or at least 20 time points after the subject has received the treatment. Sample collection from a subject can be ongoing during and/or after treatment to monitor the subject’s response to the treatment.
[0579] In some embodiments, samples are not collected from a subject prior to diagnosis of a condition (such as a cancer) or prior to receiving a treatment. In such embodiments, wherein the response of a subject to a treatment or the course or stage of a condition (such as a cancer) in the subject is being monitored over time, genetic and/or epigenetic signatures, and/or cell types are compared between samples taken at at least 2-10, at least 2-5, at least 3-6, or at least 2, such as at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, or at least 20 time points collected after the subject has been diagnosed and/or after the subject has received the treatment. Sample collection from a subject can be ongoing during and/or after treatment to monitor the subject’s response to the treatment.
[0580] In some embodiments of the disclosed methods, one or more samples is collected from a subject at least once per year, such as about 1-12 times or about 2-6 times, such as about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 times per year. In other embodiments, one or more samples is collected from the subject less than once per year, such as about once every 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 months. In some embodiments, one or more samples is collected from the subject about once every 1-5 years or about once every 1-2 years, such as about every 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5 years.
[0581] In other embodiments of the disclosed methods, one or more samples (such as one or more whole blood, buffy coat, leukapheresis, or PBMC samples) are collected from a subject at least once per week, such as on 1-4 days, 1-2 days, or on 1, 2, 3, 4, 5, 6, or 7 days per week. In certain embodiments, one or more samples are collected from the subject at least once per month, such as 1-15 times, 1-10 times, 2-5 times, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 times per month. In other embodiments, one or more samples is collected from the subject every month, every 2 months, every 3 months, every 4 months, every 5 months, every 6 months, every 7 months, every 8 months, every 9 months, every 10 months, every 11 months, or every 12 months. In some embodiments, one or more samples is collected from the subject at least once per day, such as 1, 2, 3, 4, 5, or 6 times per day. Selection of the one or more sample collection timepoints (e.g., the frequency of sample collection), or of the number of samples to be collected at each timepoint, depends upon the use to which the methods described herein are to be put by, for example, a research scientist or a clinician (such as a physician).
[0582] In certain embodiments, the customized therapies described herein are typically administered parenterally (e.g., intravenously or subcutaneously). Pharmaceutical compositions containing an immunotherapeutic agent are typically administered intravenously. Certain therapeutic agents are administered orally. However, customized therapies (e.g., immunotherapeutic agents, etc.) may also be administered by methods such as, for example, buccal, sublingual, rectal, vaginal, intraurethral, topical, intraocular, intranasal, and/or intraauricular, which administration may include tablets, capsules, granules, aqueous suspensions, gels, sprays, suppositories, salves, ointments, or the like.
[0583] Therapeutic options for treating specific genetic-based diseases, disorders, or conditions, other than cancer, are generally well-known to those of ordinary skill in the art and will be apparent given the particular disease, disorder, or condition under consideration.
III. Kits
[0584] Also provided are kits for use in the methods as described herein. In some embodiments, the kit comprises one or more conversion reagents. The conversion reagents may comprise reagents for any combination of steps described herein, including but not limited to in the numbered embodiments above and in any one of the workflows shown in the figures.
[0585] In some embodiments, the kit comprises adapters. In some embodiments, the kit comprises PCR primers, wherein the PCR primers anneal to a target region or to an adapter. In some embodiments, the kit comprises additional elements elsewhere herein. In some embodiments, the kit comprises instructions for performing a method described herein.
[0586] In some embodiments, the kit further comprises a deaminase and a polymerase. In some embodiments, the deaminase is a CpG-deaminase. In some embodiments, the CpG-deaminase is a methyl -sensitive deaminase (e.g., MsddA or a modification-sensitive DNA deaminase A (MsddA)-like deaminase) or methyl-insensitive deaminase (e.g., A3 A). In some embodiments, the polymerase is a DNA polymerase. In some embodiments, the DNA polymerase is a uracil- intolerant polymerase (e.g., Q5® High-Fidelity DNA Polymerase). In some embodiments, the polymerase is a AP site-intolerant DNA polymerase. In some embodiments, the kit comprises a uracil-DNA glycosylase. In some embodiments, the kit comprises an AP lyase (e.g., endonuclease VIII). In some embodiments, the kit comprises a uracil-specific excision reagent enzyme. In some embodiments, the kit comprises a mismatch endonuclease (MME). [0587] In some embodiments, a kit comprises a first reagent for end repair to generate end- repaired DNA, wherein the first reagent comprises at least one type of dNTP that comprises a modified base. In some embodiments, the kit further comprises a second reagent for ligating adapters to the end-repaired DNA to generate adapted DNA, wherein the second reagent also seals nicks present in the end-repaired DNA. In some embodiments, the kit further comprises a third reagent for sequencing that is capable of identifying the base modification in the at least one type of dNTP. The kit may comprise the first, second, and/or third reagents and additional elements as discussed below and/or elsewhere herein. In some embodiments, a kit comprises instructions for performing a method described herein.
[0588] In some embodiments, the kit further comprises a plurality of oligonucleotide probes and/or primers for sequencing. In some embodiments, the first reagent of the kit comprises at least one type of dNTP that comprises a modified base selected from a dNTP comprising 5- carboxylcytosine (5-caC), a dNTP comprising 4-methylcytosine (4mC), a dNTP comprising 5- methylcytosine (5mC), a dNTP comprising 5 -hydroxymethyl -cytosine (5hmC), a dNTP comprising N6-methyladenosine (6mA), a dNTP comprising bromodeoxyuridine (BrdU), a dNTP comprising 8-oxoguanine (8oxoG), dUTP, a dNTP comprising fluorodeoxyuridine (FldU), a dNTP comprising iododeoxyuridine (IdU), and/or a dNTP comprising ethynyldeoxyuridine (EdU). In some embodiments, the DNA polymerase of the kit does not have 5 ’-3’ exonuclease activity and/or is not a strand displacing DNA polymerase. In some embodiments, the DNA polymerase of the kit is T4 DNA polymerase, T7 DNA polymerase or Klenow fragment. In some embodiments, the DNA polymerase of the kit has 5 ’-3’ exonuclease activity and/or is a strand displacing DNA polymerase. In some embodiments, the kit further comprises a reagent for performing an A-tailing reaction. In some embodiments, the reagent for performing the A- tailing reaction comprises a DNA polymerase that does not possess 5’-3’ exonuclease activity and/or is not a strand displacing DNA polymerase, optionally the reagent for performing the A- tailing reaction is HemoKlen Taq. In some embodiments, the reagent for performing the A- tailing reaction comprises a Taq DNA polymerase, Tfl DNA Polymerase, Bst DNA Polymerase, Large Fragment or Tth DNA polymerase. In some embodiments, the reagent for performing the A-tailing reaction comprises a DNA polymerase that does not possess 3 ’-5’ exonuclease activity, optionally wherein the reagent for performing the A-tailing reaction is Klenow Fragment lacking 3'-5' exonuclease activity. In some embodiments, the reagent for performing the A-tailing reaction comprises a DNA polymerase that has 5 ’-3’ exonuclease activity and/or is a strand displacing DNA polymerase.
[0589] Kits may further comprise a plurality of oligonucleotide probes that selectively hybridize to least 5, 6, 7, 8, 9, 10, 20, 30, 40 or all genes selected from the group consisting of ALK, APC, BRAF, CDKN2A, EGFR, ERBB2, FBXW7, KRAS, MYC, NOTCH1, NRAS, PIK3CA, PTEN, RBI, TP53, MET, AR, ABL1, AKT1, ATM, CDH1, CSFIR, CTNNB1, ERBB4, EZH2, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, MLH1, MPL, NPM1, PDGFRA, PROC, PTPN11, RET,SMAD4, SMARCB1, SMO, SRC, STK11, VHL, TERT, CCND1, CDK4, CDKN2B, RAFI, BRCA1, CCND2, CDK6, NF1, TP53, ARID 1 A, BRCA2, CCNE1, ESRI, RIT1, GATA3, MAP2K1, RHEB, ROS1, ARAE, MAP2K2, NFE2L2, RHOA, and NTRK1 . The number of genes to which the oligonucleotide probes can selectively hybridize can vary. For example, the number of genes can comprise 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, or 54. The kit can include a container that includes the plurality of oligonucleotide probes and instructions for performing any of the methods described herein.
[0590] The oligonucleotide probes can selectively hybridize to exon regions of the genes, e.g., of the at least 5 genes. In some cases, the oligonucleotide probes can selectively hybridize to at least 30 exons of the genes, e.g., of the at least 5 genes. In some cases, the multiple probes can selectively hybridize to each of the at least 30 exons. The probes that hybridize to each exon can have sequences that overlap with at least 1 other probe. In some embodiments, the oligoprobes can selectively hybridize to non-coding regions of genes disclosed herein, for example, intronic regions of the genes. The oligoprobes can also selectively hybridize to regions of genes comprising both exonic and intronic regions of the genes disclosed herein.
[0591] Any number of exons can be targeted by the oligonucleotide probes. For example, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, , 295, 300, 400, 500, 600, 700, 800, 900, 1,000, or more, exons can be targeted.
[0592] The kit can comprise at least 4, 5, 6, 7, or 8 different library adaptors having distinct molecular barcodes and identical sample barcodes. The library adaptors may not be sequencing adaptors. For example, the library adaptors do not include flow cell sequences or sequences that permit the formation of hairpin loops for sequencing. The different variations and combinations of molecular barcodes and sample barcodes are described throughout, and are applicable to the kit. Further, in some cases, the adaptors are not sequencing adaptors. Additionally, the adaptors provided with the kit can also comprise sequencing adaptors. A sequencing adaptor can comprise a sequence hybridizing to one or more sequencing primers. A sequencing adaptor can further comprise a sequence hybridizing to a solid support, e.g., a flow cell sequence. For example, a sequencing adaptor can be a flow cell adaptor. The sequencing adaptors can be attached to one or both ends of a polynucleotide fragment. In some cases, the kit can comprise at least 8 different library adaptors having distinct molecular barcodes and identical sample barcodes. The library adaptors may not be sequencing adaptors. The kit can further include a sequencing adaptor having a first sequence that selectively hybridizes to the library adaptors and a second sequence that selectively hybridizes to a flow cell sequence. In another example, a sequencing adaptor can be hairpin shaped. For example, the hairpin shaped adaptor can comprise a complementary double stranded portion and a loop portion, where the double stranded portion can be attached (e.g., ligated) to a double-stranded polynucleotide. Hairpin shaped sequencing adaptors can be attached to both ends of a polynucleotide fragment to generate a circular molecule, which can be sequenced multiple times. A sequencing adaptor can be up to 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,
45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70,
71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96,
97, 98, 99, 100, or more bases from end to end. The sequencing adaptor can comprise 20-30, 20-
40, 30-50, 30-60, 40-60, 40-70, 50-60, 50-70, bases from end to end. In a particular example, the sequencing adaptor can comprise 20-30 bases from end to end. In another example, the sequencing adaptor can comprise 50-60 bases from end to end. A sequencing adaptor can comprise one or more barcodes. For example, a sequencing adaptor can comprise a sample barcode. The sample barcode can comprise a pre-determined sequence. The sample barcodes can be used to identify the source of the polynucleotides. The sample barcode can be at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more (or any length as described throughout) nucleic acid bases, e.g., at least 8 bases. The barcode can be contiguous or non-contiguous sequences, as described above. [0593] The library adaptors can be blunt ended and Y-shaped and can be less than or equal to 40 nucleic acid bases in length. Other variations of the can be found throughout and are applicable to the kit.
IV. Computer Systems
[0594] Methods of the present disclosure can be implemented using, or with the aid of, computer systems. FIG. 3 shows a computer system 301 that is programmed or otherwise configured to implement the methods of the present disclosure. The computer system 301 can regulate various aspects sample preparation, sequencing, and/or analysis. In some examples, the computer system 301 is configured to perform sample preparation and sample analysis, including (where applicable) nucleic acid sequencing, e.g., according to any of the methods disclosed herein. [0595] The computer system 301 includes a central processing unit (CPU, also "processor" and "computer processor" herein) 305, which can be a single core or multi core processor, or a plurality of processors for parallel processing. The computer system 301 also includes memory or memory location 310 (e.g., random-access memory, read-only memory, flash memory), electronic storage unit 315 (e.g., hard disk), communication interface 320 (e.g., network adapter) for communicating with one or more other systems, and peripheral devices 325, such as cache, other memory, data storage, and/or electronic display adapters. The memory 310, storage unit 315, interface 320, and peripheral devices 325 are in communication with the CPU 305 through a communication network or bus (solid lines), such as a motherboard. The storage unit 315 can be a data storage unit (or data repository) for storing data. The computer system 301 can be operatively coupled to a computer network 330 with the aid of the communication interface 320. The computer network 330 can be the Internet, an internet and/or extranet, or an intranet and/or extranet that is in communication with the Internet. The computer network 330 in some cases is a telecommunication and/or data network. The computer network 330 can include one or more computer servers, which can enable distributed computing, such as cloud computing. The computer network 330, in some cases with the aid of the computer system 301, can implement a peer-to-peer network, which may enable devices coupled to the computer system 301 to behave as a client or a server.
[0596] The CPU 305 can execute a sequence of machine-readable instructions, which can be embodied in a program or software. The instructions may be stored in a memory location, such as the memory 310. Examples of operations performed by the CPU 305 can include fetch, decode, execute, and writeback. [0597] The storage unit 315 can store files, such as drivers, libraries, and saved programs. The storage unit 315 can store programs generated by users and recorded sessions, as well as output(s) associated with the programs. The storage unit 315 can store user data, e.g., user preferences and user programs. The computer system 301 in some cases can include one or more additional data storage units that are external to the computer system 301, such as located on a remote server that is in communication with the computer system 301 through an intranet or the Internet. Data may be transferred from one location to another using, for example, a communication network or physical data transfer (e.g., using a hard drive, thumb drive, or other data storage mechanism).
[0598] The computer system 301 can communicate with one or more remote computer systems through the network 330. For embodiment, the computer system 301 can communicate with a remote computer system of a user (e.g., operator). Examples of remote computer systems include personal computers (e.g., portable PC), slate or tablet PC's (e.g., Apple® iPad, Samsung® Galaxy Tab), telephones, Smart phones (e.g., Apple® iPhone, Android-enabled device, Blackberry®), or personal digital assistants. The user can access the computer system 301 via the network 330.
[0599] Methods as described herein can be implemented by way of machine (e.g., computer processor) executable code stored on an electronic storage location of the computer system 301, such as, for example, on the memory 310 or electronic storage unit 315. The machine executable or machine-readable code can be provided in the form of software. During use, the code can be executed by the processor 305. In some cases, the code can be retrieved from the storage unit 315 and stored on the memory 310 for ready access by the processor 305. In some situations, the electronic storage unit 315 can be precluded, and machine-executable instructions are stored on memory 310.
[0600] In an aspect, the present disclosure provides a non-transitory computer-readable medium comprising computer-executable instructions which, when executed by at least one electronic processor, perform at least a portion of a method described herein. For example, the method may comprise: (a) contacting DNA in a sample with a deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs;
(b) selectively amplifying DNA in the converted sample that comprises methylated CpGs or conversion products of methylated CpGs. [0601] The code can be pre-compiled and configured for use with a machine have a processor adapted to execute the code or can be compiled during runtime. The code can be supplied in a programming language that can be selected to enable the code to execute in a pre-compiled or as- compiled fashion.
[0602] Aspects of the systems and methods provided herein, such as the computer system 301, can be embodied in programming. Various aspects of the technology may be thought of as "products" or "articles of manufacture" typically in the form of machine (or processor) executable code and/or associated data that is carried on or embodied in a type of machine readable medium. Machine-executable code can be stored on an electronic storage unit, such memory (e.g., read-only memory, random-access memory, flash memory) or a hard disk. "Storage" type media can include any or all of the tangible memory of the computers, processors or the like, or associated modules thereof, such as various semiconductor memories, tape drives, disk drives and the like, which may provide non-transitory storage at any time for the software programming.
[0603] All or portions of the software may at times be communicated through the Internet or various other telecommunication networks. Such communications, for example, may enable loading of the software from one computer or processor into another, for example, from a management server or host computer into the computer platform of an application server. Thus, another type of media that may bear the software elements includes optical, electrical, and electromagnetic waves, such as those used across physical interfaces between local devices, through wired and optical landline networks, and over various air-links. The physical elements that carry such waves, such as wired or wireless links, optical links, or the like, also may be considered as media bearing the software. As used herein, unless restricted to non-transitory, tangible "storage" media, terms such as computer or machine "readable medium" refer to any medium that participates in providing instructions to a processor for execution.
[0604] Hence, a machine-readable medium, such as computer-executable code, may take many forms, including but not limited to, a tangible storage medium, a carrier wave medium or physical transmission medium. Non-volatile storage media include, for example, optical or magnetic disks, such as any of the storage devices in any computer(s) or the like, such as may be used to implement the databases, etc. shown in the drawings. Volatile storage media include dynamic memory, such as the main memory of such a computer platform. Tangible transmission media include coaxial cables; copper wire and fiber optics, including the wires that comprise a bus within a computer system. Carrier-wave transmission media may take the form of electric or electromagnetic signals, or acoustic or light waves such as those generated during radio frequency (RF) and infrared (IR) data communications. Common forms of computer-readable media therefore include for example: a floppy disk, a flexible disk, hard disk, magnetic tape, any other magnetic medium, a CD-ROM, DVD or DVD-ROM, any other optical medium, punch cards, paper tape, any other physical storage medium with patterns of holes, a RAM, a ROM, a PROM and EPROM, a FLASH-EPROM, any other memory chip or cartridge, a carrier wave transporting data or instructions, cables or links transporting such a carrier wave, or any other medium from which a computer may read programming code and/or data. Many of these forms of computer readable media may be involved in carrying one or more sequences of one or more instructions to a processor for execution.
[0605] The computer system 301 can include or be in communication with an electronic display that comprises a user interface (UI) for providing, for example, one or more results of sample analysis. Examples of UIs include, without limitation, a graphical user interface (GET) and webbased user interface.
[0606] Additional details relating to computer systems and networks, databases, and computer program products are also provided in, for example, Peterson, Computer Networks: A Systems Approach, Morgan Kaufmann, 5th Ed. (2011), Kurose, Computer Networking: A Top-Down Approach, Pearson, 7th Ed. (2016), Elmasri, Fundamentals of Database Systems, Addison Wesley, 6th Ed. (2010), Coronel, Database Systems: Design, Implementation, & Management, Cengage Learning, 11th Ed. (2014), Tucker, Programming Languages, McGraw-Hill Science/Engineering/Math, 2nd Ed. (2006), and Rhoton, Cloud Computing Architected: Solution Design Handbook, Recursive Press (2011), each of which is hereby incorporated by reference in its entirety.
[0607] While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the disclosure be limited by the specific examples provided within the specification. While the disclosure has been described with reference to the aforementioned specification, the descriptions and illustrations of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the disclosure. Furthermore, it shall be understood that all aspects of the disclosure are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the disclosure described herein may be employed in practicing the disclosure. It is therefore contemplated that the disclosure shall also cover any such alternatives, modifications, variations or equivalents. It is intended that the following claims define the scope of the disclosure and that methods and structures within the scope of these claims and their equivalents be covered thereby. [0608] While the foregoing disclosure has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be clear to one of ordinary skill in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the disclosure and may be practiced within the scope of the appended claims. For example, all the methods, systems, computer readable media, and/or component features, steps, elements, or other aspects thereof can be used in various combinations.
[0609] All patents, patent applications, websites, other publications or documents, accession numbers and the like cited herein are incorporated by reference in their entirety for all purposes to the same extent as if each individual item were specifically and individually indicated to be so incorporated by reference. If different versions of a sequence are associated with an accession number at different times, the version associated with the accession number at the effective filing date of this application is meant. The effective filing date means the earlier of the actual filing date or filing date of a priority application referring to the accession number, if applicable. Likewise, if different versions of a publication, website or the like are published at different times, the version most recently published at the effective filing date of the application is meant, unless otherwise indicated.
EXAMPLES
[0610] The following examples are provided to illustrate certain aspects of the disclosed methods. The examples do not limit the disclosure.
Example 1: Enrichment of methylated target regions (Option li)
[0611] The workflow described in this example is illustrated in Fig. 1 A. A set of patient samples is analyzed by a blood-based assay at Guardant Health (Redwood City, CA, USA) to detect the presence or absence of cancer. DNA is extracted from the blood of these patients. [0612] After DNA extraction, the DNA is converted using a methyl-insensitive, CpG specific deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs and methylated CpGs in the DNA are converted to TpGs. Conversion of DNA using a methyl-insensitive, CpG specific deaminase provides a converted sample in which at least a portion of the methylated CpGs in the DNA are converted to TpGs and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs.
[0613] The DNA in the converted sample that comprises conversion products of methylated CpGs is subsequently amplified using a uracil-intolerant DNA polymerase.
[0614] The amplified DNA is analyzed (e.g., by sequencing, including next-generation sequencing, or qPCR) to identify enriched methylated TpGs, e.g., to quantify a level of methylation at one or more differentially methylated regions of the DNA.
Example 2: Enrichment of methylated target regions (Option lii)
[0615] The workflow described in this example is illustrated in Fig. 1A. A set of patient samples is analyzed by a blood-based assay at Guardant Health (Redwood City, CA, USA) to detect the presence or absence of cancer. DNA is extracted from the blood of these patients.
[0616] After DNA extraction, the DNA is converted using a methyl-sensitive, CpG specific deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs. Conversion of DNA using a methyl-sensitive, CpG specific deaminase provides a converted sample in which the methylated CpGs in the DNA remain as methylated CpGs and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs.
[0617] The DNA in the converted sample that comprises methylated CpGs is subsequently amplified using a uracil-intolerant DNA polymerase.
[0618] The amplified DNA is analyzed (e.g., by sequencing, including next-generation sequencing, or qPCR) to identify enriched methylated CpGs, e.g., to quantify a level of methylation at one or more differentially methylated regions of the DNA.
Example 3: Enrichment of methylated target regions (Option 2i)
[0619] The workflow described in this example is illustrated in Fig. IB. A set of patient samples is analyzed by a blood-based assay at Guardant Health (Redwood City, CA, USA) to detect the presence or absence of cancer. DNA is extracted from the blood of these patients. [0620] After DNA extraction, the DNA is converted using a methyl-insensitive, CpG specific deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs and methylated CpGs in the DNA are converted to TpGs. Conversion of DNA using a methyl-insensitive, CpG specific deaminase provides a converted sample in which at least a portion of the methylated CpGs in the DNA are converted to TpGs and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs.
[0621] The uracils of the DNA in the converted sample that comprises conversion products of methylated CpGs are converted to apyrimidinic sites (AP sites) using a uracil-DNA glycosylase (UDG).
[0622] The DNA in the converted sample that comprises conversion products of methylated CpGs is subsequently amplified using an AP site-intolerant DNA polymerase.
[0623] The amplified DNA is analyzed (e.g., by sequencing, including next-generation sequencing, or qPCR) to identify enriched methylated TpGs in the DNA sample, e.g., to quantify a level of methylation at one or more differentially methylated regions of the DNA.
Example 4: Enrichment of methylated target regions (Option 2ii)
[0624] The workflow described in this example is illustrated in Fig. IB. A set of patient samples is analyzed by a blood-based assay at Guardant Health (Redwood City, CA, USA) to detect the presence or absence of cancer. DNA is extracted from the blood of these patients.
[0625] After DNA extraction, the DNA is converted using a methyl-sensitive, CpG specific deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs. Conversion of DNA using a methyl-sensitive, CpG specific deaminase provides a converted sample in which the methylated CpGs in the DNA remain as methylated CpGs and at least a portion of the unmethylated cytosines of CpGs in the DNA are converted to UpGs.
[0626] The uracils in the DNA in the converted sample that comprises methylated CpGs are converted to AP sites using a UDG.
[0627] The DNA in the converted sample that comprises methylated CpGs is subsequently amplified using an AP site-intolerant DNA polymerase.
[0628] The amplified DNA is analyzed (e.g., by sequencing, including next-generation sequencing, or qPCR) to identify enriched methylated CpGs in the DNA sample, e.g., to quantify a level of methylation at one or more differentially methylated regions of the DNA. Example 5: Enrichment of methylated target regions (Option 3i)
[0629] The workflow described in this example is illustrated in Fig. 1C. A set of patient samples is analyzed by a blood-based assay at Guardant Health (Redwood City, CA, USA) to detect the presence or absence of cancer. DNA is extracted from the blood of these patients.
[0630] After DNA extraction, the DNA is converted using a methyl-insensitive, CpG specific deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs and methylated CpGs in the DNA are converted to TpGs. Conversion of DNA using a methyl-insensitive, CpG specific deaminase provides a converted sample in which at least a portion of the methylated CpGs in the DNA are converted to TpGs and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs.
[0631] The uracils in the DNA in the converted sample that comprises conversion products of methylated CpGs are converted to AP sites using a UDG.
[0632] The DNA that contains AP sites is subsequently cut using an AP lyase (e.g., endonuclease VIII).
[0633] The DNA that was not cut by the AP lyase is subsequently amplified using a DNA polymerase. The amplified DNA is analyzed (e.g., by sequencing, including next-generation sequencing, or qPCR) to identify enriched methylated TpGs in the DNA sample, e.g., to quantify a level of methylation at one or more differentially methylated regions of the DNA.
Example 6: Enrichment of methylated target regions (Option 3ii)
[0634] The workflow described in this example is illustrated in Fig. 1C. A set of patient samples is analyzed by a blood-based assay at Guardant Health (Redwood City, CA, USA) to detect the presence or absence of cancer. DNA is extracted from the blood of these patients.
[0635] After DNA extraction, the DNA is converted using a methyl-sensitive, CpG specific deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs. Conversion of DNA using a methyl-sensitive, CpG specific deaminase provides a converted sample in which the methylated CpGs in the DNA remain as methylated CpGs and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs.
[0636] The uracils in the DNA in the converted sample that comprises methylated CpGs are converted to AP sites using a UDG. [0637] The DNA that contains AP sites is subsequently cut using an AP lyase (e.g., endonuclease VIII).
[0638] The DNA that was not cut by the AP lyase is subsequently amplified using a DNA polymerase. The amplified DNA is analyzed (e.g., by sequencing, including next-generation sequencing, or qPCR) to identify enriched methylated CpGs in the DNA sample, e.g., to quantify a level of methylation at one or more differentially methylated regions of the DNA.
Example 7: Enrichment of methylated target regions (Option 4)
[0639] The workflow described in this example is illustrated in Fig. ID. A set of patient samples is analyzed by a blood-based assay at Guardant Health (Redwood City, CA, USA) to detect the presence or absence of cancer. DNA is extracted from the blood of these patients.
[0640] After DNA extraction, the DNA is contacted to a methyl-sensitive, CpG specific deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs. Conversion of DNA using a methyl-sensitive, CpG specific deaminase provides a converted sample in which the methylated CpGs in the DNA remain as methylated CpGs and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs.
[0641] The DNA is subsequently cut using a mismatch endonuclease (MME).
[0642] The DNA that was not cut by the MME is subsequently amplified using a DNA polymerase. The amplified DNA is analyzed (e.g., by sequencing, including next-generation sequencing, or qPCR) to identify enriched methylated CpGs in the DNA sample, e.g., to quantify a level of methylation at one or more differentially methylated regions of the DNA.
Example 8: Analyzing epigenetic target regions
[0643] The workflow described in this example is illustrated in Fig. 2. A set of patient samples is analyzed by a blood-based NGS assay at Guardant Health (Redwood City, CA, USA) to detect the presence or absence of cancer. DNA is extracted from the blood of these patients.
[0644] After DNA extraction, the DNA is subjected to end-repair and A-tailing reactions with a deaminase-resistant modified cytosine (e.g., 5-caryboxylcytosine (5-caC)).
[0645] After end-repairing and A-tailing reactions, adapters are added to the DNA by ligation to the 3’ ends thereof, the 5’ ends thereof, or both the 3’ and 5’ ends thereof. These adapters contain non-unique molecular barcodes. [0646] After ligation, the DNA is contacted to a methyl-insensitive, CpG specific dsDNA deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs and methylated CpGs in the DNA are converted to TpGs. Conversion of DNA using a methyl-insensitive, CpG specific deaminase provides a converted sample in which at least a portion of the methylated CpGs in the DNA are converted to TpGs and at least a portion of the unmethylated CpGs in the DNA are converted to UpGs.
[0647] The DNA in the converted sample that comprises methylated CpGs is subsequently amplified using a uracil-intolerant DNA polymerase.
[0648] The amplified DNA is analyzed by next-generation sequencing (NGS), e.g., to quantifying the level of methylation at one or more differentially methylated regions of the DNA in the DNA sample. A methylated CpG of the DNA in the sample is read as TpG using NGS, and the deaminase-resistant modified cytosine added during the end-repair reaction is read as CpG using NGS.

Claims

What is claimed is:
1. A method of enriching methylated DNA in a sample comprising:
(a) contacting the DNA in the sample with a deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs; and
(b) selectively amplifying DNA in the converted sample that comprises methylated CpGs or conversion products of methylated CpGs.
2. The method of claim 1, wherein selectively amplifying DNA in the converted sample comprises amplifying the DNA using a uracil-intolerant DNA polymerase.
3. The method of claim 1, wherein selectively amplifying DNA in the converted sample comprises:
(i) contacting the DNA with a uracil-DNA glycosylase (UDG), thereby converting uracils in the DNA to apyrimidinic sites (AP sites); and
(ii) amplifying the DNA using an AP site-intolerant DNA polymerase and/or a uracil -intolerant DNA polymerase.
4. The method of claim 1, wherein selectively amplifying DNA in the converted sample comprises:
(i) contacting the DNA with a UDG, thereby converting uracils in the DNA to AP sites;
(ii) cutting DNA comprising the AP sites using an AP lyase; and
(iii) amplifying DNA that was not cut by the AP lyase using a DNA polymerase.
5. The method of the immediately preceding claim, wherein the AP lyase is an endonuclease VIII.
6. The method of claim 4 or 5, wherein the DNA comprises adapters and amplifying DNA that was not cut by the AP lyase using the DNA polymerase comprises amplification using primers that bind sites in the adapters.
7. The method of claim 1, wherein selectively amplifying DNA in the converted sample comprises:
(i) contacting the DNA with a uracil-specific excision reagent enzyme, thereby converting uracils in the DNA to AP sites;
(ii) cutting the DNA; and
(iii) amplifying DNA that was not cut by the uracil-specific excision reagent enzyme using a DNA polymerase.
8. The method of the immediately preceding claim, wherein the DNA comprises adapters and amplifying DNA that was not cut comprises amplification using primers that bind sites in the adapters.
9. The method of claim 4 or 7, wherein the DNA polymerase is an AP site-intolerant DNA polymerase or a uracil-intolerant DNA polymerase.
10. The method of claim 1, wherein the deaminase is a dsDNA deaminase, and wherein selectively amplifying DNA in the converted sample comprises:
(i) cutting DNA comprising UpGs using a mismatch endonuclease (MME); and
(ii) amplifying DNA that was not cut by the MME using a DNA polymerase.
11. The method of the immediately preceding claim, wherein the MME is mismatch endonuclease I.
12. The method of claim 10 or 11, wherein the DNA comprises adapters and amplifying DNA that was not cut comprises amplification using primers that bind sites in the adapters.
13. The method of any one of the preceding claims, wherein selectively amplifying DNA in the converted sample comprises amplifying the DNA using rolling circle amplification (RCA).
14. The method of any one of the preceding claims, wherein the DNA comprises barcodes.
15. The method of any one of the preceding claims, wherein the method comprises ligating adapters comprising barcodes to the DNA.
16. The method of any one of the preceding claims, wherein the method comprises ligating adapters comprising barcodes to the DNA prior to the amplifying.
17. The method of any one of the preceding claims, wherein the method comprises ligating adapters comprising barcodes to the DNA prior to the contacting the DNA with the deaminase.
18. The method of any one of claims 4-13, wherein the method comprises ligating adapters to the DNA after cutting the DNA.
19. The method of any one of claims 12 or 15-16, wherein the adapters are Y-shaped adapters.
20. The method of any one of the preceding claims, wherein the deaminase is thermally inactivated after step (a).
21. The method of any one of claims 4-6, wherein the steps of contacting the DNA with the UDG and cutting DNA comprising the AP sites using the AP lyase are in the same reaction mixture.
22. The method of any one of the preceding claims, wherein the deaminase is a dsDNA deaminase.
23. The method of any one of claims 1-9, wherein the deaminase is a ssDNA deaminase.
24. The method of any one of claims 1-9, wherein the deaminase is a methyl insensitive deaminase.
25. The method of the immediately preceding claim, wherein the methyl insensitive deaminase is A3 A.
26. The method of any one of claims 1-23, wherein the deaminase is a methyl sensitive deaminase.
27. The method of the immediately preceding claim, wherein the methyl sensitive deaminase is MsddA.
28. The method of any one of the preceding claims, further comprising, prior to step (a): subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules, wherein the end repair is performed using deoxynucleotide triphosphates (dNTPs), wherein at least one type of dNTP comprises a modified base, and the at least one dNTP comprising a modified base is incorporated into a repaired region of the end-repaired DNA molecules at one or more locations.
29. The method of claim 28, wherein the end repair is performed using a DNA polymerase that does not have 5’-3’ exonuclease activity and/or is not a strand displacing DNA polymerase.
30. The method of claim 28, wherein the end repair is performed using a DNA polymerase that has 5’-3’ exonuclease activity and/or is a strand displacing DNA polymerase.
31. The method of any one of claims 28-30, wherein the at least one type of dNTP which comprises a modified base, wherein the modified base includes a dNTP comprising 5- caryboxylcytosine (5-caC), 4-methylcytosine (4mC), a dNTP comprising 5-methylcytosine (5mC), a dNTP comprising 5 -hydroxymethyl -cytosine (5hmC), a dNTP comprising N6- m ethyl adenosine (6mA), a dNTP comprising bromodeoxyuridine (BrdU) and/or a dNTP comprising 8-oxoguanine (8oxoG).
32. The method of any one of the preceding claims, further comprising performing an A- tailing reaction, optionally after a step of subjecting a DNA sample to end repair.
33. The method of claim 32, wherein the end-repair and the A-tailing reaction are performed in the same reaction mixture, optionally wherein the end-repair and the A-tailing reaction are performed a single tube and/or optionally wherein the end-repair and the A-tailing reaction are performed without an intervening clean-up step.
34. The method of claim 32 or 33, wherein the A-tailing is performed using a DNA polymerase that does not possess 5 ’-3’ exonuclease activity and/or is not a strand displacing DNA polymerase, optionally wherein the DNA polymerase is HemoKlen Taq.
35. The method of any one of claims 32-34, wherein the A-tailing is performed using a thermostable DNA polymerase.
36. The method of any one of the preceding claims, prior to step (a), performing a methylation-preserving amplification of the DNA of the sample.
37. The method of the immediately preceding claim, wherein the methylation-preserving amplification is a linear, methylation-preserving amplification.
38. The method of any one of claims 36-37, wherein the methylation-preserving amplification comprises contacting the DNA with a methyltransferase.
39. The method of any one of claims 36-38, wherein the methylation-preserving amplification comprises one or more of polymerase chain reaction, linear amplification, rolling circle amplification, ligase chain reaction, strand displacement amplification, nucleic acid sequence-based amplification, and self-sustained sequence-based replication.
40. The method of any one of claims 36-38, wherein the methylation-preserving amplification comprises thermocycled amplification.
41. The method of any one of claims 36-38, wherein the methylation-preserving amplification comprises isothermal amplification.
42. The method of any one of the preceding claims, wherein the step of contacting the DNA in the sample with a deaminase, thereby providing a converted sample in which unmethylated CpGs in the DNA are converted to UpGs, comprises APOBEC-coupled epigenetic (ACE) conversion, enzymatic methyl-seq (EM-seq) or single-enzyme 5-methylcytosine sequencing (SEM-seq) method.
43. The method of any one of the preceding claims, further comprising sequencing at least a portion of the amplified DNA.
44. The method of any one of the preceding claims, further comprising quantifying a level of methylation at one or more differentially methylated regions of the DNA.
45. The method of the immediately preceding claim, wherein quantifying the level of methylation at one or more differentially methylated regions of the DNA comprises sequencing at least a portion of the amplified DNA or quantitative PCR.
46. The method of claim 43 or 45, wherein the sequencing is next-generation sequencing (NGS).
47. The method of the immediately preceding claim, wherein the NGS is pyrosequencing, sequencing-by-synthesis, semiconductor sequencing, sequencing-by-ligation, or sequencing-by- hybridization.
48. The method of claim 43 or 45, wherein the sequencing comprises nanopore-based sequencing or single-molecule real time (SMRT) sequencing.
49. The method of claim 43, 45, or 48, wherein the sequencing comprises nanopore-based sequencing and the method further comprises subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules, wherein the end repair is performed using at least one type of dNTP which comprises a modified base including a dNTP comprising 5- caryboxylcytosine (5-caC), a dNTP comprising 4mC, a dNTP comprising 5mC, a dNTP comprising 5hmC, a dNTP comprising 6mA, a dNTP comprising BrdU, dUTP, a dNTP comprising fluorodeoxyuridine (FldU), a dNTP comprising 5-iododeoxyuridine (IdU), and/or a dNTP comprising 5-ethynyldeoxyuridine (EdU), and the at least one type of dNTP comprising a modified base is incorporated into a repaired region of the end-repaired DNA molecules at one or more locations.
50. The method of claim 43, 45, or 48, wherein the sequencing comprises single-molecule real time (SMRT) sequencing and the method further comprises subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules, wherein the end repair is performed using at least one type of dNTP which comprises a modified base including a dNTP comprising a 4mC, a dNTP comprising 5mC, a dNTP comprising 5hmC, a dNTP comprising 6mA, and/or a dNTP comprising 8oxoG, and the at least one type of dNTP comprising a modified base is incorporated into a repaired region of the end-repaired DNA molecules at one or more locations.
51. The method of any one of claims 43-50, wherein the DNA sample comprises cell-free DNA (cfDNA).
52. The method of the immediately preceding claim, further comprising analyzing the sequence data to determine a level of measured artifacts in the cfDNA.
53. The method of any one of the preceding claims, further comprising subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules, wherein the end repair is performed using at least one type of dNTP which comprises a modified base, wherein the modified base is other than 5mC or 5hmC, and the at least one type of dNTP comprising a modified base is incorporated into a repaired region of the end-repaired DNA molecules at one or more locations.
54. The method of any one of claims 1-52, further comprising subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules, wherein the end repair is performed using at least one type of dNTP which comprises a modified base, wherein the modified base is a methylated cytosine, optionally wherein the methylated base is 5mC or 5hmC, and the at least one type of dNTP comprising a modified base is incorporated into a repaired region of the end-repaired DNA molecules at one or more locations.
55. The method of any one of claims 1-52, further comprising subjecting the DNA in the sample to end repair to generate end-repaired DNA molecules, wherein the end repair is performed using at least one type of dNTP which comprises a modified base, wherein the modified base is a methylated cytosine, optionally wherein the methylated base is 5mC or 5hmC, wherein the at least one type of dNTP comprising a modified base is incorporated into a repaired region of the end-repaired DNA molecules at one or more locations, and the repaired region is defined as:
(i) the sequence between two non-methylated cytosines which span one or more methylated CpH cytosines; and/or
(ii) the sequence between a methylated CpH cytosine and an end of a sequence read, wherein the methylated CpH cytosine is the CpH cytosine most distant from the end of the sequence read, or a subsequence thereof comprising one or more methylated CpH cytosines.
56. The method of any one of claims 28-35 or 53-55, wherein adapters are ligated to the end- repaired DNA molecules or the adapters are ligated to the DNA molecules.
57. The method of the immediately preceding claim, wherein the adapters comprise molecular barcodes.
58. The method of any one of the preceding claims, further comprising enriching the DNA for a plurality of target regions, optionally prior to the step of selectively amplifying DNA in the converted sample, or optionally prior to a step of sequencing the DNA.
59. The method of the immediately preceding claim, wherein the plurality of target regions comprises epigenetic target regions.
60. The method of the immediately preceding claim, wherein the epigenetic target regions comprise hypermethylation variable target regions.
61. The method of claim 59 or 60, wherein the epigenetic target regions comprise hypomethylation variable target regions.
62. The method of any one of claims 58-61, wherein the plurality of target regions comprise sequence-variable target regions.
63. The method of any one of the preceding claims, wherein the DNA sample comprises cell- free DNA (cfDNA) or DNA from formalin fixed paraffin embedded samples.
64. The method of the immediately preceding claim, wherein the DNA sample comprises cell-free DNA.
65. The method of any one of the preceding claims, wherein the DNA sample is from a subject.
66. The method of any one of the preceding claims, wherein the DNA sample is from a subject and the method further comprises determining the presence or absence of cancer in the subject based at least in part on the sequencing data.
67. The method of any one of claims 65-66, wherein the subject is an animal.
68. The method of the immediately preceding claim, wherein the subject is a human.
69. The method of any one of claims 65-68, wherein the subject has or is at risk of having a cancer.
70. The method of any one of claims 65-68, further comprising determining the presence or status of a cancer in the subject.
PCT/US2025/021808 2024-03-28 2025-03-27 Methods for methylation enrichment using cpg-specific deamination Pending WO2025207921A1 (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202463570986P 2024-03-28 2024-03-28
US63/570,986 2024-03-28
US202463667401P 2024-07-03 2024-07-03
US63/667,401 2024-07-03
US202463669082P 2024-07-09 2024-07-09
US202463669078P 2024-07-09 2024-07-09
US63/669,082 2024-07-09
US63/669,078 2024-07-09
US202463670035P 2024-07-11 2024-07-11
US202463670034P 2024-07-11 2024-07-11
US63/670,035 2024-07-11
US63/670,034 2024-07-11

Publications (1)

Publication Number Publication Date
WO2025207921A1 true WO2025207921A1 (en) 2025-10-02

Family

ID=95399281

Family Applications (6)

Application Number Title Priority Date Filing Date
PCT/US2025/021843 Pending WO2025207939A1 (en) 2024-03-28 2025-03-27 Methods for separating methylated dna using methyl-sensitive deamination and binding of cpg-binding proteins
PCT/US2025/021812 Pending WO2025207924A1 (en) 2024-03-28 2025-03-27 Methods for selective deamination using cpg-binding proteins
PCT/US2025/021813 Pending WO2025207925A1 (en) 2024-03-28 2025-03-27 Methods for methylation enrichment using preferential ligation of adapters
PCT/US2025/021808 Pending WO2025207921A1 (en) 2024-03-28 2025-03-27 Methods for methylation enrichment using cpg-specific deamination
PCT/US2025/021845 Pending WO2025207941A1 (en) 2024-03-28 2025-03-27 Methods for separating cpg-dense dna by binding of cpg-binding proteins and methyl-sensitive deamination
PCT/US2025/021817 Pending WO2025207926A1 (en) 2024-03-28 2025-03-27 Methods for selective deamination using methyl-sensitive deaminases

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PCT/US2025/021843 Pending WO2025207939A1 (en) 2024-03-28 2025-03-27 Methods for separating methylated dna using methyl-sensitive deamination and binding of cpg-binding proteins
PCT/US2025/021812 Pending WO2025207924A1 (en) 2024-03-28 2025-03-27 Methods for selective deamination using cpg-binding proteins
PCT/US2025/021813 Pending WO2025207925A1 (en) 2024-03-28 2025-03-27 Methods for methylation enrichment using preferential ligation of adapters

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US2025/021845 Pending WO2025207941A1 (en) 2024-03-28 2025-03-27 Methods for separating cpg-dense dna by binding of cpg-binding proteins and methyl-sensitive deamination
PCT/US2025/021817 Pending WO2025207926A1 (en) 2024-03-28 2025-03-27 Methods for selective deamination using methyl-sensitive deaminases

Country Status (1)

Country Link
WO (6) WO2025207939A1 (en)

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053519A1 (en) 1990-12-06 2001-12-20 Fodor Stephen P.A. Oligonucleotides
US20030152490A1 (en) 1994-02-10 2003-08-14 Mark Trulson Method and apparatus for imaging a sample on a device
WO2005005660A1 (en) * 2003-07-04 2005-01-20 Epigenomics Ag Method for the detection of cytosine methylations in dna by means of cytidine deaminases
US7537898B2 (en) 2001-11-28 2009-05-26 Applied Biosystems, Llc Compositions and methods of selective nucleic acid isolation
US20110160078A1 (en) 2009-12-15 2011-06-30 Affymetrix, Inc. Digital Counting of Individual Molecules by Stochastic Attachment of Diverse Labels
US9598731B2 (en) 2012-09-04 2017-03-21 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US9738894B2 (en) 2003-03-21 2017-08-22 Roche Innovation Center Copenhagen A/S Short interfering RNA (siRNA) analogues
US9850523B1 (en) 2016-09-30 2017-12-26 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
US9902992B2 (en) 2012-09-04 2018-02-27 Guardant Helath, Inc. Systems and methods to detect rare mutations and copy number variation
WO2018119452A2 (en) 2016-12-22 2018-06-28 Guardant Health, Inc. Methods and systems for analyzing nucleic acid molecules
US20180362960A1 (en) * 2017-06-15 2018-12-20 New England Biolabs, Inc. Method for performing multiple enzyme reactions in a single tube
US10260088B2 (en) 2015-10-30 2019-04-16 New England Biolabs, Inc. Compositions and methods for analyzing modified nucleotides
WO2020160414A1 (en) 2019-01-31 2020-08-06 Guardant Health, Inc. Compositions and methods for isolating cell-free dna
US10961525B2 (en) 2017-07-05 2021-03-30 The Trustees Of The University Of Pennsylvania Hyperactive AID/APOBEC and hmC dominant TET enzymes
CN116287152A (en) * 2023-02-22 2023-06-23 青岛大学 Gene methylation detection method based on methylation-sensitive cytidine deaminase
WO2023196572A1 (en) * 2022-04-07 2023-10-12 Illumina Singapore Pte. Ltd. Altered cytidine deaminases and methods of use
WO2024073043A1 (en) 2022-09-30 2024-04-04 Illumina, Inc. Methods of using cpg binding proteins in mapping modified cytosine nucleotides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1568786A3 (en) * 2004-02-13 2007-08-29 Affymetrix, Inc. (A US Entity) Analysis of methylation status using nucleic acid arrays
DE102005034628B4 (en) * 2005-07-19 2007-08-23 Epigenomics Ag Method for the investigation of cytosine methylations in DNA
US8361746B2 (en) * 2008-07-24 2013-01-29 Brookhaven Science Associates, Llc Methods for detection of methyl-CpG dinucleotides
US20150099670A1 (en) * 2013-10-07 2015-04-09 Weiwei Li Method of preparing post-bisulfite conversion DNA library
WO2022087309A1 (en) * 2020-10-23 2022-04-28 Guardant Health, Inc. Compositions and methods for analyzing dna using partitioning and base conversion
WO2022147420A1 (en) * 2020-12-30 2022-07-07 Guardant Health, Inc. Detection of epigenetic status using sequence-specific degradation
CN119923475A (en) * 2022-07-21 2025-05-02 夸登特健康公司 Methods for detecting and reducing sample preparation-induced methylation artifacts
WO2024137880A2 (en) * 2022-12-22 2024-06-27 Guardant Health, Inc. Methods involving methylation preserving amplification with error correction
AU2023421715A1 (en) * 2023-01-06 2024-09-26 Illumina, Inc. Reducing uracils by polymerase

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US20010053519A1 (en) 1990-12-06 2001-12-20 Fodor Stephen P.A. Oligonucleotides
US20030152490A1 (en) 1994-02-10 2003-08-14 Mark Trulson Method and apparatus for imaging a sample on a device
US7537898B2 (en) 2001-11-28 2009-05-26 Applied Biosystems, Llc Compositions and methods of selective nucleic acid isolation
US9738894B2 (en) 2003-03-21 2017-08-22 Roche Innovation Center Copenhagen A/S Short interfering RNA (siRNA) analogues
WO2005005660A1 (en) * 2003-07-04 2005-01-20 Epigenomics Ag Method for the detection of cytosine methylations in dna by means of cytidine deaminases
US20110160078A1 (en) 2009-12-15 2011-06-30 Affymetrix, Inc. Digital Counting of Individual Molecules by Stochastic Attachment of Diverse Labels
US9902992B2 (en) 2012-09-04 2018-02-27 Guardant Helath, Inc. Systems and methods to detect rare mutations and copy number variation
US9598731B2 (en) 2012-09-04 2017-03-21 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10260088B2 (en) 2015-10-30 2019-04-16 New England Biolabs, Inc. Compositions and methods for analyzing modified nucleotides
US9850523B1 (en) 2016-09-30 2017-12-26 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
WO2018119452A2 (en) 2016-12-22 2018-06-28 Guardant Health, Inc. Methods and systems for analyzing nucleic acid molecules
US20180362960A1 (en) * 2017-06-15 2018-12-20 New England Biolabs, Inc. Method for performing multiple enzyme reactions in a single tube
US10961525B2 (en) 2017-07-05 2021-03-30 The Trustees Of The University Of Pennsylvania Hyperactive AID/APOBEC and hmC dominant TET enzymes
WO2020160414A1 (en) 2019-01-31 2020-08-06 Guardant Health, Inc. Compositions and methods for isolating cell-free dna
WO2023196572A1 (en) * 2022-04-07 2023-10-12 Illumina Singapore Pte. Ltd. Altered cytidine deaminases and methods of use
WO2024073043A1 (en) 2022-09-30 2024-04-04 Illumina, Inc. Methods of using cpg binding proteins in mapping modified cytosine nucleotides
CN116287152A (en) * 2023-02-22 2023-06-23 青岛大学 Gene methylation detection method based on methylation-sensitive cytidine deaminase

Non-Patent Citations (51)

* Cited by examiner, † Cited by third party
Title
"a database of DNA methylomes across a variety of species", NUCLEIC ACIDS RES, 2018
"GeneBank", Database accession no. tig00001818-10-11279730_497
"UniProt", Database accession no. trlAOAl V 4SQ451AOA 1 V 4SQ45 RUMHU
BASHTRYKOV PI ET AL.: "The UHRF1 protein stimulates the activity and specificity of the maintenance DNA methyltransferase DNMT1 by an allosteric mechanism", J BIOL CHEM., 2014
BLANCO ET AL., J. BIOL. CHEM., vol. 264, 1989, pages 8935 - 8940
BOCK ET AL., NAT BIOTECH, vol. 28, 2010, pages 1106 - 1114
CORONEL: "Database Systems: Design, Implementation, & Management", 2014
ELMASRI: "Fundamentals of Database Systems", 2010
FIILLGRABE ET AL., BIORXIV, 2022
FREIER ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 4429 - 4443
GAJULA ET AL., NUCLEIC ACIDS RES., vol. 42, no. 15, September 2014 (2014-09-01), pages 9964 - 75
GALE ET AL., PLOS ONE, vol. 13, 2018, pages 0194630
GANSAUGE ET AL., NATURE PROTOCOLS, vol. 8, 2013, pages 737 - 748
GOUILKENIRY, ESSAYS IN BIOCHEMISTRY, vol. 63, 2019, pages 639 - 648
GRETARSSON KRISTJAN H ET AL: "andcounteract de novo methylation to establish a permissive epigenome for development", NATURE STRUCTURAL & MOLECULAR BIOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 27, no. 8, 22 June 2020 (2020-06-22), pages 706 - 716, XP037212597, ISSN: 1545-9993, [retrieved on 20200622], DOI: 10.1038/S41594-020-0445-1 *
HENNION ET AL., GENOME BIOLOGY, vol. 21, 2020
IURLARO ET AL., GENOME BIOL., vol. 14, 2013, pages 119
JANG ET AL., GENES (BASEL)., vol. 8, no. 6, June 2017 (2017-06-01), pages 148
KINDE ET AL., PROC NAT'L ACAD SCI USA, vol. 108, 2011, pages 9530 - 9535
KO ET AL., NATURE, vol. 468, 2010, pages 839 - 843
KOU ET AL., PL S ONE, vol. 11, 2016, pages 0146638
KUROSE: "Computer Networking: A Top-Down Approach", 2016
KUTYAVIN, BIOCHEMISTRY, vol. 47, no. 51, 2008, pages 13666 - 1367
LIU ET AL., NAT CHEM BIOL, vol. 13, 2017, pages 181 - 187
LIU ET AL., NAT CHEM BIOL., vol. 13, no. 2, February 2017 (2017-02-01), pages 181 - 187
LIZARD ET AL., NAT. GENETICS, vol. 19, 1998, pages 225 - 232
LOU ET AL., PROC. NATL. ACAD. SCI., vol. 110, no. 49, 2013, pages 19872 - 19877
MULLER ET AL., NATURE METHODS, vol. 16, 2019, pages 429 - 436
NOTOMI ET AL., NUC. ACIDS RES., vol. 28, 2000, pages 63
PARDOLL, NATURE REVIEWS CANCER, vol. 12, 2012, pages 252 - 264
PETERSON: "Cloud Computing Architected: Solution Design Handbook", 2011, RECURSIVE PRESS
ROBERTSON ET AL., NUCLEIC ACIDS RES., vol. 39, 2011, pages 8740 - 8751
SCHUTSKY ET AL., NATURE BIOTECHNOLOGY, vol. 36, 2018, pages 1083 - 1090
SCHUTSKY ET AL., NUCLEIC ACIDS RES., vol. 45, no. 13, 27 July 2017 (2017-07-27), pages 7655 - 7665
SCOTT, C.A.DURYEA, J.D.MACKAY, H. ET AL.: "Identification of cell type-specific methylation signals in bulk whole genome bisulfite sequencing data", GENOME BIOL, vol. 21, 2020, pages 156
SONG ET AL., NAT BIOTECH, vol. 29, 2011, pages 68 - 72
SONG ET AL., NAT. BIOTECH., vol. 29, 2010, pages 68 - 72
TROLL ET AL., BMC GENOMICS, vol. 20, 2019, pages 1023, Retrieved from the Internet <URL:https://doi.org/10.1186/s12864-019-6355-0>
TUCKER: "Programming Languages", 2006, MCGRAW-HILL SCIENCE/ENGINEERING/MATH
VAISVILA ET AL., MOL CELL, vol. 84, no. 5, 7 March 2024 (2024-03-07), pages 854 - 866
VAISVILA ET AL.: "Discovery of novel DNA cytosine deaminase activities enables a nondestructive single-enzyme methylation sequencing method for base resolution high-coverage methylome mapping of cell-free and ultra-low input DNA", BIORXIV, 2023, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2023.06.29.547047v1.>
VAISVILA R ET AL.: "EM-seq: Detection of DNA methylation at single base resolution from picograms of DNA", BIORXIV, 2019, Retrieved from the Internet <URL:www.biorxiv.org/content/101101/2019.12.20.884692v1>
VAISVILA ROMUALDAS ET AL: "Discovery of novel DNA cytosine deaminase activities enables a nondestructive single-enzyme methylation sequencing method for base resolution high-coverage methylome mapping of cell-free and ultra-low input DNA", BIORXIV, 19 December 2023 (2023-12-19), XP093237351, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2023.06.29.547047v2.full.pdf> DOI: 10.1101/2023.06.29.547047 *
WARDLE JBURGERS PMCANN IKDARLEY KHESLOP PJOHANSSON ELIN LJMCGLYNN PSANVOISIN JSTITH CM: "Uracil recognition by replicative DNA polymerases is limited to the archaea, not occurring with bacteria and eukarya", NUCLEIC ACIDS RES., vol. 36, no. 3, February 2008 (2008-02-01), pages 705 - 11
WARDLE JBURGERS PMCANN IKDARLEY KHESLOP PJOHANSSON ELIN LJMCGLYNN PSANVOISIN JSTITH CM: "Uracil recognition by replicative DNA polymerases is limited to the archaea, not occurring with bacteria and eukarya.", NUCLEIC ACIDS RES., vol. 36, no. 3, February 2008 (2008-02-01), pages 705 - 11
WEIRATHER ET AL., F 1000RESEARCH, vol. 6, 2017, pages 100
WEIRATHER JL ET AL., FL000RESEARCH, vol. 6, 2017, pages 100
WEIRATHER JL ET AL.: "Comprehensive comparison of Pacific Biosciences and Oxford Nanopore Technologies and their applications to transcriptome analysis", FL000RESEARCH, vol. 6, 2017, pages 100
YANG ET AL., BIO-PROTOCOL, vol. 12, no. 17, 2023, pages 4496
YANG WEIWEI ET AL: "The discovery of 5mC-selective deaminases and their application to ultra-sensitive direct sequencing of methylated sites at base resolution", BIORXIV, 8 December 2024 (2024-12-08), XP093237307, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2024.12.05.627091v1.full.pdf> DOI: 10.1101/2024.12.05.627091 *
YU ET AL., CELL, vol. 149, 2012, pages 1368 - 80

Also Published As

Publication number Publication date
WO2025207925A1 (en) 2025-10-02
WO2025207939A1 (en) 2025-10-02
WO2025207924A1 (en) 2025-10-02
WO2025207941A1 (en) 2025-10-02
WO2025207926A1 (en) 2025-10-02

Similar Documents

Publication Publication Date Title
EP4638781A2 (en) Methods involving methylation preserving amplification with error correction
US20240191290A1 (en) Methods for detection and reduction of sample preparation-induced methylation artifacts
US20260022424A1 (en) Nucleic acid methylation profiling method
US20250101494A1 (en) Methods for analyzing cytosine methylation and hydroxymethylation
US20250084464A1 (en) Compositions and methods for synthesis and use of probes targeting nucleic acid rearrangements
US20240263241A1 (en) Methods and compositions for copy-number informed tissue-of-origin analysis
WO2024006908A1 (en) Enrichment of aberrantly methylated dna
WO2025090956A1 (en) Methods for detecting nucleic acid variants using capture probes
WO2025029475A1 (en) Methods to enrich nucleotide variants by negative selection
US20240093292A1 (en) Quality control method
WO2024229143A1 (en) Quality control method for enzymatic conversion procedures
WO2024138180A2 (en) Integrated targeted and whole genome somatic and dna methylation sequencing workflows
WO2024264065A1 (en) Methods and compositions for quantifying immune cell nucleic acids
WO2025207921A1 (en) Methods for methylation enrichment using cpg-specific deamination
WO2026015794A1 (en) Methods for modifying dna using cpg-specific deamination and uracil base excision
WO2025090954A1 (en) Methods for detecting nucleic acid variants
WO2025160433A1 (en) Methods for analyzing sequencing reads
US20260009024A1 (en) Non-invasive monitoring of genomic alterations induced by gene-editing therapies
WO2026015607A1 (en) Methods for partitioning hyper-, hypo-, and non-methylated dna
WO2025235889A1 (en) Methods involving multiplexed pooled pcr
WO2025038399A1 (en) Methylated enrichment methods for single-molecule genetic and epigenetic sequencing
WO2025137620A1 (en) Methods for high quality and high accuracy methylation sequencing
WO2025155895A1 (en) Nucleic acid modification profiling method
WO2024229433A1 (en) Methods for analysis of dna methylation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25719229

Country of ref document: EP

Kind code of ref document: A1